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Angiogenesis is the process of formation of blood vessels from pre­
existing blood vessels. It occurs in a series of orchestrated network of 
cooperative interactions. This process plays a vital role in reproduction, 
growth and healing. The hypothesis made by Judah Folkman in 1971 forms 
the groundwork for the entire angiogenesis research. This hypothesis stated 
that blood vessel formation is integral to tumour progression. Equilibrium 
between positive and negative regulators of angiogenesis is the key 
determinant to the state of the capillary networks. Malignant transformations 
are characterised by the onset of angiogenesis, which occur when this balance 
tips in favour of the inducers of the process. During the last decade numerous 
angiogenic genes and gene products have been isolated and purified from both 
normal and neoplastic tissues. These regulatory molecules induce or inhibit 
blood vessel formation by both paracrine and autocrine mechanisms. 
Comprehensive pre-clinical research activities have translated the various 
advances in basic angiogenesis research into possible clinical therapies by 
using a number of in vitro, in vivo and transgenic animal models.
Biomedical research at present is going through an era of Structural 
Genomics and hence the elucidation of protein structures has become 
fundamental to the understanding of complex molecular mechanisms. Protein 
crystallography is an essential tool for solving the three-dimensional structure 
of proteins. It enables a detailed insight into the function of proteins by virtue 
of their three-dimensional structure.
One of the main themes of the research carried out in our laboratory is 
concerned with the structure determination of proteins involved in the process 
of angiogenesis and inflammation. The work described in this thesis involved 
the use of X-ray crystallography for structural studies on some important 
angiogenic molecules: Placenta Growth Factors (PIGF-1 and P1GF-2), 
Vascular Endothelial Growth Factor-B (VEGF-B) and Matrix 
Metalloproteinase-1 (MMP-1) and the Tissue Inhibitor of Metalloproteases-1 
(TIMP-1).
Placenta Growth Factor (P1GF) is a member of the cysteine-knot 
family of growth factors. P1GF exists in three different forms with all the three 
isoforms differing from one another in the number of residues in the mature 
protein and their ability to bind heparan sulphate proteoglycans (HSPGs). 
P1GF-1 shares around 42% amino acid sequence identity with another growth 
factor, Vascular Endothelial Growth Factor-A (VEGF-A). In this study, the 
crystal structure of recombinant P1GF-1 was elucidated at both 2.0A and 
1.55A resolution. This study provides a structural basis for altered specificity 
of this molecule based on biochemical and mutagenesis data based on both the 
native structure of P1GF-1 as well as modelling studies on P1GF-1 with its 
tyrosine-kinase receptor, Vascular Endothelial Growth Factor Receptor-1 
(VEGFR-1). Also discussed in this thesis are some preliminary structural 
results obtained for P1GF-2 using Circular Dichroism.
Vascular Endothelial Growth Factor-B (VEGF-B) is another important 
member of the cysteine-knot family of growth factors. The molecule exists as 
two splice variants: VEGF-B167 and VEGF-B186. VEGF-B is a functional 
homologue of P1GF based on its binding specificity to VEGFR-1. However 
VEGF-B seems to be more similar to VEGF-A at the primary sequence level. 
Recombinant VEGF-Bio_k)8 (truncated form of VEGF-B167) was crystallised 
using 2,4-dimethyl pentane diol (MPD) as a precipitant by the hanging-drop 
vapour-diffusion method. X-ray diffraction data have been collected to 3.50 A 
resolution at 100 K using synchrotron radiation. The crystals belong to the 
hexagonal space group P6(4) with unit-cell parameters a = b = 121.62, c =
40.04.
The Matrix Metalloproteinases (MMPs) is a large family of zinc 
endopeptidases (26 members) characterised by the presence of a structural 
zinc ion. MMP activity is regulated by tissue-inhibitor of metalloproteinases 
(TIMPs). Preliminary diffraction studies on the crystals of the nTIMP- 
1»MMP-1:CD complex have been discussed. The crystals belong to C2 space 
group and diffract to 2.54 A resolution.
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C hapter I Macromolecular X-Ray Crystallography
1. INTRODUCTION
Macromolecular crystallography is a science that deals with the 
detailed study of the three-dimensional structure of macromolecules that form 
crystals using X-ray diffraction techniques. This structural information is of 
great importance because it provides a platform to elucidate the molecular 
mechanism of biological reactions mediated by macromolecules such as 
proteins and enzymes.
1.1 PRINCIPLES OF X-RAY DIFFRACTION
W. L. Bragg in 1913 was the first to elucidate the crystal structures of 
NaCl, KC1, KBr and KI using X-ray analysis (Bragg, 1913). This came as the 
final proof to establish the wave nature of X-rays. The electromagnetic wave 
nature of X-rays allows us to draw an analogy between the formation of an 









Fig 1.1 A schematic illustration o f the the analogy between (a) scattering and (b) 
diffraction. (Rays 1 and 2 represent the incident beam whereas Rays 1 ' and 2 ' represent 
diffracted beam making an angle 0 with PI and P2. . PI and P2 are a pair o f parallel 
planes with an interplanar spacing o f d
1
In the case of light rays (Fig 1.1a), the scattered rays may be combined 
using an objective lens to reconstitute the image of an object. This is the 
principle on which a light microscope works. However, since there is no lens 
capable of focussing X-rays, it is not possible to carry out a direct 
recombination of the scattered X-rays. In case of X-rays, a finely collimated 
beam is used to record the diffraction pattern, say for a protein crystal, on an 
image plate, a photographic film or a CCD detector.
Bragg’s Law
The scattering of X-rays by a protein crystal follows the Bragg's Law. 
The crystal planes are illuminated at an angle 0 and X-rays are scattered at an 
angle of reflection also equal to 0. Constructive interference between rays 
scattered from successive planes in the crystal will take place only if the path 
difference between the rays is equivalent to an integral number of 
wavelengths.
In Figl.lb, the separation between two successive planes of atoms is d. 
The path difference between the two rays is AB+BC = 2dsin0. Hence, for 
constructive interference:
2dsin0 = nX (Bragg's Law) 
where, X is the wavelength of the X-rays and n is any integer. This basic 
equation predicts the position of any diffracted ray in space. The closer the 
separation between the planes the larger is the diffraction angle.
1.1.1 X-RAY DIFFRACTION BY A CRYSTAL
A crystal is a regular arrangement of molecule(s), repeated 
translationally, on a three-dimensional lattice. This repeating motif is the unit 
cell, the basic block from which the whole volume of the crystal can be built. 
The edges of the unit cell are conventionally defined by three vectors a, b and 
c with axial lengths a, b and c respectively. The angles between these vectors 
are denoted by a, p and y as shown in Fig 1.2. A unit cell may contain one or 
more asymmetric units. An asymmetric unit is the fundamental repeating motif 
(made of one molecule or multiple copies of the same molecule), which is
2
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related to all the other identical motifs in the unit cell governed by symmetry 
rules. This format allows for compact packing of the molecules within the
Fig 1.2 The unit cell: a, b and c represent the unit cell axes in x, y  and z 
direction and a, ft and y describe the angles between these axes.
There are four basic types of symmetry operations possible for a 
crystal lattice: Rotation, Reflection, Inversion and Translation. Based on the 
highest rotational symmetry element present, crystals can be grouped into 7 
crystal systems and these can be further divided into 14 space lattices called 
the Bravais Lattices (Blundell and Johnson, 1976), depending upon the type of 
lattice (primitive or non-primitive) chosen to describe the unit cell {Table 1.1).
A combination of these symmetry elements gives rise to 230 space groups, of 
which only 65 are permitted for proteins.
Table 1.1 The fourteen Bravais Lattices
Name Bravais Lattice types Lattice
Triclinic P a=* b =£ c a * p  * y
Monoclinic P,C a *  b * c a  = y = 90° * p
Orthorhombic P, C, I, F a *  b * c
oOoIIIICO.IIS
Tetragonal P,I a=b * c a  = p = y = 90°
Trigonal P a = b * c a  = p = 90°, y=120°
orR p II cr II o P = p = y < 120°, * 90°
Hexagonal P a = b ^ c a  = p = 90°, y=120°
Cubic P ,I,F a =b = c a  = p = y = 90°
3
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1.1.2 THE CONCEPT OF RESOLUTION
The resolution of a crystal structure refers to the minimum interplanar 
spacing of the reflections included in structure determination. The unit of 
resolution is Angstrom (A = 10‘8 cm). Resolution is an important term in 
defining the quality of the structure of a macromolecule. The main features of 
the macromolecule that can be viewed at different resolutions are as follows 




1.5 A resolution 
1.0 A resolution
Outline of the molecule, secondary structure 
features such as helices and strands, can be 
identified.
Course of the polypeptide chain can be traced 
and topology of the folding can be established. 
With the aid of amino acid sequence, it is 
possible to place the side chains within the 
electron density map.
Main chain conformations can be established 
with great accuracy. Details of side chain 
conformations can be interpreted easily without 
amino acid sequence data. Bound water 
molecules, metal ions and cofactors can also be 
identified.
Individual atoms are almost resolved. It is 
possible to make out the solvent structure. 
Hydrogen atoms may become visible. It is also 
possible to see multiple conformations for some 
side chains.
1.1.3 FROM REFLECTIONS TO A 3-D STRUCTURE
In X-ray diffraction the dimensions of the scattering objects are of the 
same order of magnitude as the wavelength of the X-rays. The diffraction 
pattern appears for example, on X-ray film or on a detector screen, as an array 
of discrete spots. The spots where X-rays impinge are also called reflections 
because they emerge from the crystal as if reflected from planes of an atom.
4
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The darker the spot stronger is the intensity of the X-ray reaching that spot. 
The position of each spot gives the direction in which the X-ray was diffracted 
by the crystal. The array of points which form the vertices of the unit cells 
make up the Real space lattice. Because of the inverse relationship between 
the lattice points and the spots or reflections on the diffraction pattern is also 
known as the Reciprocal space lattice (Rhodes, 1993).
The diffraction pattern of a single molecule is called the molecular 
transform of that molecule. Since a crystal is basically a three-dimensional 
lattice where a molecule is repeated at each of its lattice points, the Fourier 
transform of the crystal is nothing but the product of the diffraction pattern of 
the molecule with that of the lattice. So, if a spot appears to be dark then it is 
because of the underlying molecular transform at that point and vice-versa.
Just like each vertex in the unit cell is assigned a set of three 
coordinates x, y, z, each individual reflection in the reciprocal space lattice is 
designated h, k, I. These are termed as the Miller indices. These indices 
characterise the crystal lattice in terms of a set of planes. They are a symbolic 
vector representation for the orientation of an atomic plane in a crystal lattice 
and are defined as the reciprocals of the fractional intercepts, which the plane 
makes with the crystallographic axes.
1.1.3.1 TREATING REFLECTIONS AS WAVES
The reflections are treated as waves because of the electromagnetic 
nature of the X-rays. Recombination of these waves produces the image of the 
molecules in the unit cell. The periodic function of a simple wave can be 
represented by the following equation:
f(x) = Fcos2II (hx + a) 
where, f(x) is the vertical height of the wave at any horizontal position x along 
the wave, F is a constant, which specifies the amplitude of the wave and a  is 
the phase of the wave. For each f(x) there exists another function F(h) which is 
the Fourier transform of the f(x) and the units of h are reciprocals of the units 
ofx.
5
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The sum of each simple periodic function is known as the Fourier 
series and the Fourier series that describes a diffracted X-ray is known as the 
Structure Factor Equation. Hence, for each reflection the sum of all the waves 
that describe that reflection is represented in terms of Structure Factor, F/,*/. 
Each reflection in the diffraction pattern carries information from each atom in 
the unit cell. So the structure factor for a diffracted ray can be written as:
FA*, = fl + C + f3 +....................... fn
where, 1, 2, 3............. n each represents an atom within the unit cell. Each
single term in the above series is called an atomic structure factor, fhki, which 
represents the contribution of a single atom within the unit cell to the 
reflection hkl.
Fhki = fj exp 2IIi (hxj + kyj + Izj)
where, fj is the atomic scattering factor of the atom j.
Atomic scattering factor is the integration of the individual 
contributions over the volume of an atom (which is taken as a single sphere of 
electron density). Since each element will have different number of electrons, 
the diffraction of X-rays by each element differs. The phase of a wave depends 
on the atomic coordinates x, y, z of the atom and is implicit in the exponential 
formula of the structure factor. Thus for a unit cell with n number of atoms, 
Fhki will be the sum of all the fhki values for individual atoms.
n
Fhti = Zf} exp 2Ili (hxj + kyj + Izj) 
j=i
The same equation, if considered in terms of contributions of the 
varying electron density from each atom in the unit cell can be rewritten as:
Fhu = J p (x,y,z) exp 2Ui (hxj + kyj + Izj) dV
V
where, V is the volume of the unit cell and p is the electron density of an 
element centred at x, y, z. Each element contributes to Fhki with a phase 
determined by its coordinates (x, y, z) (Blundell and Johnson, 1976; Rhodes, 
1993). When the scattered X-rays impinge on the detector or the photographic 
film, all the phase information is lost and what is recorded is only the energy
6
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or in other words the intensity of each diffracted ray. Intensity and Structure 
Factor are related to each other by the following equation:
I (h k l)  =  F (h k i ) 2
1.1.3.2. UNDERSTANDING THE DIFFRACTION PATTERN
The geometric construction by Ewald (Ewald, 1921) is a most useful 










Fig 1.3 The Ewald sphere construction
The above geometric construction shares the properties of Bragg's law. 
The angle between the incoming and outgoing beams is always two times 
theta. If the angle of the lattice plane with respect to the incoming beam is 
changed then the outgoing beam will change its direction but its endpoint will 
always be on the circle. The vector connecting the points of exit, of the 
diffracted beam and the direct beam, from the circle depends on the radius of 
the circle, R and the angle 0.
S = 2RsinO 
S = 2sin0/A, (R = 1 A.) 
where, S is the reciprocal space vector. When compared with Bragg’s Law, 
the length of the vector S corresponds to 1/d. If the center of the circle 
represents the origin of the real space, the point of its exit from the circle, the
7
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origin of the reciprocal space then a given reflection will only diffract if its 
reciprocal lattice point intersects the circle. This circle when extrapolated into 
three-dimensional space represents the Ewald sphere.
1.13 3 .  MOLECULAR TOPOLOGY: THE ELECTRON DENSITY
The X-ray beams are actually diffracted by the electron cloud that 
surrounds each atom. Diffraction by each electron in the atom should in 
essence reveal the electron density of the atom. Since the crystal lattice is an 
ordered array of molecules, the electron density can also be represented in 
terms of a periodic function. Since, Fhki is a Fourier transform of p (x,y,z) and 
Fourier transforms are reversible, electron density in essence is the Fourier 
transform o f the structure factors, which represents the hazy shape of the 
molecule (Blundell and Johnson, 1976; Rhodes, 1993).
p (x,y,z) = 1/V E S S  Fhkl exp[-2ITi (hx + ky +lz)
A k  /
1.1.3.4. THE PHASE PROBLEM
The Fhki in the above equation represents both the amplitude as well as 
the phase for a given reflection, hkl. So in order to calculate the electron 
density we need to know both the amplitude as well as the phase of the 
recorded reflections. But as the phase information is lost during diffraction 
data collection, it is not possible to elucidate a structure directly from the 
diffraction images. This fundamental hurdle in X-ray crystallography is 
termed as the phase problem. However, there are four principle methods used 
to determine the approximate phase angles of the protein structure factors:
• Multiple/Single Isomorphous Replacement (MIR/SIR) method: In this 
method a heavy atom is introduced into a protein structure and used as a 
marker atom to provide the initial phases.
• Multiple/Single Anomalous Dispersion (MAD/SAD) method: Phases 
are obtained from anomalous scatterers whose absorption frequency is 
close to the experimental wavelength.
• Combination of Isomorphous Replacement and Anomalous Scattering 
(MIRAS/SIRAS) method.
8
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• Molecular Replacement (MR) method: This method calculates the 
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Fig 1.4 A flow diagram representation o f the stages involved in structure 
determination
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1.2.1. CRYSTALLISATION OF PROTEINS
The order and symmetry within crystals is a reflection of their ability 
to diffract X-rays. Macromolecular crystals differ from small molecule 
crystals in being rather small in size with volumes not exceeding 10 mm and 
are also very fragile. Water molecules occupy about 30 - 80% of the crystal 
volume and only a small portion of the protein surface is involved in contacts 
with neighbouring protein molecules. The integrity of the crystal depends on 
the almost faultless repetition of the protein-protein interactions.
Crystallogenesis is a multi-parametric process and there is absolutely 
no definitive theory or a principle that can guarantee crystal growth. The idea 
however, is to bring a supersaturated solution to a lower, more stable energy 
state by reduction of solute concentration. The basic principles of protein 
crystallisation are the same in most respects as those for small molecules like 
salts or amino acids (Fig 1.5). This metastable protein solution might be 
achieved by a gradual change of various factors affecting crystallisation like 
precipitant or protein concentration, change of pH or temperature. The 
crystalline state when reached is usually thermodynamically most stable and 
of far lower solubility than the closest amorphous state. When the solution is 
in a metastable state, the crystal nuclei exist in a state of equilibrium of 
formation and dissolution. This continues till appropriate molecular aggregates 
or nuclears slowly reach a critical size from which the growth of the crystal 









Fig 1.5 The solubility curve diagram for crystallisation ofproteins
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1.2.1.1. FACTORS AFFECTING CRYSTALLISATION
Identification of the right condition, required to produce good 
diffraction quality crystals, can be a difficult task in view of the large number 
of conditions that need to be screened. The two most essential stipulations 
surrounding protein crystallisation are the purity and the availability of the 
protein sample. Even small amounts of impurities represent a high enough 
concentration in small volumes that are used during crystallisation 
experiments. This leads to contamination of the crystal lattice and hence poor 
quality crystals or more often than not, hinders crystal growth. Protein 
crystallographers also need to grow crystals of a substantial size, as intensity 
of the X-ray diffraction pattern from a crystal is roughly proportional to the 
crystal volume. Higher concentration of the protein means that more protein is 
available for crystal growth and therefore the probability of obtaining large 
crystals increases (McPherson, 1992; Ducruix and Giege, 1999). Factors 
affecting solubility of proteins are as follows:
• Ionic Strength- The ionic strength of the solvent changes the 
interactions of the ions with the water molecules and thus modifies the 
solubility. At low concentrations solubility of the proteins tend to increase as it 
increases the possibilities of favourable interactions with the water molecules. 
Proteins are known to be more soluble in the presence of small amounts of 
electrolytes than in pure water. This phenomenon is known as 'salting in'. As 
the ionic strength increases the ions added begin to compete with each other 
and the surrounding protein molecules for the surrounding water. The 
resulting removal of water molecules from the solute begins to decrease the 
solubility. This phenomenon is known as 'salting out'. These phenomena 
indicate that one may decrease the solubility of the protein dissolved in a 
medium of low ionic strength by increasing or decreasing the concentration of 
ions in an attempt to induce crystallisation of proteins.
• pH  and Counter Ions- The net charge on proteins can be 
modified by adding or withdrawing protons i.e. by changing the pH or by 
specifically binding ions to the polar groups of the protein. The more the net
11
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charge a protein contains the more soluble it is. The point of least solubility is 
when the protein has a net charge of zero. This is the isoelectric point. The 
solubility in the absence of electrolytes changes with pH and shifts the 
conditions for salting out. The solubility reaches a minimum in the region of 
isoelectric point and increase on the addition of either acid or base at this 
point.
• Temperature- Temperature coefficient of solubility varies from 
protein to protein, and with conditions such as ionic strength and presence of 
organic solvents. Variation of temperature at high ionic strength and pH 
affects the solubility of proteins in the absence of electrolytes. At high ionic 
strength most proteins are less soluble at 25°C than at 4°C. The solubility 
sometimes decreases ten-fold on warming up a protein in ammonium sulphate 
solution. The negative temperature coefficient of solubility of proteins is 
characteristic only of high ionic strength media. At low ionic strength media 
the solubility increases with increasing temperature. In pure water the 
temperature coefficient is positive for most proteins.
• Organic Solvents- The addition of organic solvents also 
produces marked changes in the solubility of proteins in aqueous solutions. 
This is because of decrease in the dielectric constant of mixtures of water and 
organic solvents when compared to the dielectric constant of water alone. This 
decrease increases the attraction between unlike charges on the protein 
molecules and lowers the solubility. Generally the protein solubility decreases 
with decrease of temperature when substantial amounts of organic solvent are 
present. Organic solvents often denature proteins and this could be minimised 
by crystallizations at low temperature (Blundell and Johnson, 1976).
1.2.1.2 METHODS FOR PROTEIN CRYSTALLISATION
There are different methods that can be employed to set up 
crystallisations.
1. Batch Method- The traditional approach to crystallisation is the batch
method, which involves adding precipitant or changing the pH until the
12
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protein comes to the limit of its solubility. The major limitation of batch 
experiments is that the precipitant conditions remain static and it also 
consumes a lot of the protein sample. The only change in the time course of 
the experiment is the decrease in the protein concentration.
2. Dialysis- Dialysis procedures have also been quite successful where a 
range of precipitant conditions are automatically screened but the protein 
concentration remains constant. Dialysis methods are not economical on the 
protein but they do allow more flexibility, as amorphous precipitates in failed 
attempts to produce crystals can be re-dissolved with appropriate solution 
placed outside of the chamber, and another condition tested with the same 
sample.
3. Vapour Diffusion- Vapour diffusion has been the most successful 
method used to date. In this method, evaporation of the protein solution is 
controlled by equilibration against a reservoir a slightly higher concentration. 
As the two solutions tend towards equilibrium, the solvent is transferred from 
the protein solution to the reservoir through the vapour phase. This makes the 
protein solution more concentrated and thus crystals tend to form by achieving 
supersaturation in the drop. The protein drops can either be suspended from 
siliconised cover slips used to seal the reservoir contained in a vessel {hanging 
drop; Fig 1.6a), placed on a support above the reservoir {sitting drop; Fig 
1.6b) or by placing the drop sandwiched between the support and the coverslip 
{sandwich drop; Fig 1.6c). Vapour diffusion has the benefit of automatically 
screening a range of precipitant concentrations. It allows for optimising a 
crystallisation so that the precipitant concentration slowly reaches the 
nucleation region of the solubility phase diagram and thereafter increases just 
fast enough to compensate for the loss of protein to the crystals. This requires 
not only optimising the end point of the experiment but also the rate of 
equilibration. The simplest way to vary the rate of equilibration is to vary the 
surface to volume ratio (the size) of the drop. In general, larger drops 
equilibrate more slowly than the smaller drops (Blundell and Johnson, 1976).
13
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a)
>  siliconised coverslip 








>  siliconised coverslip
->> sitting drop 
—>  well
->► reservoir solution 
^  Microbridge
c)
>  siliconised coverslip 
>  sandwich drop
well
>  reservoir solution
Fig 1.6 The different physical techniques o f protein crystallisation involving the 
vapour diffusion method.
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4. Gel Crystallisations- In recent years, the application of gels in 
crystallisation has been the focus of ever increasing attention. The gels mainly 
used for bio-molecular crystallisations are hydrogels like silica gel and agarose 
(Robert et al., 1999). There are several gel properties related to crystal growth 
that are making them a popular alternative to the conventional solution 
techniques. Some of these advantages are as follows:
a) In a gel network, there is no convection as a result of which the 
mass transfer from solution to the crystal proceeds only by 
diffusion
b) Crystals grow uninterrupted at their nucleation site and do not 
sediment like they do in free solution.
c) Nucleation occurs homogeneously in the whole volume and 
they usually appear at the same time. Gels have also known to 
show reduced heterogeneous and secondary nucleation thereby 
preventing a shower of tiny crystals.
All the current methods of protein crystallisation like the batch method and the 
vapour diffusion method can be used to grow crystals either outside or inside 
the gel instead of free solutions.
5. Seeding- Seeding is more of a technique for optimising a screened 
condition than a method on its own. A seed (usually a tiny crystal or part of a 
crystal) acts as a template for the assembly of macromolecules. The addition 
of a seed to an already equilibrated drop redistributes the protein separated 
between the solution phase and the aggregate phase. This disturbs the 
equilibrium and thus slows down the rate of crystal growth. Seeding helps to 
partition nucleation phase from crystal growth. The most important stage of 
seeding is the pre-seeding stage. In this stage, the protein solution to be seeded 
is pre-equilibrated with the crystallisation solution in such a way that 
spontaneous nucleation is avoided before the introduction of the seed. Seeding 
can be done using four different methods. These methods are:
a) Streak seeding: This is usually used as an analytical method to 
determine the conditions, eg the supersaturation threshold, that 
would be most suitable for seeding to succeed.
b) Microseeding: In this method, microscopic crystal fragments
15
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are introduced into a protein solution.
c) Macroseeding: In this method, a single crystal is introduced 
into a pre-equilibrated protein solution.
d) Epitaxial nucleation: Impurities like the cellulose fibres 
sometimes provide surfaces that are suitable for bio- 
macromolecular crystal growth.
1.2.2. DIFFRACTION DATA COLLECTION
Protein molecules crystallise with large unit cell when compared to 
small molecules, and a large number of reflections have to be measured at any 
given resolution. Therefore, an efficient method of data collection is required 
to make the measurement of intensities as precise as possible and at the same 
time minimize the exposure time of the crystal to the X-ray beam.
1.2.2.1 X-ray Sources and Detectors- X-ray sources are of two types: 
Laboratory sources and Synchrotron radiation sources. The X-rays are 
produced in laboratories either by sealed tube sources or by a copper-rotating 
anode (fixed wavelength of 1.5418A for Cu-Ka radiation). Although they are 
very convenient and reliable, they produce about 100-1000 times less flux than 
the sources at the synchrotron. Synchrotron sources, on the other hand, 
produce electromagnetic radiation by an electron storage ring. The X-rays are 
produced when the electrons are radially accelerated by electric fields in a 
linear accelerator to reach a final energy of lGeV to 8GeV (Helliwell, 1997). 
The electrons within the storage ring are constrained to move in a circular path 
using magnetic fields. The X-rays are produced when the electrons change 
direction in the magnetic devices. The current of the beam decays with time in 
the storage ring because of loss of electrons. Hence the beam is regularly 
dumped and the storage ring is refilled with fresh beam, usually at about 
300mA. These X-rays are very intense and hence very well suited for very 
small crystals. Even crystals that diffract very weakly at the laboratory sources 
are able to give data with better signal-to-noise ratio at the synchrotron 
sources. This gain in intensity translates into a very short exposure time and 
therefore fast data collection. Protein crystallography has benefited to a great
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extent from the synchrotron sources because of the highly monochromatic and 
tunable nature of the beam as well as the good detector systems like the 
present day CCD systems. The ability to choose wavelengths to collect 
diffraction data at the absorption edge of a heavy metal has made isomorphous 
replacement and anomalous dispersion experiments, a routine, everyday 
research tool for phasing. The national Synchrotron Radiation Source (SRS) is 
situated in Daresbury, UK (http://www.srs.ac.uk/srs). The SRS has a 2GeV 
electron storage ring that offers a variety of experimental facilities with 
provision for simultaneous, multi-user experiments requiring a range of 
radiation from infrared rays to X-rays.
1.2.2.2 Crystal Mounting- The type of data collection governs the method 
employed for crystal mounting. For room temperature data collection, the 
crystal is drawn into a thin-walled glass or quartz capillary tube by suction. 
The excess mother liquor is then removed using thin strips of filter paper. 
Usually a very small quantity of mother liquor is left surrounding the crystal 
before both the ends of the tube is sealed off with wax, as shown in Fig 1.1a, 
to prevent the crystal from drying up. Also the surface tension of the mother 
liquor surrounding the crystal prevents it from slipping within the capillary. It 
is important not to let the crystal dry up because it affects their diffraction 
quality. On the other hand, it is also important that the crystal is dry enough so 






^  crystal coated with 
cryoprotectant
b)
Fig 1.7 Crystal mounting methods: a) Capillary tube method and b) loop 
method
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Data collection of biological macromolecules these days is usually 
performed at temperatures ranging between 80-100 K. Ciyo-techniques have 
become a pivotal tool in crystallography because of the higher quality of data 
collected at these temperatures in comparison to those collected at room 
temperature. The technique usually used for cryogenic data collection is the 
loop mounting method (Teng, 1990; Rudman, 1976). In order to collect data at 
freezing temperatures it is necessary to prepare a cryoprotectant or a 
cryosolution, which is usually made up of the mother liquor and an anti-freeze 
[e.g. Glycerol, MPD (2, 4-dimethyl pentane diol)]. The crystal is dipped in the 
cryoprotectant and mounted on to a loop (Fig 1.7b) made up of a very thin 
fibre (e.g. nylon or mohair) where it is held by means of the surface tension of 
the liquid. The crystal is then immediately placed under a direct stream of a 
cryogen or plunged into a cryogen at around 100 K. The cryogen commonly 
used is liquid nitrogen. The liquid nitrogen solidifies the thin film of the 
cryosolution in the loop and thus holds the crystal in place. The anti-freeze in 
the solution prevents ice formation around the crystal during data collection 
(Garman and Schneider, 1997). Data collection at such low temperatures 
prolongs the life of a crystal and reduces radiation damage and thus, in most 
cases, makes it possible to collect an entire dataset from a single crystal.
1.2.2.3 Steps in Data Collection - The process of data collection is not just a 
mere technique but is a scientific process that needs important decisions to be 
input by the experimenter in order to collect data of high quality and as 
complete as possible. The completeness of the data in terms of quantity 
depends a lot on the geometry of the crystal lattice and the detector set up. The 
qualitative completeness of the data depends on the strategies employed 
during the process of data collection. Factors influencing quality of data 
(Dauter, 1997) are as follows:
• Oscillation (rotation) Method: As understood from the Ewald
sphere construction, Bragg’s Law is fulfilled only if the reciprocal lattice point 
lies on the surface of the Ewald sphere. This gives rise to a diffracted beam. 
For any given orientation of the crystal, only a few reflections will lie on the 
surface of the Ewald sphere. So in order to collect a complete dataset, in terms 
of the number of recorded reflections, the crystal is rotated about a single axis.
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That is, successive reciprocal lattice points are moved to the surface of the 
Ewald sphere (the radius of the sphere is constant because of the use of 
monochromatic X-rays) to observe diffraction from a different set of 
reflections. The reciprocal lattice points are arranged in planes and each plane 
of reflection projects on to the detector as an ellipse. The ellipses from a 
family of parallel planes form a lune. These lunes are more pronounced if the 
reciprocal lattice planes are perpendicular to the X-ray beam. Hence, the axis 
along which the crystal is rotated during data collection is perpendicular to the 
beam. Since the axes perpendicular to the rotation angle are limiting to the 
data collected, the crystal is always aligned along its longest dimensions 
(Dauter, 1997).
• Crystal Mosaicity (partial and fu lly  recorded reflections): Mosaicity 
is a measure of the angular range over which a given reflection satisfies to the 
trigonometric condition of Bragg’s law (nX = 2dsin0). The Ewald sphere 
represents a situation where the reciprocal lattice points are dimensionless, i.e. 
perfect points. However, in the real case scenario, the crystals are made of 
molecules, all of which do not share the same orientation. And because the X- 
rays are monochromated to a defined narrow wavelength window, the Ewald 
sphere gets broadened, causing diffraction by a particular reflection to spread 
over a range of crystal rotation and period of time. This causes the reflections 
to start diffracting during one exposure and finish in the next time interval. As 
a result these reflections are termed partial reflections as their intensity gets 
divided over two or more images. Full reflections are those reflections whose 
intensities get recorded on a single image. The higher the mosaicity more are 
the number of partial reflections recorded, as the lunes are wider which tend to 
overlap. When the mosaic spread equals the oscillation range, there are only 
partial reflections recorded and is it not possible to distinguish the individual 
lunes on the diffraction images.
• Oscillation: The optimal rotation angle is usually decided upon after
the diffraction quality of the crystal is assessed from the first image. The 
degree of oscillation chosen depends on several factors like mosaic spread, the 
ciystal-to-detector distance and the unit cell dimensions. It is important to 
select the rotation range per single exposure in such a way so as to avoid
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overlapping of the lunes. The total rotation range depends on the crystal 
system as discerned after indexing the first diffraction image as well as the 
crystal orientation. It is one of the most important factors that govern data 
completeness. Since a 360° of data is always at the expense of the expensive 
beam time at the synchrotron sources, the strategy employed is to reach high 
completeness as soon as possible with all the unique reflections measured at 
least once. However, with the modem day fast data collection techniques it is 
possible to collect a highly redundant data to decrease the errors in intensity 
measurements.
• Crystal-to-detector Distance: This helps in deciding upon the 
maximum obtainable resolution for collecting data from a crystal. The 
distance also affects the spot size in the diffraction pattern. Thus the distance 
set should be such that the reflection profiles are resolvable and are not 
overlapping. In cases where one of the unit cell dimensions is large, data 
collected at the maximum diffraction resolution would have more number of 
partially recorded reflections as compared to the fully recorded reflections. 
This would decrease data completeness. Hence, it is always better to trade off 
resolution in favour of data completeness.
• Wavelength: The wavelength of the laboratory sources is usually 
fixed at the value characteristic for the metal of which the rotating anode is 
made of (1.5418A for Cu-Ka radiation). However, at the synchrotron 
wavelength can be chosen according to the nature of the experiments, e.g. 
different wavelengths can be chosen according to the anomalous scatterer or 
heavy atom for a MAD or MIR experiment. For native data collection, any 
wavelength will do, especially as the beam intensity at the synchrotrons is 
quite high. Usually shorter wavelength is used because it is favourable for 
high-resolution data collection and reduces radiation damage by crystals.
• Exposure Time: This factor controls the intensity of each 
reflection. Longer exposure times is useful in recording the high-resolution 
weak reflections. However, this leads to saturation of some spots (or 
reflections). These are referred to as overloads. This problem can be overcome 
by collecting low-resolution data with shorter exposures.
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1.2.2.4 Preliminary Characterisation o f the Crystal- A crystal form of a 
protein can be initially characterised from the diffraction pattern. Most 
importantly the unit cell dimensions and the space group in which the protein 
has crystallised can be inferred from the inter-spot spacing and the symmetry 
of the diffraction pattern, and possibly the systematic absences of some 
reflections. The ratio of the volume of the unit cell to the molecular mass of 
the protein contained in the cell gives the solvent content of the crystal 
(Matthews, 1968). If the molecular mass is known, then the number of protein 
molecules in the asymmetric unit can be deduced from the unit cell 
dimensions and the space group. The crystallographic space group can 
sometimes provide information on the symmetry present in the quaternary 
structure of an oligomeric protein (Louie, 1995).
1.2.2.5 Data Integration and Reduction- Data processing essentially means 
to index each reflection in the diffraction pattern and in turn all the diffraction 
patterns in the dataset. There are several software packages that use different 
algorithms, which are applied with the aim of reducing raw data into a set of 
indices for each reflection and the corresponding measured intensities of each 
spot in the diffraction pattern. The commonly used packages are the 
MOSFLM (CCP4, 1994) and the HKL package (Otwinowski and Minor, 
1997). The HKL package comprises of DENZO, which helps in the analysis of 
each image mathematically, the XdisplayF, which helps to visualise the each 
image/diffraction pattern and SCALEPACK, which helps in scaling the 
processed data.
Data processing involves autoindexing of the spots to determine the 
unit cell dimensions and the space group of the crystal lattice. The program 
writes out a list of probable lattice types on the basis of the symmetry rules in 
the International Tables for X-ray Crystallography in the International Union 
of Crystallography, Vol I (Henry and Lonsdale,1952). The space group used 
as the input for the rest of data processing is the one that has highest symmetry 
with least percentage of distortion. Once data is processed, the program 
SCALEPACK is used to average and merge the processed data taking into 
account the errors, which appear due to air and crystal absorption, crystal 
decay etc. The output of the scaling process is a list of reflections with
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systematic absences characteristic of the space group determined earlier 
during autoindexing. The quality of the processed and scaled data can be 
assessed by three values:
• Percent completeness: Higher the percentage of complete data,
more is the information held by the processed data.
•  R Sym ' This is the estimate of the disagreement between the measured 
and the observed intensities. The value of depends on data multiplicity. 
The lower the (the disagreement) higher is the data precision although 
this value increases with higher multiplicity. This value is called Rmerge when 
more than one dataset are scaled together.
R mewc — “  (h k l)\im ,W h k l)‘
hid i hJd
The removal of outliers from the merging process improves the Rmerge 
value. The percentage of rejected outliers should not be more than 1% because 
this will decrease data multiplicity and thus adversely affect data quality. Also 
weak reflections should not be removed from the merging process as the 
weaker intensities also contain some information and their removal can 
introduce intensity distribution bias. An overall Rmerge of up to 10-12% is 
within the accepted range for a 2.0A dataset.
• I /d :  a l is the error in measuring the intensity of a reflection. 
Basically, if the value of I/crl is 1.0, the intensities can provide some reliable 
information. However, the acceptable resolution limit for scaling data is 
usually where the value of I/ctI is above 2.0.
1.2.3. DETERMINATION OF PHASES - STRUCTURE SOLUTION
We need both amplitudes and the phases to calculate an electron 
density map. F/,*/ is a vector quantity that comprises of the amplitude, |F^/| and 
its phase, a/,*/. Thus, the electron density equation can be written as:
p(x, y, z) = 1/V S E E  |Fm/| exp[-2ITi (hx + ky +lz - a**#)
h k I
What is known from this equation is the frequency of the wave and the
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amplitude of the wave, which is the square root of the measured intensity, Ihid 
of the reflection hid. The information that we cannot access from the 
experimental data is the phase or the angle at which the X-ray is diffracted. 
Thus we are faced with what is known as the “phase problem” (Blundell and 
Johnson, 1976).
There are various methods to evaluate or approximate the phases 
required to reconstruct a three-dimensional structural image from experimental 
diffraction data. All of them are somewhat indirect since there is no direct 
method to obtain phases from diffraction measurements. Determination of 
phases is a very important step in macromolecular crystallography since an 
erroneous phase will lead to an inaccurate electron density map and thus result 
in wrongly determined structure. There are three major methods used for 
obtaining the phase information:
1.2.3.1 ISOMORPHOUS REPLACEMENT
Max Perutz and his co-workers pioneered the use of Isomorphous 
Replacement method (Green et al., 1954). This classical method is usually the 
pre-dominant method for initial phasing when a close structural homologue of 
the protein in question is unavailable. A number of heavy atoms have been 
used quite successfully in crystal structure analyses. The historic example of 
horse haemoglobin made use of mercury (Hg) and silver (Ag) compounds 
bound to a sulphydryl group on the surface of the molecule. Since then this 
method has proven to be a milestone in protein phasing.
The screening of suitable heavy atoms is a rate-limiting step next to 
crystallisation. Stabilising solutions like the mother liquor in which the 
crystals can be maintained for long periods of time expedite the search for 
heavy atoms. The stabilising solution is of a similar condition as the reservoir 
in which the native crystals grew but with higher precipitant concentration. 
The stabilising solution, because it lacks in protein, should compensate for its 
absence and not affect the quality of crystal diffraction (Rould, 1997). The 
chances of obtaining an isomorphous derivative increases if a single 
stabilising solution is used for native as well as derivative data collection. The
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term isomorphous derivative means a crystal where a few heavy atoms replace 
some of the water molecules without changing the unit cell dimensions or the 
structure of the protein itself.
Protein crystals are usually derivatised by direct soaking of the crystals 
in the heavy atom solution. Binding of the heavy atom to a specific position 
on the protein surface is driven by entropy within the crystal. As a result, 
usually the binding of heavy atoms lacks specificity or the sites may only be 
partially occupied. A good heavy atom derivative depends on the amino acid 
sequence, the spatial arrangement of the side chains in the tertiary structure of 
the protein, the heavy atom compound, pH as well as the concentration of the 
buffer used. Strategy for screening for derivatives involves different stages. 
The search for derivatives should coincide with availability of beam time at 
the synchrotron radiation sources and lots of good crystals (Rould, 1997; 
Blundell and Johnson, 1976). The heavy atom solution used for soaking 
contains very low concentration of the heavy compound. The right 
concentration, which does not destroy the crystal, is usually found by a trial 
and error method, starting with the highest possible concentration and smallest 
crystals. A good heavy atom solution is the one in which crystals when soaked 
do not show loss of birefringence and do not exhibit decrease in diffraction 
quality or increase in mosaicity. A good isomorphous derivative will show 
significant isomorphous differences between the native and the derivative 
dataset without changing the native crystal lattice (a change of up to 5% is 
normally within acceptable limits).
An initiative undertaken by Islam et a l (1998) resulted in a 
computer-based archive of experimental as well as derived information. This 
is the Heavy Atom Databank (HAD). It provides a wealth of information on 
crystal structures solved so far with the use of heavy atoms and the 
coordinates of the heavy atoms. HAD is an assembly of information based on 
the analyses of the various successes and failures faced by protein 
crystallographers, in preparation of heavy atom derivatives 
(http ://www.bmm. icnet.uk/had/)
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• Isomorphous Replacement Equation
The structure factor equation representing the ‘n’ number of atoms of 
the native or parent crystal, P, is
Fp(hkl) = S /p  exp 2TIi (hxp + kyp + lzp)
Similarly, the structure factor equation for the ‘m’ number of heavy 
atoms, H, can be represented as:
FH(hkl) = 2 /h  exp 2ni (hxH + kyH + lzH) m
The derivative will contain the heavy atoms in addition to all the light 
atoms in the native crystal. Hence, the structure factor equation for an 
isomorphous derivative (FPH) will be equal to the sum of the structure factor 
of the protein (FP) and the heavy atom (FH).
Fph = Fp + Fh
The contribution of heavy atoms to the overall intensity is not 
proportionate and hence they change the scattered intensity quite significantly 
when introduced into a crystal lattice. This allows for the change to be easily 
measured (Ke, 1997).
Fig 1.8 Vectorial representation o f structure factor for the derivative, 
protein and the heavy atom
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• Single/Multiple Isomorphous Replacement (SIR/MIR) method
Vectorial representation of the structure factors (Fig 1.8) helps one to 
visualise the above equation as a triangle where the lengths of all the three 
vectors defining the three sides of the triangle are known. Since we also know 
the orientation of Fh all that remains is to calculate the phases for Fp using a 
simple equation:
F2rh = F2p + F2h +FPFh cos0
From the above equation it is obvious that there are two possible 
phases for Fp depending upon how the triangle is drawn as illustrated in Fig 
1.9.
Fph
Fig 1.9 Two possible ways to calculate phases for the protein depending 
on the way the triangle is constructed
The ambiguity in the choice of the right phase can be overcome by the 
use of a second heavy atom derivative that binds to the protein at sites 
different from the first one. The information derived from the second/third 
derivative will be consistent with all the observations for only one of the two 
phases. The more the number of derivatives lesser is the phase ambiguity. The 
steps involved in structure solution using the MIR method can be summed up 
with following flow-chart (Fig 1.10).
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Scale each derivative 
dataset to the native dataset
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Location of heavy atom sites by
calculating isomorphous
difference Patterson maps
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x
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Calculation of initial phases
Calculation of difference 
Fourier to locate other 
heavy atom sites
jj
Calculation of protein phases 
and electron density map
Fig 1.10 Steps involved in Multiple Isomorphous Replacement method.
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• Patterson Function
Phase information from the heavy atoms can be obtained by 
determining their positions. The Patterson function (Patterson, 1934) is a very 
valuable tool towards this end. Patterson function is a Fourier transform of the 
measured intensities. The resultant Patterson map, calculated using the 
experimental intensities, represents vectors between the scattering objects 
within the unit cell.
In a protein with N number of atoms, there will be N number of self­
vectors and N (N-l) number of cross-vectors. The self-vectors appear as large 
peaks. They are also known as the origin peaks because a vector between an 
atom in one cell and the same atom in a neighbouring cell will always fall on 
the origin. Since the density in the Patterson map corresponds to the square of 
the number of electrons present in the scattering atom, heavy atoms tend to 
dominate the map by virtue of having more number of electrons than the 
lighter atoms usually found in a protein structure. The Patterson map is a 
collection of set of both self and cross vectors and hence densities depend on 
the number of atoms present as well. As a result there is a lot of overlapping 
of both self and cross peaks. The self vectors can be removed by subtracting 
the average intensity from I(hki) before Fourier transformation. But despite this 
the Patterson map remains non-interpretable. However, only heavy atom 
peaks dominate a Patterson map calculated from isomorphous difference 
amplitudes. Such a Patterson map is an invaluable tool for determining the 
initial phases for the macromolecule (Blundell and Johnson, 1976).
Patterson-space unit cells are of the same dimensions as real-space 
cells. The dimensions of Patterson vector space are called (u, v, w) and these 
correspond to the x, y and z dimensions of real space. Patterson maps are 
centrosymmetric as they contain equal peaks corresponding to a vector 
between atom 1 and atom 2 and a vector from atom 2 to atom 1. The height of 
the Patterson peak is proportional to the product of the heights of these two 
peaks in the electron density map.
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Heavy atom sites in a second derivative can be located by calculating a 
difference Fourier transform using weighted phases calculated from the first 
derivative (Fph2 -  F 0b s). Also, a double difference Fourier can be calculated 
using phases calculated from the known positions of a derivative to locate 
further sites of the same heavy atom in that derivative (F p h i -  ( F p  + F h )).
• Harker vectors and Harker sections (Harker, 1956)
The peaks in a difference Patterson map represent vectors between all 
pairs of heavy atom sites within the unit cell of a crystal. The vectors between 
symmetry-related atoms are known as the Harker vectors. The Patterson peaks 
generated by symmetry operations are found on Harker sections. These harker 
sections tell us the location of the atoms relative to the cell axes. Inter-atomic 
peaks not related by symmetry fall on non-harker sections.
• Refinement of heavy atom parameters
The basic idea behind refinement of heavy atom parameters is to 
minimise the error between the calculated value of |Fph| and the measured 
value to produce a set of parameters that best fitted the measurements. There 
are several programs that can be used to bring to convergence these two 
values. Perhaps the most popular by far is MLPHARE (Collaborative 
Computational Project, 1994) and SHARP (de La Fortelle and Bricogne, 
1997). The MLPHARE program uses the maximum likelihood method of 
refinement to arrive at a set of parameters that maximises the likelihood of the 
measurements being correct by evaluating all possible phases during 
refinement.
• Statistics
One of the difficulties usually faced is, not knowing, if the heavy atom 
positions found are correct. There are several indicators that can be used to 
monitor the progress of refinement and to adjudge a heavy atom derivative as 
valid. These quantities are as follows:
1) Real Occupancy
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2) Rcuiiis: Reduction in Rcuiiis (Cullis et al., 1961) as a function of 
resolution is the most useful signal for a useful derivative. It is the ratio of the 
lack of closure to the isomorphous difference. The lack of closure, €j, is 
graphically illustrated in Fig 1.11. Isomorphous differences are the differences
^  lack of closure
G j -  F p h  (Obs) -  F p h  (calc)
Fig 1.11 A vectorial representation of the lack of closure.
in the intensities o f  the reflections (acentric or centric) between the native and 
the derivative dataset. Rcuiiis (centrics) < 0.6 is considered to be very good 
whereas if  Rcuiiis is between 0.6 and 0.9, the derivative is only just usable. A 
site is considered to be probably incorrect if  its addition does not reduce the 
Cullis R-faCtOr (Rcuiiis)-
R cuiiis =  Z  1 1 F p h  ±  F p  I -  F h  (calc) 1
X I Fph - Fp |
3) Phasing power. This value should increase with resolution. A phasing 
power of up to 0.5 is usable and if it is more that 1.5 then it is considered an 
excellent derivative.
PHASING POWER = |F h |  / probability-weighted lack of closure
4) Figure o f Merit: the higher the figure of merit the better would be the 
phases derived from the derivative (Please refer to Appendix B (Page 176) for 
the definition of Figure of Merit).
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1.2.3.2 ANOMALOUS SCATTERING/DISPERSION METHODS
Anomalous Scattering/Dispersion is another technique used in 
macromolecular crystallography to determine phases. These phasing methods 
are commonly known as Multiple/Single Anomalous Dispersion (MAD/SAD) 
methods. Like the isomorphous replacement method, it also exploits the 
abrupt changes to the scattering power (diffraction) of heavy atoms near their 
absorption edges (Hendrickson et a l, 1985). The light atoms in the unit cell 
do not have absorption edges near the wavelength of the X-rays used in 
crystallography. The changes in diffraction result in differences between the 
reflections measured at different wavelengths.
The principle behind anomalous scattering breaches the Friedel’s Law, 
which states that members of a Friedel pair have equal amplitudes but 
opposite phases, where the Friedel pair are Bragg’s reflections related by an 
inversion through the origin. This method is useful when the protein has a 
metal ligand attached to it like in metalloproteins.
\Ffikl\ F/jfr/l tyhkl ty/ikl (Friedel’s Law)
When X-rays of high energy are incident on the atoms in a protein 
molecule, some photons are scattered normally. Whereas some photons are 
absorbed and re-emitted at a lower energy when the wavelength of the X-rays 
is strongly coupled to the absorption energy edge of the scattering object. 
Hence, the normal atomic scattering coefficient fo of the scattered photon 
gains an imaginary component to its phase, i , or in other words the photon 
scatters with a phase delay. Since f* is always positive both the amplitude and 
the phase relationship do not hold true when some atoms in the crystal lattice 
scatter anomalously. The scattering factor for the atom can be written as:
f = f 0 +  A f  + i A f "
where, Af is the dispersion component of the anomalous scattering and Af1 is 
the imaginary absorption component. Both Af and Af' are sensitive to 
wavelength especially near the absorption edge. The absorption coefficients
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for the light atoms are small enough to be ignored. However, for the 
anomalous scatterers, these coefficients cannot be ignored, especially as the
x-ray energy (eV)
Fig 1.12 Schematic representation o f hypothetical values o f f'and  f "  as 
a function o f X-ray energy
absorption edge for these elements is close to the wavelength of X-rays 
commonly used. By applying mirror symmetry on these complex structure 
factors Fp, Fh and Fph for the reflection (-h-k-1) through the real axis so that 
they superimpose on those for the reflection (hkl), it will be seen that |F p h +| 
and |F p h -| are unequal, i.e. Friedel's relation no longer holds.
It is obvious from Fig 1.12 that the change in both the dispersion 
coefficient (real part) and the absorption coefficient (imaginary part) is 
dependent on wavelength. This is indicative of the fact that the diffraction 
images collected at different wavelengths especially near the absorptional 
edge of the anomalous scatterer present would show differences. These 
anomalous differences are equivalent to isomorphous differences and are thus 
used to calculate the initial phases. The advantage of these changes in the 
diffraction pattern at different wavelengths is that they are perfectly 
isomorphous changes as the data is collected from the same crystal at all 
wavelengths. Hence, the data is not subject to errors on account of non­
isomorphism. The tunable nature of wavelength at the synchrotron radiation 
sources is of much importance in such experiments. Some commonly 
available anomalous scatterers are Sulphur, Iron and Zinc. In the modem 
times, molecular biology techniques are also being used to aid MAD/SAD
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experiments. For example by substituting sulphur in methionine residues with 
selenium (selenomethionine derivative), replacing the N-terminal amino acid 
of the protein with a heavy atom modified amino acid, or iodination of the 
tyrosyl side chains. The steps involved in a MAD/SAD data collection 
experiment can be summed up in the following flow-chart (Fig 1.13).
Fluorescence scan about the absorption 
edge (depends on the anomalous 
scatterer)
Excitation scan to make sure that the 
crystal does contain an anomalous 
scatterer
Wavelength selection
Selection of distance and 
exposure times at different 
wavelengths
Data collection begins
Fig 1.13 Steps involved in MAD/SAD data collection.
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1.2.3.3 MOLECULAR REPLACEMENT
Molecular Replacement method is a technique that determines the 
orientation and the position of a molecule in the unit cell using a previously 
solved structure as the search model (Rossmann and Blow, 1962). The method 
works mainly by computing three rotation angles to correctly orient the model 
and then by searching for the translation vector, to place the search model in 
the unit cell of the unknown protein. The search model can come from various 
places. It can be a structural homologue, NMR model, a mutant of the native 
protein or the structure of the same protein but solved in a different space 
group.
UNIT CELL OF THE TARGET MOLECULE
ROTATION







Fig 1.14 A schematic illustration o f the Molecular replacement method.
Traditionally the molecular replacement methods were based on 
Patterson function properties. A Patterson function can be computed without 
phase information. When the Patterson map calculated from the observed 
intensities is rotated against itself, i.e. when the search and the target functions 
are the same, the resulting function is known as the self-rotation function. This 
helps in computing the rotational non-crystallographic symmetry (NCS). On 
the other hand, when the Patterson map calculated from the observed 
intensities is compared with that computed from the atomic coordinates of the 
structural homologue, the rotation function describes the cross-Patterson 
vectors. So, if the search model is properly oriented and placed in the unit cell 
then the observed and the calculated Patterson maps should have similar 
features. This is the cross rotation function that exploits the intra-molecular 
vectors of the Patterson function, as they are independent of the position of the
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atoms within the unit cell. The translation function, as opposed to cross­
rotation function, exploits the inter-molecular Patterson vectors, which depend 
on both the orientation as well as the position of the molecule within the unit 
cell. The overlap between the observed and the calculated Patterson map is 
quantified by multiplying the corresponding peaks in both the maps, which is 
maximum when the two Patterson maps overlap best. The success of 
molecular replacement depends on various parameters:
• Sequence homology: The general rule of thumb for molecular 
replacement to be successful is for the search model to share at least 35-40% 
sequence identity with the unknown protein.
• Quality o f the search model: A good and well-refined search model up 
to at least 2.0-2.5A resolution means that the phases calculated from the model 
will be closer to the true phases (observed phases).
• Resolution: Both high and low-resolution limits affect structure 
solution.
• Radius o f integration: This is chosen in such a way so as to try and 
include only the intra-molecular vectors. The radius should be smaller than the 
smallest of the unit cell dimensions and the volume of the sphere defined by 
this radius should not be more than the volume of the asymmetric unit. 
Usually 75% of the longest cell dimension is considered an optimal value.
• Model cell: The norm is to try and choose the search model box size 
in such a way so as to reduce interference by inter-molecular vectors between 
search models related by unit cell translations.
Once the search model is correctly oriented, it needs to be placed 
within the unit cell relative to the symmetry of the crystal. A P I (triclinic) cell 
has no symmetry elements and hence the search model can be placed 
anywhere within the unit cell whereas for other space groups, it is imperative 
to chose the position of model relative to the symmetry axes in the crystal.
Doing a rigid body refinement can optimise the solution so obtained 
and the R-factor or the Reliability index can be used as a measure to know if 
the structure solution is correct or not. The R-factor is an estimate of error
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between the observed and the calculated structure factors. The correct solution 
will give the lowest R-factor. The next step would be to check for crystal 
packing on the graphics to ensure that there are no clashes between symmetry 
related molecules.
1.2.4. PHASE IMPROVEMENT
Most of the solvent content in the protein crystals is disordered. A 
continuous disordered solvent channel surrounds the protein molecules within 
the crystal lattice. The electron density maps hence phased from MIR or 
anomalous scattering methods are not sufficient to determine the correct 
structure. The process of density modification is applied in such cases to 
convert an uninterpretable, poor quality map into an interpretable one. The 
method involves features like solvent flattening, histogram matching, and if 
some features of the molecule are known from X-ray analysis, then they can 
also be incorporated (Zhang et al., 1997). This process is also used sometimes 
as a starting point to reduce model bias when using phases from a molecular 
replacement model. This is especially powerful in cases with high non­
crystal lographic symmetry. NCS averaging reduces model bias and improves 
the phases by increasing signal-to-noise ratio by a factor of VN, where N is the 
number of copies of the molecule in the asymmetric unit. The phase 
improvement calculation is a cyclic process and involves modification of the 
phases in order to obtain best agreement with the known constraints on the 
electron density and the observed structure factor data.
Fig 1.15 A diagrammatic representation of phase improvement protocol
Amplitudes and phases 
from heavy atoms or 
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1 . 2 . 5 .  C R Y  S T  A L L O G R A P H I C  R E F I N E M E N T ,  M O D E L  B U I L D I N G  
A N D  S T R U C T U R E  V A L I D A T I O N
The process of refinement is absolutely necessary because:
1) Manual fitting will inevitably contain errors.
2) Quality of the electro density map is insufficient for better 
interpretation.
Crystallographic refinement is carried out in a cyclic process of 
gradual improvement of the model. Refinement is a process by which the 
model is changed during model building at the graphics display in such a way 
that the structure factors calculated from the built model get closer to the 
observed amplitudes. It is a process by which the continuous electron density 
is represented by discrete atoms. Iterative cycles of refinement optimise the 
atomic model, allow for improved phases and thus help compute electron 
density maps that show finer details of the molecular structure. During 
refinement the parameters of the model get adjusted to the information content 
of the data. The higher the resolution of the data, more are the parameters that 
need to be refined. A model that is under parameterised is not as informative 
as it could be, as it does not represent the data properly. On the other hand, it 
is not good to over parameterise the model also as it might lead to modelling 
of abnormalities and noise. The observation to parameter ratio is usually not 
high enough to introduce and refine each parameter one-by-one. Hence, 
restraints and constraints are usually used to increase the number of 
observations. These restraints and constraints reduce the number of parameters 
to be refined either by forcing a parameter to have a certain value or by setting 
up relationships between parameters. Although the atomic positions of the 
structure are unknown, the relationship between them is used as weighted 
information that effectively increases the observations.
The target function for crystallographic refinement can be expressed 
by the following expression:
E  — E chem "*■ W x r a y  E xray 
where, EChem is an empirical function of potential energy of all atomic 
positions. It contains information about describing all covalent and non-
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covalent interactions between atoms. Exray is the difference between the 
observed and calculated diffraction data, while the term Wxray is the weight that 
balances the forces arising from each term. The target function is a 
mathematical score that describes how best a model fits the data. It can be a 
least squares (LS) target wherein the target function is the weighted sum of 
the squares of the deviations between observed and calculated quantities or it 
can be a maximum likelihood target. This target function can be of three types:
• MLF: Target based on amplitudes
• MLI: Target based on squared amplitudes or intensities
• MLHL: Target based on amplitudes and prior phase information 
encoded by Hendrickson-Lattman coefficients.
The basic principle behind maximum likelihood function is that the 
best model will be most consistent with the observations. Consistency can be 




The ratio represents the number of models in an exhaustive set of equally 
likely models ( M pr0babiiity) that produce an observed value to the total number 
of possible models (Mpossibiiity). To apply maximum likelihood it is important 
to account for the different types of errors in the model such as coordinate 
errors, missing atoms, and errors in temperature factors (B-factors).
In order to improve the model and subsequently refine (minimise) the
target function we use a mathematical algorithm or in other words, an
optimisation method. These techniques provide the model to overcome the 
barriers of being trapped in false/local minima during minimisation by 
providing the system with the necessary potential energy. There are different 
algorithms used like Simulated annealing (used by CNS; Brunger et al., 1998; 
Briinger and Rice, 1997), Full-matrix (used by SHELXL; Sheldrick and 
Schneider, 1997), Conjugate gradient method (a second derivative target 
function in which information is derived from the history of the refinement 
run). This method identifies the nearest minimum in target function by 
increasing the radius of convergence.
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Annealing is a physical process in which a solid is heated to 
temperatures wherein all the molecules of the solid are randomly arranged in a 
liquid-viscous phase, and then it is cooled down slowly so that the molecules 
transcend from their liquid phase into solid phase, re-arranging themselves in 
the lowest energy state possible. During crystallographic refinement, this 
process can be simulated, by defining the target energy function as the resting 
energy of the system. The simulated annealing algorithm used for refinement 
follows the torsion angle molecular dynamics (fixed bond lengths and bond 
angles). This is based on the observations that the deviations from ideal values 
are usually small for X-ray crystal structures.
The torsion angle molecular dynamics is coupled with temperature 
during simulated annealing. The annealing schedule generally followed during 
the course of refinement is a slow-cooling protocol with a starting temperature 
of around 5000K and a drop of 25K every 25 seconds. The sampling of 
several conformations at higher temperatures allows for better results and 
avoids trapping of structures in false minima. The choice of temperature 
depends on the quality of the model and resolution of the data.
Each atom can be described by at least 6 parameters. These are the 
scattering factor for the atom type, the three positional coordinates (x, y, z), 
the B-factor and the occupancy. B-factors are atomic displacement factors and 
are very closely associated with coordinates of the model. They represent the 
distribution of positions occupied by an atom over a period of time (dynamic 
disorder) as well as variations in the position of an atom between different unit 
cells (static disorder). Static disorder arises because the observations from the 
diffraction data represent an averaged structure wherein each conformation for 
a particular portion of the structure is given a weighting factor according to the 
fraction of unit cells containing that particular conformation. Hence, large B- 
factors are indicative of errors in the model coordinates. The method 
employed for refinement of B-factors depends on the resolution and 
completeness of the data. Atoms with different atomic displacement 
parameters (ADPs) contribute differently to diffraction intensities. At a 
resolution of about 2.5A or better, B-factors are refined isotropically, i.e.
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refinement is based on enforcing similarity of correlation coefficients between 
pairs of displacement parameters. When the mean atomic displacement 
parameter is large, then the distribution of these parameters will be wide and 
so their contribution toward high-resolution intensities will be weak. On the 
other hand, when the mean atomic displacement parameter is small then most 
atoms would contribute towards diffraction intensities over the whole 
resolution range. Atomic resolution (1.5A or better) means a higher 
observations-to-parameter ratio and better signal-to-noise ratio. Also the 
observed intensities at atomic resolution are sufficiently accurate to be able to 
determine the positional parameters of the model with accuracy. This allows 
for refinement of the full atomic parameters of the model.
Gross errors in the model cannot be corrected by these refinement 
protocols. Visual inspection of electron density maps calculated from a given 
set of phases (either initial phases at the beginning of refinement or at a later 
stage) is necessary. These Fourier maps (usually 2 | F 0b s |- |F Caic| a n d  | F 0b s |- |F caic | 
maps) can be used to build the structure of the molecule in question with the 
aid of the known amino acid sequence of the molecule. They aid in 
identification of the errors in the model. The | F 0b s |- |F Caic| maps highlight the 
areas in the map that reflect the greatest difference between the observed and 
the calculated phases. Such unexplained features in the Fourier maps clearly 
indicate whether or not a model has been accurately refined and complete. 
These maps help in identifying solvent molecules as well as ligands and ions 
that are either an integral part of the structure or sometimes get incorporated 
into the crystal lattice from the crystallisation buffer. Modelling of solvent in 
the difference densities depends on the peak height (~3-4a above threshold) as 
well as geometric considerations (the interactions of the water molecule with 
protein residues). At high resolutions the difference maps also highlight 
alternative conformations for the side chains of some of the amino acid 
residues. These residues are usually found on the solvent exposed surface of 
the protein structure and maybe significant for the protein’s biological 
function.
The quality of the map depends on the accuracy or the inaccuracy of
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the phases determined as well as on the resolution. Model building is done on 
a graphics workstation with the program O (Jones et a l, 1991), which allows 
for the manual fitting of the amino acids into the electron density map. There 
are now a number of automatic fitting and tracing programs like ESSENS, 
ffear and warpNtrace, but they all require a high enough resolution (~2.0A) to 
be successful. Highly disordered regions of the structure usually occur because 
of model bias. As a result the Fourier maps around that area are not quite 
interpretable. Such problems can be dealt (to a certain extent) by calculating 
omit maps. The coordinates for atoms in the disordered region of the structure 
are left out from Fourier calculation. As a result the density seen for that 
region in the omit map is completely unbiased and solely based on observed 
phases.
The primary measure of a refining structure is given by the residual 
index or the R-factor. As the model improves the measured Fs (F0*5) and the 
calculated Fs (Fcalc) converge and the value of the R-factor drops. This can be 
represented by the following equation:
Rcrys/ ~  £  IIFqA.J ~ IFra/rll
2  \Fobs\
where, FQbs is derived from the measured reflection intensity and Fcaic is the 
corresponding structure factor obtained from the current model. This 
conventional parameter is known as the crystallographic R (Rcrysd*
There is another parameter, which states the quality of a structure. It is 
the Rfree value. This concept was developed by Briinger (1992a) in order to 
avoid over-fitting of the model. This cross-validation parameter is a more 
objective indicator of model quality than the Rcr^. Setting apart a set of 
reflections, usually 5-10% of the total reflections, and refining the structure 
against the remaining data reduces model bias. As the model improves, with 
iterative model building and refinement cycles, both the R ^ ,  and the R/ree 
values drop. Decreasing R-factor values are complimented by another 
parameter called the Figure o f Merit (FOM). This value indicates the fraction 
of the model that represents true structure factors.
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In addition to the R-factors, the quality of the model can be assessed by 
means of Ramachandran plots (Ramachandran and Sasisekharan, 1963). 
These plots underline the stereochemistry, conformation (planarity of the 
peptide bonds, bond lengths, bond angles etc) and the backbone 
conformational angles (<(>, vj/) of the current model based on the expected 
values for simple organic molecules. These plots give information about the 
outliers (residues with unusual properties) in the protein model. These outliers 
can be because of inaccuracy in the modelling process or they may be a 
genuine feature of the structure e.g. cis-peptides. The program PROCHECK 
(Collaborative Computational Project, 1994) is a useful validation program 
and can be used to assess the quality of the structure at various stages of 
refinement.
Another statistical value that helps in assessing the quality of the 
structure is the deviation from ideal geometry given by root mean square 
deviation (r.m.s.d.) value. If the refinement is successful in imposing the 
restraints, based on fixed bond lengths and bond angles, then the value for 
r.m.s.d. will be quite low. For very well refined structures this value is usually 
between 0.005 -  0.010. This value is usually output by the refinement program 
CNS after the annealing schedule.
1.2.6. STRUCTURE ANALYSIS AND PDB DEPOSITION
Once the structure is complete the next step is to deposit the 
coordinates with the Protein Data Bank (PDB) at either European 
Bioinformatics Institute (EBI; http://www.ebi.ac.uk/) or with the Research 
Collaboratory for Structural Bioinformatics (RCSB; http://www.rcsb.org/). 
The PDB is a vast global repository of all the three-dimensional crystal 
structures elucidated so far. The PDB helps in providing access to structural 
information (for proteins, nucleic acids, ligands and other biological 
macromolecules) to scientists all over the world.
Understanding of the functional aspects of the protein comes from
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understanding the three-dimensional structure of the protein. Hence, it is 
necessary to analyse the structural data obtained. The final coordinates of the 
refined model not only reveal the detailed architecture of the polypeptide 
chain folds but also give an insight into how proteins evolved, the basis on 
which they interact with each other and how they bind with other molecules. 
There are several programs (CCP4 supported) available that are used in 
structure analysis (http://www.ccp4.ac.uk/html/INDEX.html). Some of these 
programs are DSSP (for assigning secondary structure elements in the 
structure) CONTACTS (for analysing Hydrogen-bonding interactions), SC 
(analysis of the shape complimentarity between two interacting protein 
surfaces), AREAIMOL (to calculate the solvent accessible area in a protein 
structure), CAVENV (to visualise cavities in the protein structure), PROSA 
(to determine the native structural fold of the protein).
1.3 CIRCULAR DICHROISM
Light can be represented as a transverse electromagnetic wave that is 
composed of fluctuating electric and magnetic fields, mutually perpendicular 
to each other. The magnetic field component remains same whereas the 
electric field component is constantly changing as it propagates (Fig 1.16). 
Light is linearly polarised if it is made up of waves that fluctuate in only one 
specific plane. In a linearly polarised light, the direction is constant and 
magnitude is modulated. However, if the waves are 90 degrees out of phase 
(i.e. one is at maximum when the other is at a zero), the resulting light is 




Magnetic field in 
the yz plane
direction of propagation of the wave
Fig 1,16 Vectorial representation o f the electric and magnetic 
field components o f light.
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Dichroism is a phenomenon that is observed when an optically active 
matter absorbs right and left handed circularly polarised light slightly 
differently. This arises due to structural asymmetry and this difference is 
measured by Circular Dichroism (CD) spectroscopy.
1.3.1. CIRCULAR DICHROISM ON PROTEINS
The absence of a regular structure results in zero CD intensity whereas 
a regular structure can produce positive as well as a negative CD signal. The 
CD intensity is a result of peptide bond (Far-UV spectral region), disulphide 
bonds and amino acids such as tyrosine, tryptophan and phenylalanine (Near- 
UV spectral region) that act as chromophores in the proteins at different 
wavelengths. Far-UV experiments are carried out in the region of 190-250nm 
whereas the Near-UV experiments are carried out in the region of 250-350nm. 
Choice of buffer is very important for Far-UV experiments e.g. reagents like 
DTT, histidine, imidazole, EDTA should not be used as buffer as they absorb 
radiation in the far-UV region. Far-UV experiments can determine the 
approximate fraction of each secondary structure element (a-helix, (3-sheets, 
and random coils and turns) present in the protein structure. On the other hand, 
the Near-UV CD signals are used to analyse whether or not the protein has 
folded into a well-defined structure. It is also sensitive to structural changes 
upon protein-protein interaction, denaturation effects of changes in the 
protein’s environment and so forth. The protein sample used should be free of 
contaminants. Concentration of the sample must always be checked prior to a 
CD experiment. Usually 200pl of the protein solution with a concentration in 
the range of 50pg/ml to 1 mg/ml is required for obtaining a Far-UV spectrum 
whereas a Near-UV spectrum would require 1ml solution at a concentration of 
about 2.0mg/ml. The higher the concentration better is the absorbance and 
thus a good CD signal can be recorded.
There are several programs available to analyse the CD spectra of a 
protein (http://www.ciyst.bbk.ac.uk/cdweb/html/home.html/). In general, the 
CD spectral analysis is 97% accurate for a-helices and only ~70% for p-sheets 






Angiogenesis is the process of formation of vascular sprouts from pre­
existing microvasculature. Physiological angiogenesis occurs only during foetal 
development, a woman's endometrial cycle, wound healing and muscular 
growth. The process of vascularisation is also essential for the progression of 
several diseases. Pathological conditions pertaining to this process can be a 
function of either uncontrolled angiogenesis as seen in psoriasis, rheumatoid 
arthritis, atherosclerosis, and many cancers (Folkman 1971; Folkman 1995; 
Norrby 1997) or dysfunctional angiogenesis that can be associated with 
ischemia of the heart, poorly healing wounds and fractures, ulcers and infertility 
(Arnold et al., 1987; Folkman 1998).
An angiogenic stimulus triggers off a highly regulated sequence of 
events leading to the formation of blood vessels. A vessel wall is composed of 
an endothelial cell lining, a basement membrane, and a layer of cells called 
pericytes that partially surrounds the endothelium. The construction of a 
vascular network requires different sequential steps usually starting with the 
disappearance of the pericytes. The proteases released from the endothelial- 
lining breakdown the basement membrane resulting in the binding of the 
released angiogenic factors to their receptors on the endothelial cells (ECs). 
This leads to their proliferation and subsequent migration into the interstitial 
space. The migrating endothelial cells reach the site of stimulus and 
reorganise themselves as a lumen. The fusion of these newly formed vessels 
with the generation of a new basement membrane initiates blood flow.
Overall, angiogenesis is the result of an extensive interplay between 
oncogenes and suppressor genes, stimulatory and inhibitory molecules, 
proteases and endogenous inhibitors and environmental factors such as the 
oxygen level (Suri et a l , 1996). Angiogenesis is such a complex phenomenon 
that a clear-cut distinction between angiogenic factors as being either inducers 
or inhibitors is an oversimplification. Some angiogenic factors act as both 
direct and indirect inducers of the process while some function contextually, 
sometimes as inducers and sometimes as inhibitors. In other words, 
angiogenesis is a process tightly regulated by environmental and genetic
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angiogenic regulators that display spatially and temporally co-ordinated 
activities.
During physiological angiogenesis, there exists a dynamic balance 
between the positive and the negative regulators of the process whereas during 
pathological circumstances the rate of blood vessel formation exceeds that of 
its inhibition. It has been experimentally established that the loss of control of 
termination and stabilisation of the blood vessels is due to the up-regulation of 
the positive regulators as well as due to the exhaustion of the endogenous 
inhibitors of the process of blood vessel formation.
2.2 TUMOUR ANGIOGENESIS
More often than not, tumour growth starts with uncontrolled cell 
proliferation. The rapidly dividing tumour mass soon reaches a steady state 
due to lack of nutrients and oxygen. The tumour may remain dormant for 
several months or years yet when the circumstances are beneficial it can 
switch to an angiogenic phenotype. This event can be triggered off by 
environmental stress factors such as hypoxia, low pH and pressure generated 
by proliferating endothelial cells (ECs), immune responses, and genetic 
factors such as activation of oncogenes or deletion of tumour-suppressor 
genes that control the production of factors regulating the process of 
angiogenesis (Fig 2.1).
Some tumours and metastases in particular do not initiate in an 
avascular manner (Pezzella, 1997; Holash et a l, 1999). They rather grow by 
homing in on a host vessel and start off as a vascular tumour. Soon after 
tumour co-option the host vessels begin to die as a result of apoptosis and the 
tumours become secondarily avascular and hypoxic. This leads to a definitive 
increase of tumour derived Vascular Endothelial Growth Factor (VEGF). The 
induced VEGF leads to a new burst of angiogenic sprouting from the 
regressing blood vessels. Thus the onset of a robust new angiogenesis allows 
the tumour to survive and grow further.
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Fig 2.1 A schematic o f events that can trigger o ff the angiogenic switch 
in dormant tumours
2.3 MODELS TO STUDY THE PROCESS OF ANGIOGENESIS
Considerable insight in the molecular and cellular biology of 
angiogenesis has been obtained by in vitro and in vivo studies. However, 
comparison between different studies is rather difficult because of the great 
diversity in the models being used. Also, any given compound that is 
angiogenic in vitro may not show any response in vivo, where it might be 
activated or inactivated by other molecules and thereby show results opposite 
to that of the in vitro model. Likewise, substances with no obvious effects, 
chemotactic and/or mitogenic, in vitro may play a crucial role in vivo in 
angiogenesis. Hence, both in vitro and in vivo models must be employed in 




2.3.1 in vitro MODELS
Most steps in the angiogenic cascade can be understood by using 
endothelial cells to analyse processes such as proliferation, migration and 
differentiation. It is easier to control the spatial and temporal concentrations of 
the various angiogenic mediators involved while using in vitro models to 
study angiogenesis.
Chemotaxis can be examined in a Boyden Chamber. The chamber consists of 
two wells, an upper well and a lower well, separated by a membrane filter. 
The chemotactic solution is placed in the lower well and the cells in the upper 
well and after a period of incubation, the cells on the lower surface of the 
membrane are counted which gives an indication of the number of cells that 
have migrated towards the chemotactic stimulus (Fan et al., 1993).
Proliferation studies are based on cell counting, thymidine incorporation, or 
immuno-histochemical staining. The increase in the number of cells is 
calculated by measuring Proliferating Cell Nuclear Antigen (PCNA; Hall et 
a l , 1990) or by measuring apoptosis (by the Tunel Assay; Mori et a l , 1994).
Differentiation can be studied by culturing the ECs in different extra-cellular 
matrix (ECM) components, including two- and three-dimensional fibrin clots, 
collagen gels and matrigel (Benelli and Albini, 1999).
2.3.2 in vivo MODELS
Classical in vivo angiogenic assays include the Chick Chorioallantoic 
Assay (CAM), the rabbit cornea assay, sponge implant models, matrigel plugs 
and conventional tumour models. The first evidence of tumour induced 
angiogenesis used a syngenic combination of tumour and mouse cornea, 
without involvement of inflammation (Muthukkaruppan and Auerbach, 1979; 
Muthukkaruppan et a l , 1982).
CAM assay: The CAM assay is a relatively simple, inexpensive and most 
widely used assay for large-scale screening as the early chick embryo lacks a 
mature immune system (Auerbach et a l , 1974). The major disadvantage of 
the model is the presence of a developed network of blood vessels that makes
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it difficult to differentiate between the newly developed capillaries and the 
already existing ones.
Rabbit cornea assay: This assay is more reliable than the CAM assay as it 
represents an in vivo avascular site and thus makes it easier to differentiate 
between newly developed blood vessels and already existing ones. Computer 
image analysis after perfusion of the cornea with India ink helps to measure 
the vascular response. It is not a practical model for large-scale screening as it 
is technically very demanding and very expensive as well.
Implantation models: Subcutaneous implantation of various artificial sponges 
like gelatin and polyvinyl alcohol (incorporated/injected with the compounds 
to be evaluated) provides another means to study the process of angiogenesis. 
However, the implantation of these sponges result in some non-specific 
immune responses which in turn may result in a vascular response even in the 
absence of exogenous growth factors in the sponge (Andrade et al., 1987).
Matrigel: Matrigel generated from Engelbreth-Holm-Swarm (EHS) murine 
sarcoma contains basement membrane components (collagens, laminin, and 
proteoglycans) as well as matrix degrading enzymes/their inhibitors and 
growth factors. Role of the ECM receptors and enzymes in tumour 
progression has been well characterised using a matrigel incorporated with 
tumour cells (Passaniti et al., 1992).
Transgenic models: Transgenic models are fast becoming the gold standard 
for manipulating the angiogenic candidate molecules in a controllable manner. 
In the transgenic approach, a particular candidate disease gene is chosen and 
re-engineered using molecular tools, confirmed as the desired gene, and is 
then introduced into the model so it becomes a part of that model's genome. 
Transgenic models have allowed us to study the consequences of deficiencies, 
mutations and conditional expression of the different gene products.
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2.4 ANGIOGENIC PROTEINS
The field of angiogenesis is very vast and complicated and it is not 
possible to put across the complexity of the process and detail all that is 
known about each angiogenic molecule within the realm of this thesis. What 
follows is a brief description of the properties of the angiogenic proteins that I 
have studied during my PhD. For a recent and exhaustive review on this 
subject, please see Iyer and Acharya (2002).
2.4.1 CYSTEINE-KNOT SUPERFAMILY OF GROWTH FACTORS
The most important and extensively studied class of angiogenic 
regulators are the Growth Factors. The growth factors and the cytokines 
present in the tumour’s microenvironment regulate a variety of genes 
associated with malignant properties of tumour cells such as growth, 
migration, invasion, and metastatic capacities. Several of the angiogenic 
polypeptide growth factors belong to the cysteine-knot superfamily of growth 
factors (Fig 2.2). These bioactive proteins exemplify the development of 
distinct biological functionalities during the process of blood vessel formation. 
These polypeptides display a common structural architecture despite little 
sequence homology. The crystal structures of these growth factors 
demonstrate that all have a similar topology based on a cyclic-knot of 
cysteines involved in both intra-chain and inter-chain disulphide bonds.
THE CYSTEINE-KNOT SUPERFAMILY















This cysteine connectivity stabilises the Ca framework of these 
growth factors for elaboration of the solvent exposed loop regions that form 
the receptor-binding surface on these polypeptides. The members of this 
family occur as either homo- or hetero-dimers. Sequence alignment also 
shows these cysteines to be highly conserved (Fig 2.3). These molecules 
differ on the basis of the number of disulphide bonds, the orientation of the 
monomers relative to the dimer axis and the extent of buried surface, thus 
varying the residues that are involved in the dimer formation. The disulphide 
bonds spatially bring the key residues involved in receptor recognition into 
close proximity of each other. The cysteine-knot members, although 
topologically similar, act via distinct cell-surface receptors with which they 
form complex signalling systems. The parent molecule to the two proteins 
(Placenta Growth Factor and Vascular Endothelial Growth Factor-B) that I 
have studied is the Vascular Endothelial Growth Factor-A (VEGF-A). Any 
study on angiogenesis would be incomplete without the mention of this all- 
important molecule. VEGF-A shares around 35-40% amino acid sequence 
identity with P1GF-1 and VEGF-B.
r iG M  S S E V E V V P F O E V  WG  R S Y C R A L E R L V D V V 5 E Y P S E V E -  - H U
VEGF-A — N H H E V V  K F M D V Y O R 5  Y C H P I E T I V D I  F O E Y F D E I  E-  - Y l
VEGF-B - H O R K V V S W I  D V Y T  R A T C O  P R E V V V P  L T V E  L M G T V A - - K O
VEGF-C - N T E I  L K S I D N E W R K T O C M P  R E V C I  D V G K E F G V A T N -  - T F
PDGF-A  S I  E E -  A V P A V C K T R T V I  Y E I P R S O V D P T 5 A N F L
PDGF-B - • S L G S L T I  A E P A M I  A E C K T R T E V F E I  5 R R L I  D R T N A M F L
PIG F I  F S P S C V S L L R C T  0 C  C G D E D L H C V P V E T A H V T M O L L K I  R S G
VEGF-A F K P S C V P  L M R C G  g f C  C N D E G L  E C V P T E E S  Ml  T  MO  I MR I  K P H
VEGF-B L V P S C V T V O R C G  F l C  C P  D D G L  E C V P T G O H O V R M O I  L Ml  R Y P
VEGF-C F K P P C V S V Y R C  G 0 C  C M S  E G L  O C M N T i  T S  Y L S K T  L F El  T V P
PDGF-A I WP  P C V E V K R C T  0 C  C M T S S V K C Q P S  R V H H R S V K V A K V E Y V
PDGF-B V W P P C V E V O R C S  0 C  C M NRI i l  V O C  R P T O V O L  R P V O V  R Kl  E l  V
PIGF-I D-  - - R P S Y V E I T F S O H V R C E C R P L  R E K .......................................................
VEGF-A O -  - - G O H I  G E M 5 F L O H N K C E C R P K K D R .......................................................
VEGF-B - - - - S S O L G E M S L E E H S  O C  E C R P K K K D .......................................................
VEGF-C L S O -  G P K P V T I  S F A MH T  S C R G  MS  K L D ...........
PDGF-A R K K P  K L  K E V O V R L  E E H L  E C A C A T T 5  L U P  D Y R E E D T G R P  R E
PDGF-B R K K P I  F K K A T V T  L E D H L A C K C E T V A A A ...........
Fig 2.3 Sequence alignment o f the members o f the cysteine-knot superfamily 
(PDGF-family) highlighting the conserved cysteines (8 in all). The Glycine 
(shaded blue) is also conserved in order to accommodate the motif.
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2.4.1.1 VASCULAR ENDOTHELIAL GROWTH FACTOR-A (VEGF-A)
Vascular endothelial growth factor (VEGF) is the most potent and 
pivotal regulator of angiogenesis and vasculogenesis. A highly specific 
mitogen for vascular endothelial cells, VEGF promotes extravasation of 
proteins from tumour-associated blood vessels. Disruption of genes encoding 
VEGF results in severe defects and abnormalities in the development of the 
cardiovascular system (Ferrara et al., 1996; Ferrara, 2002). VEGF induces cell 
signalling in different ECs as for example in HUVECs (Human Umbilical 
Vein Endothelial Cells) and initiates a variety of biological effects. Hypoxia is 
one of the major up-regulators of VEGF expression and is thought to drive 
angiogenesis during organogenesis. In developing organs, increasing distance 
between the migrating cells and the existing blood vessels creates hypoxic 
conditions. This stimulates the formation of new vasculature towards the 
VEGF producing cells (Stone et al., 1995; Pierce et al., 1995). Besides hyper­
proliferation, blood vessels undergo unregulated and excessive fusion leading 
to formation of vessels with exceptionally large lumens. On the other hand, 
limited/reduced VEGF supply to the tissues leads to inhibition of organ 
development (Folkman and Hanahan, 1991; Drake and Little, 1995; Ferrara et 
al,  1998).
C
Fig 2.4 Crystal Structure o f Vascular Endothelial Growth Factor -  A 
(PDB code: 2VPF; Muller et al., 1997)
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Crystal structure of VEGF-A (Fig 2.4) at 1.93 A resolution (Muller et 
al., 1997b) showed that each protomer consists of three intra-chain disulphide 
bonds and one inter-chain disulphide bond. The monomers are perpendicular 
to the dimer axis such that there are two disulphide bonds related to each other 
by the dimer axis. Receptor dimerisation via a VEGF bridge activates signal 
transduction events that lead to a variety of mitogenic and chemotactic 
responses that are specific to VEGF-A depending upon where it is expressed.
VEGF is expressed in spatial and temporal association with 
physiological as well as tumour angiogenesis in vivo (Shweiki et al., 1993; 
Jakeman et al., 1993; Kim et al., 1993; Millauer et a l, 1993). Expression of 
VEGF induces the formation of vesiculo-vacuolar organelles that channelise 
the blood bome proteins into the tumours. This forms an extravascular fibrin 
gel that stimulates ECs and tumour cells to proliferate and migrate and also 
supports the invasion of stromal cells into the growing tumours (Dvorak et a l,
1995). The similarity of mechanism of VEGF induction during physiological 
as well as tumour angiogenesis explains why VEGF plays a central role in so 
many types of diverse tumours. A plethora of cytokines, growth factors and 
other external factors regulate VEGF production and thus indirectly 
stimulate/inhibit angiogenesis. These include FGF, PDGF, TGF-p, TNF-a, 
IL-6 , IL-10 and IL-13.
Alternative splicing of VEGF mRNA produces 5 isoforms: VEGF121, 
VEGF145, VEGF165, VEGF189 and VEGF206- These isoforms differ in their 
heparin and heparan sulphate binding ability. Binding of VEGF to ECM- 
associated heparan sulphate proteoglycans (HSPGs) releases angiogenic 
growth factors such as the basic-FGF (Jonca et al., 1997). Heparin and not 
heparin like molecules enhance the binding of VEGF165 to vascular 
endothelial growth factor receptor-2 (VEGFR-2). HSPGs, like the Glypican, 
act as a chaperone and restore the binding of VEGF165 to VEGFR-2 after 
oxidative damage. The same however is not true for VEGF121 (Gitay-Goren et 
al., 1992; Weksberg e ta l, 1996).
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PIGF VEGF-B VEGF-C VEGF-D
VEGF,2, VEGFh, VEGF165 VEGF,*, VEGF; PIGF-2
membrane
s-FIt-1 Flt-1 KDR Flt-4 NP-1 NP-2 HSPGs
Fig 2.5 A schematic representation o f the various receptors characterised for 
the members o f the cysteine-knot family o f growth factors. Flt-1, KDR and Flt-4 
are tyrosine kinase receptors. s-Flt-1 is the soluble truncated form o f Flt-1. NP- 
1 and NP-2 are neuropilins that belong to the family o f semaphoring receptors. 
HSPGs represent heparan sulphate proteoglycans that act as binding partners 
for some o f the growth factors. The receptors have been coloured individually. 
The arrows point to the ligands that bind each o f these receptors and these have 
been coloured according to the receptor they represent.
Apart from binding to cell surface HSPGs/heparin, VEGF binds two 
receptors (Fig 2.5) belonging to the tyrosine kinase receptor family: VEGFR- 
1/Flt-1 (fms-like tyrosine kinase receptor -1) and VEGFR-2/KDR (kinase - 
insert domain containing receptor). These two receptors are, predominantly, 
expressed by the ECs, monocytes, trophoblasts and tumorigenic cell types like 
melanomas. Residues from both the monomers of the active VEGF dimer 
contribute to each of the two receptor-binding domains, located at opposite 
ends of the molecule. (Keyt et al., 1996; Muller et al., 1997a). Since VEGF is 
known to bind both VEGFR-1 as well as VEGFR-2, there is some evidence 
that the two receptors can heterodimerise via a VEGF bridge (Wiesmann et 
al., 1997). Activation of VEGFR-2 by VEGF results in a mitogenic response
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while that of VEGFR-1 does not induce cell proliferation. Some isoforms of 
VEGF namely the VEGF145 and VEGF165 bind another class of receptors 
called the neuropilins-1 and 2 (Soker et a l , 1998). The binding of the VEGF 
isoforms to these receptors is mediated by the exon 7 of the VEGF gene 
(Soker et a l , 1997) that is absent in VEGF121. Gene disruption studies indicate 
that neuropilins may act as co-receptors of VEGF165 because a dysfunctional/ 
absent neuropilin leads to an impaired development of cardiovascular system 
leading to the death of mouse embryos. Recently, it was shown that VEGF-A 
could also strongly induce lymphangiogenic response. Over-expression of 
VEGF-A results in giant lymphatics that are structurally and functionally 
abnormal (Nagy et a l , 2002).
Inhibition of VEGF signalling inhibits the development of many 
tumours. Impaired VEGF function abrogates tumour metastasis (Millauer et 
a l, 1996; Skobe et a l, 1997). Production of antagonistic VEGF mutants 
(Siemeister et al, 1998), VEGF receptor inhibitors (Strawn et a l, 1996), 
antisense mRNA expressing constructs (Cheng et a l, 1996), inhibitory soluble 
receptors (Kendall and Thomas, 1993; (Lin et a l, 1998), humanised 
monoclonal antibodies against human VEGF (Presta et a l, 1997) are some of 
the strategies that are being undertaken to treat VEGF induced tumour 
angiogenesis. VEGF is also being used to develop therapeutics for the 
treatment of diseases related with dysfunctional angiogenesis (Walder et a l, 
1996; Magovem et a l, 1997; Baumgartner et a l, 1998).
2.4.1.2 PLACENTA GROWTH FACTOR
The human term placenta seems to be a source of several angiogenic 
factors. A human cDNA coding for one such angiogenic protein was isolated 
from a placental cDNA library and named as the Placenta Growth Factor 
(P1GF). P1GF belongs to the PDGF family of growth factors. The gene 
encoding this protein is located on chromosome 14 of the human genome 
(Maglione et a l, 1993). DNA sequence analysis of the P1GF gene showed that 
an alternative splicing mechanism is responsible for the production of the 
different forms of P1GF. PIGF-mRNA is abundantly expressed in the placental 
tissue and is also present in very small amounts in heart, lung, thyroid, goitre
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and skeletal muscle. No expression of P1GF has been detected in kidney and 
pancreas (Ziche et al., 1997). The P1GF coding sequence is encoded by seven 
exons spanning approximately an 8000-kb long DNA interval. The PDGF-like 
domain exhibited by the P1GF protein is encoded by exons 3 and 4. There are 
three isoforms of P1GF, namely P1GF-1, P1GF-2 and P1GF-3 (Fig 2.6), which 











Fig 2.6 A schematic representation o f the three spliced variants o f the 
PIGF gene. The gene has 7 exons (each coloured differently) separated by 
introns (shaded). PlGF-1 and PIGF-3 mRNAs lack exon 6. PIGF-3 mRNA 
has a 216 base insert between exon 4 and 5. The length o f the amino acid 
sequence indicated for each isoform corresponds to that o f the mature 
protein (Maglione et al., 1993).
Until recently the biological significance or the relevance of the 
different forms of PIGF with different composition was not known, but 
hybridisation studies reveal that PIGF is well conserved in the mammalian, 
bovine, chicken, amphibian and insect genomes. This suggests that the PIGF 
gene has specific and indispensable functions. The importance of this protein 
is emphasised by the fact that a dysfunctional/absent gene in a mouse embryo 
leads to impaired blood vessel network and subsequently the death of the 
embryo. PIGF occurs in the placenta, thyroid and lungs. It is important for 
maintaining the network of blood vessels between the mother and the growing 
baby. The development and cell-specific regulation of the process of 
alternative mRNA splicing may have important consequences for 
physiological and pathological processes. Studies reveal a preferential
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expression of P1GF-2 in the placental tissue and cell lines, suggesting that this 
long form of PIGF may be involved in the growth and maintenance of 
pregnancy (Maglione et al., 1993; Iyer and Acharya, 2002a).
Purification of P1GF-1 from over-expressing eukaiyotic cells and 
measurement of angiogenic activity of the purified P1GF-1 in vivo in the rabbit 
cornea and CAM assays showed induction of a strong neo-vascularisation 
process that was blocked by affinity-purified anti-PlGF-1 antibody. In the 
avascular cornea, P1GF-1 induced angiogenesis in a dose-dependent manner. 
P1GF-1 has been shown to induce comparable cell growth and migration of 
endothelial cells from bovine coronary post-capillary venules and from human 
umbilical veins (HUVECs) in vitro (Ziche et al., 1997).
Experiments reveal that PIGF is induced in human keratinocytes during 
wound healing (Failla et al., 2000). PIGF expression is regulated by key 
cytokines released during an injury or a wound. It has also been shown that 
melanoma progression in humans is accompanied by deregulated, constitutive 
PIGF expression (Graeven et a l, 2000). PIGF, however, serves no apparent 
autocrine role in melanoma proliferation. In case of P1GF-2 it has been 
established that the recombinant, purified protein is able to stimulate bovine 
aortic endothelial cells (BAECs) and HUVECs (Hauser and Weich, 1993), but 
not the ECs from hepatic sinusoids (Sawano et al, 1996). PIGF isoforms have 
very little mitogenic or permeability-enhancing activity. However, they 
significantly potentiate the action of low concentrations of VEGF in vitro and 
more strikingly in vivo (Park et a l, 1994). The credibility of these findings were 
further cemented by recent experiments with knock out mice (Carmeliet et a l, 
2001). Synergistic cooperation between PIGF and VEGF (Fig 2.7) in 
pathological conditions is specific. Upregulation of PIGF by ECs leads to 
displacement of VEGF from VEGFR1. As a result, increased amounts of VEGF 
are available to bind to the mitogenic response inducing receptor, VEGFR2. 
These experiments have implicated PIGF in pathological angiogenesis unlike 
VEGF that is essential for both physiological as well as pathological 
angiogenesis. This makes PIGF a novel target for therapeutic treatment.
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Fig 2.7 Modification o f the EC response to VEGF by PIGF-1 during 
pathological conditions:
A) low concentration o f PIGF B) increasing concentration o f PIGF
P1GF-1 also forms heterodimers with VEGF-A in tissues where both 
the molecules are co-expressed (Disalvo et al., 1995; Cao et al., 1996). It acts 
as an antagonist of VEGF-A activity when both the growth factors are 
synthesised by the same population of cells. The underlying mechanism was 
experimentally determined as formation of PIGF-1/VEGF-A heterodimers that 
are functionally inactive (Eriksson et al., 2002). These results have again 
shown that despite being weak in comparison to VEGF-A as an angiogenic 
molecule, P1GF-1 plays an important dual role of regulating VEGF-A, both 
positively and negatively.
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2.4.1.3 VASCULAR ENDOTHELIAL GROWTH FACTOR-B (VEGF-B)
Vascular Endothelial Growth Factor-B (VEGF-B) is yet another 
angiogenic growth factor with the cysteine-knot motif that defines all 
members of the PDGF family. It was first discovered by accident when 
searching for new retinoic acid binding proteins in a murine library. Later, it 
was mapped on to chromosome 11 ql 3 of the human genome (Paavonen et al.,
1996). The gene encoding this macromolecule is made up of seven exons (Fig 
2.8). Alternative splicing of exon 6  due to use of different splice-acceptor sites 
results in a frameshift and hence in two overlapping reading frames. These 
encode the two splice variants, VEGF-B167 and VEGF-B 186- These isoforms 
have distinct, non-homologous C-terminal domains with the C-terminus of the 
longer variant more hydrophobic. Of the two isoforms, VEGF-B 167 retains the 
ability to bind heparin (by virtue of exon 6  which is homologous to the exon 6  
of the PIGF gene) whereas VEGF-B 186 is unable to bind heparin because of 
the frameshift.





Fig 2.8 A schematic representation of the two spliced variants of the 
VEGF-B gene. The gene has 7 exons (each coloured differently) separated 
by introns (shaded). A frameshift in the exon 6 gives rise to the two 
isoforms
VEGF-B 167 and VEGF-B 186 travel as 2 1  and 32 kDa proteins under 
reducing conditions during gel electrophoresis. Amino acid sequence 
alignment of VEGF-B with other cysteine-knot proteins reveals that it shares 
highest homology of about 43% with VEGF-A165. The next closest relative is 
PIGF152. Like other cysteine-knot proteins VEGF-B also exists as a 
disulphide-linked homodimer. Both the isoforms can form heterodimers with 
VEGF-A when co-expressed. VEGF-B 167 remains associated with the cell 
surface unless released by heparin treatment whereas VEGF-B 186 is secreted
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in a soluble form because of the lack of the basic, heparin-binding region. One 
unique feature of VEGF-Big6 is that unlike other PDGF family members it is 
the only member that is O-glycosylated.
VEGF-B is expressed abundantly in skeletal and cardiac muscles 
with the two isoforms seemingly being expressed in equal amounts in the 
various tissues. VEGF-B is known to bind both Flt-1 (VEGFR-1) and 
neuropilin-1 receptors with high affinity. VEGF-B can bind to VEGFR-2 and 
VEGFR-3 but with very low affinity and hence its inability to induce a strong 
mitogenic signal for endothelial cells. However, it was later found that the 
ability of VEGF-B to stimulate cell proliferation is enhanced when it interacts 
with tenascin-X in the extracellular matrix (Ikuta et a l , 2000). It is believed 
that perhaps VEGF-B acts in a paracrine mode, as the receptor to which it 
selectively binds is exclusively present in the endothelial cells (Aase et al.,
1999). The binding of VEGF-B to Flt-1 regulates the expression and activity 
of urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator 
Inhibitor 1 (PAI-1; Olofsson et al., 1998).
It is becoming increasingly evident that VEGF-B has potential 
clinical use in therapeutic angiogenesis. It was found that mice lacking in 
Vegfb gene have smaller hearts and are unable to recover completely from 
cardiac ischemia suggesting that the gene was essential for the development of 
a fully functional coronary vasculature (Bellomo et a l, 2000). The partial 
overlapping of expression patterns of VEGF-B with that of VEGF-A suggests 
that the VEGF-B/VEGF-A heterodimers may be biologically important to 
regulate the bio-availability and signalling properties of VEGF-A.
2.4.2 MATRIX METALLOPROTEINASES (MMPS) AND TISSUE 
INHIBITORS OF MATRIX METALLOPROTEINASES (TEMPS)
Matrix metalloproteinases are a family of structurally related zinc- 
containing endopeptidases that mediate the breakdown of connective tissue 




Table 2.1 The different members o f the MMP family
Mol wt Substrates
Sub-type MMP Pseudonym Collagen Other substrates
Latent Active substrates
MMP-1 Fibroblast i, n, m, vn, vm Casein, gelatin, MMP-2
collagenase 55 45 and X & MMP-9
MMP-8 Neutrophil i, n, m, v, vn, Gelatin, aggrecan,
Collagenases collagenase 75 48 VIII and X fibronectin






MMP-2 72 kDa type IV i,n ,m ,iv ,v ,vn, Gelatin, aggrecan,
collagenase 72 66 X and XI elastin, versican, 
laminin, fibronectin
Gelatinases MMP-9 92 kDa type IV IV, V, vn, X and Gelatin, aggrecan,
collagenase 92 86 XIV elastin, versican, 
a-PI
MMP-3 Stromelysin-1 57 45
n, m, iv, ex, x
and X
Gelatin, aggrecan, 
elastin, versican, casein, 
laminin, activates 
MMP-1, 8 and 13
Stromelysins MMP-10 Stromelysin-2 57 44
III, IV and V
Gelatin, aggrecan, 
elastin, casein, 
activates MMP-1, 7, 8 
and 9
MMP-11 Stromelysin-3 51 44 a-PI, laminin
MMP-14 MT1-MMP Aggrecan, elastin,
66 56 I, n and in MMP-2,13, gelatin
MMP-15 MT2-MMP 72 60 Fibronectin,
Membrane MMP-16 MT3-MMP 64 52 MMP-2
type- MMPs MMP-17 MT4-MMP 57 53 Fibrin and gelatin
MMP-24 MT5-MMP 63 45
MMP-25 MT6-MMP
not known
IV Gelatin, laminin-1 
fibronectin,
This table has been taken from a review’ by Elliot and Cawston (2001).
These proteases are normally synthesised as latent forms known as
zymogens. This conversion may occur via other enzymes or auto-catalytically 
(Okada 2001). It is hypothesised that the proteases interact with each other 
resulting in the activation of other proteases that then collectively degrade all
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the extra-cellular matrix (ECM) components. Over-expression and activation 
of one protease may provide a proteolytically active environment for the onset 
of local proteolysis of the basement membrane during angiogenesis. 
Degradation of the extracellular matrix is also important for tumour cell 
invasion. Experiments have revealed that most proteases can degrade the 
ECM components both extracellularly at neutral pH under normal 
physiological conditions and at acidic pH under pathological conditions 
(Griffiths, 1991; Montcourrier et al., 1997; Baron, 1989). Coopman et al. 
(1996) have shown a correlation between the invasive ability of different 
cancer cell lines and their ability to phagocytose the ECM.
The MMPs form a large family of enzymes consisting of at least 26 
MMPs although the exact role of each member, in both normal physiology 
and pathological conditions is still not very clear (Elliott and Cawston, 2001). 
All MMPs share several common features. They all exhibit a common domain 
structure, where each domain contributes towards a particular function of the 
enzyme. The MMPs have an N-terminal catalytic domain, and a C-terminal 
domain, which is involved in substrate binding and in proper orientation and 
presentation of the N-terminal domain at the catalytic site (Becker et al., 1995; 
Lovejoy et al., 1999). Apart from these common features, some MMPs 
contain additional domains that confer particular function to the enzyme. For 
example, MT-MMPs (with the exception of MMP-17 and MMP-25) contain a 
trans-membrane domain as well as a cytoplasmic tail (Femandez-Catalan et 
al., 1998). MMPs are all characterised by the presence of calcium and zinc 
ions, which have a role to play in both the activity and structural integrity of 
the enzyme. The active site of the enzyme remains blocked in the latent form 
of these molecules. Upon activation the pro-peptide gets cleaved off and the 
enzyme gets activated. The catalytic zinc is coordinated to the conserved 
amino acid residues that form the active site in the metalloproteinases, 
indicating a structural basis for the ion-dependent activity of all MMPs (Bode 
etal., 1999).
MMP activity is regulated by tissue-inhibitor of metalloproteinases 
(TIMPs). The phylogeny of the TIMP indicates that TIMP from Drosophila
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forms the root of the evolutionary tree. Cluster analysis (Fig 2.9; Brew et al.,
2000) and topological analysis reveal that TIMPs in humans have evolved by 
the process of gene duplication at various time intervals. Humans have four 
isoforms of TIMP identified so far: TIMP-1, -2, -3 and -4. Human TIMPs are 
homologous to TIMPs from insects, C. elegans, chicken, amphibians and 
fishes, both at the cDNA and the protein level. Of the four known human 
TIMPs, TIMP-1 is the closest to the Drosophila TIMP. Mammalian TIMPs 
have two domains, namely the N-terminal and the C-terminal domain. The N- 
terminal domain, which exemplifies a characteristic OB-fold (oligonucleotide- 
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Fig 2.9 Phylogenetic trees representation o f the sequence divergence 
among the TIMPs (Brew et al, 2000). Figure reproduced, from the reference 
mentioned, human-1, 2, 3, and 4 refer to the four isoforms o f TIMP.
The TIMP genes show a conserved nature with respect to gene 
organisation within the synapsin locus, right across the animal kingdom, from 
Drosophila to humans (Pohar et al., 1999). The sequence comparison of 
TIMPs (Fig 2.10) suggests that they may be concurrent with the origins of 
metazoan connective tissue. The four human TIMPs are differentially 
expressed in tissues and are temporally regulated by the influx of MMPs. 
These four TIMPs inhibit different MMPs with different inhibition 
efficiencies. The TIMPs bind to the MMPs in a slow, non-covalent and
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Fig 2.10 Sequence alignment of the four isoforms of human TIMPs: TIMP-1, 
TIMP-2, TIMPS and TIMP-4 with the Drosophila TIMP (DmTIMP)
Although the four TIMPs show a high degree of divergence in their 
sequence, different TIMPs can bind to most MMPs. But there are differences 
in their inhibitory properties. The three-dimensional structures of TIMPs with 
MMPs resolved so far have enhanced our understanding of the interactions 
between TIMPs and MMPs (Gomis-Ruth et al., 1997; Femandez-Catalan et 
al., 1998). Structural studies on other MMP/TIMP complexes will help us 
understand the complexities of interactions between these multi-domain 
molecules and further our knowledge about the biological relevance of having 
such a variety of MMPs and TIMPs.
An imbalance in the activity of MMPs and the TIMPs is believed to be 
the underlying reason for several major pathological conditions such as 
inflammatory and degenerative diseases like rheumatoid arthritis (Cawston, 
1998), cancer and tumour progression. The central role played by the 
metalloproteinases and their inhibitors in a wide range of proteolytic events,
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h T M * * -l  
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r u l e r
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both in normal and pathological circumstances, has projected the MMPs and 
TIMPs as potential therapeutic targets.
2.5. ROLE OF HEPARAN SULPHATE PROTEOGLYCANS IN 
ANGIOGENESIS
Proteoglycans are negatively charged polysaccharide chains composed 
of repeating disaccharide units, attached to a core protein (Lindahl et al., 
1994). Proteoglycans are found in almost all cell types. The wide spectrum of 
their biological functions ranges from being a purely mechanical support 
molecule to the one with complex cellular functions such as adhesion, 
proliferation and differentiation. These biological effects are due to the ability 
of these molecules to act as receptors for a wide range of molecules. One 
group of proteoglycans known as the Heparan Sulphate Proteoglycans or 
HSPGs is involved in both physiological as well as pathological angiogenesis.
The biological functions of HSPGs are due to their ability to bind to 
different kinds of angiogenic molecules including growth factors, extracellular 
matrix proteins, and protease inhibitors (Lindahl et al., 1994). Some of the 
angiogenesis related HSPG binding molecules are:
• Fibroblast Growth Factors
• Vascular Endothelial Growth Factor
• Placenta Growth Factor
• Heparin-binding Epidermal Growth Factor
• Hepatocyte Growth Factor




• Macrophage Inflammatory Protein
• Interferon-y inducible protein-1




The interaction of HSPGs with the molecules depends on distinct 
structural features. These interactions depend mainly on the size of the 
polysaccharide chain and on the degree and distribution of the sulphate groups 
(Maccarana, 1993). HSPG binding does not depend solely on the sulphate 
groups (Table 2.2). The interaction also depends on the biochemical properties 
of the protein. The HSPG binding regions on most proteins have been 
identified as a cluster of basic amino acids (Zhang et al., 1991; Zhu et al., 
1990; Eriksson e t a l , 1991).
Table 2,2 The different sulphate groups required on HSPGs for 
potentiation o f binding o f these ligands to their receptors.
Angiogenic The important sulphate groups
molecules
FGF-2 2-0- and N-sulphate groups (Maccarana,
1993)
FGF-1 and FGF-4 2-0- and 6 -O-sulphate groups (Guimond et
a l, 1993)
HGF 6 -O-sulphate groups of GICNSO3 (Lyon and
Gallagher, 1994)
HIV-Tat Protein 2-0- and 6-0- and N-sulphate groups
(Rusnati, et al., 1994)
Interleukin- 8 6 -O-desulphated heparin, N-desulphated/N-
acetylated heparin (Rusnati et a l, 1994)
P1GF-2 2-0- and 6 -O-sulphate groups (Midgal et a l,
1998)
HSPGs mediate the binding of these growth factors to their respective 
tyrosine kinase receptors (Mustonen and Alitalo, 1995). For example recent 
solution experiments have shown that heparin although is not absolutely 
necessary for the formation of the receptor-ligand complex, it does enhance 
the binding of FGFR to FGF-2 (Rusnati et al., 1994). What is common about 
the ternary interaction among the HSPGs, growth factors and the receptors is
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the ligand-induced receptor dimerisation for activating the tyrosine kinase 
receptors that is required to induce a mitogenic response (Ruoslahti and 
Yamaguchi, 1991; Vlodavsky et a l, 1991). The storage of the HSPGs in the 
ECM increases the local concentration of the growth factors and a decrease in 
the radii of diffusion. This favours ligand oligomerisation, receptor interaction 
and thus signalling (Fig 2.1 /).
A ternary complex of
Cell-surface receptor







Fig 2.11 Role of HSPGs in ligand-induced receptor dimerisation and 
thus cell signalling
Molecules that bind to an angiogenic growth factor that will interfere 
with the latter interacting with ECM associated proteoglycans are potential 
compounds with angiostatic activity (Table 2.3). These molecules fall into two 
categories:
• Molecules that compete with the heparin-binding growth factors for HSPG 
interaction (eg. poly-cationic compounds).
• Molecules that compete with the HSPGs for growth factor binding 
interaction (eg. poly-anionic compounds).
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Table 2 3  Some known inhibitors o f HSPGs
Inhibitors Mechanism of action
Protamine Compete with the heparin-binding growth 
factors for HSPG interaction
Chemokines Compete with the heparin-binding growth 
factors for HSPG interaction
Tecogalan sodium Compete with the heparin-binding growth 
factors for HSPG interaction
Alpha-2 Compete with the HSPGs for growth factor
Macroglobulin binding interaction
Suramin and its Compete with the HSPGs for growth factor
derivatives binding interaction
Pentosan Compete with the HSPGs for growth factor
polysulphate and receptor binding interaction
CHAPTER-3
THE CRYSTAL STRUCTURE OF 
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3.1 INTRODUCTION
Two decades earlier there were not many angiogenic molecules that 
had even been purified. Ten years down the line they are not only being 
purified by several laboratories, but one can now access the complete amino 
acid sequence of most of the angiogenic molecules known. In the past decade 
or so, the field of angiogenesis can claim three-dimensional structures of 
several molecules. In 1997, Muller et a l (1997b) determined the three- 
dimensional crystal structure of Vascular Endothelial Growth Factor-A 
(VEGF-A), the molecule central to the understanding of the process of blood 
vessel formation. While important physiological relevance of this polypeptide 
was and is still being discovered, a gene encoding another growth factor was 
located on Chromosome 14 of the human genome. This growth factor was 
named as the Placenta Growth Factor-1. It became apparent from its amino 
acid sequence that it was closely related to VEGF-A. It was found that despite 
-40% similarity, there were significant differences in the physiological 
behaviour of the two moleules. Although both of them share the ability to bind 
one of the tyrosine kinase receptors, Flt-1 (VEGFR1), they do not elicit the 
same kind of angiogenic response. These interesting differences between 
VEGF-A and P1GF-1 prompted us to undertake structural studies on P1GF-1. 
What is described in this chapter is how we went about determining the crystal 
structure of the protein in question. Initially, the structure was solved at 2.0A 
resolution (Iyer et a l , 2001). More recently a higher resolution dataset was 
collected and the structure and the resolution of the structure extended to 
1.55 A (Iyer and Acharya, unpublished results).
3.2 MATERIALS AND METHODS
3.2.1 EXPRESSION AND PURIFICATION OF P1GF-1
Placenta Growth Factor-1 protein was provided to us by our 
collaborators (Drs. D. Maglione and M.G. Persico, CNRS, Napoli, Italy). The 
material used for ciystallographic studies was recombinant human P1GF-1 
(rhPlGF-1). Production of pure rhPlGF-1 was based on recombinant DNA 
technology. The gene encoding the mature protein was cloned into a 
prokaiyotic expression vector by polymerase chain reaction (PCR). This 
vector was then used to transform DE3 Escherichia coli strain, and ImM
69
Chapter III Crystal Structure of Placenta Growth Factor-1
isopropyl-2-D-thiogalactopyranoside was used to induce the synthesis of 
P1GF-1. Inclusion bodies were purified from the induced bacteria and refolded 
in denaturing buffer and oxidising/reducing buffer. The refolded P1GF-1 
protein was then purified first by anion exchange chromatography followed by 
reverse phase chromatography. Final recovery of the protein was about 140mg 
per litre of initial bacterial culture. The angiogenic nature of the protein was 
tested using a CAM assay; the purified recombinant P1GF-1 was able to 
induce a strong and dose-dependent angiogenic response (Iyer et al., 2001; 
Maglione e ta l, 1991).
P1GF-1 is biologically active as a dimer. The dimeric nature of the 
material used for crystallisation was confirmed by the SDS-PAGE (Fig 3.1), 
under reducing conditions, done on samples from the peak of reverse-phase 





Fig 3.1 An SDS-PAGE analysis of the protein, rhPlGF-1, under non­
reducing (lane 1) and reducing (lane 2) conditions. The lane marked 
‘AT shows the Molecular weight markers used for the experiment. The
gel was stained with coomassie.
3.2.2 CRYSTALLISATION STRATEGY FOR P1GF-1
Crystals of recombinant human P1GF-1 were available at the time I
started my PhD study (grown by Dr. D.D. Leonidas, a former member of our
laboratory). I could reproduce these crystals for high-resolution structure
determination. They were grown using the hanging drop vapour diffusion
method. The drops contained 8mg/ml protein at pH 6.0 in 0.05M MES buffer,
lOmM CaCh and 7.5% (v/v) 2-methyl-2, 4-pentanediol (MPD) equilibrated
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against a reservoir solution containing 0.1M MES buffer (pH 6.0), 20mM 
CaCh and 15% (v/v) MPD. Single crystals appeared after 5-6 days at 16°C. 
The crystals show highly ordered pyramidal morphology (Fig 3.2). These 
crystals could be flash-frozen at 100K using a cryoprotectant solution 
containing 0.1M MES buffer (pH 6.0) and 30% (v/v) MPD.
A
B
Fig 3.2 (A) Crystal of Placenta Growth Factor-1. (B) PlGF-1
crystal held in the loop during X-ray data collection
3.2.3 DATA COLLECTION, PROCESSING, AND SCALING
Initially a complete dataset to 2.0A was collected at 1 0 0 K from a 
single crystal using the Synchrotron Radiation Source (station PX 9.5, 
Daresbury, UK). I used this dataset structure determination (Iyer et al., 2001). 
The data was recently extended to 1.55A resolution (collected at 100K on 
station PX 9.6, Daresbury, UK). A total of 515 images were collected 
(^=0.87A) using a CCD-ADSC detector system. Both high and low-resolution 
dataset were merged to get a master dataset at 1 .55A.
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Fig 3.3 A typical diffraction image from a PlGF-1 crystal diffracting to 1.55A 
resolution (1.5A at the edge). The inset represents a portion of the image 
zoomed in to show the high-resolution spots. The circles have been drawn to 
mark the resolution range. The data collection parameters used were: A = 
0.87A; A(p = 0.8°and exposure = 10 seconds.
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Data processing was performed with the HKL package (Otwinowski 
and Minor, 1997) in the tetragonal space group, P4. Data reduction was 
carried out using the program, TRUNCATE, of the CCP4 suite (Collaborative 
Computational Project, 1994). Even though the crystal diffracted to 1.5A 
resolution, reflections in the last shell were very weak giving a very high R sym 
of 71%. Hence the data was seeded to only 1.55A. The following table (Table
3.1) details the differences between the 2 . 0 A  and the 1.55A  datasets.
Table 3.1 Comparison o f data processing statistics o f both the 2.0A and 
the 1.55 A  resolution datasets
Data parameters P1GF-1
( 2 . 0 A )
P1GF-1 (1.55 A )
Unit cell dimensions ( A ) a=b= 62.6, c= 84.1 a=b= 62.2, c= 84.1
Reflections measured 161,044 1,078,548
Unique reflections 21,067 48,576
-^sym (%) 6.3 7.8
I/al (outermost shell) 19.6 (3.6) 10.3 (3.4)
Completeness 99.4 (98.8) 99.4 (98.9)
(outermost shell) (%)
The outermost shell corresponds to the resolution bin covering 2.07 -2 .00  A
The solvent content for the crystal was calculated using the CCP4 
supported program, matthewscoeff. This helped to determine the number of 
molecules in the asymmetric unit. Calculations showed that for one P1GF-1 
dimer (molecular weight of -29,000 Da) in the asymmetric unit, the 
Matthew’s coefficient was 2.6A3/D with the solvent content of around 51%.
Although the crystal lattice was determined as tetragonal (P4), it still 
remained to be determined which of the subgroups the crystal belonged to. 
This was confirmed by looking at the systematic absences in each of the sub­
space groups. Two criteria were chosen for a reflection to be deemed as 
present. Reflections that hold true to the general as well as special conditions
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specified for a particular subgroup should be present and the I/ctI value for 
each reflection that conforms to the former criterion should be greater than 2. 
To assign the correct space group, data were scaled in all the subgroups (P4i, 
P42, and P4 3 ) and comparisons were made. Those belonging to the higher 
subgroup (P422) were ignored on the basis of more number of asymmetric 
units in each of the higher sub-space groups, as this did not correspond to a 
sensible value for Matthew’s coefficient. Examination of the systematic 
absences showed that the actual space group was one of the two enantiomers, 
P4i or P4 3  and not P4 2 -
3.2.4 STRUCTURE SOLUTION
The structure of P1GF-1 was determined by molecular replacement 
using the program AMoRe (Navaza, 1994) in the CCP4i module. The 
SCALEPACK reflection file was converted into an MTZ format suitable for 
input to AMoRe (SCALEPACK2MTZ). The first routine in AMoRe 
(SORTING) sorted the reflection file according to the space group symmetry. 
A poly-alanine (homodimer) model based on the structure of VEGF-A 
elucidated at 1.93A resolution [PDB code-2VPF; Muller et a l , 1997b] was 
used as the search model (TABLING) to aid structure solution (one 
homodimer per asymmetric unit). Data in the range 15.0-3.0A were used for 
both the rotation and the translation function searches. A sphere radius of 20A 
was used for the cross rotation search (ROTING). Both P4i and P4 3  gave clear 
top solution with a peak height of 19.0 and an R-factor of 61%. However, 
space group ambiguity between the two enantiomers was resolved during the 
translation search (TRAING). The best solution was found in the P4 3  space 
group with a peak height of 26.3 and an R-factor of 58.1%. The peak height of 
the corresponding solution in the P4i space group decreased to 17.5 and had 
an R-factor of 60.0%. The optimised solution had a correlation coefficient of 
56% and an R-factor of 51% after rigid body refinement (FITING) against 
data in the above range (Table 3.2). The initial coordinates for 
crystallographic refinement were obtained by applying the appropriate 
rotation and translation parameters to the search model (MR2IC and 
PDBSET). The use of a well-refined search model and the high degree of
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sequence homology between P1GF-1 and VEGF-A helped in finding a clear 
solution in AMoRe without having to vary any of the search parameters like 
the resolution range, sphere radius or the model cell dimensions.
Table 3.2 Molecular Replacement results for PlGF-1
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The optimised solution from FITING is highlighted in yellow. The rotational parameters are 
described by a, p, and y. The translation search parameters are described by Ta Ty and Tr Rf refers 
to the R-factor corresponding to each solution and CC_I gives the correlation coefficient based on 
observed intensities.
3.2.5 CRYSTALLOGRAPHIC REFINEMENT
3.2.5.I P1GF-1 AT 2.0A RESOLUTION
All crystallographic refinement and model building was carried out 
using the programs CNS (Briinger et al., 1998) and O (Jones et a l, 1991), 
respectively. Procedures carried out with CNS included the slowcool protocol 
of simulated annealing at 2500K using a maximum likelihood target function, 
restrained individual B-factor refinement, conjugate gradient minimisation, 
and bulk solvent correction. The behaviour of the value [using a test set 
comprising of 811 (3.7%) reflections] was monitored throughout refinement. 
Iterative cycles of refinement alternated with model building in ‘O’ improved 
the quality of the structure and brought down both the conventional (R cry st)  as 
well as the R&ee values. During the final stages of refinement, water molecules
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were inserted into the model based on the 2Fo-Fc and Fo-Fc density using the 
program ARP-WARP (Lamzin and Wilson, 1993). One bound MPD molecule 
per monomer from the crystallization medium was identified and was 
included in the final stages of the refinement. The program PROCHECK 
(Laskowski et al., 1993) was used to assess the quality of the final structure. 
Analysis of the Ramachandran plot showed all the residues to be within 
allowed regions of the plot. The final coordinates of the structure were 
deposited with the Protein Data Bank (PDB code 1FZV, Iyer et al., 2001).
3.2.S.2 PlGF-1 at 1.55A resolution
Refinement of the PlGF-1 structure at high resolution was performed 
using the program SHELXL (Sheldrick and Schneider, 1997). The initial 
model used was the refined structure at 2.0A resolution. The refinement was 
carried against F -values rather than the F-values using the conjugate gradient 
least square algorithm during the early stages.
Table 3.3 Refinement statistics for PIGF-1, both at 2.0A and 1.55A
2 M  1.55 A
“Rayst(%) 21.6 18.1
^  free (%) 24.7 21.4
Number of protein atoms (homodimer) 1,546 1,566
Number of solvent molecules (homodimer) 132 155
Number of MPD molecules (homodimer) 2 2
R.m.s. deviation in bond lengths (A) 0.010 0.016
R.m.s. deviation in bond angles (°) 1.5 1.5
Average B-factor for protein atoms (A2) 32.6 36.6
Average B-factor for main-chain atoms (A2) 32.6 34.8
Average B-factor for side-chain atoms (A2) 32.7 38.5
Average B-factor for solvent molecules (A2) 44.8 42.6
Average B-factor for MPD atoms (A2) 31.9 31.9
B-factor (from Wilson plot) (A2) 33.9 26.9
“Rcryst =  Z  \\Fobs\ -  |Fcalc\\/Z \Fobs\, where F0 and Fc are observed and calculated 
structure factors, respectively.
bRfree is equal to Rcrystfor a random subset o f  reflections (3.7%) not used in refinement
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In the later stages, restrained anisotropic refinement was carried out for 
the protein molecule to increase the radius of convergence and for handling 
disordered regions in the structure. The solvent molecules as well as the 2 
MPD molecules (one per monomer) were not subjected to anisotropic 
refinement. Positions of difference electron density map peaks were modelled 
as waters and included in the next round of refinement. This was repeated in a 
iterative process till the Rfree value reached its minimum. The final round of 




The crystal structure of PlGF-1 was initially determined at 2.0A 
resolution with a crystallographic R-factor of 21.6% and an Rfree value of 
24.7% (Iyer et a l, 2001). Later on a higher resolution dataset was collected 
and the resolution was extended to 1.5 5A. The following is a description of 
the structure at 1.55A resolution, which refined to an Rcryst value of 18.1% and 
an Rfree value of 21.4%. Examination of the Ramachandran plot (Fig 3.4) 
shows 93.2% (as compared to 91.5% in the 2.0A structure) of the residues in 
allowed regions and no residues in the disallowed regions. PlGF-1 consists of 
a homodimer, organised in an anti-parallel arrangement with the two-fold axis 
perpendicular to the plane of the p-sheet (Fig 3.5). Two inter-chain disulphide 
bonds covalently link the homodimer. The most prominent feature of the 
structure is the presence of a ‘cysteine-knot’ motif, positioned symmetrically 
opposite at one end of each monomer. The ‘knot’ consists of an eight-residue 
ring formed by one inter-chain and three intra-chain disulphide bonds. The 
ring structure formed by two disulphide bonds on two, adjacent P-strands, p3 
and p7, has the third intra-chain disulphide bond penetrating the covalent 
linkage and connecting strands pi and p4. Cys60 and Cys69 (from each 
monomer) represent the cysteines involved in the formation of the two inter­
chain disulphide bridges, which determine the anti-parallel dimerisation of 
PlGF-1. The cysteine ring contains a conserved glycine residue at position 6 8 , 
which seems to be important in optimising the conformation of the side-chains
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in the ‘knot’. The ‘cysteine-knot’ motif appears to be important for the 
stabilisation of the dimer, as there are only a few contacts between the 13- 
strands (P l-P H  at the dimer interface.
-ISO -135 -CO
Phi •; degrees i
Fig 3.4 Ramachandran plot for the refined structure of PlGF-1 at 1.55A 
resolution. The red coloured region of the plot (A,B,L) represents residues in the 
most favoured regions; yellow region (a,b,l,p) represents residues in additional 
allowed regions; grey/buff coloured region (~a,~b,~l,~p) represents residues in 
generously allowed region and white area of the plot represents the sterically 
disallowed regions. The glycine residues are represented by triangles; A/a/~a 
represent alpha helices; B/b/~b represent beta strands, L, I, ~/ represent left- 
handed helices; p/~p represent epsilon.
The structural core of the PlGF-1 monomer consists of a four-stranded, 
highly irregular, solvent accessible p-sheet. The hydrophobic core on the 
opposite end of the ‘cysteine-knot’ provides additional stability to the central 
portion of the structure. The hydrophobic core is formed by residues from 





Fig 3.5 The three-dimensional crystal structure of Placenta Growth Factor-1 (PlGF-1; 
Iyer et al., 2001). The structure has been colour coded to differentiate between the two 
subunits. Monomer A has been coloured purple and monomer B is in cyan. The cysteine- 
knot motif (consisting of three intra-chain and one inter-chain disulphide bonds) and the 
receptor-binding surface have been highlighted at each pole of the homodimer. The 
secondary structure elements have been labelled as a  for helices and ft for strands from 
chain A and as a ' and p'from chain B. The numbering of the elements follows the chain 
from N-terminal to the C-terminal end. The figure was drawn using the program 
MOLSCR1PT (Kraulis, 1991). (Please refer to Page 178 for details on the cysteine-knot).
Fourteen potential hydrogen bond interactions (Table 3.4) are observed
between the two monomers. Two water-mediated hydrogen bonds (Fig 3.6)
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between Glu-39 from each monomer form a bridge between two strands (pi 
and pi ' )  across the centre of the dimer interface.
Table 3.4 Hydrogen bonding interactions between the two subunits of the 
PlGF-1 dimer
SOURCE (subunit A) TARGET (subunit B) DISTANCE (A)
Val24 N Thr86 0 2.8
Val24 O Gln88N 2.9
Phe26N Gln88 Oel 2.9
Arg32 Ne Glu39 Oel 2.7
Arg36 Np2 Glu39 Oel 2.8
Glu39 Oel Arg32 Ne 2.8
Glu39 Osl Arg36 Nr|l 3.0
Cys60 O Ser33 Oy 2.8
Thr86 0 Val24 N 2.8
Gln88 N Val24 0 2.9
Gln88 Oel Phe26N 2.9







Fig 3.6 The two water-mediated hydrogen bonds between chain A and B, 
across the centre of the dimer interface.
The 1.55A structure consists of a total of 155 water molecules (23 
more than that found in the 2.0A structure) and 2 MPD molecules (one ligand 
per monomer). Out of these 155 solvent molecules, 65 waters are assigned to
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chain A and 58 to chain B. Six water molecules are common to both the 
monomers and around 50 water molecules are conserved between PlGF-1 and 
VEGF-A. The total surface area of the homodimer is 11617.4A2 (calculated 
using a CNS script). Dimerisation leads to a loss of 2614.05A2 surface area, 
buried at the dimer interface (similar values were calculated for the 2.0A 
structure). The structure at both these resolutions are very similar and do not 
show many significant differences apart from the higher resolution structure 
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Fig 3.7 Pictures depicting the quality of electron density map at high 
resolution (1.55A) as opposed to the same regions in the 2.0A map.
A) a well defined Tyrosine, B) alternate conformation for Glutamate and 
C) complete side-chain density for Lysine with added interactions at high 
resolution
3.3.2 PIGF-1: SIMILARITIES AND DIFFERENCES WITH VEGF- 
A,2j AND THE OTHER CYSTEINE-KNOT PROTEINS
The cysteine-knot family of growth factors comprises of polypeptides 
like Platelet-Derived Growth Factor-BB, Vascular Endothelial Growth Factor- 
A, VEGF-B, VEGF-C, VEGF-D and P1GF. Alignment of the amino acid 
sequences (Fig 2.3) of all these molecules show that the cysteines involved in 
the formation of the disulphide ring structure have been conserved through 
evolution, maintaining the structural integrity (Fig 3.8) of the members of this 
family.
R.m.s. deviations were calculated (Table 3.5) after superpositioning 
the Ca traces of different members of the cysteine-knot superfamily using the 
program O. Overall, the structure of PlGF-1 exhibits remarkable topological 
similarity with that of VEGF-A121 (Muller et al., 1997a; 1997b) despite 
significant functional diversity. The Ca traces of PlGF-1 and VEGF-A121
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homodimer superimpose onto each other with an r.m.s deviation of 1.37A 
using 177 C“ atoms.
PDGF-BBVEGF-A
GF-p2 NGF
Fig 3.8 Ca traces of VEGF-A (2VPF; Muller et al., 1997b), PDGF-BB 
(1PDG; Oefner et al., 1992) and TGF-/32 (1TFG; Schlunegger and Grutter, 
1992) and NGF (1BTG; Holland et al., 1994) highlighting the conserved 
cysteine-knot motif in all the members, similar to that of PlGF-1 (1FZV; 
Iyer et al, 2001).
Table 3.5 Comparison of PlGF-1 with other members of the cysteine-knot 
family of growth factors with the rmsd values in A.
PIGF-1 VEGF-A PDGF-BB NGF TGF-p2
PIGF-1 - 1.4(177) 1.7(116) 25.3 (200) 24.4(190)
VEGF-A - 1.8(113) 25.2(192) 24.4(190)
PDGF-BB - 25.4(172) 25.3 (172)
NGF - 19.9 (206)
TGF-p2 -
The number in the bracket represents structurally equivalent residues.
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3.3.3 RECEPTOR RECOGNITION
V E G F-A  recognises both Flt-1 and K D R , w hich have overlapping 
binding sites on the polypeptide (M uller et al., 1997a; 1997b). It has also been 
show n that dom ains 2 and 3 o f  Flt-1 are necessary and sufficient for binding 
V E G F-A  w ith  near-native affinity. The crystal structure o f  V E G F-A  in 
com plex w ith  F lt- lo 2 at 1.7A reso lu tion  has revealed that dom ain 2 is 
p redom inantly  involved in hydrophobic in teractions w ith  the ‘p o les’ o f  the 
V E G F-A  dim er (W iesm ann et al., 1997). PIGF-1 is know n to bind and bring 
about autophosphorylation o f  Flt-1 receptor only. O f  the tw o grow th factor 
m olecules, Flt-1 has a h igher affinity  for PIGF-1. PIGF-1 can displace V EG F 
from  both truncated  and full-length  Flt-1 receptors (C lauss et al., 1996; 
B arleon et al., 1996).
3.3.3.1 STRUCTURAL DIFFERENCES BETWEEN PIGF-1 AND 
VEGF-A AT THE RECEPTOR-BINDING INTERFACE
The receptor-binding interface is m ade o f  residues from  both the 
subunits o f  the hom odim er. In PIGF-1, the interface com prises o f  residues 25- 
33 (16-24)* from  the a l  helix , residues 70-75 (61-66) from  the loop betw een 
p3 -p4  and residues 112-114 (103-105) from  p7 strand o f  one m onom er and 
residues 55-57 (46-48) o f  strand P2' and residues 88-98 (79-89) from  p '5 , 
loop betw een p 5 '-P 6 ' and p6 ' *(the num bers in brackets represent 
corresponding residues in V EG F-A ).
P I G F - l
VEGF
Fig 3.9 Stereo view o f the superpositioned Ca traces o f PIGF-1 and 
VEGF-A. The PIGF-l trace is in cyan and that for VEGF-A is in brown.
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Superposition o f  the C a traces o f  V E G F-A  and P1GF-1 (Fig 3.9) reveal 
conform ational differences betw een P1GF-1 and V E G F-A  at the N -term inal 
region, som e loop regions and the C -term inal region. Interestingly, these loop 
regions form  a  part o f  the receptor-b inding  in terface in both m olecules.
3.3.3.2 LACK OF KDR RECOGNITION
A detailed m utagenesis study o f  V E G F-A  by M uller et al (1997a)
identified  eight am ino acid residues form ing part o f  the K D R  binding site.
These w ere grouped as m ajor and m inor ‘hot-spots ’ for receptor recognition.
A m ino acid sequence alignm ent (Fig 3.10) show s that o f  the six  m ost
im portant K D R  binding determ inants (the m ajor hot-spot) o f  V E G F-A , only
tw o residues from  V E G F-A  (G lu-64 and Ile-83) are conserved in P1GF-1
(G lu-73 and Ile-92) and both residues from  the m inor hot-spot are conserved
in the tw o structures.
a l  p i  a 2  ft2AW
S S E V E V V  PI  Q E V W G R S A C R A L E R L V D V V S E Y P S E V E H M F S  
- N H H E V V K K M D V Y Q R S Y  C H P  I E T L V D  I F Q E Y P D E I E Y  I F K
MAAAAAM AAA
P S C V S L  L R C T G C C G D F M  H C V P V E T A N V T M Q L L K  R S G D R  
P S C V P L M R C G G C C N  D E G I  E C V P T E E S N  I T M Q  I Y I R 1 K P I  QG
(36 P7
P S Y V E L T F S Q  H V R C E C R P L R E  K Helix
Q H I G E M S F L Q H N K C E C R P K K D R
>  ** <«*{► Strand
Fig 3.10 The sequence alignment o f PlGF-1 (top sequence) and VEGF-A 
(bottom sequence). PlGF-1 residue numbering starts from 18 and that for 
VEGF-A starts from 10. Residues coloured red represent helix and blue coloured 
residues make up the strands. The alignment highlights the residues that are 
receptor-binding determinants. The residues coloured green recognise Flt-1 and 
KDR in VEGF-A. The corresponding residues in PlGF-1 (for Fit-1) have also 
been shaded similarly for comparison. The conserved cysteines are shown in 
pink.
85
Chapter III Crystal Structure of Placenta Growth Factor-1
In PlG F-1, residues A sp-72, G lu-73, V al-52, M et-55, V al-45, Asp-43 
and Ser-59 form  the w alls o f  the groove. The corresponding groove in V EG F- 
A is form ed by residues A sp-63, G lu-64, Ile-43, Ile-46, Phe-36, A sp-34 and 
Ser-50, w hich are im plicated  for recognition o f  dom ain 3 o f  Flt-1 (Fig 3.11).
This com parison show s that there is a high degree o f  conservation o f  
residues in th is region betw een the tw o m olecules. H ow ever, at the structural 
level one can visualise significant changes in conform ation  that could be one 






Fig 3.11 Superpositioned Ca trace representations o f the groove between 
the two subunits o f PlGF-1 (residues coloured in brown) and VEGF-A 
(residues coloured in cyan). The amino acids o f PlGF-1 are labelled with 
small lettering whereas the corresponding amino acids in VEGF-A are with 
capital lettering.
3.3.4. PIGF-1*FLT-1D2: A MODELLED COMPLEX
The crystal structure o f  V EG F-A  in com plex w ith F it-102  w as 
determ ined at 1.7A reso lu tion  (W iesm ann et al. ,  1997). I f  w e visualise a 
sim ilar picture for a hypothetical com plex, PlGF-1 •F lt-1 , w ith  d o m ain -1 o f  
the receptor pointing aw ay from  PlG F-1, the dom ain  2-3 linker region will 
occupy the groove (6 .8A w ide) betw een the tw o m onom ers and dom ain  3 will 
m ake contact w ith its bottom  face. This w ould  bring dom ain 4 o f  the receptor
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at each pole o f  the d im er into d irect contact w ith  each other, m aking in ter­
receptor contacts and hence leading to  receptor dim erisation.
U sing the structural data from  the V E G F * F lt-lo 2 com plex, we 
constructed  a  m odel to visualise the b inding m ode betw een PlGF-1 and Flt-1. 
The PlGF-1 •F lt- l  D2 com plex (Fig 3.12) w as m odelled  by superim posing the 
atom ic co-ord inates o f  the V E G F«Flt-lD 2 com plex [PDB code-1 FLT; 
W iesm ann et a l,  1997] on to  the PlGF-1 m odel fo llow ed by energy 
m inim isation  using the program  X -PL O R  (B runger, 1992b).
Fig 3.12 The modelled PlGF-1 •Flt-l complex based on the crystal 
structure o f VEGF»Flt-l0 2  complex [PDB code-1 FLT; Wiesmann et al, 
1997]. The two monomer o f PlGF-1 have been coloured differently with 
chain A in orange and chain B in cyan. The Flt-l02 domains at the two poles 
o f the homodimer are also in different colours (green and purple).
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In order to quantify  the shape com plem entarity  (Sc) o f  the receptor- 
ligand interfaces and get an estim ate  o f  the  "goodness o f  fit" betw een the tw o 
protein  surfaces, the coord inates ou tput after m inim isation in X PLO R  were 
put through SC (C C P4, 1994) to com pute values o f  Sc for the interface region 
betw een tw o m olecules. Shape com plem entarity  statistic for interface betw een 
PlGF-1 and Flt-1 w as calculated  to  be around 0.43 for a probe radius o f  1.7A. 
W hen com pared w ith  the Sc value (0.63) for the receptor-ligand interface in 
the crystal structure o f  V E G F-A *F lt-l com plex, the Sc statistics for the 
m odelled  com plex is on the low er side. B ut since this value is not com puted 
from  actual experim ental data, it appears to be reasonable. A lso the buried 
surface area (2614.05A 2) at the in terface (com puted using a CN S script) is 
sim ilar to w hat is expected  from  tw o interacting protein surfaces.
A H223A ' ix .V i  "TC
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Residues at the interface o f the PlGF-1 •Flt-1 complex model.











Residues at the ligand-binding interface o f Flt-1.
Fig 3.13 Stereo representations o f the residues from the modelled complex
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The residues at the interface of PlGF-l*Flt-lD2 complex seem to 
comprise of about 25 amino acids from the PlGF-1 molecule, residues being 
contributed by both the monomers and around 17 residues from each of the 2  
Flt-1 d2 molecules, one at each pole of the PlGF-1 homodimer. The binding 
appears to be mainly mediated through a large number of hydrophobic 
interactions. The general mechanism of Flt-1 recognition by PlGF-1 seems to 
be very similar to that reported for VEGF-Flt-1 interaction. The stereo pictures 
in Fig 3.13 show the residues from both the components of the receptor-ligand 
complex (model), which interact at the binding interface.
Table 3.6 Putative intermolecular polar interactions (3.4A) between 
PlGF-1 and Flt-10 2  at the receptor-ligand interface in PlGF-1 •Flt-l 
complex.
PlGF-1 Flt-1 D 2 Distance (A)
Molecule A
Gln27 O el Asn219N82 2.9 (3.2)
Asp72 081 Arg224 Ne 3.2 (3.3)
Asp72 081 Arg224 Nr|2 3.2 (3.2)
Ala74N Arg224 Nr|2 3.0 (3.1)
Molecule B
Gln27 O el Glul41 0 3.2 (3.5)
Gln27 O el Pro143N 3.2 (3.5)
Tyr34 OH Lyzl71N^ 3.1 (3.3)
Glull2 0 e 2 Aspl75 081 3.2 (3.0)
Asp72 081 Arg224 Ne 3.0
TyrlOO OH Prol43 O 3.2
The values in the brackets are from the modelling studies using the 2.0A structure. The 
interactions given in bold font are exclusive to the complex where the 2.0A structure 
was used.
The intermolecular hydrogen-bonding interactions between the Flt-1 
receptor and PlGF-1 at 2.0A or at 1.55A resolution were almost identical 
except for the absence of the two contacts highlighted in Table 3.6. A similar
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case was observed with the van der Waals contacts between the receptor and 
the ligand at both resolutions. Also, it was observed that the interactions in the
Table3,7 Putative intermolecular van der Waals contacts 
PlGF-1 and Flt-10 2  at the receptor-ligand interface in the
between
modelled
PIG F-1 FIt-lni C ontacts
M olecu le  A  o f  P lG F -1
Phe26 P ro l43 , L eu221(2) 3
G ln27 P ro l43 (5), L eu204(3), A sn219(4) 12
Trp30 L eu221 1
Tyr34 L y sl7 1 , P h e l7 2 , Pro 173 (2) 4
A sp72 T yrl99 , Ile202(12), Arg224 14
Ala73 Arg224 3
A la74 A rg224 5
Leu75 T y rl9 9 (4), Ile202 5
G ln88 lie  142 1
TyrlOO I le l4 2 (3), Pro 143 4
G lu ll2 L eu174 1
P r o l15 T yrl99 11
M olecu le  B  o f  PIG F-1
Phe26 P ro l43 (4), Leu221(2) 6
G ln27 G 1 u 1 4 1 (3), I le l4 2 (2), P ro l4 3 (10), L eu204(2), A sn219(3) 20
Gly31 P h e l7 2 2
Tyr34 P h e l7 2 3
A sp72 Ile202(6),A rg 2 2 4 (7) 13
A sn74 A rg224 6
Leu75 T yrl99 2
G ln88 lie  142 3
Leu90 He 145 2
Ile92 H is223 1
TyrlOO Ile l4 2 (4), Pro 143 5
G lut 12 A sp 175 4
P r o l15 T yrl99 10
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VEGF-A«Flt-l complex were largely similar to those in the modelled complex 
as far as van der Waals contacts were concerned (Table 3.7).
3.3.5. MUTAGENESIS STUDIES ON PIGF-1
Based on the native structure of PIGF-1 and the interactions between 
PIGF-1 and domain 2 of the receptor, Flt-1 D2, five residues from PIGF-1 
seemed to stand out more than the others, those which were involved in either 
polar or van der Waals interactions with the Flt-1 residues. These residues 
were Gln27, Asp72, Glu73, Pro98 and TyrlOO {Table 3.7 and 3.8). So, in order 
to assess the contribution of each of these residues towards binding to Flt-1, it 
was decided to perform mutagenesis studies on PIGF-1. All these 5 residues 
were mutated to alanine. The mutations involved 4 single mutations: Q27A, 
D72A, P98A and Y100A and one double mutant: D72AE73A. The double 
mutant was decided upon because they were the only two residues making 
direct hydrogen bonds with the Flt-1 residue, Arg224. The variants were then 
tested for their ability to bind to soluble Flt-1 (sFlt-1). These experiments were 
performed by our collaborators and the results of this mutagenesis study is 
represented graphically in Fig 3.14 and Fig 3.15.
-+-Q27A 
•  DE7273AA 
-o -Y lO O A
6 8 10 12 
Human PIGF variants ng/ml
Binding Assay  to  soluble F lt-1 (0 ,5  ug/ml)
1.4
— WT 
- X -  D72A 
-A -P 9 8 A
Fig 3.14 Affinities of the wild-type PIGF-1 and the various mutants as determined 
by using a binding assay that measures binding affinities using varying 
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Fig 3.15 Percentage binding of human PIGF-1 variants to soluble sFlt-1. 
The bar on the extreme left represents 100% binding by the Wild-type (WT) 
human PIGF-I. The bars for the various mutants have been coloured red.
It can be seen from the graphs that as expected the double mutant 
D72AE73A loses its ability to bind to sFlt-1 completely. The corresponding 
residues in VEGF-A produce similar effects. What is unexpected though is the 
effect of Q27A mutation. This mutation seems to be affecting P1GF more than 
it did VEGF-A. However, the mutagenesis studies with VEGF-A were done to 
determine the binding affinities for KDR and not Flt-1 (Muller et a l, 1997a).
3.4. DISCUSSION
Placenta Growth Factor-1 is yet another example of a functionally 
diverse protein arisen through gene duplication. Divergent evolution has given 
rise to proteins that have very little sequence identity but exhibit remarkable 
topological similarities. The members of the cysteine-knot superfamily are all 
dimeric forms although each one is stabilised in different ways. The 
disulphide bonds bring together the p hairpins, which display a topologically 
equivalent hydrogen-bonding pattern. The identical alignment of the
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equivalent half cysteines in the disulphide cluster is a result of a remarkably 
similar hydrogen-bonding pattern around the disulphide cluster.
Structure-based drug design of small molecule antagonists or agonists 
requires a detailed three-dimensional structural and functional characterisation 
of the target molecule. The structure of PIGF-1 shows that although it has a 
structural fold very similar to that of VEGF-A, it displays important 
conformational differences, especially in the flexible loops that form part of 
the receptor-binding region of PIGF-1. It has been known that the solvent- 
exposed loops undergo concerted movements, which decide the receptor- 
specificity for VEGF-A. In PIGF-1, the flexibility of the loop connecting 
strands 05 and 06 is somewhat restricted compared to the corresponding loops 
in VEGF-A. This is because of amino acid changes involving two prolines that 
affect the movement of the loop vis-a-vis their physical properties. There are 
some other changes in the sequence of PIGF-1 at the receptor-binding 
interface that probably correspond to the inability of PIGF-1 to induce 
proliferation of endothelial cells despite its ability to bind Flt-1 like VEGF-A. 
These changes include R93K, G95H and Y100I. These changes might also 
explain why PIGF-1 has a lower affinity for Flt-1 than VEGF-A and its 
inability to displace VEGF from Flt-1. A single change from Ile46 in VEGF to 
Met55 in PIGF-1 significantly affects its binding affinity for KDR. 
Structurally, it was seen that unlike Ile46 in VEGF-A, the side chain of Met55 
is facing away (Fig 3.11) from the groove where Flt-1 /KDR is proposed to 
bind the ligand (Muller et al., 1997a; Keyt et al., 1996).
The structure of the PIGF-1 •Flt-1 complex is yet to be elucidated. 
However, based on the structure of the VEGF-A*Flt-l complex (Wiesmann et 
al., 1997) it can be postulated that Flt-1 binds at the monomer-monomer 
interface of PIGF-1 and not exclusively to each of the subunits in the dimer. 
Domain deletion experiments had revealed that domain 2 and 3 of Flt-1 
contain the key determinants required for signalling. These experiments have 
mapped the ligand-binding residues to the second domain and those important 
for receptor dimerisation have been characterised as domain 3 residues (Davis-
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Smyth et a l, 1996). Mutagenesis studies and the crystal structure of the 
complex reveal the binding determinants on Flt-1 for VEGF-A. Davis-Smyth 
et al (1996) have identified Glul37, Argl59, Lysl71, Glu208, His223 and 
Arg224 as critical determinants of PIGF-1 binding. Modelling studies showed 
that Gln27, Tyr34, Asp72, TyrlOO and G lull2 could make both hydrogen 
bonding and van der Waals contacts with the residues implicated in PIGF-1 
binding. However, these modelling data need to be substantiated with the 
complex structure of PIGF-1 with Flt-1 that will unravel the exact orientation 
of PIGF-1 when it binds Flt-1. This would be very useful, as the modelling 
study is based on the assumption that both PIGF-1 and VEGF-A bind to Flt-1 
in an analogous fashion.
The native structure of PIGF-1 contains 155 solvent molecules out of 
which 30 are buried structural waters that bring together the different 
secondary structure elements within the two monomers. The nature of 
interaction of protein residues with solvent molecules, especially at the 
receptor-ligand interface is of great interest as it has direct implications for 
drug design. The energetics of complex formation involves considerable 
tradeoffs between loss of protein-water interactions and gain of protein-protein 
interactions. A careful analysis of the solvent structure in the native PIGF-1 
reveals that there is an apparent correlation between the number of water 
molecules bridging the receptor and the protein in the modelled PlGF-l*Flt-l 
complex and the number of water molecules found at the protein surface in the 
unliganded molecule. Although most of the receptor-ligand interactions are 
mediated via hydrophobic residues in both Flt-1 and PIGF-1, there are about 
11 waters at the receptor-binding interface of PIGF-1 that make hydrogen- 
bonding interactions with the same residues (Gln27, Trp30, Gly31, Tyr34, 
Asp72, Ala73, TyrlOO and Prol 15) that contact Flt-1 {Table 3.6) in the 
modelled complex. These solvent molecules can perhaps be assigned as 
displaceable water molecules. These will most probably be sacrificed when 
PIGF-1 forms a complex with the Flt-1 receptor and the interactions they 
make in the unbound protein will be compensated by protein-protein 
interactions.
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The unliganded structure of PIGF-1 is a starting point for designing 
drug molecules that can either activate Flt-1 and therefore potentiate VEGF-A 
stimulation or inhibit Flt-1 stimulation by binding either to Flt-1 or PIGF-1 
itself. The drugs can either be small molecule activators/inhibitors or peptides 
that target the protein-protein interaction sites. Such peptides have a great 
pharmacological value and are possible candidates that can be developed 
further as potential therapeutics.
Only certain types of tumours, namely thyroid tumours and germ cell 
tumours, produce P1GF, unlike VEGF-A, that is produced by all tumour types. 
P1GF is expressed in these tumours and in inflamed tissues (Takahashi et al, 
1994; Kodama et a l, 1997), and this expression is probably a consequence of 
angiogenic factors being released from the extracellular matrix. Most of the 
earlier experiments were done with recombinant human PIGF-1, which was 
angiogenic only under certain conditions. These raised several doubts and 
questions regarding the role of endogenous PIGF-1 in angiogenesis. The 
recent results reported by Carmeliet et a l (2001) based on gene inactivation 
experiments in mice, answer some of these queries. Their experiments showed 
that loss of P1GF correlated with impaired angiogenesis. Although P1GF 
deficiency hardly affects vascular development, the absence of the protein 
affected VEGF-dependent endothelial cell survival, migration and 
proliferation. Their results indicate that even though P1GF on its own is not an 
effective inducer of angiogenesis, it does potentiate the activity of VEGF-A in 
physiological conditions. Also, the expression of P1GF in pathological 
conditions indicates that it might induce the angiogenic switch by increasing 
the bio-availability of VEGF.
Another important aspect that links P1GF and VEGF is the ability of 
the two cytokines to form heterodimers. It has been now proven that PIGF-1 
binds to VEGF-A and reduces the bio-availability of VEGF-A (Cao et a l,
1996) or, at the other extreme, augments the activity of low concentrations of 
VEGF-A (Park et a l, 1994). P1GF/VEGF heterodimers are somewhere 
between P1GF and VEGF-A homodimers vis-a-vis their mitogenic ability. 
Chick chorioallantoic membrane (CAM) assays show that the heterodimers,
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unlike the P1GF homodimers, can bind to KDR through which they exert their 
stimulatory effects on endothelial cell proliferation (Kurz et a l, 1998).
VEGF-A is the angiogenic cytokine that has been experimentally 
shown to be responsible for initiation of angiogenesis. It is believed that 
VEGF is a promising candidate in therapeutic angiogenesis because of its 
ability to induce vasodilation and enhance vascular permeability. Therapeutic 
angiogenesis, as opposed to anti-angiogenesis therapy, involves stimulation of 
blood vessel formation in diseases like ischemia, atherosclerosis, thrombosis, 
restenosis etc. Studies based on VEGF-mediated angiogenesis therapy show 
mixed results (Isner, 1999), and as a consequence it is not possible to draw 
any substantial conclusion from them. Also, such a therapy is shrouded by 
risks of unwanted neo-vascularisation (Zachary et a l, 2000; Maglione et a l, 
2000).
Recently, however, P1GF seems to be making waves not only because 
of its similarity to VEGF but also because of its ability to augment the activity 
of VEGF. A fundamental reason that makes P1GF such a promising factor is 
that on its own P1GF cannot initiate endothelial cell stimulation. Relatively 
speaking, PIGF-1 has no permeability activity compared to VEGF (Maglione 
et a l, 2000). So, in effect, this growth factor should not have any adverse 
effects on the blood vessels, both near and far off from the site of 
administration. P1GF would only enhance the effects of the available low 
concentrations of endogenous VEGF (Park et a l, 1994). Another important 
factor that goes in favour of P1GF is that it can stimulate the recruitment and 
activation of monocytes via the Flt-1 receptor (Clauss et a l, 1996). Monocyte 
recruitment is yet another essential step in the process of formation of mature 
vascular networks, especially collateral growth of blood vessels. It is not 
known as yet whether or not VEGF alone is sufficient for collateral vascular 
growth.
It was shown in animal models that recombinant PIGF-1 explicates 
protection from isoprenaline-induced ischemic lesions in the heart without 
influencing the heart beat rate (Maglione et a l, 2000). Although these findings 
need to be confirmed with human-based experiments, it is safe to suggest that
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PIGF-1 could be considered as a potential therapeutic agent for ischemic 
myocardial infarction. Also, evidence and reasoning seem to suggest that since 
P1GF acts synergistically with VEGF (Carmeliet et a l , 2001), a combination 
therapy of VEGF and P1GF would probably be more effective in the treatment 
of cardiovascular diseases.
3.5 FURTHER CRYSTALLOGRAPHIC STUDIES WITH PIGF-1
3.5.1 INTRODUCTION
Concomitant with the identification of inducers of blood vessel 
formation, came the discovery of molecules that inhibit the process. 
Thrombospondin-1 (TSP-1), endostatin, angiostatin, interferon-y (IF-y), 
prolactin etc are some of the endogenous inhibitors of angiogenesis. VEGF-A 
is a primary regulator of the process and stimulates mitogenesis of vascular 
endothelial cells by interactions with KDR (VEGFR-2) and/or is involved in 
organisation of the vasculature by interactions with Flt-1 (VEGFR-1). Because 
of association of VEGF-A with various pathological conditions like tumours, 
arthritis, atherosclerosis, cancer etc, antagonists targeting VEGF-A are 
clinically very important. A variety of antagonists have been described e.g. 
small-molecule inhibitors, endogenous inhibitors like angiostatin and 
endostatin, synthetic inhibitors and peptide inhibitors. Natriuretic peptides 
were the first peptide inhibitors shown to inhibit endothelial cell proliferation 
and invasion by inhibition of VEGF synthesis (Pedram et al., 1997). Inhibition 
of EC proliferation can also be brought about by peptides that are derived 
from exon 7 of the VEGF-A gene (Soker et al, 1997). This exon represents 
the structural difference between VEGF-A121 and VEGF-A165 (Leung et a l , 
1989; Keck et a l , 1989; Houck et a l, 1991; Poltorak et al 1997) and 
facilitates the binding of VEGF-A165 to neuropilin- 1  (NP-1).
Since KDR plays an important role in VEGF-A mediated proliferation 
and invasiveness of ECs during vascularisation and tumour-induced 
angiogenesis, most of the peptide inhibitors identified target VEGF-A-KDR 
interaction. Of the isolated peptides that bind KDR specifically, the peptide 
with the sequence ATWLPPR completely inhibited VEGF-A mediated
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angiogenesis by blocking VEGF-A binding to KDR (Binetruy-Toumaire et 
al, 2000). Screening of phage display library led to the construction of two 
different types bi-specific antibodies. One diabody was directed against two 
different epitopes on KDR (VEGFR-1) and blocked VEGF-A induced 
activation of the receptor as well as mitogenesis of human ECs. More recently, 
however, a bi-functional diabody was constructed against both the VEGF-A 
receptors, Flt-1 (VEGFR-1) and (KDR) VEGFR-2. This antibody completely 
inhibits all of VEGF-A activities (Lu et a l, 2001).
In 1998, Fairbrother et al (1998) used a technique involving a 
multicopy display of random peptides on fl filamentous phage particles to 
identify small disulphide-constrained peptides targeting the receptor-binding 
site of VEGF-A. These peptides were able to block interaction of VEGF-A 
with both Flt-1 (VEGFR-1) and KDR (VEGFR-2) by binding to a region that 
contained the binding determinants for both the tyrosine kinase receptors. 
Since receptor-dimerisation is an important consequence of receptor-ligand 
interaction, prevention of this step would inhibit signal transduction and 
eventually prevent blood-vessel formation.
With the increasing evidence linking PIGF-1 with VEGF-A, especially 
on account of their ability to form heterodimers (Cao et a l, 1996) and the 
synergistic relationship between the two (Carmeliet et a l, 2001), it is 
becoming evident that PIGF-1 inhibitors are just as important. Now that the 
crystal structure of the native protein has been solved the next step is 
structure-based design of inhibitors. The VEGF-A binding peptide 
(Fairbrother et a l, 1998) provided a starting point for this experiment, the aim 
of which was to elucidate the structure of PIGF-1 in complex with the 
receptor-blocking peptide.
3.5.2 CRYSTALLISATION STRATEGIES
Recombinant human PIGF-1 was provided to us by our collaborators 
(Drs. D. Maglione and M.G. Persico, CNRs, Naples, Italy). The pure protein 
was used to grow native crystals for soaking experiments as well as to grow 
co-crystals of PIGF-1 with the inhibitor peptide. Two different peptides were
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synthesised, a 20mer and a hexamer, at Department of Biochemistry, School 
of Medical Sciences, Bristol. Peptide I (the 20mer) was the same as the 
receptor-blocking peptide (vl08) used to determine the structure of the 
complex of the peptide and VEGF-A (Wiesmann et al., 1998). The sequence 
of the peptide was ‘RGWVEICAADDYGRCLTEAQ’. Peptide II (the 
hexamer) was derived from the 2 0 mer but was based on the peptide sequence 
designed to bind PDGF and prevent the ligand-induced receptor- 
autophosphorylation. These novel growth factor binding molecules have 
potent anticancer and anti-angiogenic activity (Blaskovich et a l, 2000). The 
sequence of the hexamer used for crystallisation purposes was ‘AADDYG’.
The concentrations of the peptides used for soaking experiments were 
0.5mM, l.OmM, 2,0mM, 3.0mM and 5mM. For co-crystallisation experiments 
the concentrations initially used were according to that used for growing 
crystals of VEGF-A with vl08 [10% molar excess of 20mg/ml of VEGF-A 
w.r.t. 1.5mM peptide (vl08); Wiesmann et al., 1998]. Since, most of the initial 
co-crystallisation trials produced very tiny crystals, the concentration of P1GF- 
1 was dropped from 27mg/ml to 16mg/ml (the same as that used to grow 
native PIGF-1 crystals).
First attempts at crystallisation were done with the 20mer peptide 
(vl08). Soaking experiments were carried out with various concentrations (as 
mentioned above). Since soaking experiments did not work favourably, two 
possibilities were tried. One was to truncate the 20mer to a hexamer (based on 
Blaskovich et al., 2000) to facilitate the entry of the peptide into the crystal 
lattice and to set up co-crystallisation experiments. Initially, the native PIGF-1 
conditions (Iyer et a l, 2001) were used to crystallise the complex. Later on a 
variety of crystallisation conditions were tried. The crystals were grown at 
16°C by the hanging drop vapour diffusion method. Drops containing 2 pi of 
the PIGF-Npeptide solution and 2pi of the reservoir solution were 
equilibrated against 700pl of the reservoir. Crystals appeared after 3-4 days 
when grown using native PIGF-1 condition. But the other crystallisation 
conditions produced crystals after about 10-15 days. Some of the conditions
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that produced crystals have been summarised in the form of a table (Table 
3.8).
Table 3.8 Some o f the crystallisation trials for PIGF-1 with the peptide
Crystallisation Condition Observations
20mM CaCl2, 1.0M MES (pH Very small, pyramidal
a 6.0), 15.0% (v/v) MPD crystals
0.2M ammonium acetate, 0.1M Big pyramidal crystals
b Na citrate (pH 5.6), 30% MPD
30% MPD, 5% PEG 4000, 01M Big pyramidal crystals
c Na HEPES (pH 7.5)
30% MPD, 10% PEG 4000, Big pyramidal crystals
d 01M Imidazole HC1 (pH 8.0)
e 47% MPD, 2% tert-butanol Big pyramidal crystals
f 50% MPD Big pyramidal crystals
3 . 5 . 3  D A T A  C O L L E C T I O N ,  P R O C E S S I N G  A N D  S C A L I N G
X-ray diffraction data sets were collected on different stations at SRS, 
Daresbury, UK. Data collection from these crystals was performed by 
transferring the crystal into their respective cryoprotectant solution, mounting 
them in a loop and then exposing them to the X-rays under a stream of liquid 
nitrogen at 100K. Data processing statistics are given in Table 3.9.
3 . 5 . 4  S T R U C T U R E  R E F I N E M E N T  A N D  R E S U L T S
Since all the crystals were characterised to belong to the same space 
group as the native PIGF-1 crystal, it was not necessary to determine the initial 
protein phases. The structure of PIGF-1 solved to 2.0A resolution (Iyer et a l, 
2001) was used as a starting model for refinement purposes. A single round of 
refinement including simulated annealing lowered the R-factors considerably. 
Both 2|F0bS|-|Fcaic| and | F 0bS|- |F c a ic | maps were calculated for each dataset. 
Examination of the electron density maps did not reveal any region of the map 
that was not accounted for.
100
Chanter III Crystal Structure of Placenta Growth Factor-1






CRYSTALLISATION TRIALS WITH THE 20MER (v!08)
5.0mM soak 1.55 1,078,548 48,576 99.4 (98.9) 10.3 (3.4) 7.8(50.1)
3.0mM soak 2.7 107,223 9169 89.5 (89.8) 8.6 (2.2') 10.4(41.8)
Native condition 1.7 541,655 37,720 95.6 (79.7) 19 (3.7) 5.0 (31.3)
CRYSTALLISATION TRIALS WITH THE HEXAMER
2.0mM soak 2.0 380,550 21,388 99.9 (99.9) 23.5(4.1) 8.0 (54.3)
l.OmM soak 2.59 111,530 10,116 98.9(92.1) 11.2(2.3) 12.0 (55.6)
0.5mM soak 2.6 144,574 10,021 99.9 (99.8) 22.2 (7.7) 10.4
crystal b 2.2 149,240 15,533 96.0 (96.8) 13.2 (3.3) 7.6(41.9)
crystal c 2.27 161,420 15,070 99.7 (100) 177.5 (9.9) 7.5 (15.4)
crystal d 2.13 382,862 17,846 98.9 (95.5) 24.2 (10.5) 7.7 (15.4)
crystal e 2.13 177,288 18,331 99.8 (99.6) 21.0 (9.6) 6.7 (13.0)
crystal f 2.13 268,211 17,372 97.3 (92.7) 19.7 (9.4) 7.8 (14.5)
The crystals b, c d, e and f  represent crystals grown from conditions tabulated in Table 3.8. All the crystals grown in these 
conditions belonged to space group P43 and their unit cell dimensions were isomorphous with the native PIGF-1 crystals.
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3 . 5 . 5  D I S C U S S I O N
The use of the inhibitor peptide (vl08) in the present study was based 
on the crystal structure of this peptide in complex with VEGF-A (Wiesmann 
et al., 1998). This peptide was shown to bind to the receptor-binding surface 
of VEGF-A. The crystal structure of this showed that the inhibitor peptide 
contacts VEGF-A residues via the a2-p2 loop region and the p strands P5 and 
P6  of one monomer and residues from the helix a l  of the other monomer (Fig 
3.10). The residues identified at the interface form the binding site for both 
Flt-1 and KDR (Keyt et a l, 1996; Muller et al., 1997a; Wiesmann et al.,
1997). The significant degree of overlap between the receptor-binding and the 
peptide-binding sites on VEGF-A and the fact that the general mechanism of 
Flt-1 recognition by PIGF-1 seems to be very similar to that of VEGF-A 
justified the use of the same peptide for PIGF-1 as well.
In order to make sure that the interactions between the peptide and 
PIGF-1 were similar to that between VEGF-A and the inhibitor, we decided to 
dock the peptide against the native structure of PIGF-1. This was 
accomplished by superimposing the complex of VEGF-A with the receptor- 
blocking peptide on to the native PIGF-1 structure (Iyer et al., 2001) followed 
by energy minimization using the program X-PLOR (Briinger, 1992).
Fig 3.16 Interface residues in the modelled PIGF-1 »Peptide complex 
(based on the crystal structure of VEGF-A in complex with the inhibitor 
peptide (vl08); Wiesmann et al., 1998). The residues from the peptide 
have been coloured in green and the PIGF-1 residues have been 
coloured in cyan.
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Interactions between PIGF-1 and the peptide residues at the binding 
interface (Fig 3.16) seem to be similar to that between VEGF-A and the 
inhibitor. Residues Gln27, Ile92, TyrlOO and Prol 15 of PIGF-1 make 
hydrogen-bonding interactions (Table 3.10) with the residues from the 
peptide. Similar to VEGF-A residues, these residues form a part of the 
receptor-binding surface in PIGF-1.
Table 3.10 The Hydrogen bonding interactions between the 
peptide residues and the PIGF-1 residues at the interface in the 
modelled PIGF-1 •Peptide complex.







Our initial attempts at obtaining the complex through soaking 
experiments failed although several concentrations of the peptide as well as 
different soaking times were tried. Inspection of the packing of PIGF-1 in the 
crystal lattice with its symmetry related molecules (Fig 3.17) showed it was a 
very tight arrangement. There wasn’t enough space between the molecules for 
a 20 amino acid long peptide to be able to enter the crystal lattice through 
simple soaking. This prompted the truncation of the 20mer to a hexamer (Fig 
3.18). The six amino acids retained were based on the results of a study 
undertaken by Blaskovich et al. (2000) wherein they designed a molecule 
GFB-111 that bound PDGF (Platelet-derived Growth Factor) at its receptor- 
binding site and had a highly potent anticancer and anti-angiogenic activity. 
Experiments with the hexamer, both soaking and co-ciystallisations trials did 
not come through. Interestingly, the crystallisation conditions (Table 3.8) 
indicated MPD to be a common and perhaps an important factor for crystal
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Fig 3.17 Packing arrangement 
of PIGF-1 and its symmetry 
related molecules in the crystal 
lattice.
G F B P : G D D Y
2 0 - m e r :  R G  W V E I C  A  A  D D  Y  G R C L T E  A Q
H e x a m e r :  A A D D Y G
Fig 3.18 The amino acid sequences of the GFB (growth 
factor binding peptide), the 20mer (v!08) and the hexamer.
growth as none of the conditions without MPD ever produced any crystals. 
MPD seems to be very important for crystal contacts as a result of which all 
the crystallisation conditions, despite varying buffer and pH, produce 
tetragonal crystals in identical space group and with almost similar cell 
dimensions. A careful inspection of the region around MPD in the PIGF-1 
crystal lattice shows that MPD and the peptide have overlapping binding sites 
(Fig 3.19). Although they do not interact with the same PIGF-1 residues, the 
presence of MPD molecule appears to hinder the incorporation of the peptide 
into the crystal lattice during crystal growth. Since conventional attempts at 
producing co-crystals have been unsuccessful, perhaps mutation of residue 
Thrl04 might help arriving at a condition that does not require MPD for 
crystal growth. It is evident from these observations that it is imperative to 
displace MPD from its position in order to facilitate binding of the peptide to
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PIGF-1. De-convolution of common structural features (those involved in 
interactions with PIGF-1) between MPD and the peptide might help in the 
design of a small molecule inhibitor targeting the receptor-binding site on 
PIGF-1.
Fig 3.19 Overlay of the native structure of PIGF-1 (yellow) and the 
modelled PIGF-l•PEP complex. Both the MPD (magenta) in the 
native structure and the peptide (green) in the modelled structure 
occupy an overlapping position.
3.6 FUTURE PROSPECTS
Conformational differences at the receptor-binding interface between 
the structures of PIGF-1 and VEGF-A121, despite a high degree of sequence 
homology, have uncovered crucial structural insights that are valuable in the 
rational design of novel angiogenesis inhibitors. Further structural studies are 
required on PIGF-1 that would be largely based on receptor-ligand complexes. 
The structural basis behind Flt-1 receptor specificity of PIGF-1 and the other 
isoforms may lead to the development of receptor/ligand specific therapeutics.
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This needs to be complemented with the characterisation of the entire 
sequence of events that occur during PIGF-1 induced signal transduction. The 
next step would then be to correlate the signalling events with the topological 
details of the ligand and the receptor at the binding interface. Also, the 
elucidation of the three-dimensional structure of P1GF-2, the heparin binding 
isoform, will take our understanding of these proteins a step further. Although 
P1GF-2 has a highly basic insert of 21 amino acids at the C-terminal end of the 
molecule, the cysteines involved in the formation of the ring structure are all 
conserved and hence the structural core of P1GF-2 should be very similar to 
PIGF-1. These two isoforms do not have any other differences in their 
sequence apart from the insert. It would be interesting to see how different 
P1GF-2 is from its isoform, and mapping of the binding determinants for 
heparin as well as NP-1 should enhance our understanding of molecular 
details involved in P1GF recognition.
CHAPTER-4
STRUCTURAL STUDIES ON 
PLACENTA GROWTH 
FACTOR-2 (PLGF-2)
Chapter IV Structural Studies on Placenta Growth Factor-2
4. INTRODUCTION
An alternative splice variant of P1GF was isolated from 
choriocarcinoma cell lines and characterised as a P1GF isoform (Maglione et 
al., 1993). The mRNA, expressed in these cell lines, contained an additional 
stretch of 63 nucleotides as compared to the placental cDNA (Maglione et al., 
1991). This mRNA encoded for a 170 amino acid form of P1GF that was 
identical to the previously characterised PIGF-1 except for an additional 
stretch of 21 basic amino acids at the C-terminal end (Fig 4.1). This protein 
was referred to as Placenta Growth Factor-2 or P1GF-2 (Maglione et al., 
1993).
P I G F - 1  L P A V P P Q Q W A L S A G N G S S E V E V V P F Q E V W G R S
P 1 G F - 2  L P A V P P Q Q W A L S A G N G S S E V E V V P F Q E V W G R S
P I G F - 1  Y C R A L E R L V D V V S E Y P S E V E H M F S P S C V S L L R C
P 1 G F - 2  Y C R A L E R L V D V V S E Y P S E V E H M F S P S C V S L L R C
P I G F - 1  T G C C G D E D L H C V P V E T A N V T M Q L L K I R S G D R P
P I G F - 2  T G C C G D E D L H C V P V E T A N V T M Q L L K I R S G D R P
P I G F - 1  S Y V E L T F S Q H V R C E C R P L R E K M K P E R * * * * * * * *
P I G F - 2  S Y V E L T F S Q H V R C E C R P L R E K M K P E R R R P K G R
P I G F - 1  * * * * * * * * * * *  * * * * * * * * * * £ Q j ) ^ y p j ^ j ^
P I G F - 2  G K R R R E N O R P T D C H L C G D A V P R R
Fig 4.1. Sequence comparison of PIGF-1 and PIGF-2 highlighting 
the stretch of 21 basic amino acids at the C-terminus end in PIGF-2 that 
is absent in PIGF-1. Around 50% of this insert comprises of arginines 
and lysines (Maglione et al., 1993).
4.1. PLACENTA GROWTH FACTOR-2: RECEPTORS AND HEPARIN
Placenta Growth Factor-2 (PIGF-2), like PIGF-1, can bind Flt-1 
(VEGFR-1) receptor and not KDR (VEGFR-2). It has been reported that 
PIGF-2 is more active than PIGF-1 in inducing endothelial cell proliferation, 
angiogenesis and permeabilisation of blood vessels (Ziche et al., 1997). P1GF- 
2 is also known to bind Neuropilin-1 (NP-1; Midgal et al., 1998) and 
Neuropilin-2 (NP-2); (Gluzman-Poltorak et al., 2000). The neuropilins are
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class 3 semaphorins and serve as axon guidance factors during embryogenesis 
(Giger et al., 1998). NP1 is made of a large extracellular domain and a short 
cytoplasmic domain of 40 amino acids. The extracellular domain is further 
subdivided into 3 sub-domains: a, b and c. NP-1 plays an important role in 
embryonic vasculogenesis and maturation of blood vessels (Kawasaki et al, 
1999). This was proved by gene knockout experiments in mice (Kitsukawa et 
a l, 1997) that died in about 12.5 embryonal days and showed severe 
abnormalities in the cardiovascular system and defective angiogenesis in the 
CNS and the pericardium (Yamada et a l, 2001). The biological role of NP-2 
in the vascular system is not as well characterised as NP-1. Fuh et al (2000) 
showed that Flt-1 forms a complex with the extracellular domain of NP-1. 
This binding (Kd = 1.8nm) is mediated by the tandem repeat, blb2, in the b- 
domain of NP-1 (Mamluk et a l, 2002).
The 21 basic amino acids encoded by exon 6 of the P1GF gene confers, 
on PIGF-2, a heparin binding ability that is lacking in other P1GF forms 
(Hauser and Weich, 1993). Binding of PIGF-2 to NP-1 is dependent on 
heparan sulphate (Midgal et a l, 1998). The binding of PIGF-2 to NP-1 is 
potentiated by the presence of sulphate moieties on the glucosamine-O-6 and 
on the iduronic acid-O-2 groups of heparin. Heparin competes with Flt-1 to 
bind to NP-1 suggesting that both heparin and Flt-1 bind to the same site 
(blb2 domain) on NP-1 (Mamluk et a l, 2002). The overall picture that 
emerges from this is that heparin physically interacts with both PIGF-2 and 
Flt-1 to regulate interactions of PIGF-2 with NP-1. While heparin potentiates 
binding of PIGF-2 to NP-1 by binding to NP-1 itself, Flt-1 negatively 
regulates angiogenesis by competitively binding NP-1.
The two P1GF isoforms, PIGF-1 and PIGF-2, do not have any other 
differences in their sequence apart from the highly basic insert of amino acids. 
Despite this addition at the C-terminal end of the PIGF-2 sequence, the 
cysteines involved in the formation of the ring structure are all conserved and 
hence the structural core of PIGF-2 should be very similar to PIGF-1. The 
binding determinants on Flt-1 are already known (Davis-Smyth et a l, 1998). 
Given the interesting complexity of the role played by PIGF-2 with ability to
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interact with multiple structurally unrelated ligands (Fit-1, NP-1 and heparin), 
the next aim of the present study was to determine the three-dimensional 
crystal structure of P1GF-2 (native or in complex with heparin). This would 
help in identification of binding determinants of heparin on P1GF-2. The 
characterisation of the specific interactions of heparin with P1GF-2 could be of 
interest in understanding structure-function relationships, especially since 
different kinds of angiogenic molecules including growth factors, extracellular 
matrix proteins, and protease inhibitors have the ability to bind heparin or 
heparan sulphate proteoglycans.
4.2. EXPERIMENTAL PROCEDURES
4.2.1. PURIFICATION OF PLACENTA GROWTH FACTOR-2
Recombinant, lyophilised human-Placenta Growth Factor-2 protein 
(rhPlGF-1) was provided to us by our collaborators (Drs. D. Maglione and 
M.G. Persico, CNRS, Napoli, Italy). The gene encoding the mature protein 
was cloned into a prokaryotic expression vector by polymerase chain reaction 
(PCR). After preparation and induction of the inclusion bodies, the protein 
was refolded by solubilising the inclusion bodies in a denaturing buffer (8M 
urea + 50mM Na-Phosphate buffer (pH 7.5) + 20mM ethylenediamine). The 
solution was diluted using a dilution buffer to get an OD of 0.5 at 280nm. 
Oxidised and reduced glutathione were added to the solution, which was then 
incubated for 20hrs at 20°C under agitation. The refolded P1GF-2 protein was 
purified in a two-step process. Phase-I of the chromatographic purification 
process involved a column containing S-sepharose Fast Flow resin followed 
by reverse phase chromatography in Phase n. The material from the reverse 
phase was ultra-filtered against water using a cut-off of 10,000 Da. The 
dimeric nature of P1GF-2 used for crystallisation was confirmed by the SDS- 
PAGE.
4.2.2. CRYSTALLISATION TRIALS
Finding the winning combination that supports crystal growth often 
begins with experiments designed on a coarse grid aiming to seek important
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Table 4.1 Overview o f  the crystallisation conditions triedfor PlGF-2
Experimental Design Total no of 
conditions
Results
MDL Structure Screen 1 50 range from clear drops to cloudy amorphous precipitates
MDL Structure Screen 2 50 range from clear drops to cloudy amorphous precipitates
FGF condition (Pellegrini et a l ,  2000) 1 amorphous precipitate
P1GF-1 condition (Iyer et a l ,  2001) 1 clear drop
Sodium malonate @ pH 7.2 (McPherson et a l ,  2001) 4 amorphous precipitate
MEMBFAC conditions @ pH 7.5 range from clear drops to cloudy amorphous precipitates
(Hampton Research) 13
Fibronectin fragment condition 1 crystalline precipitate
Conditions from the BMCD 16 protein denaturation in all the cases except one which produced 
CaCl2 crystals
JB Screen 7 (MPD based) 24 range from clear drops to cloudy amorphous precipitates; one 
condition gave a crystalline precipitate
JBScreen 8 (MPD/Alcohol based) 24 range from clear drops to cloudy amorphous precipitates; about 5-6 
conditions gave light crystalline precipitation.
JB Screen 9 (Alcohol and salt based) 24 range from clear drops to cloudy amorphous precipitates
Cross seeding o f the clear drops from all the trials with P1GF-1 32 the P1GF-1 crystals did not dissolve when seeded into the drops
crystals
Optimisation o f  conditions based on JBScreen 8 18 cloudy amorphous precipitates
Use o f  glycerol for conditions that had given crystalline precipitation 2 these conditions gave clear drops instead o f  crystalline precipitate.
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experimental variables that can then be navigated in greater detail. 
Crystallisation trials for P1GF-2 also started with the sparse-matrix conditions 
from Molecular Dimensions Limited (MDL Structure Screens 1 and 2). The 
following table {Table 4.1) gives an overview of all the conditions tried in an 
attempt to crystallise the protein. The vapour diffusion hanging drop method 
was the preferred crystallisation technique. A variety of conditions were tried 
at different temperatures (10°C, 16°C and 22°C), maintaining a drop size of 
3pl, containing equal volumes of the protein solution and the reservoir 
solution, equilibrated against 700pl - lOOOpl of the reservoir.
4.2.3. CIRCULAR DICHROISM ON P1GF-2
Circular dichroic spectra for P1GF-1 and P1GF-2 were recorded using 
an in-house Jasco 600 spectropolarimeter with computer control. Spectra were 
recorded at ambient temperature as an average of 8 to 15 scans. Protein 
samples (along with appropriate controls) at 580pg/ml concentration in lOmM 
sodium-potassium phosphate, pH7.0, were measured using a quartz cuvette 
with a 0.02cm path-length. The start wavelength for the far UV experiment 
was 210nm and the end wavelength was 188nm. Data points with 0.2nm step 
resolution were collected at a speed of lOnm/minute. The ellipticities were 
determined assuming a mean residue weight of 16725.4 for P1GF-1 (131 
amino acids) and 19325.3 for P1GF-2 (152 amino acids).
4.3. RESULTS AND DISCUSSION
Nucleation and crystal growth are affected by chemical and physical 
parameters, as well as the crystallisation method used. A wide range of 
different conditions (-300) based on the various screening kits available from 
Hampton Research and Molecular Dimensions were used for attempting to 
crystallise P1GF-2. Almost all of the conditions tried resulted in producing a 
cloudy amorphous precipitate. Some produced clear drops although a couple 
of conditions gave some kind of crystalline precipitate. But despite varying 
different parameters in these conditions, the attempts to grow P1GF-2 crystals 
were so far not successful. Even cross-seeding all the drops of the previous 
experiments that were still clear, with P1GF-1 crystals, did not produce the
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desired result. Heparin disaccharide was also used in one of the experimental 
designs in the hope that perhaps association of the macromolecule with one of 
its binding partners would help to stabilise the system and thus help initiate 
crystal growth. Despite the inability to arrive at the right combination of 
crystallisation conditions for P1GF-2, some basic observations can be made 
based on the results from all the trials so far. The protein seems to like MPD 
(as a precipitant preferably at a concentration lower than 50%) and Sodium 
acetate (either as a salt or a buffer). It was also seen that Tris-HCl at any pH 
caused turbidity of the protein solution in the drop as soon as it was added,
While crystallisation trials were being carried out, Circular Dichroism 
(CD) experiments were also performed to obtain come information on the 
secondary structure of P1GF-2. Since it is believed that the core structure of 
P1GF-1 and P1GF-2 are same, CD spectra for P1GF-1 were also recorded to 
allow comparisons between the two isoforms. The two spectra, surprisingly, 






188 200 220 240 250
Wavelength [nmj
Fig 4.2 Far \JV CD spectra of PlGF-1 (---------) and PlGF-2 (_____ )
in lOmM sodium/potassium phosphate buffer (pH 7.0).
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The P1GF-1 spectrum  suggests that P1GF-1 prim arily  contains p -tum s 
and random  coil structure. It show s a positive m axim um  at about 230nm . This 
feature is quite sim ilar to that seen for brain-derived neurotrophic factor 
(BD N F; N arhi et al., 1993). The positive peak can be attribu ted  to the 
presence o f  the cysteine-knot m otif. It could  be possib le that the signal from  
the d isu lphides is so intense that it appears to m ask the true structure that 
arises from  the arom atics like tryptophan, tyrosine and phenylalanine. This 
peak interferes w ith  the spectrum  in the region o f  about 220nm  and thus 
m akes it d ifficult to fit the spectrum  w ith  the available m odel system s. P1GF-2 
spectrum , on the o ther hand, is m ore in trad ition  w ith a usual CD spectrum  and 
therefore easier to analyse (Fig 4.2). A nalysis o f  the P1GF-2 CD spectrum  
using the program s, C O N TIN L and K 2D  found on the D ichrow eb w ebsite 
(h ttp ://w w w .cryst.bbk .ac.uk/cdw eb/h tm l/hom e.h tm l/), predicted  a  p-sheet 
protein, w hich is in agreem ent w ith  w hat is expected. H ow ever, w hat is not 
explained is the absence o f  the positive peak in the P1GF-2 spectrum . The 
presence o f  a sim ilar d isulphide structure w ould have confirm ed the hom ology 
betw een the tw o proteins as am ino  acid sequence alignm ent (Fig 4.1) clearly 
indicates that all the cysteines involved in form ation o f  the d isu lphide ring 
structure are located in a sim ilar environm ent in both P1GF-1 and P1GF-2. The 
only difference betw een the tw o isoform s is the stretch o f  positively  charged 
residues inserted at the C -term inal end o f  P1GF-2. The m ost probable 
explanation for the absence o f  the positive peak at about 230nm  in P1GF-2 
could be that th is insert som ehow  overrides the signal from  the d isu lphide ring 
and thus allow s recording o f  the true structure in term s o f  a -h e lice s  and P- 
sheets. A lso it could  be possib le that the basic residues o f  the insert interact 
w ith  the surrounding negatively charged residues o r the phosphate ions from  
the buffer used for CD and fold into a helical structure. This could m ean that 
the cysteine-knot conform ation is d isrupted  in P1GF-2 because o f  the addition 
o f  the insert. H ow ever, these are only assum ptions and each needs to  be 
validated  or o therw ise by a three-d im ensional structure o f  P1GF-2.
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4.4. FUTURE WORK
Over the past few decades, much of the work in the field of 
angiogenesis has been devoted to VEGF-A, as this molecule seems to be of 
utmost importance in both physiological and pathological conditions. A deeper 
understanding of the biology of VEGF-A will come from studies that involve 
additional members of the VEGF family. These include P1GF, VEGF-B, 
VEGF-C and VEGF-D. Unlike previous findings, recent experiments by 
Carmeliet et al (2001) have brought into focus the significance of P1GF 
isoforms in their roles as angiogenic molecules. P1GF-2, the longer isoform, is 
believed to more angiogenic than P1GF-1. Hence, elucidation of the three- 
dimensional structure of P1GF-2 would be a major advance in this field, 
especially since the structure of the heparin binding form of VEGF-A (VEGF- 
A165) is still unknown.
Once the three-dimensional structure of P1GF-2 is known it can be 
used to identify regions of the protein responsible for its function by 
comparing it with proteins that are structurally different and yet functionally 
similar (e.g. Fibroblast Growth Factor). It will serve as a starting point for a 
rational program of experimentation such as site-directed mutagenesis, 
receptor and ligand-binding studies and so forth.
P1GF-2 can bind Flt-1 (Park et a l , 1994), heparan sulphate 
proteoglycans (HSPGs; Hauser and Weich, 1993; Mamluk et a l, 2002) and 
neuropilins 1 (Midgal et a l, 1998) and 2 (NP-1 and NP-2). Each of these 
ligands plays an important individual role in the development of the vascular 
system. However, it is also possible that, since P1GF-2 can bind receptors that 
associate with VEGF-A, functional redundancy could compensate for the loss 
of VEGF-A. All these views can be substantiated by structure determination of 
PlGF-2»Flt-l complex, PlGF-2«heparin complex and P1GF-2«NP-1 complex. 
The PlGF-2«Flt-1 complex and P1GF-2«NP-1 complex will also help improve 
our understanding of the common mechanisms of angiogenesis and 
neurogenesis. Since heparin is very heterogeneous in nature, the P1GF- 
2 «heparin complex will contribute to our limited knowledge of the structural
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requirements for heparin binding to proteins. The structural and functional 
characterisation of the interaction between P1GF-2 and its binding partners 
might lead to additional therapeutic opportunities as well as to the refinement 
of the current strategies that are aimed at growing or blocking vessel 
formation.
CHAPTER-5
STRUCTURAL STUDIES ON 
VASCULAR ENDOTHELIAL 
GROWTH FACTOR-B (VEGF-B)
Chapter V Structural Studies on Vascular Endothelial Growth Factor-B
5. INTRODUCTION
Cancer research, over the past few decades, has focussed on tumour 
growth accompanied by increased vascularity. Over the past few years the 
quest for understanding the biology of VEGF-A has been in the forefront 
because VEGF-A is central to angiogenesis research. The discovery of the two 
tyrosine-kinase receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), 
demonstrated the crucial role played by both these receptors as binding 
partners of VEGF-A in the development of the vascular system. A unique 
feature of Flt-1 is that although it has much weaker tyrosine-kinase activity 
than KDR, it has 10-fold higher affinity for VEGF-A (Ferrara and Davis- 
Smyth, 1997; Shibuya, 1999; Mustonen and Alitalo, 1995; Kendall and 
Thomas, 1993 and Sawano et a l, 1996). Because of its stronger ability to trap 
VEGF-A, Flt-1 negatively regulates physiological angiogenesis in the embryo 
(Fong et a l, 1995 and Hiratsuka et a l, 1998). However, when an Flt-1 
specific ligand is over-expressed in certain pathological conditions, this 
receptor acts as a positive inducer of blood vessel formation. One such Flt-1 
specific ligand is a VEGF-related protein, Vascular Endothelial Growth 
Factor-B (VEGF-B).
VEGF-B is a functional homologue of P1GF based on its binding 
specificity to Flt-1 (VEGFR-1). Like P1GF, VEGF-B also cannot bind KDR 
(VEGFR-2). However, amino acid sequence alignment shows that VEGF-B is 
more similar to VEGF-A than P1GF (Fig 5.1). These differences and 
similarities between VEGF-B and the other two members of the cysteine-knot 
family makes VEGF-B an attractive target for a structure-based initiative to 
further angiogenesis research.
This is a collaborative project with Sergio D. B. Scrofani from 
AMRAD Operations, Australia. The protein used for crystallisation was 
purified by our collaborators. The protocol used for expression and 
purification of refolded recombinant V E G F - B  from Escherichia coli inclusion 
bodies is described in (Scrofani et a l, 2000). Both truncated ( V E G F - B i o - i o s )  
and the full-length ( V E G F - B 167)  forms were used for crystallisation purposes.
116
C hapter V Structural Studies on Vascular Endothelial Growth Factor-B
* * * ★  . + *  it
VEGF-A IC tP  E riiV D l|Q E lP D E IE | BKPSCVE1 J'UCGGCCNDE 
PIGF |c § A  ER’jVDVV S Ej|P S EVe 1 m§S P 9CVS L’uHCTGCC GD E 
VEGF - B  EVWPL TVELMG TVAlQLVP 9CVTVQBCGGCC PDBI
it i t  r r it - i r + * r r i t ' i r i t i r i t i t r  r it
t k i fc k k i b fcfc • » i
VEGF -A  NX THQIMIlKP ^ QGQHIGEM3|QQBNlCEClP^B|ABQENPCGPCSE




VEGF-A pH .FygD --------------------------------------PQ rcpCSCjN ID Sf C j AfagEIiN
PIG F | ------- ------- ----------------------------------- p ------------- HGBGKHHHEIQiPTB
VEGF-B PQPBSVPGfD9 APGAP9 PADITHPTPAPGP9 AHAAP9 ITSALTPGPAAAA
VEGF-A ERIC
VEGF-B ADAAA9 rGA
Fig 5.1 Sequence alignment o f VEGF-A
B (49765). The residues indicated by a *  represent identical residues in all the 
three sequences.
Fig 5.2 Reducing and Non-reducing SDS-PAGE/Coomassie analysis o f  
purified VEGF-B jo-ios before and after cleavage o f the His-tag.
Lane A Molecular weight markers (from Pharmacia)
Lane B 6-His tagged VEGF-B m-ios (Non-reduced)
Lane C VEGF-Bjo-ios (Non-reduced)
Lane D 6-His tagged VEGF-B jo-ios (Reduced)
Lane E VEGF-B 10-108 (Reduced)
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5.1. CRYSTALLISATION OF VEGF-Bi67 AND VEGF-Bio-ios
Most of the times all the efforts and resources in order to crystallise a 
protein is invested into screening of optimal conditions. Since, VEGF-B 167 has 
an amino acid composition very similar to that of VEGF-A167 and P1GF-2 and 
has a similar pi value (8.46), the first set of conditions that were tried were 
those that were reported for VEGF-A (Christinger et a l , 1996). However, 
none of these conditions were successful. The protein either precipitated out of 
solution or the drop remained clear. The next step was to try the sparse matrix 
conditions from Structure Screens 1 and 2 (Molecular Dimensions Ltd). Since 
protein material was limited, only conditions at pH 7.5 and 8.5 were tried, to 
begin with, from both the screens. Condition #8 of Structure Screen 2 
produced crystalline spherulites whereas condition #11 of Structure Screen 2 
produced a shower of fine and veiy tiny needles. Optimisation of both these 
conditions were carried out in parallel, however, the latter turned out to be 
more promising. The original condition comprised of 0.5M (NFL^SO^ 0.1M 
HEPES buffer (pH 7.5) and 30% MPD. Optimisation of this condition was 
carried out by varying MPD concentration (10-60%), substituting MPD with 
PEG400, varying ammonium sulphate concentration (0.2-2.4M) and varying 
the salts (e.g. Na2 S0 4 , Li2 S0 4 , MgSO^ ZnS0 4 , NaCl, HCOONa at different 
concentrations). These variations did not improve the crystal size and some of 
them did not produce any crystals e.g. substitution of MPD with PEG400 was 
not favourable as it lead to aggregation of the protein solution. Since some of 
these changes that gave positive results still produced very tiny needles, the 
protein concentration was dropped from 15mg/ml to lOmg/ml. As the protein 
seemed to prefer MPD for crystallisation, JBScreen 7 (MPD based) and 
JBScreen 8 (MPD and alcohol based) were also tried. Most of the conditions 
resulted in clear drops and only one condition produced fine needles once 
again. This condition was the same as condition #11 of Structure Screen 2. 
None of these trials resulted in any improvement in crystal morphology, so 
different methods of crystallisation such as microdialysis, batch crystallisation, 
crystallisation under oil were tried. One experimental design was based on a 
fine pH variation covering the whole range of HEPES buffer (pH 6.6-8.5). 
The crystal morphology seemed slightly better at pH 6.8 and therefore all 
further trials were carried out at this pH.
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Fig 5.3 Needle-like crystals o f VEGF-Bio-/o8- Panel A shows 
the initial crystals that were obtained for VEGF-B/o-ws- Panel B 
shows the slight improvement in crystal size and in the reduction 
o f the oil-like droplets due to the addition o f acetic acid.
It seem ed that the sm all size o f  the crystals w as probably because the drops 
form  oil-like coacervates (Fig 5.3A) in the presence o f  the organic solvent, 
M PD . This led to several nucleation sites w ith in  these droplets and hence very 
sm all and thin needle like crystals were being form ed. A t th is point our
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collaborators suggested  that w e reconstitu te the protein  in 1 .OmM acetic acid. 
They used acetic  acid  to  reconstitu te  their sam ples for N M R  studies. It w as 
believed that acetic  acid  w ould  nullify  the coacervate-like effect. A lthough the 
problem  o f  d roplets w as reduced to som e extent, the size o f  the crystals still 
did not im prove (Fig 5.3B).
A bout th is tim e w e obtained  a  truncated form  o f  this protein, V E G F- 
B 10-108- The pH -refined  cond ition  w as tried for th is form . The crystals w ere 
better looking than  the very th in  needles obtained previously  for the full- 
length form . Then, like the full length V EG F-B (V E G F -B ,67), VEGF-B,o-io8 
was also  reconstitu ted  in l.Om M  acetic acid to give a  stock concentration o f  
lOm g/m l. T his, w hen used for crystallisations, im proved the crystal size ever 
so slightly.
Since w e had narrow ed dow n the various param eters in the 
crystallisation condition , it seem ed like a good idea to try crystallisations 
w ithin a gel. B oth  hanging  drop m ethod and capillary d iffusion  m ethods w ere 
used. The hanging  drop  crystals gave positive results, how ever they w ere still 
not big enough to  be used for da ta  collection.
approx. 0.05mm in all three 
dimensions
Fig 5.4 Crystals o f VEGF-B/o-ios (truncated form). The 
arrow is pointing towards the crystal from which the 3.5A 
dataset was collected recently.
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The next option that w as explored w as that o f  varying the pro tein  
concentration. These trials show ed that the m inim um  protein concentration 
required w as around 2.5 m g/m l in the drop. This concentration w as used to  set 
up a streak seeding experim ent. A lthough the nucleation sites in troduced in 
each drop w as still very high, one o f  the drops did produce rod shaped 
crystals, one o f  w hich w as big enough (Fig 5.4) to be fished out for da ta  
collection, albeit w ith lot o f  d ifficulty  especially  because o f  skin form ation  in 
the drop. A  dataset to 3 .5A w as collected  w ith  th is crystal at SRS, D aresbury 
(UK). A t present further op tim isation  trials w ith  gel crystallisations and 
seeding experim ents are being carried  out to im prove the crystal quality  and 
size by controlling  num ber o f  nucleation sites as well as the vapour d iffusion  
rate.
Fig 5.5 A diffraction image from a VEGF-B jo-ios crystal. The inset 
represents a portion o f the image zoomed in to show the spots. The circles 
have been drawn to mark the resolution range. The data collection 
parameters used were: A. = 0.98A; A(p =  1.5° and exposure = 30 seconds 
at SRS, Daresbury, UK.
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5.2 DATA COLLECTION, PROCESSING AND SCALING
A low-resolution dataset to 3.4A was collected at 100K from a single 
crystal using the Synchrotron Radiation Source (station PX 14.2), Daresbury, 
UK. Figure 5.5 shows the first image that was collected from the crystal. 
Autoindexing of the first image using HKL2000 (Otwinowski and Minor, 
1997) revealed that VEGF-Bio-ios had crystallised in the hexagonal space 
group, P6. A total of 71 images were collected (A,=0.87A,) using a CCD- 
ADSC detector system. Due to poor quality of the crystals data were collected 
only to 3.4A, which is reflected I the high value (see Table 5.1).
Table 5.1 Data collection and reduction statistics





I/ctI (outermost shell) 6.9 (2.8)
Completeness (outermost shell) (%) 98.8 (100)
The outermost shell corresponds to the resolution bin covering 3.52 -  3.39 A
The solvent content for the crystal was calculated using the C C P 4  
supported program, matthewscoeff, in order to determine the number of 
molecules in the asymmetric unit. Calculations showed that for one VEGF- 
B10-108 dimer (molecular weight of 29,000 Da per dimer) in the asymmetric 
unit, the Matthew’s coefficient was 3.0A3/D with the solvent content of 
around 57%. This indicated that the crystal belonged to one of the lower space 
groups ( P 6 i ,  P 6 2 ,  P 6 3 ,  P 6 4  and P 6 5 ) .  The higher subgroups ( P 6 2 2 )  were not 
considered as a possibility because the value for Matthew’s coefficient did not 
lie in the accepted range (between 1.6-3.5A3/D), due to the higher number of 
asymmetric units for these space groups. To assign the correct space group, 
data were scaled in all the possible lower subgroups ( P 6 1 ,  P 6 2 ,  P 6 3 , P 6 4  and 
P 6 5 ) .  Since the data was only up to 3.4 A, the scaling of the data in different
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space groups did not produce a list of systematic absences and thus the space 
group could not be determined in this way.
5.3. STRUCTURE SOLUTION
The structure of VEGF-B10-108 was determined by molecular 
replacement using the program AMoRe (Navaza, 1994) in the CCP4i module. 
The SCALEPACK reflection file was converted into an MTZ format suitable 
for input to AMoRe (SCALEPACK2MTZ). The first routine in AMoRe 
(SORTING) sorted the reflection file according to P6 space group symmetry. 
A tailored model based on the structure of VEGF-A elucidated at 1.93A 
resolution [PDB code-2VPF; Muller et al., 1997b] with non-identical residues 
between VEGF-A and VEGF-B mutated to alanine was used as the search 
model (TABLING). Data in the range 20.0-4.0A were used for both the 
rotation and the translation function searches. A sphere radius of 20A was 
used for the cross rotation search (ROTING). In order to resolve the space 
group ambiguity, translation searches (TRAING) were carried out for all the 5 
sub-groups. Both P61 as well as P6 4  gave clear top solution. However, the best
Table 5.2 Molecular Replacement Solutions for VEGF-Biq_iq8_____________
Peak
Rotation a  (3____^ Tx Tv Tz Rf_______ht CC_I
SOLUTIONRC 29.5 87.8 277.06 0.000 0.000 0.000 61.2 9.7 7.3
SOLUTIONRC 30.2 92.2 97.01 0.000 0.000 0.000 61.1 9.7 7.2
SOLUTIONRC 19.9 154.4 122.85 0.000 0.000 0.000 61.4 1 1 .0 5.8







277.06 0.4762 0.2381 0.000 







SOLUTIONTF20 19.9 154.4 122.85 0.8889 0.8254 0.000 61.1 10.4 9.9
Fiting a P X Tx Ty Tz Rf CC I
SOLUTIONF 1 27.6 87.4 279.61 0.47280.2344 0.000 52.6 44.5
SOLUTIONF2 30.2 92.3 97.74 0.1383 0.5689 0.000 53.6 40.4
SOLUTIONF 20 16.3 151.63 119.71 0.88490.8237 0.000 55.2 39.8
The optimised solution from FIT/NG is highlighted in yellow. The rotational parameters 
are described by a, f  and y. The translation search parameters are described by Tx, Ty 
and Tz. Rf refers to the R-factor corresponding to each solution and CC I gives the 
correlation coefficient based on observed intensities.
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solution was found in the P 6 4  space group after optimisation of the solutions 
in the FITESfG routine of AMoRe. The correct solution had a correlation 
coefficient of 44.5% and an R-factor of 52.6% after the FITING {Table 5.2). 
The initial coordinates for crystallographic refinement were obtained by 
applying the appropriate rotation and translation parameters to the search 
model (MR2IC and PDBSET). The use of a well refined search model and the 
high degree of sequence homology between VEGF-B and VEGF-A produced 
a top solution in AMoRe straightaway, without having to vary any of the 
search parameters like the sphere radius or the model cell dimensions.
5.4 CRYSTALLOGRAPHIC REFINEMENT
In the first round of refinement of the molecular replacement solution, 
the entire protein molecule was considered as a rigid body to find the best 
position for the molecule in the new crystal cell. This was followed by the 
annealing procedure at a constant temperature of 1200K, which brought down 
the R-factors to 43% (R cry st)  and 47.6% (R free)*  Since the data was only up to 
3.5A, the number of observations at this resolution was very low. The 
parameters for refinement could not be defined accurately as the ratio of 
observations to variables (atomic coordinates, occupancy and B-factors) was 
not sufficient to justify refinement of even the overall B-factor for all the 
atoms. For this reason, electron density maps (2F0-FC and F0-Fc maps) were 
calculated after positional refinement of the structure. The maps were 
examined for very obvious regions of gross error (if any) and difference 
density for side-chains for the residues that had been modelled as alanines in 
the MR search model. Some regions of the map were quite reliably defined. 
However, there were some places where it was difficult to replace alanines 
with the original VEGF-B10-108 residues and also some regions of the structure, 
especially the loop regions, were quite disordered. These regions were left as it 
is and the modified model was put back into the rigid-body refinement 
protocol of CNS (Briinger et a l, 1998). The R-factors dropped to 38% (R cry st)  
and 43.7% (R fr e e )  with an rmsd in bond length of 0.009A. The Figure of Merit 
(FOM) of the refined structure at this stage was around 64% indicating that the 
refinement was proceeding in the right direction. However, because of the lack 
of sufficient number of independent reflections, the structure could not be
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refined further. As a result a detailed structural analysis of the VEGF-B 
structure has to be left to a later date when a high-resolution dataset becomes 
available.
5 . 5  F U T U R E  D I R E C T I O N
Analysis of the role of VEGF-B in blood vessel formation and function 
will be facilitated by the three-dimensional structure of VEGF-B. At present, 
we have only a partially refined structure of VEGF-Bio-ios at 3.5A. In order to 
improve this resolution, attempts at present are directed towards improving 
crystal quality. Excessive nucleation is producing a large number of small 
protein crystals that are not suitable for X-ray diffraction analysis. The crystals 
grown at the moment are consistently tiny and very fragile. The formation of 
oil-like droplets and skin do not help towards the desired end. In order to 
obtain large single crystals it is imperative that the nucleation phase does not 
overlap with the growth phase as suggested by Saridakis and Chayen (2000). 
Also it might be worthwhile to drop the protein concentration further. At 
present some drops have been set up at 4°C at three different stock 
concentrations of protein (5mg/ml, 3.5mg/ml and 2.8 mg/ml). Recently 
another experimental design has been tried which is based on adding a series 
of additives (about 48 in all). Attempts to improve the quality of VEGF-B167 
(full-length form) crystals are also in progress.
Once a refined structure of VEGF-B becomes available, the next step 
would be to elucidate the structure-function relationship for VEGF-B, 
especially in heart development vis-a-vis' its ability to bind Flt-1 and heparin. 
Recently, Scotney et al (2002) have characterised VEGF-B specific 
monoclonal antibodies that are being used in several animal-based assays to 
assess the role of VEGF-B in cardiovascular and other diseases as well as to 
identify potential therapeutic applications for these neutralising monoclonal 
antibodies (mAbs). Crystal structures of VEGF-B in complex with its various 
binding partners (Flt-1, heparin, neutralising mAbs etc) will help identify 
important VEGF-B residues that facilitate the angiogenic activity of the 
protein. Analysis based on mutagenesis studies and comparison of protein- 
protein interactions in the different complex structures (as mentioned above)
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will facilitate the rational design of small molecule antagonists specific for 
VEGF-B. This will be crucial for underlining the precise role of the Flt-1 
receptor in angiogenesis especially since its importance seems to be 
undermined by all the controversies surrounding it.
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THE AMINO TERMINAL 
DOMAIN OF TIMP-1 
(NTIMP-1 :MMP-1: CD)
Chapter 6 Structural Studies on N-TIMP-1»MMP-1:CD complex
6. INTRODUCTION
The matrix metalloproteinases (MMPs) are a family of enzymes that 
can degrade all the components of the extra-cellular matrix. It is a well-known 
fact that proteolytic degradation of the proteoglycans and collagens in the 
extra-cellular matrix (ECM) leads to tissue damage. Matrix can be regenerated 
if proteoglycan alone is removed. However, when collagen is lost or degraded, 
the extra-cellular matrix cannot be regenerated (Elliot and Cawston, 2001), as 
the interstitial triple helical collagens are the major structural proteins of the 
connective tissue. Members of the MMP family that cleave collagen are 
known as collagenases. MMP-1 (fibroblast collagenase), MMP-8 (neutrophil 
collagenase) and MMP-13 (collagenase-3) are the only MMPs that can cleave 
collagens type I, II and III (Welgus et al., 1981; Hasty et al., 1987).
Crystal structures of the catalytic domain of several MMPs have been 
elucidated. The MMPs exhibit remarkable topological similarities in the 
overall structural fold of their catalytic domain. The catalytic-domain of the 
MMPs is spherical and encompasses a five-stranded P sheet and three a  
helices (Fig 6.1) and as the name suggests this domain is responsible for the 
enzymatic activity of the enzymes. The amino acid sequence of the catalytic 
domain is hiehlv conserved amone the MMP familv (Fig 6.2).
/  
/
Fig 6.1 Crystal structure o f the catalytic 
domain o f MMP-1 (PDB code: 1CGE) 
(Lovejoy, et al., 1994). The two zinc ions 
are coloured white and the three calcium 
ions are in black.
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MMP-1  RWEQTHLTYRIENYTPDLPRADVDHAIEKAFQLWSNVTPLTFTK-VS--------
MMP- 2  R K -P KWDKNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSR-IH-----------------
MMP- 3  FRTFPGIPKWRKTHLTYRIVNYTPDLPKDAVDSAVEKA1KVWEEVTPLTFSR-LY-----------------
MMP- 8  N------------ PKWERTNLTYRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTR-IS-----------------
MMP-i eg q a | i m i s f v r g d h r d n s p f H p | g| l a h a f q p g p Bi g g | a h f | e d | r w tn - n f r — EYNLH
MMP-2 DGEA|lMINFGRWEHGDG Y P F^K |G §L A H A FA PG T |v | g| S  H F§DD|LWS LGKGV-GY SLF
mmp- 3  e g e a | i m i s f a v r e h g d f y p f | p | n| l a h a y a p g p | i | g| a h f | d d | qw tk- d t t - g t n l f





Fig 6.1 Sequence alignment o f the catalytic domains o f MMP-1, MMP-2, MMPS and MMPS. The regions sharing 
the same secondary structure are coloured green, the residues ligating with the structural and catalytic zinc have been 
shaded yellow, the residues shaded red and magenta represent residues that ligate the two calcium ions.
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The catalytic domain of MMP consists of a catalytic-zinc ion and a 
structural-zinc ion. The residues that coordinate with the two zinc ions are 
conserved among all the members of the MMP family (The amino acid 
sequences in Fig 6.2 represent different types o f members o f the MMP family: 
MMP-1 and MMPS represent the collagenases, MMPS represents the 
gelatinases and MMPS represents the stromelysins). The catalytic domain 
also comprises of three calcium ions, which seem to be important for the 
structural integrity of the enzyme. The catalytic or the N-terminal domain of 
all MMPs is separated from the C-terminal domain by an active site cleft. This 
cleft is made of the p-strand number IV, the 2nd a-helix (Helix B) and a 
random coil next to the second helix (Fig 6.1). The catalytic zinc lies at the 
bottom of this active site cleft. On the right hand side of this catalytic site, lies 
the selectivity/specificity pocket, SI' subsite, framed by the ST loop. The 
major difference between the catalytic domains of different MMPs lies in the 
variable size of this well-defined hydrophobic pocket (Lovejoy, et a l, 1999).
The activity of different MMPs is regulated by endogenous inhibitors 
known as the tissue inhibitors of metalloproteinases (TIMPs). There are four 
isoforms of the human TIMP known so far: TIMP-1, TIMP-2, TIMP-3 and 
TIMP-4. The domain organisation is the same for all the TIMPs. It consists of 
an N-terminal domain and a C-terminal domain (Fig 6.3) (Williamson et al, 
1990; Pohar et a l, 1999). Despite the two separate domains the TIMP 
structures have a superficial appearance of being continuous because of the 
tight packing of the two domains. The N-terminal domain of the TIMPs is 
characterised by the widely distributed OB fold (oligonucleotide-binding 
fold). The three dimensional crystal structures of TIMP-1 (Gomis-Ruth et al., 
1997) and TIMP-2 (Tuuttila et al., 1998) are available at present. The wedge­
like structure consists of a six-stranded p-sheet in the N-terminal domain, a 
central helix separating the two domains and a C-terminal domain comprising 
of four p strands and a small a-helix. Although the OB fold is relatively rigid 
in the TIMP structure, the loop connecting the first two p strands in the N- 
terminal domain and the area of the molecule that attaches to the p-sheet via
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the Cys-l-Cys-70 and the Cys-3-Cys99 disulphide bonds are very mobile 
(Williamson et al., 1997; Femandez-Catalan et al., 1998).
Val69
Fig 6.3 Secondary structure o f TIMP-1 (full-length form) based on 
the crystal structure o f MMPS •TIMP-I complex (PDB code: 1UEA; 
Gomis-Ruth et al, 1997). The residues important for the activity oj 
the protein have been highlighted.
All TIMPs inhibit active MMPs except for TIMP-1, which cannot 
inhibit MT-MMPs (Willenbrock and Murphy, 1994). Mutagenesis studies on 
TIMP-1 have revealed that Thr2 and some other residues such as Val4, Ser68 
and Val69 influence the affinity of different MMPs and hence are important 
for selectivity of the endogenous inhibitors towards these different proteases 
(Nagase et al., 1999). These studies have provided a crucial platform for 
engineering of MMP-selective TIMPs.
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Three-dimensional structures of the MMP«TIMP complexes help us 
address the structural basis of the MMP inhibitory action of TIMP. At present, 
the crystal structures that are available for the enzyme-inhibitor complexes are 
the catalytic domain of MMP-3 in complex with the full-length TIMP-1 (PDB 
code: 1UEA; Fig 6.4) Gomis-Ruth et al., 1997), MTl-MMP*TIMP-2 (PDB 
code: 1BR9) (Tuuttila et al., 1998) and the latent MMP-2 in complex with the 
full-length TIMP-2 (PDB code: 1GXD) (Morgunova et al., 2002). The crystal 
structure of MMP-3 in complex with the full-length TIMP-1 revealed that 
Thr2 of TIMP-1 occupies the S I ' specificity pocket of the MMP-3 in order to 
mediate its inhibitory effect on the enzyme (Gomis-Ruth et al., 1997). The 
characteristic feature of this enzyme-inhibitor interaction is the bi-dentate 
coordination of the amino and the carbonyl group of Cys-1 of TIMP-1 with 
the catalytic zinc of MMP-3. The carbonyl group of Thr2 interacts with the 
catalytically important residue, Glu202 of MMP-3 (Glu219 of MMP-1) and 
displaces a water molecule that is important for the proteolytic activity of the 
enzyme. The residues in the loop  of the N-terminal domain of TIMP-1
MM P-3
(catalytic domain)
Fig 6.4 Crystal structure o f the catalytic domain o f MMPS in 
complex with the full-length form o f TIMP-1 (PDB code: IUEA) 
(Gomis-Ruth et al., 1997). The two zinc ions are shown as grey 
spheres and the three calcium ions have been represented as black
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molecule, loopsbetween p-strands 1 & 2 and between 5 & 6, also facilitate 
binding of the inhibitor to the protease. The active site residues are shown in 
Fig 6.5.
Fig 6.5 The active site residues o f the metalloproteinase. A) Native 
structure o f MMP-l. B) MMP-3 in complex with TlMP-1. The interaction 
with the water molecule in the native structure is replaced by the carbonyl 
atom o f Cysl from TIMP-l.
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Association of the two molecules results in a structural change in the 
catalytic domain of the enzyme. Superposition of the structure of the bovine 
TIMP-2 bound to MT1-MMP with the free human TIMP-2 yielded an rmsd. 
value of 1.32A. The N-terminal domain on its own corresponded to a 
difference of 1.11A (Femandez-Catalan et al., 1998). Apart from the mobility 
of the loop regions in the N-terminal domain of TIMP-2, a large 
conformational change of nearly 15A is also effected (Bode et al., 1999). 
TIMPs and MMPs rapidly associate in the ratio of 1:1 to form a reversible 
intermediate followed by a slower, rate-limiting step during which the 
intermediate complex slowly isomerises to form a more stable and tight- 
binding irreversible complex. The second step is believed to be a consequence 
of the association of the hemopexin domain of the MMP with the TIMP 
molecule. Kinetic studies have also shown that the single isolated N-terminal 
domain of TIMPs still retain the MMP inhibitory activity although the full- 
length TIMP-1 has at least 8-10% higher free energy of interaction as 
compared to the association of the MMPs with the N-terminal domain of 
TIMP on its own (Huang et al., 1997).
The matrix metalloproteinases play a very important role in the 
physiological turnover of the ECM leading to tissue remodelling during 
development and wound healing. MMPs have both cancer-promoting and 
cancer-inhibiting functions. MMPs promote angiogenesis by increasing the 
bioavailability of angiogenic inducers like VEGF-A (Hashimoto et al., 2002), 
TGF-a and basic-FGF. On the other hand, they inhibit blood vessel formation 
by activating the latent TGF-p. But MMPs are known for their role in 
pathological degradation of the ECM during inflammation. Their unregulated 
activity leads to several chronic degenerative diseases like the rheumatoid 
arthritis (RA) and osteroarthritis (OA). These diseases lead to destruction of 
the cartilage and loss of joint function.
So far, despite the available crystal structures, the mechanism of MMP 
inhibition by TIMPs is not very clear, especially since there are 25 MMPs and 
only 4 TIMPs to regulate their activity. Studies have revealed that the serum
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levels of both MMP-1 and TIMP-1 are imbalanced in both rheumatoid arthritis 
(inflammatory) as well as knee osteoarthritis (degenerative). The crystal 
structure of MMP-1 in complex with TIMP-1 is not yet known. It will 
facilitate a further insight into the molecular biology of the MMPs and TIMPs. 
The structure can be used to compare interactions that stabilise complex 
formation between different MMPs and TIMPs and also provide new direction 
for the design of drugs that have selective specificity towards individual 
MMPs. With this aim we embarked into the structural studies of the catalytic 
domain of MMP-1 in complex with the N-terminal domain of TIMP-1 
(nTIMP-1 »MMP-1 :CD complex).
6.1 CRYSTALLISATION OF THE nTIMP-l»MMP-l:CD COMPLEX
The amino-terminal domain of TIMP-1 (nTIMP-1) was purified along 
with the catalytic domain of MMP-1 (MMP-1: CD) as a complex in the ratio 
of 1:1 by our collaborator, Professor Keith Brew (Department of Biomedical 
Sciences, Florida Atlantic University, Florida, USA). The crystallisation trials 
were initiated by setting up drops with conditions already published for 
various MMPs, both with and without small molecule inhibitors and TIMP-1. 
This strategy was not very fruitful and did not produce any crystals other than 
that of CaCl2. So, conditions from both Structure Screen 1 and 2 were used. 
Structure Screen 1, condition #20 as well as Structure Screen 2, condition #19 
produced diffraction quality crystals (Fig 6.6). These crystals grew overnight 
at 16°C to a reasonable size.
SSI #20
Fig 6.6 Crystals o f the nTIMP-1 •MMP-1: CD complex from two 
different conditions (SSI #20 and SS2 #19). The crystals used for data 
collection were grown from SS2 #19 (0.1M HEPES (pH 7.5), 10% PEG 
8000 and 8%o Ethylene Glycol).
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6.2 DATA COLLECTION, PROCESSING AND SCALING
A complete dataset to 2.54A was collected at 100K from a single 
crystal, grown from Structure Screen 2 condition #19, using the Synchrotron 
Radiation Source (station PX 9.6, Daresbury, UK). The crystals from 
Structure Screen 1 condition #20 were also exposed to the X-rays but despite 
their beautiful morphology these crystals did not diffract beyond 3.0A. A total 
of 150 images (Fig 6. 7  representing the first image recorded from the crystal)  
were collected (A,=0.87A,) using a CCD-ADSC detector system.
2 . 2 8  A
Fig 6.7 A typical diffraction image from the nTIMP-1 *MMP- 
1 :CD complex crystal diffracting to 2.54A resolution (2.28A at the 
edge). The inset represents a portion o f the image zoomed in to 
show the high-resolution spots. Data collection parameters used 
were: A = 0.87A; A(p =1.0° ,  Distance = 245mm and exposure =  
15 seconds.
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Data processing was performed with the HKL package (Otwinowski 
and Minor, 1997) in the C-centred monoclinic space group, C2. Data 
reduction was carried out using the program, TRUNCATE, of the CCP4 suite. 
Even though the crystal diffracted to 2.28A resolution, reflections in the last 
shell were very weak, hence the data was scaled to only 2.54A. The following 
table {Table 6.1) details the data processing and scaling.
Table 6.1 Data collection and reduction statistics




*  sym ( % ) 8.8 (45.1)
I/crl (outermost shell) 8.3 (2.8)
Completeness (outermost shell) (%) 98.4 (99.4)
The outermost shell corresponds to resolution bin covering 2.63-2.54A.
6 . 3  S T R U C T U R E  S O L U T I O N  A T T E M P T S
6 . 3 . 1  M O L E C U L A R  R E P L A C E M E N T  T R I A L S
The attempts to solve the structure of the nTIMP-1 «MMP-1 :CD 
complex were initiated with molecular replacement trials since the three- 
dimensional structures of both the catalytic domain of MMP-1 (Lovejoy et al., 
1999) and the N-terminal domain of TIMP-1 (Gomis-Ruth et al., 1997) were 
available. The number of molecules in the asymmetric unit was deduced to be 
two nTIMP-1 *MMP-1 :CD complexes based on Matthews coefficient. The 
resulting solvent content for the crystal was calculated to be -64%. The first 
attempt at structure solution was made with AMoRe (Navaza, 1994). The 
crystal structure of the MMP-3 (catalytic domain) in complex with the full- 
length TIMP-1 (Gomis-Ruth et a l, 1997) was used as the search model. The 
TIMP-1 part of the structure was trimmed to retain just the N-terminal domain 
whereas for the MMP-3 part of the complex, the residues identical to MMP-1
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were kept and the others were mutated to alanines. The two zinc ions and the 
three calcium ions from MMP-3 were excluded from the search model with 
the view that appearance of Fourier difference density for the zinc ions would 
confirm the solutions found. The number of molecules in the asymmetric unit 
was confirmed through calculation of the self-rotation function using 
POLARRFN (Fig 6.8) (CCP4, 1994).
90.0
-9 0  0
Section kappa = 180
Fig 6.8 Self rotation function as a stereographic projection of the section
k  = 180 °for the nTimp-1 •MMP-T.CD data. The top peak height was lOOcr
Cross rotation function did not yield a unique solution. Hence, the 
search for the two complexes in the asymmetric unit was then carried out in 
two different runs, one for each domain comprising the complex, MMP-1: CD 
and N-TIMP-1. Molecular replacement calculations were computed in 
AMoRe (Navaza, 1994), XPLOR (Brunger, 1992b; Brunger and Rice, 1997),
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Beast (Read, 2001), Molrep (Vagin and Teplyakov, 1997), EPMR (Kissinger 
et a l, 1999) and CNS (Brunger, 1992b; Brunger et al, 1998). Several 
parameters like the radius of integration, resolution range, search model (N- 
TIMP-1, MMP-3 and MMP-1: both all-alanine models as well as the whole 
structure) were tried for molecular replacement calculations in AMoRe and 
Molrep. None of this yielded a unique solution although one of the search runs 
using Molrep for the MMP-1 domain of the complex did produce a solution 
that seemed promising. For this run of Molrep, the search model used was the 
1.9A structure of the catalytic domain of MMP-1 (PDB code: 1CGE; Lovejoy 
et a l, 1999). Rigid body and positional refinement of this solution in CNS 
(Brunger, 1992b; Brunger et al, 1998) resulted in an R ^ t  of 45.5% and Rfree 
of 50.8% with a FOM of around 44.2%. Parameters similar to those used for 
the MMP-1 domain search were used for N-TIMP-1 as well, but this did not 
prove to be a fruitful exercise. XPLOR and CNS molecular replacement 
protocols were used to compute a Patterson search in different resolution 
ranges but this did not produce a distinct solution. Consequently, a direct 
rotation search was employed using a Patterson correlation (PC) target 
function in which the search model was rotated every 5° about all Euler angles 
in the asymmetric unit of the rotation function. At each orientation, PC target 
function was calculated using all data (again for different resolution ranges) 
and each orientation was subjected to PC refinement to further define the 
correct orientation of the molecule in the asymmetric unit. The top solution 
was 7a higher than the average correlation coefficient for the search and 
increased to 8a after PC refinement. Translation search was carried out 
against all data in the same resolution range. This search produced a solution 
that was about 6a above the mean correlation coefficient for the search and 2a 
above the second highest solution. To find the second molecule in the 
asymmetric unit, self-rotation function was calculated and used in the second 
translation search. The solution thus found did not show a significant increase 
in its correlation coefficient. A rigid body refinement of the two molecules 
proved that the solutions were not correct.
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Unsuccessful attempts with AMoRe, Molrep, XPLOR and CNS, made 
us try other molecular replacement programs. First to be tried was Beast, 
which is based on using maximum-likelihood targets for calculating rotation 
and translation functions. This usually works best when the search model is 
derived from a well-refined crystal structure of at least medium resolution. 
Again for MMP-1 domain of the complex the 1.9A structure of the catalytic 
domain of MMP-1 (PDB code: 1CGE; Lovejoy et al., 1994) was used. As for 
the N-TIMP-1 domain, the TIMP-1 part from the MMP-3 •TIMP-1 complex 
(PDB code: 1UEA; Gomis-Ruth et al., 1997) and laminin-binding domain of 
agrin (PDB code: 1JB3; (Stetefeld et al., 2001)) was used. The laminin- 
binding domain of agrin was used because it is structurally related to the N- 
terminal domain of TIMP-1 and the structure available is a well-refined model 
at 1.6A. Beast also failed to produce any solution with significantly positive 
Log Likelihood Gain (LLG) scores despite varying (increase) the estimate of 
the effective RMS error.
The next program tried was EPMR. The random orientations it 
generated could not be translated into an optimised solution and thus EPMR 
also ended up being an unsuccessful attempt at structure solution. A careful 
read through the literature at this point of time revealed that molecular 
replacement calculations were not quite straightforward for almost all the 
structures solved previously for MMPs and TIMPs. This was attributed to 
high flexibility of the TIMP molecules in the structure. So, AMoRe (Navaza, 
1994) was tried once again in order to find the position and orientation of the 
two complexes in the asymmetric unit. But this time, the loop regions in both 
MMP-1 and NTIMP-1 domains were excluded from the search model and 
only the secondary structure elements were used in both rotation and 
translation searches. Again molecular replacement calculations were 
computed for each component of the complex separately and as a complex. 
MMP solutions were found, which turned out to be the same as the ones found 
using Molrep but TIMP search was yet again unsuccessful. Since the same 
solutions were obtained for MMP-1 twice, tracing of the TIMP-1 molecules 
was attempted with FFFEAR (Cowtan, 1998) and with BONES in ‘O’ (Jones
Chapter 6 Structural Studies on N-TIMP-1 •MMP-1 ;CD complex
et a l, 1991). However, the electron density for the TIMP-1 molecules was 
very patchy and not as well defined as for MMPs, which made the tracing not 
possible.
6 . 3 . 2  S I N G L E  A N O M A L O U S  D I S P E R S I O N  ( S A D )  C L O S E  T O
T H E  Z I N C  E D G E
While structure solution trials using molecular replacement methods 
were being carried out, the presence of the two zinc ions in MMP-1 prompted 
us to collect a SAD dataset close to the zinc edge on PX 14.2, SRS, Daresbury 
(UK). The statistics of data processing and scaling are given in Table 6.2. A  
total of 366 images (a full sphere of data) were collected with an exposure 
time of 12 seconds for each image.
Table 6.2 Data collection and reduction statistics for anomalous data





I/al (outermost shell) 26.7 (4.4)
Completeness (outermost shell) (%) 99.9(100)
The data was collected at X = 1.042A at a distance o f  210mm and Aq> =1.0° .  The 
outermost shell corresponds to the resolution bin covering 2.70-2.61 A.
The reflection file output by SCALEPACK was converted into an 
MTZ format using the SCALEPACK2MTZ routine. The SCALEIT program 
was then used to analyse the dataset for large anomalous differences (if any). 
The scaled dataset was then used to calculate difference anomalous Patterson 
map with FFT. The Patterson map thus produced was plotted along the Harker 
section using NPO and contoured at 1.5a (Fig 6.9).
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Fig 6.9 Anomalous difference Patterson map for Zinc
As mentioned before, the crystals belonged to monoclinic C2 space 
group (unique b axis) with two molecules in the asymmetric unit. Since each 
MMP-1 molecule has two zinc atoms bound to it (a catalytic zinc and a 
structural zinc), a total of 4 zinc sites had to be identified. The equivalent 
positions for this space group are x, y, z; -x, y, -z; 1/2+x, 1/2+y, z and 1/2-x, 
1/2+y, -z. The CCP4 program, PEAKMAX, was used to compute a list of 
predicted peaks from the Patterson map. The top peak was compared with the 
anomalous zinc sites deduced manually from the Harker section plot. One of 
the peaks from the plot was the same as the top peak. This zinc site was
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refined in MLPHARE. Difference Fourier map was calculated to find more 
sites. The top peak (2nd site) found in the second run of PEAKMAX was 
checked for consistency with the Patterson peaks like before. Although the 
peak did not correspond to any of the Patterson peaks, it was input as the 2nd 
site in another run of MLPHARE. This addition did not improve the phasing 
power or the FOM in any way. Further addition of sites resulted in worsening 
of the statistics. So, phases were calculated from the first two sites and 
subjected to Density Modification (DM; Cowtan and Zhang, 1999) to improve 
and extend phases. The sign of the sites were reversed in order to compute 
phases for the other hand. These phases were also subjected to DM. None of 
the two trials produced an interpretable map.
63.3 MULTIPLE ISOMORPHOUS REPLACEMENT (MIR)
ATTEMPTS
MIR attempts for the crystals of the nTIMP-1»MMP-1: CD complex 
was carried out with different heavy atom compounds like Potassium 
tetrachloroplatinate (II) [K^PtCLj], [K^ PdCL*] and Osmium chloride. The soak 
concentrations used were lOmM (with 5mM in the drop). The crystals were 
monitored for deterioration during the soak. The Platinum (Pt), Palladium (Pd) 
and the Osmium (Os) datasets were collected in X I1, Hamburg, Germany. An 
overview of the data processing and scaling statistics is given in Table 6.3. All 
the datasets were collected at a wavelength of 0.811A and a ciystal-to-detector 
distance of 260mm with an oscillation width of 1.0° and 15 seconds exposure 
time.
Table 6.3 Data processing and scaling statistics for derivative datasets
Dataset Completeness R sy m Resolution I/a l
(soak time) (last shell) % (last shell) % ( A )
Pt (45 min) 84.0 (83.4) 13.5 (42.9) 3.1 7.0 (3.25)
Pt (50 min) 67.8 (69.5) 20.4 (68.1) 3.5 5.44 (2.0)
Pt (-4 hrs) 86.5 (88.3) 15.4(11.6) 4.5 5.42 (7.8)
Pd (~2hrs) 97.6 (94.8) 7.7 (38.4) 2.7 10.6(2.1)
Os (50 min) 92.1 (93.9) 11.6(40.9) 3.0 6.06 (2.0)
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Programs from the CCP4 package (CCP4, 1994) as well as SHELXS- 
97 (Sheldrick, 1997) were used to locate and refine heavy atom positions. All 
these datasets were merged using the program CAD (CCP4, 1994). The 
derivative datasets were then scaled against the native 2.54A dataset using 
SCALEIT (CCP4, 1994). The log file created by SCALEIT program analyses 
the derivative dataset against the native and outputs statistical values (Table 
6.4) like the Rfac and DiSO (the isomorphous differences between the native and 
derivative dataset). The log file lists out, for each derivative to native scaling, 
Rfac value for each resolution bin. A decrease in the Rfac value around 4.0A 
and subsequent increase at higher resolution gives a slight indication of 
whether or not the heavy atom is bound. This trend was seen only for the 
Osmium (Os) dataset. The log file also outputs the level acceptable 
differences for each derivative dataset, which is subsequently used as sigma 
level when plotting Difference Patterson maps for each derivative.
Table 6.4 Statistics produced by SCALEIT for each derivative dataset
Dataset Overall Rfac D iso
Pt (45 min) 28.6% 63.4
Pt (~4 hrs) 31.6% 87.8
Pd (~2hrs) 50.6% 87.2
Os (50 min) 19.3% 39.7
Since the Osmium dataset seemed more promising than others, 
Patterson maps were calculated first for this dataset using FFT (CCP4, 1994). 
Possible heavy atom positions determined by manual deconvolution of the 
Patterson synthesis as well as cross verification of the peaks with those 
predicted by PEAKMAX (CCP4, 1994). Heavy atoms located were refined in 
MLPHARE (CCP4, 1994). A similar protocol was applied for other 
derivatives as well. Cross difference Fourier synthesis between the different 
derivatives were carried out to verify the heavy atom sites found 
independently. These sites were not confirmed by this procedure, perhaps 
because of very weak or no substitution at all.
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Since we had initially found a zinc site from the anomalous dataset 
collected previously, the anomalous dataset and all the derivative datasets 
were scaled against the native data using SCALEIT. Heavy atom sites for Pt 
were determined and these were then used to calculate a difference Fourier to 
locate Zinc sites and confirm these sites with the ones found previously 
(independently). Two zinc sites and one platinum site thus identified were 
refined with their relative occupancies in MLPHARE. The statistical 
parameters output after heavy atom refinement revealed that the Pt sites 
identified had very low occupancies indicating perhaps a rather weak 
substitution. Overall refinement of the sites together produced a phasing 
power of just 1.10 and an Rcuiiis of 0.92. The low phasing power and an Rcuiiis 
of nearly 1 was not good enough to produce good model phases. Since a 
partial MR model from Molrep for the MMP-1 component of the complex 
was available a map with a combination of these phases was calculated. 
However, the peaks corresponding to the identified Pt and Zn sites could not 
be located in the resulting Fourier map.
6.4. DISCUSSION AND FUTURE WORK
It is not quite clear as to why the Molecular Replacement trials failed 
to result in structure solution. Past experiences of other scientists working in 
this field with MMP-TIMP complexes suggest that the TIMP molecule is 
highly flexible. The high solvent content of ~64% in our crystals also 
indicates that there must be regions in the protein that have very high thermal 
motion. Perhaps this may be one of the reasons why all the MR programs 
either failed or did not yield a correct solution. Inspection of the Fourier 
synthesis for the entire asymmetric unit, calculated using the Molrep solution 
for the MMP-1 component of the complex, revealed patchy difference density, 
which perhaps accounts for the missing portion of the asymmetric unit, 
namely the two TIMP-1 molecules. However, what is interesting is that this 
difference density is not in the region as would be expected from the MMP- 
3•TIMP-1 complex structure (Gomis-Ruth et a l, 1997). It can be possible that 
in our case, the orientation of the two protein molecules is different from what 
is expected based on other MMP-TIMP complexes, which may be another
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reason why our search with the complex as a search model failed to yield any 
solution. Also the structure for the N-terminal domain of TIMP-1 (residues 1- 
126) was obtained from the full-length structure of TIMP-1 in the MMP- 
3»TIMP-1 complex (Gomis-Ruth et al., 1997). Perhaps there is some 
difference in the orientation of the N-terminal domain of TIMP-1, when it 
forms a complex with the C-terminal domain and this variation may be 
another reason for the additional difficulty in finding a unique solution of thie 
structure.
The unsuccessful attempt with the SAD data can perhaps be attributed 
to the fact the data was not collected at the exact zinc edge. The wavelength at 
which the data was collected was 1.042A whereas the exact wavelength for 
collecting anomalous zinc data is 1.2008A. In other words, anomalous 
contribution or the strength of the anomalous signal from the zinc atoms in the 
observed data is perhaps very weak and probably does not contribute much to 
the observed structure factor. As a result, the quality of the phase estimates 
that were calculated on basis of single wavelength data collected away from 
the zinc edge, containing very weak anomalous signal, was poor and thus 
could not yield an interpretable map. However, due to limitation of the station, 
PX 14.2 at SRS, Daresbury, (UK), we could not optimise our data collection 
at the exact Zinc edge.
Recently, attempts were made to collect fresh anomalous data at the 
exact zinc edge at PX9.5, SRS, Daresbury (UK). However, non-availability of 
good quality, fresh crystals hindered the attempt. This was because the 
metalloenzyme, MMP-1 has a tendency to degrade over a period of time and 
thus crystallisation trials with old samples failed to produce good quality 
crystals. Crystallisation trials with a new batch of proteins are currently 
underway and we hope to collect a SAD dataset at the exact Zinc edge at 
ESRF, Grenoble (France) in February/March, 2003. We may also need to 
screen for more potential derivatives. Hopefully, a combination of 
isomorphous replacement and anomalous scattering methods should help in 
solving the structure of this complex.
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FUTURE WORK IN THE FIELD OF ANGIOGENESIS
The aim of angiogenesis research is to characterise the endothelial cells 
that originate from tumour tissues. Today, one of the major future directions 
for angiogenesis research is to continue to identify the biochemical targets and 
elucidate the three-dimensional structures of all the macromolecules involved 
in the process of angiogenesis. It is important to model and quantify the 
structure-functional relationship of these macromolecules in parametric terms 
and correlate the dynamics of the process with these parameters. This will 
help in incorporating the molecular properties of these targets in a cellular 
context, which will unravel the complex pathways that are integrated into the 
process of blood vessel formation. Also, it is necessary to develop new 
experimental models for angiogenesis so that the authenticity of the molecule 
being tested can be verified to a larger extent than now. For this we also need 
to evaluate angiogenesis in human tumours as opposed to animal tumours as a 
prognostic tool.
Every year at least one major event in cancer research takes place 
somewhere in the world. A vast array of research is being done by both basic 
and clinical researchers who are striving towards communicating the biology of 
their work into drugs and inhibitors. It is becoming increasingly important to 
design small molecule antagonists taking into account the macromolecular 
target in terms of its biological endpoint, especially since at least 50 different 
diseases (including all cancers) are caused by persistent blood vessel growth. 
The therapeutic applications that need to be developed should promote tumour 
regression by death of tumour cells and not normal, healthy cells. Also the need 
of the hour is to develop drugs that are easy to deliver, free of delivery risk and 
with low dosage requirements to combat poor immunogenicity, which is one of 
the major obstacles to the development of successful antagonists.
The structures of P1GF-1 and VEGF-B solved during the course of this 
thesis have laid a foundation for future work in the area of drug design based on 
their structures. However, further structural studies based on receptor-ligand 
complexes are required to gain useful insights into the desired and undesired
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interactions for the key residues at the binding interface. Since both the 
molecules are close homologues of VEGF-A, the most potent inducer of 
angiogenesis, therapeutic approaches targeting these molecules will have a 
significant impact on the field of angiogenesis. Structural studies based on the 
ligand specificity of Flt-1, for P1GF-1 and VEGF-B, as opposed to the dual 
receptor specificity of VEGF-A. The structural basis behind the affinity of Flt-1 
for P1GF-1 and VEGF-B may lead to the development of receptor/ligand 
specific therapeutics. P1GF-2, on the other hand, binds Flt-1, heparan sulphate 
proteoglycans (HSPGs) and the semaphorin receptors: neuropilins-1 and 2 (NP- 
1 and NP-2). It is known that the binding of heparin to P1GF-2 increases its 
affinity for the neuropilins. Also interesting is the fact that Flt-1 and NP-1 
interact to form a receptor-receptor complex. Access to the three-dimensional 
macromolecular structures of these complexes is essential for the functional 
characterisation of the interactions between P1GF-2 and its binding partners. 
Therapeutics and drugs available to date for these angiogenic molecules, 
especially VEGF-A, are based on mutagenesis studies and the crystal structure 
of VEGF-A on its own and with its receptor, Flt-1. Since the activities of these 
growth factors, VEGF-A, PIGFs, VEGF-B, are all correlated in several tissues 
(e.g. heart), the next step would be to elucidate the crystal structure of all these 
complexes. This is important to understand the different modes of interaction 
between the molecules in order to minimize unwanted activities as well as 
enhance desired ones. These target structures would have a tangible effect on 
the production and optimisation of drug candidates for combating cancer and 
other angiogenesis related diseases like ischemia of the heart and arthritis.
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APPENDIX A
The work described in this thesis involved the use of several computer 
programs. These invaluable programs have been developed by scientists with 
the aim to assist non-programmers in the process of structure determination. 
These different programs are used right from the time of data collection to the 
very end when a structure is analysed or even when the results need to be 
graphically represented. The following contains a brief description of all the 
programs that I have used in my Ph.D. work.
Al. Data Collection, Processing And Scaling: THE HKL PACKAGE 
(Otwinowski and Minor, 19971
In the present scenario data collection has become an interactive 
process. One can process data in tandem with data collection. Quick scaling of 
the first few images collected helps in planning the strategy for further data 
collection as well as making optimum use of the expensive synchrotron 
facilities, both in terms of the quantity of data collected as well as the quality 
time spent in doing so.
All the datasets presented in this thesis were collected at the 
Synchrotron Radiation Source, Daresbury, UK. The HKL package was used 
for the purpose of data processing and scaling. The programs in the HKL 
package were written by Zbyszek Otwinowski and Wladek Minor. This data 
processing suite for macromolecular crystallography comprises of three 
programs.
• XdisplayF: This program enables visualisation of diffraction 
images.
• Denzo: This program enables numerical analysis of the raw 
diffraction data. Denzo reduces the data to a set of hkl indices 
and the intensity for each recorded reflection.
• Scalepack: This program provides the complete statistics on the 
collected dataset. It gives both the weighted (x2) and the
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unweighted (R m erge) statistical values, which help to establish 
the quality of the dataset.
HKL2000 (Otwinowski and Minor, 1997): The p-version of this program is 
installed in SRS, Daresbury, UK. This is a graphical user interface (GUI) 
based data processing suite, which includes all the various features of 
XdisplayF, Denzo and Scalepack.
A2. Reflection Data Utilities: CCP4 suite (CCP4.19941
The reflection data file (the one produced by Scalepack) needs to be 
converted into a format that is suitable to input into the phasing program that 
will be used for structure solution eg all programs in the CCP4 suite use MTZ 
reflection files.
• Scalepack2mtz: This program converts the scalepack reflection 
file into an mtz format.
• Truncate: This program is used to calculate structure factor 
amplitudes from the observed intensities.
• Cad: This program can be used to combine and sort reflections 
from several files into a single file or can be used to extend 
reflection data for space group PI or simply place the reflection 
data in the CCP4 asymmetric unit and sort them out into a 
standard order.
• Uniqueify: This program can be used to complete a dataset with 
reflections allowed for a given unit cell with a given symmetry 
for a given resolution limit, regardless of whether or not data 
have been measured for those reflections.
Mtz2various: This utility helps covert an mtz reflection file into formats that 
will be suitable for the different programs specified by the keyword 
“OUTPUT”. The programs supported by this utility are SHELX, 
CNS/XPLOR, MULTAN, TNT, MAIN, CIF, SCAL. The OUTPUT type 
“USER” can be used to define a format specific for the user’s needs. The user 
can specify which columns are to be output, how many and in what format.
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Mtz2utils: This utility, like Cad, can be used to edit or re-arrange an mtz 
reflection file.
A3. PHASING: Molecular Replacement (MR)
A3.1 AMoRe (Navaza, 1994): This is the state-of-the-art program for 
structure solution and it comprises of 5 separate routines to run a complete 
molecular replacement. The five routines are:
1. SORTING: In this routine the data is read, extended to cover a 
hemisphere of reciprocal space, sorts out the reflections according to 
the space group symmetry and reformats the mtz file into an hkl file for 
use by the next routines in AMoRe.
2. TABLING: This routine reads in model coordinates and calculates 
structure factors for the model.
3. ROTING: This routine calculates the rotation function and produces a 
list of several possible solutions by Patterson overlap.
4. TRAING: This routine calculates the translation function for each of 
the possible rotation solution found in step 3
5. FITING: This routine does a rigid-body refinement of all the solutions 
found by the rotation and translation search.
6. REORIENTATING: This applies the MR solution on the initial 
coordinates of the search model. It uses the Eulerian angles and the 
Centre of Mass values from the tabling output as well as the rotation 
and translation search values from the fifing routine as input.
The better the Patterson overlap the higher is the correlation coefficient 
and lesser are the R-factors. Usually the top solution is the right one but NOT 
ALWAYS so. If there are several molecules in the asymmetric unit then one 
can find them by fixing the rotation and translation parameters of the first 
molecule in the second translation run and so on until all the molecules are 
found. As and when the right solutions are found the correlation coefficient 
increases with a simultaneous decrease in the R-factor. Nevertheless, it is 
important to check the packing of the solutions on the graphics.
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A3.2 BEAST (Read, 2001): This program, written by Randy J. Read, uses 
maximum-likelihood targets for calculating rotation and translation functions. 
Like AMoRe, Beast also facilitates searching for multiple molecules in the 
asymmetric unit by fixing ones already known. Beast makes it possible to use 
several possible search models in the same run.
A3.3 CNS/XPLOR (Brunger, 1992b): Both CNS and XPLOR use 
Patterson correlation (PC) refinement based method for molecular replacement 
calculations. For rotation searches, a stationary Patterson map is calculated 
from the observed intensities. The Patterson map to be rotated in reciprocal 
space is calculated from either the observed intensities (for computing the self­
rotation function) or from the search model (for computing the cross-rotation 
functions). The translation search can be performed for each rotation solution 
obtained from the PC refinement. CNS/XPLOR can also perform a packing 
analysis for each listed peak. The solution output is translated according to the 
highest translation function value.
A3.4 EPMR (Kissinger et aL, 1999): This program by Charles R. 
Kissinger, Daniel K. Gehlhaar and Bradley A. Smith computes molecular 
replacement calculations using evolutionary search algorithms. It randomly 
generates rotation and translation parameters for the search model and 
computes correlation coefficient for each orientation. The solutions with 
correlation higher than a given threshold are kept. The program then makes 
random alterations to the rotation and translation parameters of these solutions 
and the correlation coefficient for each of the altered solutions is computed 
again. The high scorers of the round survive and the whole procedure is 
repeated for ‘n’ number of cycles. At the end of the specified no of cycles, the 
program performs a round of rigid-body refinement on the optimised 
solutions. These solutions are then checked on the graphics for their packing.
A3.5 MOLREP (Vagin and Teplyakov, 1997): The authors of Molrep are 
Alex Vagin and A. Teplyakov. Molrep like AMoRe calculates overlapping 
functions between the observed and the calculated Pattersons. However, unlike 
AMoRe, Molrep calculates rotation function for three different orientations of
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the model and averages them thus reducing noise level. Also, during the 
translation search, Molrep removes incorrect solutions on the basis of their bad 
packing by multiplying the translation function with the packing function for 
each peak computed.
A4. PHASING: Multiple Isomorphous Replacement (MIRVAnomalous 
Dispersion fMAD/SAD)
A4.1 SCALEIT (CCP4, 1994): This program, written by Phil Evans, 
Eleanor Dodson and Richard Dodson, applies a derivative to native scaling 
function on the reflection dataset. This program is normally run after all the 
datasets, both native and derivative, have been merged into one file using 
CAD. The scaling factor is determined from the squared amplitudes and can 
be an overall scale factor, an isotropic or an anisotropic temperature factor. 
The program outputs a list of statistics that can be used to analyse the quality 
of data. It gives an estimate of the acceptable isomorphous and anomalous 
differences for each derivative and outputs a list of reflections that have 
abnormally high differences. These reflections can then be excluded while 
searching for heavy atom or anomalous sites during Patterson calculations.
A4.2 FFT (CCP4, 1994): The program is an abbreviation for Fast Fourier 
Transform and was written by Lynn F. Ten Eyck. It is used to prepare different 
types of Fourier transforms from a binary reflection data file. These transforms 
include Fourier synthesis, double difference Fouriers, Patterson maps and 
difference Patterson maps.
A43  PEAKMAX (CCP4, 1994): Phil Evans and Ian Clifton wrote this 
program to search the electron density map for peaks with heights above a 
given threshold. The program lists these peaks in descending order of their 
height. The top peak is compared with the difference Patterson to see if it 
appears there. This format of peaks is suitable for input to MLPHARE (a 
program for heavy atom refinement).
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A4.4 NPO (CCP4, 1994): This program by Sam Motherwell was originally 
written under the name of “pluto”. Phil Evans and Eleanor Dodson later 
modified the program for plotting maps and protein molecules respectively. 
NPO can be used for plotting maps that are output from FFT, either as simple 
sections or as stacks.
A4.5 XPLOT84DRTVER (CCP4, 1994): This program is used to view the 
plots created by NPO and was written by Jan Zelinka.
A4.6 MLPHARE (CCP4, 1994): This program refines the heavy atom 
parameters and calculates phases from them. The refinement is based on 
maximum-likelihood function. MLPHARE allows for the use of cross 
difference Fouriers to find sites in other derivatives relative to the same origin 
as the sites from the first derivative. The results of the refinement are output in 
the form of statistical analysis as a function of Figure of Merit (FOM) or 
resolution range.
A4.7 SHARP (de La Fortelle and Bricogne, 1997): SHARP was originally 
written by Gerard Bricogne and Eric de La Fortelle. It was converted into GUI 
based software for refinement of heavy atom parameters by John Irwin.
A5. DENSITY MODIFICATION
Phasing programs are very closely associated with density modification 
programs as they aid in phase improvement and help in interpreting the 
electron density maps. Several programs have been written to facilitate density 
modification.
A5.1 DM (CCP4, 1994): DM by Kevin Cowtan applies real space 
constraints based on the known features of an electron density map in order in 
order to improve the experimental phases.
A5.2 SOLOMON (CCP4, 1994): This program written by J.P. Abrahams 
with the I/O sub-routines modified by Kevin Cowtan also performs density 
modification by solvent flipping instead of the solvent flattening mode
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followed by DM. Solomon is now a feature of SHARP but it can be run on its 
own as well. Solomon also features the ability to include information from a 
partial structure in the form of Hendrickson-Lattman (HL) coefficients.
A5.3 NCSMASK (CCP4, 1994): It is a mask manipulation program used 
for constructing masks in cases where non-crystallographic symmetry is 
present. This program performs operations on NCS symmetry masks 
constructed from a monomer. The masks generated by this program are ideal 
as input into DM when using NCS averaging.
A5.4 CNS (Brunger, 1992b): CNS also uses the solvent flipping mode like 
Solomon for density modification based phase improvement. CNS can also be 
used for reducing model bias when using a MR solution. This program was 
written by Alex Brunger.
A6. REFINEMENT AND MODEL BUILDING
A6.1 O (Jones et aL, 1991): This software developed by T.A. Jones and 
Morten Kjeldgaard is used for displaying the electron density maps and the 
coordinates for the model after structure solution. It is used for model building 
between iterative refinement cycles.
A6.2 CNS (Brunger et aL, 1998): CNS refinement is based on maximum- 
likelihood targets. It carries out simulated annealing refinement of crystal 
structures based on torsion-angle molecular dynamics. It automatically 
computes cross-validated cja error estimates and the weighting factor between 
the X-ray refinement target function and the geometric energy function. CNS 
also refines bulk solvent and overall B-value by performing least-squares 
minimisation before refining atomic positions by simulated annealing 
protocol.
A6.3 ARPAVARP (Lamzin and Wilson, 1993): Automated Refinement 
Procedure is a package developed by Anastassis Perrakis, Victor S. Lamzin,
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Richard J. Morris and Petrus H. Zwart. This package can be used for 
automated tracing of the protein chain, improvement of experimental phases 
via map interpretation as well as refinement of MR solutions. ARP/WARP can 
also be used to build the solvent structure for the crystal structure. Like CNS, 
structure refinement is again a function of maximum-likelihood. Apart from 
requiring data to at least ~2A, the other limitation of this program is that only 
PI and acentric space groups are supported.
A6.4 SHELXL (Scheldrick and Schneider, 1997): George Sheldrick’s 
program, SHELXL, is based on conventional SF summations rather than the 
FFT based programs. For this reason it is slower but more accurate than the 
other standard macromolecular refinement programs. SHELXL can work with 
data up to 2.5A or higher.
A7. STRUCTURE ANALYSIS
A7.1 BAVERAGE (CCP4, 1994): Eleanor Dodson’s program, baverage, 
calculates the average B-factor values over the main chain and side chain 
atom.
A7.2 CONTACT (CCP4, 1994): This CCP4 program was written by 
Tadeusz Skarzynski. It computes the contacts (both intra- and inter-molecular 
contacts) in a crystal structure. It lists out the contacts between the protein 
molecules, between protein and ligands/ions/prosthetic groups (if present) and 
between protein and waters.
A7.5 MATTHEW’S COEFFICIENT (CCP4, 1994): Given the unit cell 
dimensions and the molecular weight of the protein, this program written by 
Misha Isupov calculates the Matthew’s coefficient and the solvent content of 
the protein crystal. This helps compute the number of molecules in the 
asymmetric unit.
A7.6 PROCHECK (CCP4, 1994): This program from CCP4 analyses the 
stereochemistry of the protein structures. It produces around 10 postscript files
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detailing the stereo-chemical quality of the model, residue-by-residue. It also 
produces the RAMACHANDRAN PLOT.
A7.7 SC (CCP4, 1994): Michael C. Lawrence’s program SC analyses the 
shape complimentarity of two interacting molecular surfaces.
A7.8 CNS (Brunger et aL, 1998): There are several scripts available in CNS 
for structure analysis. The ones used for the work presented in this thesis are 
as follows:
• model stats.inp: Calculates statistical information from the input PDB 
file and reflection data file. The information it produces is required for 
the PDB header.
• buried_surfaces.inp: As the name suggests, it calculates buried 
surfaces in the molecular structure.
• xtal_pdbsubmission.inp: Prepares the refined coordinates suitable for 
submission to the Protein Data Bank.
A8. PICTURES
A8.1 MOLSCRIPT (Kraulis, 1991): Molscript is a program used to display 
both schematic and detailed representations of the molecular structures. The 
version used for this work was Molscript v2.1.2. Information supplied by 
means of an input script that specifies the coordinates of desired molecule 
along with graphics parameters enables users to render graphics images.
A8.2 ALSCRIPT (Barton, 1993): Alscript is a program that takes in a 
multiple sequence alignment file (files produced by the programs CLUSTAL, 
AMPS, GCG) and produces a PostScript file based on the set of formatting 
commands provided by the user via an input script. It does not align or edit 
sequences by itself. It only formats them according to user specifications.
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A P P E N D I X  B
Figure o f  Merit
Ambiguity in phase determination using Isomorphous Replacement 
Method or the Anomalous Scattering method arises from inaccuracy of 
intensity measurements, lack of isomorphism (for isomorphous replacement 
methods) and incorrect heavy atom positions. The total error, E ,  is given by
(E>2 = (5>2 + (e)2
where, (8) is the r.m.s. value of the structure factor amplitudes of the protein 
(Fp) and those of the derivative ( F p h )  and (e) is the error in calculation of the 
heavy atom contribution, Fn(caic), to the derivative structure factors ( F p h ) .  If we 
are to assume that Fh is small compared to Fp and Fph, the magnitude of phase 
error introduced by errors in Fp is of the same magnitude as an error in Fph. 
This means that the magnitude of phase error is not affected by regarding the 
whole error to reside in F h .
Lack of closure (in relation to refinement of heavy atom parameters) is 
also based on the assumption that Fh is small compared with Fp and Fph. If a 
Gaussian distribution of errors was to be assumed then the total probability of 
the phase angle, ap. (for Fp when several heavy atom derivatives are used 
simultaneously) is given by the product of individual probabilities,
P ( a )  =  n P j ( a )  = exp [ - S ( s j ( a ) 2 / 2 E 2 ]
j j
where, Gj is the lack of closure of the phase triangle defined by
Gj =  FpH(obs) " FpH(calc)
Blow and Crick (1959) showed that this product gives the joint 
probability curve which gives all available information about the phase of the 
reflection. This curve is then used to plot the probability map on an Argand 
diagram in order to find the centroid of the distribution. According to Blow 
and Crick, the centroid of the distribution is a better choice since it results in a 
synthesis with the least mean square error in the electron density over the unit 
cell. This takes into consideration both unimodal and bimodal probability
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functions and thus doesn’t give too much weight to uncertain phases with 
bimodal distribution.
If we consider the error in electron density arising from errors in one 
reflection, then the mean square error, over the unit cell of volume V, from 
this reflection is given by:
(Ap2) = 1/V2 (Fs -  F,)2 
where, Fs is the coefficient used in the Fourier synthesis and Ft if the true 
value. The probability of Ft having a phase angle a  can be expressed as:
Ft = F exp ia
The mean square error can now be expressed as
2n / 2n
(Ap2) = 1 /V21 (Fs -  F exp ia)2 P(a)da /  J P(a)da
a=0 a=0
This integral will have a minimum value when Fs is at the centre of gravity of 
the centroid distribution. Thus F S(best> or the best Fourier can be represented by
Fs(best) = mF exp(iabest)
Where, m is the magnitude equivalent to a weighting function and is defined 
as the ‘figure o f  m erit. The electron density map calculated using mF and 
otbest would have minimum mean square error when averaged over the entire 
unit cell.
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C ysl 1 IB  
C ysl 13B
Schematic representation of the cystine-knot motif. The cysteine residues of monomer A have been 
shown in pink and those of monomer B in black. The text box on the right hand side lists the pairing oj 
the cysteine residues involved in the knot, making a total of 8 disulphide bridges: 6 intra-chain bridges 
(3 each for monomers A and B: coloured dark green in the figure) and 2 inter-chain disulphide links 
(coloured light green in the figure).
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The angiogenic m olecule placenta growth factor 
(P1GF) is a member of the cysteine-knot family of growth  
factors. In th is study, a mature isoform o f the human 
P1GF protein, P1GF-1, was crystallized as a homodimer 
in the crystallographic asymmetric unit, and its crystal 
structure w as elucidated at 2.0 A resolution. The overall 
structure o f P1GF-1 is sim ilar to that of vascular endo­
thelia l growth factor (VEGF) w ith w hich it shares 42% 
am ino acid sequence identity. Based on structural and 
biochem ical data, w e have m apped several important 
residues on the P1GF-1 m olecule that are involved in  
recognition o f the fms-like tyrosine kinase receptor 
(Flt-1, also known as VEGFR-1). We propose a m odel for 
the association of P1GF-1 and Flt-1 domain 2 w ith  pre­
cise shape com plem entarity, consider the relevance of 
th is assem bly for P1GF-1 signal transduction, and pro­
vide a structural basis for altered specificity of th is  
m olecule.
Angiogenesis, the process of new blood vessel formation, is 
essential for development, reproduction, wound healing, tissue 
regeneration, and remodeling (1). I t also plays a major role in 
tum or progression, diabetic retinopathy, psoriasis, and rheu ­
m atoid arth ritis  (2). Angiogenesis involves proliferation of en­
dothelial cells (ECs)1 in  an  organized fashion and is m ost likely
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regulated by polypeptide growth factors (3, 4) such as acidic 
and basic fibroblast growth factors (aFGF and bFGF, Ref. 5), 
vascular endothelial growth factor (VEGF, Refs. 6-10), and 
placenta growth factor (P1GF, Refs. 11-14). P1GF, VEGF 
(VEGF-A), VEGF-B (15), VEGF-C (16), VEGF-D (17), VEGF-E 
(18), and Fos-induced growth factor (FIGF, Ref. 19) are mem­
bers of a family of structurally  related  growth factors. In tra- 
and interchain disulfide bonds among eight characteristically 
spaced cysteine residues are involved in  the formation of these 
active dimeric proteins and hence term ed as cysteine-knot pro­
teins. They also share a num ber of biochemical and functional 
features (for a review, see Ref. 20) such th a t P1GF and VEGF 
can form heterodimeric molecules in  cells in  which both genes 
are expressed (21, 22).
A lternative splicing of the P1GF prim ary transcrip t leads to 
th ree forms of the m ature hum an P1GF protein (22-24). The 
two predom inant forms, P1GF-1 and P1GF-2 (also known as 
P1GF-131 and P1GF-152, respectively), differ only by the inser­
tion of a highly basic 21-amino acid stretch  a t the  carboxyl end 
of the protein. This additional basic region confers upon P1GF-2 
the  ability to bind to heparin  (13, 23).
The exact role of P1GF in vascular development is yet to be 
established. However, purification of P1GF-1 from overexpress­
ing eukaryotic cells and m easurem ent of angiogenic activity of 
the  purified P1GF-1 in vivo in  the rabbit cornea and chick 
chorioallantoic m em brane (CAM) assays showed induction of a 
strong neovascularization process th a t was blocked by affinity- 
purified anti-PlGF-1 antibody. In the avascular cornea, P1GF-1 
induced angiogenesis in a dose-dependent m anner and seemed 
to be a t least as effective (if not more effective) as VEGF and 
bFGF under the same conditions and a t the sam e concentra­
tion. P1GF-1 was shown to induce cell growth and migration of 
endothelial cells from bovine coronary postcapillary venules 
and from hum an umbilical veins (HUVECs). In  these two in 
vitro assays, P1GF-1 seemed to have a comparable effect on the 
cultured microvascular endothelium  (e.g. capillary venule en­
dothelial cells, CVECs) to th a t of VEGF and bFGF. These 
results clearly dem onstrate th a t P1GF-1 can induce angiogen­
esis in vivo and stim ulate the m igration and proliferation of 
endothelial cells in vitro (25). In  the  case of P1GF-2 it has been 
established th a t the recombinant, purified protein is able to 
stim ulate bovine aortic endothelial cells (BAEC, Ref. 13) and 
HUVECs bu t not the ECs from hepatic sinusoids (26).
The VEGF homodimer binds to and induces autophosphoryl­
ation of two distinct kinase receptors: the fms-like tyrosine 
kinase, Flt-1 (also known as VEGFR-1) and the kinase insert 
domain-containing receptor/fetal liver kinase, KDR/Flk-1 (also 
known as VEGFR-2). Conversely, the  P1GF-1 and -2 ho­
modimer bind only to the Flt-1 receptor (22, 26-28). Likewise, 
VEGF-B also binds selectively to Flt-1 and hence appears to be
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T a b l e  I 
C rystallographic sta tis tic s
Dataset P1GF-1
Data collection  statistics
U nit cell d im ensions (P43, a =  b =  62.6 A,
1 homodim er/a.u.) c = 84.1 A
Resolution (A) 4 0 -2 .0
Reflections m easured 161,044
Unique reflections 21,067
K m  (%)“ 6.3
I/crl (outerm ost shell) 19.6 (3.6)




Num ber o f protein atom s (homodimer) 1,546
Num ber o f solvent m olecules (homodimer) 132
R.m.s. deviation in bond lengths (A) 0.010
R.m.s. deviation in bond angles (°) 1.5
Average B-factor for protein atom s (A2) 32.6
Average B-factor for m ain-chain atom s (A2) 32.6
Average B-factor for side-chain atom s (A2) 32.7
Average B-factor for solvent m olecules (A2) 44.8
B-factor (from W ilson plot) (A2) 33.9
“ ^ Sym = 2(| Ij -  (I)|)/2(I) where Ij is the observed in tensity  o f reflec­
tion j, and (I) is the average in tensity  of m ultiple observations.
6 ^cryst =  S||F0| -  |FC||/X|FJ, where F0 and Fc are the observed and 
calculated structure factor am plitudes, respectively.
c R (ree is equal to Jicryst for a randomly selected 4%  subset of reflec­
tions not used in the refinement.
a closer homolog of P1GF in its receptor-binding profile (29). 
Purified heterodimeric VEGF/P1GF has been shown also to 
bind KDR/Flk-1 (22). The extracellular portion of both recep­
tors consists of seven immunoglobulin (IgG)-like domains, and 
the receptors share 44% amino acid sequence homology. The 
IgG-like domain 2 of the Flt-1 receptor is responsible for the 
binding specificity of P1GF-1 and -2 (30-32). Furthermore, it 
has been reported that only P1GF-2 can recognize neuropilins-1 
and -2, receptor molecules found at the endothelial surface, in 
a heparin-dependent fashion (33, 34).
Since P1GF has been shown to bind and induce autophospho­
rylation of Flt-1 but not KDR/Flk-1, it appears that P1GF 
should exert its mitogenic and chemotactic effects on ECs 
through the activation of the Flt-1 intracellular signaling path­
way. P1GF induces DNA synthesis but not migration of porcine 
aortic ECs (PAE) overexpressing Flt-1 (28). However, recent 
findings that P1GF is mitogenic and chemotactic for CVECs 
and HUVECs in vitro (25) (discussed above), raise the question 
of whether P1GF induces Flt-1 directly to transduce mitogenic 
and chemotactic signals inside the cell or whether P1GF acts 
indirectly through a mechanism of decoy, as previously pro­
posed by Park et al. (14).
The recent observation that Flt-1 is able to mediate signaling 
in HUVECs in response to both P1GF and VEGF, leading to 
distinct biological responses, suggests that Flt-1 does not act as
VEGF PDGF-BB
GF-p2 NGF
F ig .  1.Structural comparison of P1GF-1 and other members of the cysteine-knot super family. A, representation of the P1GF-1 
homodim er structure. D isulfide bonds are shown in a ball-and-stick  representation. The inset presents the organization of three intra- (in yellow ) 
and one interdisulfide bridge (in green) in the cysteine-knot motif. Each monomer in the homodimer is colored differently to enhance clarity. 
Orange, m onom er A; cyan, monomer B. B, representatives of known structures from the cysteine-knot protein fam ily o f dimeric m olecules, a, VEGF  
(PDB code 2VPF, Ref. 39); b, PDGF-BB (PDB code 1PDG, Ref. 51); c, TGF-02 (PDB code 1TFG, Ref. 52); and d, NGF (PDB code 1BTG, Ref. 53). 
W ith the exception of NGF, the homodim er 2-fold axis is perpendicular to the plane o f the 0-sheet. The cysteine knots are highlighted. C,
CYSTEINE-KNOT 
V MOTIF
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a decoy receptor but is indeed able to signal intracellularly (35). 
Inhibition of P1GF translation by antisense mRNA in the hu­
man dermal microvascular endothelial cells in culture results 
in the inhibition of cell proliferation under hypoxic conditions 
(36). These new findings assign a role to P1GF in the direct 
control of endothelial cell proliferation, probably competing 
with VEGF for binding to Flt-1 and thereby forcing the binding
of VEGF to the KDR/Flk-1 and activating cell proliferation. In 
addition, both P1GF and VEGF are able to induce migration of 
39% and 51% of monocytes, respectively, through activation of 
Flt-1 (35, 39). This suggests that P1GF may induce EC migra­
tion and proliferation through activation of Flt-1, although the 
existence of a yet unknown P1GF receptor cannot be ruled out.
A considerable amount of structural information is now
structure-based sequence alignm ent o f PIGF-1 w ith VEGF (38, 39). Amino acid residues that form part o f the secondary structural elem ents  
(/3-strands and helices) as determ ined by D SSP (60) are shown in blue and red , respectively. The cysteine residues are shaded p in k . VEGF residues 
involved in Flt-1 (VEGFR-1) binding (40), and the equivalent residues in PIGF-1 (based on a m odeling study) are boxed and shaded in yellow . The 
conserved glycine residue in both structures is underlined. This figure w as created w ith  the program ALSCRIPT (61). D, stereo view  displaying  
the Ca traces o f PIGF-1 (orange) and VEGF (cyan) (39) hom odim ers after alignm ent o f the two structures with the program “O” (49). A, B, and D  
w ere created with the program MOLSCRIPT (59).
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F i t  -1 D 2
F ig . 2. Proposed model for the 
P1GF-1-Flt-1D2 complex based on the 
crystal structures of PIGF-1 (present 
study) and the VEGF F lt-lD2 complex 
(40), PDB accession code 1FLT. A, 
PIGF-1 homodimer is shown in orange  
(m olecule A) and cyan  (molecule B), 
w hereas the Flt-1D2 m olecules are shown  
in pu rp le  and green. B, stereo view s of 
contact residues (Ca atom s plus sidechain  
atoms) at the putative P1GF-1-Flt-1D2 in­
terface. R esidues from PIGF-1 monomers 
A and B are m arked in orange and cyan, 
respectively. R esidues from Flt-1 (figure 
based on model shown in A) are colored in 
green. The sidechains for Glu73 and A sn74 
in free PIGF-1 are disordered and hence 
are treated as alanines. C, stereo view s of 
contact residues (Ca atom s plus sidechain  
atoms) for PIGF-1. R esidues from mono­
mer A and B are marked in orange and 
cyan, respectively (figure based on model 
shown in A). The sidechains for Glu73 and 
A sn74 in free PIGF-1 are disordered and 
hence are treated as alanines. D, stereo  
view s of contact residues (Ca atom s plus 
sidechain atoms) for F lt-1D2 (figure based  
on model shown in A). E, stereo view s 
show ing the location of the groove in 
PIGF-1 (residues Asp72, Glu73, V al52, 
M et55, Val45, Asp43, and Ser59) and VEGF  
(Asp63, Glu64, lie43, lie 46, Phe36, Asp34, 
and Ser50), implicated for recognition of 
domain 3 of Flt-1 (40). The figure also  
show s the difference in conformation for 
segm ent 9 0 -9 5  in PIGF-1 and 8 1 -8 6  in 
VEGF. Residues lie 83, Lys84, and Pro85 
are im plicated in KDR recognition in 
VEGF (38), and the corresponding resi­
dues in PIGF-1 are lie 92, Ser94, and Arg93. 
The sidechains for PIGF-1 and VEGF are 
shown in orange  and cyan, respectively. 
Ser94 and Glu73 in the PIGF-1 structure 
are represented as alanines because of 
insufficient electron density beyond the  
C/3 atom. A -E  w as generated using MOL- 
SCRIPT (59).
P I G F - 1







available for VEGF (VEGF-A). Muller et al. (38, 39) reported 
the crystal structures of the receptor binding domain of VEGF 
in different crystal forms and have identified the KDR binding 
site using mutational analysis. Also, Wiesmann et al. (40) have 
reported the crystal structure of VEGF in complex with domain 
2 of Flt-1 (Flt-1D2). To understand the specific molecular details
of the receptor binding site and critical components of the 
homodimer, which will consequently help in understanding the 
differences in specificity and cross-reactivity among the VEGF 
homologs, we have embarked on a three-dimensional struc­
tural study of P1GF. Here we report the crystal structure of 
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F ig .  2 —continued
similar to that of VEGF. However, it shows subtle differences 
in molecular interactions at the receptor recognition site that 
appear to be relevant to signaling.
EXPERIMENTAL PROCEDURES
P rotein  Expression a n d  P urification— By polym erase chain reaction, 
the region of the hum an PIGF-1 gene coding for the m ature protein was 
cloned into a prokaryotic expression vector as described previously (11). 
The recom binant vector w as used to transform a DE3 Escherichia coli 
strain, and the syn th esis of PIGF-1 w as induced by 1 m M  isopropyl-2- 
D-thiogalactopyranoside. After preparation and refolding of the inclu­
sion bodies, the PIGF-1 protein w as purified first by anion exchange 
chrom atography followed by reverse phase chromatography. Final re­
covery o f the active protein w as about 140 mg per liter of in itial bacte­
rial culture. The identity o f the protein w as checked by various assays 
such as im m unoblotting, SDS-polyacrylam ide gel electrophoresis under 
reducing and nonreducing conditions, tw o-dim ensional electrophoresis, 
reverse phase chrom atography, and am ino-term inal sequencing. The 
angiogenic activity w as tested  using a CAM assay (41); the purified  
bacterial-derived PIGF-1 w as able to induce a strong and dose-depend­
ent angiogenic response (42).
C rysta lliza tion — Crystals o f recom binant PIGF-1 were grown using  
the hanging drop vapor diffusion method from drops containing 8 mg/ml 
protein at pH 6.0 in 0.05 M M ES buffer, 10 m M  CaCl2 and 7.5% (v/v) 
2-m ethyl-2,4-pentanediol (MPD) equilibrated against reservoirs con­
taining 0.1 M M ES buffer (pH 6.0), 20 m M  CaCl2 and 15% (v/v) MPD. 
Single crystals appeared after 5 - 6  days at 16 °C. T hese crystals could 
be flash-frozen at 100 K using a cryoprotectant solution containing 0.1 
MES buffer (pH 6.0), and 30% (v/v) MPD. The system atic absences and 
sym m etry were consistent w ith  the tetragonal space group P4, or P43, 
w ith unit cell d im ensions a = b = 62.6 A, and c =  84.1 A. There w as one 
PIGF-1 homodim er per crystallographic asym m etric unit and ~50%  of 
the crystal volum e w as occupied by solvent.
D ata Processing a n d  R eduction—X-ray diffraction data to 2.0 A were 
collected at 100 K from a single crystal using the Synchrotron Radiation  
Source (station PX 9.5) at Daresbury (U nited Kingdom). Seventy im ­
ages were collected (A = 1.0 A, oscillation range of 1.5°, 45 s exposure 
tim e) using a MAR-CCD detector system . D ata processing w as per­
formed w ith  the HKL package (43). D ata reduction w as carried out 
using the program TRUNCATE of the CCP4 su ite  (44). D etails o f data
processing statistics are presented in Table I.
P hasing— The structure o f PIGF-1 w as determ ined by molecular 
replacem ent w ith  the program AMoRe (45) using a polyalanine (ho­
m odimer) model based on the structure of VEGF at 1.93 A resolution  
(PDB code 2VPF, Ref. 39). Data in the range 15 .0 -3 .0  A were used for 
both the rotation and the translation function searches. No solution was 
found in space group P4j. In space group P43, the best solution after 
FITING had a correlation coefficient of 56% and an R-factor o f 51%. 
Rigid-body refinem ent w ith  CNS version 0.9 (46) of this model corre­
sponding to the highest peak using data in the range 4 0 .0 -2 .0  A, 
resulted in an R free and R cryat o f 44.6 and 40.6%, respectively.
R efinem ent— All crystallographic refinem ent w as carried out using  
the program CNS version 0.9 (46). Procedures carried out w ith  CNS  
included sim ulated annealing using a maximum  likelihood target func­
tion, restrained individual B-factor refinem ent, conjugate gradient m in­
im ization, and bulk solvent correction. The behavior of the R frce value  
(811 reflections) w as monitored throughout refinem ent. Several rounds 
of refinem ent (using all reflections) and model building were performed 
until the R free for the model could not be improved any further. During 
the final stages o f refinem ent, w ater m olecules were inserted into the 
model at positions where peaks in the |R0|- |R C| electron density maps 
had heights greater than 3<r and were at hydrogen bond forming dis­
tances from appropriate atoms. 2 ||F0I_ |FC|| <t>caic m aps were also used to 
verify the consistency in peaks. W ater m olecules w ith a tem perature 
factor greater than 65 A2 w ere excluded from the model and subsequent 
refinem ent. One bound MPD m olecule per monomer from the crystal­
lization m edium  was identified (interacting with the m ain-chain car­
bonyl oxygen atom of Thr-104 at one end and a w ater m olecule at the 
other end) and w as included in the final stages of the refinem ent. The 
details o f refinem ent are presented in Table I. Map calculations were 
performed with CNS with the Sigm aA protocol (47), u sing all the 
reflections in the resolution range 4 0 .0 -2 .0  A. The program PRO­
CHECK (48) w as used to assess the quality o f the final structure. 
A nalysis o f the Ram achandran (ip-ip) plot showed that all residues lie in 
the allow ed regions. The program “O” (49) w as used for map visu aliza­
tion and model building.
Accession N um ber— Final atomic coordinates of hum an PIGF-1 have 
been deposited with the RCSB Protein D ata Bank under the accession  
code 1FZV.
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T a b l e  II
Hydrogen bond interactions between the two monomers at the dimer 
interface in the PIGF-1 structure
Molecule A M olecule B D istance (A)
Val24-N Thr86- 0 2.89
Val24- 0 Gln88-N 2.89
Phe26-N Gln88-O el 3.06
Arg^-Ne Glu39-O el 2.79
Arg32-Nrj2 Glu39-Oe2 3.22
Ser33-Oy Cys60-O 2.78
Arg36-N'rj2 Glu39-O el 2.45
Glu39-O el Arg^-Ne 3.02
Glu39-O el Arg^-NTjl 2.77
Glu39—Oe2 Arg36-N'rj2 3.26
Cys60-O Ser33-Oy 2.78
Thr86- 0 Val24-N 2.89
Gln88-N Val24- 0 2.88
Gin88—Oel Phe26-N 2.86
RESULTS AND DISCUSSION
Quality o f the Structure—The crystal structure of PIGF-1 
was determ ined a t 2.0 A resolution. Details of the data collec­
tion and refinem ent statistics are shown in Table I. The protein 
crystallizes as a homodimer in  the asymmetric unit. As in  the 
VEGF structure (38), the first 17 am ino-term inal residues of 
both monomers are not visible in  the electron density m ap and 
were excluded from crystallographic refinem ent. Both mono­
mers A and B contain residues 18-117. Also, residues S er18, 
Glu51, Glu73, Asn74, and Ser94 in both molecules and residues 
Glu53 and Arg117 in molecule A have been modeled as alanines 
because of lack of sufficient density beyond C/3 atoms. The 
arrangem ent of the homodimer and the nom enclature used 
throughout the  text are shown in Fig. 1A. The final model 
(homodimer) includes 1,546 non-hydrogen protein atoms, 132 
w ater molecules, and two MPD molecules w ith a crystallo­
graphic R-factor (R ^g ^  of 21.6% in the resolution range 40.0— 
2.0 A. The i2free value is 24.7% w ith 4% of the reflections 
excluded from the refinem ent (50). The m ean coordinate error 
calculated from a plot of In crA versus (sin0/A)2 is 0.3 A. The root 
m ean square (r.m.s.) deviation in Ca atoms between each mon­
omer of the pair is 0.43 A (for 100 Ca atoms). Regions th a t 
deviate most include residues 18-19 from the am ino-term inal 
tail, p art of the loop connecting strands |33 and |34 (residues 
72-73), and the  carboxyl-terminal residue 117. Excluding these 
residues improves the r.m.s deviation to 0.17 A (for 94 Ca 
atoms). Exam ination of the R am achandran plot shows 91.5% of 
the residues in  most favorable regions and no residues in  dis­
allowed regions.
Overall Structure—The crystal structure of PIGF-1 consists 
of a homodimer, organized in  an  antiparallel arrangem ent w ith 
the 2-fold axis perpendicular to the plane of the /3-sheet (Fig. 
1A). The homodimer is covalently linked by two in terchain 
disulfide bonds between Cys60 and Cys69. The most prom inent 
feature of the  structure is the presence of a cysteine-knot motif, 
positioned symm etrically opposite a t one end of each monomer. 
This motif is found in other closely related  growth factors such 
as VEGF (38, 39), platelet-derived growth factor-BB (PDGF- 
BB, Ref. 51), transform ing growth factor-/32 (TGF-/32, Ref. 52) 
and nerve growth factor (NGF, Ref. 53) (Fig. IB). The knot 
consists of an  eight residue ring formed by one in terchain 
(Cys60-C ys69) and th ree in trachain  (Cys35-C ys77, Cys66-  
Cys111, Cys70-C ys113) disulfide bonds (Fig. 1A). The ring struc­
tu re  is formed between two adjacent /3-strands, /33 and /37, w ith 
the th ird  in trachain  disulfide bond penetrating the covalent 
linkage and connecting strands /31 and /34. The cysteine ring 
contains a  conserved glycine residue a t position 68, which 
seems to be im portant in  optimizing the conformation of the 
sidechains in  the knot. As in the VEGF structure (38, 39), this
residue adopts positive dihedral (f> angles of 141 and 149° in 
monomers A and B, respectively. Thus the cysteine-knot m otif 
appears to be im portant for the  stabilization of the  dim er as 
there are only a few contacts between the /3-strands (/31 and 
/31') a t the  dimer center. One peptide bond in  the PIGF-1 
structure adopts a cis conformation: th a t connecting Ser57 and 
Pro58 in both monomers.
The structural core of the PIGF-1 monomer consists of a 
four-stranded, highly irregular, solvent-accessible /3-sheet (Fig. 
1A). The to tal buried surface area a t the interface between the 
two monomers is 2,627 A2. A considerable proportion of th is 
(1,830 A2 or 69%) is accounted for by the  extensive intermolec- 
u la r hydrophobic core interactions a t the interface on the op­
posite end of the cysteine-knot and provides additional stability 
to the central portion of the  structure. The hydrophobic core is 
formed by residues from both monomers and is known to be 
p a rt of the  receptor binding region of PIGF-1 (see under “Re­
ceptor Recognition”). Fourteen potential hydrogen bond in ter­
actions were observed between the two monomers (Table II). 
Two w ater-m ediated hydrogen bonds between Glu39 from each 
monomer forms a bridge between two strands (/31 and /31') 
across the center of the dimer interface.
Comparison with VEGF Structure—Overall, the  structure of 
PIGF-1 exhibits rem arkable topological identity  w ith th a t of 
VEGF (38, 39) (with which it has 42% amino acid sequence 
identity) despite significant functional diversity (Fig. 1, B—D, 
r.m .s deviation of 1.47 A using 95 Ca atoms). The mode of 
dim erization for PIGF-1 is sim ilar to th a t of VEGF. Conforma­
tional differences between PIGF-1 and VEGF are observed a t 
the am ino-term inal residues (18-25), some residues from loop 
regions (loops connecting /33-/S4, /35-/S6, and a2-/32) and the 
carboxyl-terminal residues (116-117). Interestingly, these loop 
regions appear to be p art of the receptor-binding face in  both 
molecules (see below). Approximately 70 w ater molecules are 
conserved in  PIGF-1 and VEGF and appear to be im portant for 
the structural in tegrity  of the  homodimer in both molecules.
Receptor Recognition—The extracellular domain of both 
KDR and Flt-1 receptors consist of seven immunoglobulin do­
mains. M utational analysis of VEGF has revealed th a t sym­
m etrical binding sites for KDR are located a t each pole of the 
VEGF homodimer (38). Each site appears to contain two func­
tional regions composed of binding determ inants presented 
across the interm olecular interface. This experim ental evi­
dence suggested th a t only a sm all num ber of VEGF residues 
are im portant for binding to KDR, and the  binding epitope for 
KDR contains two hot-spots, each of which extends across the 
dimer interface (39, 54-56). Furtherm ore, analysis of the con­
formational variability of VEGF (based on the high resolution 
structure of VEGF, Ref. 39) showed th a t the loop connecting 
strands /35 to /36 undergoes a concerted movement. This loop is 
im portant for binding to both Flt-1 and  KDR, suggesting th a t 
these receptor molecules have overlapping binding sites on the 
ta rge t molecule. I t has also been established th a t minim ally 
domains 2 and 3 of Flt-1 are necessary and sufficient for bind­
ing VEGF w ith near native affinity, and domain 2 alone binds 
to VEGF (60-fold less tightly th an  wild-type, Ref. 38). Sim ilar 
results have been found for deletions in  the KDR (56).
Recently, the crystal structure of VEGF in complex w ith 
Flt-1D2 (at 1.7 A) has revealed th a t domain 2 is predom inantly 
involved in  hydrophobic interactions w ith  the  poles of the  
VEGF dimer (40). Based on th is structu re  and previous m u­
tagenesis data, W iesmann et al. (40) have proposed a  model of 
VEGF bound to the first four domains of Flt-1. In  the  case of 
P1GF, it has been shown th a t binding of P1GF to hum an ECs 
revealed a high affinity site and a low affinity site (35, 37). The 
high affinity site is for Flt-1 and P1GF can displace VEGF from
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T a b l e  III 
Putative intermolecular contacts
Putative intermolecular contacts between PIGF-1 and Flt-1D2 at the receptor interface in the modeled complex (left) and intermolecular contacts 
between VEGF and Flt-1D2 at the receptor interface (right) as observed from the crystal structure of VEGF • Flt-1 complex (40).
PIGF-1 Flt-1D2 
Polar (<  3.4 A)
D istance VEGF Flt-1]}2 
Polar (<  3.4 A)
D istance
A A
Molecule A Molecule A
Gln27-O el Asn219-N82 3.15 Asp63-081 Arg224-Nt)2 2.54
Asp72-081 Arg224-Ne 3.33 Asp63-082 Arg224-Ne 2.85
Asp72-081 A rg^-N r^ 3.18 His86-N81 Gln225-Ne2 2.84
Ala74-N Arg224-N7}2 3.12 Gln89-Ne2 His147-Ne2 3.40
Arg105-N-rjl Tyr199-OH 3.31
Molecule B Molecule B
Tyr34-OH Lys171—Nf 3.33 Tyr^-OH Lys171-N£ 3.35
Asp72-081 Arg224-Ne 3.04 Lys48-N£ His223-N Sl 3.22
Tyr100-OH Pro143- 0 3.19 Arg105-NTjl Tyr199-OH 3.23
Glu112-Oe2 Asp175-081 3.03 Arg105-NTj2 Tyr199-OH 3.00
Asp63-0 8 i Arg224-NT,2 2.74
Asp63-081 Arg224-Ne 3.33
Asp63-082 Arg224-Ne 2.68
PIGF-1 Flt-lj32 Contacts VEGF Flt-1D2 Contacts
van der W aals contacts0 van  der W aals contacts0
A A
Mol A Mol A
Phe26 Pro143(2), Leu221(2)6 4 Phe17 Be142, Pro143(3) 4
Gin27 Pro143(2), Leu204(3), Asn219(3) 8 Met18 Glu141, Leu204 2
Trp30 Leu221 2 Tyr21 Gly203, Leu204(6) 7
Tyr34 Lys171, Phe172(4), Pro173(2) 7 Gin22 Phe172 4
Asp72 Tyr199, Ile202(8), Arg224 10 Tyr25 Lys171, Phe172, Pro173(2) 4
Ala73c Arg224 2 Lys48 Leu221, His223 2
Ala74c Arg224 3 Asp63 Ile202(2), Arg224(8) 10
Leu75 Tyr199 5 Gly66 Arg224 1
Gin88 lie142 1 Leu66 Tyr199 1
Leu90 Be145 1 Met81 Leu221 1
Tyr100 lie142 3 His86 Gin225 6
Glu112 Leu174 1 Gin89 His147 1
Pro115 Tyr199 12 Be91 Be142 2
Cys104 Tyr199 2
Pro106 Tyr199 7
Mol B Mol B
Phe26 Pro143(4), Leu221(2) 6 Phe17 Be142, Pro143(2), Leu221 4
Glu27 Glu141(3), Be142, Pro143(9), 17 Met18 Asn219 1
Leu204, Asn219(3)
Trp30 Leu204 1 Tyr21 Gly203(2), Leu204(6), Leu221 9
Gly31 Phe172 2 Gin22 Phe172 8
Tyr34 Phe172(10), Pro173(2) 12 Tyr25 Phe172 1
Asp72 Be202, Arg224(9) 10 Asp63 Arg224 8
Asn74 Arg224 3 Gly66 Arg224 2
Leu75 Tyr199 3 Leu66 Arg224 2
Gin88 Be142 2 Met81 Pro143 1
Leu90 Be145 2 Gin89 Be145, His147 2
lie92 His223 5 Be91 Be142 5
Tyr100 Ile142(10), Pro143(2) 12 Glu103 Lys200 1
Glu112 Asp175 5 Cys104 Tyr199 2
Pro115 Tyr199 9 Arg105 Tyr199, Lys200(2) 3
Pro106 Tyr199 3
° van der Waals distances are the maximum allowed values of C-C, 4.lA; C-N, 3.8A; C-O, 3.7A; O-O, 3.3A; 0-N , 3.4A; and N-N, 3.4A.
6 Numbers in parentheses represent the number of contacts made with the indicated Flt-1 residue. Hydrogen bond parameters and van der 
Waals contacts were calculated with the program CONTACT (44).
c Glu73 and Asn74 are modeled as alanines due to insufficient electron density for the sidechain atoms in the free PIGF-1 structure.
both truncated  and full-length Flt-1 receptors. However, a t the 
present tim e it is yet be established w hether both PIGF-1 and 
VEGF bind identically to Flt-1.
Flt-1 (VEGFR-1) Receptor Interactions—The structure re ­
ported here for PIGF-1 is an unliganded structure and hence it 
is not possible to establish the precise natu re of the interaction 
of PIGF-1 w ith Flt-1. However, using the structural da ta  on the 
VEGF*Flt-lD2 complex, we have been able to construct a model 
to visualize the binding mode between PIGF-1 and Flt-1. The 
PlGF-l*Flt-lD2 complex was modeled by superim posing the 
atomic coordinates of the  VEGF-Flt-1D2 complex (Ref. 40, PDB 
code 1FLT) onto the PIGF-1 model followed by energy minimi­
zation using the program  X-PLOR (57). The resu ltan t model
showed a  reasonable fit between PIGF-1 and Flt-1 w ithout any 
obvious stereochemical impediments between the two proteins 
(Fig. 2A). The interface of the putative P1GF-1-Flt-1D2 complex 
appears to include some 22 amino acids from the  PIGF-1 mol­
ecule: residues from the a l  helix, J33-/34 loop, and /37 strand  of 
one monomer, and residues from strands j35, /36, and the /35-/36 
loop of th e  second monomer. In the modeled complex, nineteen 
residues from the Flt-1D2 segments 141-147, 171—175, 199- 
204, and 219-226 form p art of th is contact surface. Modeling 
studies based on the VEGF*Flt-lD2 complex structu re  (40) pre­
dict th a t binding between PIGF-1 and Flt-1D2 m ight also be 
m ediated through hydrophobic interactions involving p lanar 
surfaces from both the ligand and the  receptor (Table III). Such
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shape complementarity is energetically favorable for maximiz­
ing the contribution of van der W aals contacts.
Based on the P lG F -l'F lt-lD2 model, we speculate th a t both 
PIGF-1 and Flt-1D2 form extensive contacts through sidechain 
interactions (Table III, Fig. 2B). The contact residues from the 
two individual components of the modeled complex are shown 
in Fig. 2, C and D. Asp72 in PIGF-1 appears to be the  only 
residue to m ake direct H-bond interactions w ith Arg224 of Flt- 
1D2. (In the V EG F'Flt-lD2 complex structure, the conserved 
VEGF residue Asp63 makes sim ilar interactions w ith Flt-1, 
Ref. 40, Table III.) PIGF-1 residues Gin27, Tyr34, Ala74, Tyr100, 
and Glu112 in  one molecule (either A or B) are predicted to 
make both polar and van der W aals interactions w ith Flt-1, 
whereas residues Phe26, Trp30, Gly31, Glu73, Leu75, Gin88, 
Leu90, lie92, and Pro115 seem to participate in  van der W aals 
interactions w ith Flt-1 residues (Table III). Additional PIGF-1 
residues Pro25, Cys70, Gly71, Pro98, Cys111, Cys113, and Arg114 
also appear to be p art of the interface.
A general m echanism of Flt-1 recognition by PIGF-1 can be 
postulated based on the proposed dimeric model of the receptor 
binding domain of VEGF in complex w ith domains 1 -4  of Flt-1 
(40). A sim ilar picture may be visualized for P1GF-1-Flt-1 rec­
ognition w ith domain-1 pointing away from PIGF-1, the domain 
2-3 linker region occupying the groove (6.8 A wide) between the  
two monomers, and domain 3 m aking contact w ith its bottom 
face, which would bring domain 4 into direct inter-receptor 
contacts and hence involved in  dimer formation. In  the PIGF-1 
structure, the  walls of the groove are formed by residues Asp72, 
Glu73, Val52, M et55, Val45, Asp43, and Ser59. The corresponding 
groove in  VEGF was formed by residues Asp63, Glu64, lie43, 
lie46, Phe36, Asp34, and Ser50, which was implicated for recog­
nition of domain 3 of Flt-1 (40). This comparison illustrates a 
high degree of conservation of residues in  th is region between 
the two molecules (Fig. 1C). However, a t the structural level, 
one can visualize significant changes in  conformation (Fig. 2E), 
which could be one of the contributing factor for the distinct 
receptor specificity for PIGF-1 (see below).
Lack of KDR (VEGFR-2) Recognition—A detailed m utagen­
esis study of VEGF by M uller et al. (38) identified eight amino 
acid residues forming p art of the KDR binding site. These were 
grouped as major and minor hot-spots for receptor recognition. 
The major hot-spot consists of two im portant residues lie46 and 
lie83 (VEGF numbering) and four additional residues lie43, 
Glu64, Lys84, and Pro85 w ith slightly lesser importance. The 
minor hot-spot contains residues P he17 and Gin79 (38). F u r­
therm ore, recently a  varian t of VEGF, which had amino acids 
83-89  replaced w ith the analogous region of the related  P1GF 
dem onstrated significantly reduced KDR binding compared 
w ith wild-type VEGF em phasizing the  point th a t th is region is 
im portant for VEGF-KDR interaction (58). Amino acid se­
quence alignm ent (Fig. 1C) shows th a t of the six most impor­
ta n t KDR binding determ inants (the major hot-spot) of VEGF, 
only two residues from VEGF (Glu64 and lie83) are conserved in 
PIGF-1 (Glu73 and lie92) and both residues from the minor 
hot-spot are conserved in the two structures. Observation of the 
PIGF-1 structure indicates significant conformational rea r­
rangem ent corresponding to regions 43-45  and 83-85  (the 
major hot-spot residues for KDR recognition in  VEGF, Fig. 2E). 
This provides a possible structural explanation for the inability 
of PIGF-1 to recogni ze KDR. Based on the amino acid sequence 
alignm ent of VEGF-A, PIGF-1, and VEGF-B, sim ilar argu­
m ents can be pu t forward for VEGF-B, where considerable 
changes have appeared in the KDR binding determ inants and 
hence may not recognize th is receptor.
We have also performed modeling studies on the P1GF- 
l'VEGF heterodim er in complex w ith Flt-1D2 (in a sim ilar way
to th a t described above for the P1GF-1-Flt-1D2 complex). From 
th is model, it appears th a t the  putative contact residues in  the 
heterodim er are sim ilar to those listed in  Table III for Flt-1 
recognition.
Concluding Remarks—Recent s tructu ra l studies on polypep­
tide growth factors in  complex w ith the ir receptors have pro­
vided a w ealth of inform ation in  the  area of protein-receptor 
signaling. In the case of cysteine-knot proteins, the target 
molecule {e.g. VEGF, PDGF, or NGF) seems to form complexes 
w ith one or two domains of the receptor molecule. In this 
report, we have tried  to address th is question w ith another 
member of th is family, PIGF-1, referring to the  molecular de­
tails of a closely related  molecule, VEGF. As in  the case of 
VEGF, PIGF-1 appears to use only a sm all num ber of residues 
in  receptor recognition. These details would be the starting  
point for the design of sm all mimics of P1GF. Such agonists 
could be useful for the design of P1GF antagonists, which pre­
vent the interaction w ith the receptor, and may serve to be 
im portant for the trea tm en t of pathological disorders involved 
in  neovascularization during tum or growth.
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The developm ent o f a  h ie rarch ical vas­
cu lar netw ork  by rem odeling  of the  p r i­
m ary  capillary plexus is know n as angio­
genesis. This process is essential for 
m any physiological as well as patho log i­
cal conditions, including  tu m o r p rogres­
sion  (Folkm an 1995). Several in tra- and  
in tercellu la r signals con tro l th e  m echa­
nism s th a t in itia te  th e  sp rou ting  of new  
vessels o r p ru n in g  of th e  pre-existing 
ones. V ascular endothelial grow th factor 
(VEGF) an d  re la ted  grow th  factors are 
im p o rtan t regulators o f th is com plex 
m olecu lar phenom enon . VEGF is the 
m ost p o ten t angiogenic inducer an d  is 
know n to  in itia te  tw o m ajo r steps in  
blood vessel form ation: p ro liferation  and  
m ig ra tion  of the  endo thelial cells (Conn 
et al. 1990, Connolly e t al. 1989a, and  
1989b, Dvorak e t al. 1995, F erra ra  1995, 
F erra ra  and  H enzel 1989).
M em bers of the  VEGF fam ily belong 
to  the cysteine-knot superfam ily of growth 
factors. These bioactive p ro te in s display 
a  com m on structural arch itecture (based 
o n  a  cyclic-knot o f cysteines) d esp ite  
little  hom ology  in  th e ir  am in o  ac id  se­
quence. T his cyste ine-kno t m o tif  gives 
stab ility  to  the  th ree -d im en sio n al 
s tru c tu re  of th ese  p ro te in s  (M cD onald 
an d  H endrickson  1993, M urray -R ust et 
al. 1993). I t also suppo rts  the solvent- 
exposed, recep tor-binding surface of 
these polypeptides and  b rings the  key 
residues involved in  recep to r recogni­
tio n  in to  spatial proxim ity. The VEGF 
fam ily consists o f six structu ra lly  rela ted  
pro teins: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, and  p lacen ta  grow th 
fac to r (PlGF). PlGF shares —40% am ino  
ac id  sequence iden tity  w ith  VEGF.
• PlGF: Genom ic Structure 
and Splice Variants
The h u m an  PlGF gene is located on chro­
m osom e 14 of th e  genom e (M aglione et 
al. 1993) and  consists o f seven exons. 
PlGF-1 w as first iso lated  from  the h u ­
m an  p lacen ta and  w as characterized  as 
being highly hom ologous to  VEGF (M ag­
lione e t al. 1991). This w as follow ed by 
the  discovery of P1GF-2, an  isoform  of 
PIGF-1. The two isoform s (P1GF-1/P1GF131 
an d  PlGF-2/PlGF]52) a re  generated  by 
d ifferential splicing of th e  PlGF mRNA 
(M aglione et al. 1993). A th ird  isoform  
of the  PlGF gene (Figure 1) w as charac­
te rized  recently  w ith  the  use of cDNA 
from  th e  h u m an  te rm inal p lacental tis-
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Figure 1. A sc h e m a tic  rep resen ta tion  o f  the three sp liced  variants o f  the PlGF gen e. T he gen e has 7 ex o n s (each  co lored  d ifferen tly ) separated  
by in tro n s (sh ad ed ). PlGF-1 and PlGF-3 m R N A s lack exon  6. P1GF-3 m R N A  h as a 216 b ase  insert b etw een  exon  4 and 5. The len gth  o f  the a m in o  
a cid  se q u en ce  in d icated  for each  isoform  corresp o n d s to  that o f  the m ature protein  (a fter cleavage o f  the s ign al peptide).




VEGFm VEGFuj VEGF.« VEGF... VEGF
s-Flt-1 Flt-1 K D R Flt-4 NP-1 NP-2 H S P G s
Figure 2. A sc h e m a tic  rep resen ta tion  o f  the variou s receptors ch aracterized  for the m em b ers o f  the  
cyste in e-k n o t fam ily  o f  grow th  factors. Flt-1, K DR, and Flt-4 are tyrosin e  k in ase  receptors. sFlt-1 is 
the so lu b le  tru ncated  form  o f  Flt-1. NP-1 an d  N P-2 (n e u r o p ilin s)  b e lo n g  to  the fam ily  o f  sem a-  
p h orin  receptors. H SPG s rep resen t heparan  su lfa te  p ro teo g ly ca n s that act as b in d in g  partners for 
so m e  o f  the grow th  factors. T he receptors have b een  co lo red  ind ividually . T he arrow s p o in t to  the  






Figure 3. The th ree-d im en sio n a l 
crystal structure o f  P lG F -1. The struc­
ture has b een  co lor-co d ed  to differ­
en tia te  b etw een  the  tw o  subunits: 
M onom er A has b een  co lored  purple  
and M onom er B is in  cyan. The cys­
teine-knot m o tif (c o n sists  o f  3-intra  
and 1 in ter-chain  d isu lfid e  bridge  
passing through the 8-m em bered  cys­
teine ring) and the receptor-binding  
region  have b een  h igh lig h ted  at 
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Figure 4. A m ino acid  se q u en ce  a lig n m en t o f  the m em b ers o f  the cyste in e-k n o t su p erfam ily  o f  grow th  factors. T he S w issp rot d atab an k  a c c e s­
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sue. This was termed as P1GF-3. The 
PlGF isoforms, apart from their size, 
differ in their secretion properties as 
well as their binding affinities. Different 
experiments were conducted to charac­
terize the differential distribution of the 
mRNAs of the PlGF isoforms. Results 
from these studies showed that the hu­
man PlGF-cDNA hybridizes to genomes 
from species across the animal king­
dom, indicating that the gene has been 
sustained through evolution (Maglione 
et al. 1991). PlGF is expressed in the pla­
centa during different stages of preg­
nancy. PlGF-mRNA is also present in 
very small amounts in heart, lung, thy­
roid, goiter, and skeletal muscle. It is not 
expressed, however, in kidney and pan­
creas (Maglione et al. 1993, Ziche et al. 
1997). It has also been observed that 
PlGF expression corresponds more often 
with pathological conditions than with 
normal conditions.
• P lG F: M o le c u la r  C h a ra c te r iz a tio n
PlGFs are biologically active as homo­
dimers. PlGF-1 has a molecular mass of 
~46 kDa (dimer) and is composed of 131 
amino acid residues per monomer. It has 
been shown that PlGF-1 is a secretory 
protein and undergoes N-glycosylation. 
P1GF-2 consists of 170 amino acid resi­
dues prior to signal peptide (18 amino 
acid residues in length) cleavage. Com­
pared to PlGF-1, PlGF-2 that is associ­
ated with the membrane has a highly 
cationic 21 amino acid insert at the car- 
boxy-terminal of the protein (Cao et al.
1997). The insert corresponds to exon 6 
of the PlGF gene and contributes to the 
ability of PlGF-2 to bind polyanionic 
substances such as heparan sulfate pro­
teoglycans (HSPG; Hauser and Weich
1993). PlGF-3, which is the longest iso­
form of the three, has an extra 72 amino 
acid residues that correspond to the 216 
base insert between exon 4 and 5 of the 
PlGF gene. Like the first isoform, it also 
lacks amino acids that provide HSPG 
binding affinity. In the mature protein 
the PlGF monomers are N-glycosylated 
at Asn84, although it has been demon­
strated that glycosylation is not essential 
for maintaining the biological activity of 
the protein. In both PlGF and VEGF, the 
eight cysteine residues that are charac­
teristic of members of the cysteine-knot 
growth factor superfamily are conserved. 
As a result, the structural folds of these
two proteins are very similar. Hetero­
dimers of PlGF and VEGF occur natu­
rally and have been shown to be mitoge­
nic toward endothelial cells. Although the 
potency of these heterodimers as mito­
gens is lower than that of the VEGF ho­
modimers, it seems that VEGF expres­
sion and thus its activity is negatively 
regulated by heterodimerization (Disalvo 
et al. 1995, Park et al. 1994).
• P lG F: R e c e p to rs  a n d  
T h e ir  E x p re s s io n
The distinct patho-physiological roles 
of the PlGF isoforms are mediated by 
binding to the /ms-like tyrosine kinase 
receptor-1 (Flt-1/VEGFR-1; Figure 2; Park 
et al. 1994). It has been shown that PlGF-1 
binds to Flt-1 with high affinity, trans- 
phosphorylates Flt-1, and thus activates 
the signal transduction cascade. PlGF-1 
does not induce autophosphorylation 
of kinase-insert domain receptor (KDR/ 
VEGFR-2; Cao et al. 1996, Landgren et al. 
1998, Sawano et al. 1996, Terman et al.
1994). VEGF, on the other hand, is a func­
tional ligand for both Flt-1 and KDR. 
Both Flt-1 and KDR belong to the FLT- 
subfamily of endothelial cell receptors 
(for a review see Mustonen and Alitalo,
1995) and share some 44% amino acid 
sequence identity. Mutation of the criti­
cal Flt-1 binding sites in VEGF (receptor- 
selective variants) significantly reduced 
the affinity of VEGF for KDR, suggest­
ing that the binding determinants for 
KDR and Flt-1 overlap (Li et al. 2000).
The mature form of Flt-1 consists of 
1316 amino acids. The receptor is made 
up of seven immunoglobulin-like extra­
cellular domains, one transmembrane 
domain and a cytoplasmic, split tyrosine 
kinase domain (De Vries et al. 1992, 
Fournier et al. 1997, Jussila et al. 1998, 
Matthews et al. 1991, Shibuya et al. 1990, 
Terman et al. 1992). Flt-1 is also pro­
duced as a soluble (sFlt-1) form, which 
lacks the seventh immunoglobulin-like 
extracellular domain (Kendall and Thomas
1993). The occurrence of the soluble 
form is thought to be a physiological 
means to downregulate the activity me­
diated by binding of ligands to the Flt-1 
receptor. Also, it is believed that sFlt-1 
binds to VEGF with very high affinity 
and probably forces VEGF to form non­
functional heterodimers with KDR. The 
second immunoglobulin-like domain 
of the receptor is mainly responsible
for recognition of the ligands. Flt-1 is 
expressed on both endothelial cells (pro­
liferating as well as resting endothelial 
cells) and their precursor cells. Flt-1 ex­
pression is upregulated by hypoxia in 
vivo (Thieme et al. 1995). It has been 
shown that in adult tissues Flt-1 expres­
sion is highest in the lungs and in the 
developing placenta, where it is ex­
pressed in the spongiotrophoblast layer 
(Dumont et al. 1995). sFlt-1 is also ex­
pressed at high levels in the placenta.
Flt-1 is primarily responsible for 
endothelial cell morphogenesis (Fong et 
al. 1995) rather than mitogenesis, which 
is characteristic of KDR-induced signal 
transduction (Millauer et al. 1993, Terman 
et al. 1992, Waltenberger et al. 1994). 
Gene knock-out studies have shown that 
mouse embryos lacking Fit-1 do not sur­
vive; i.e., it is important for development ; 
(Fong et al. 1995). It is believed that Flt-1 
might play an important role in main­
taining vascular organisation and this role 
of Flt-1 might be dependent on its interac­
tions with other receptors (Karunagaran 
et al. 1996). It has also been shown that 
Flt-1 mediates chemotactic monocyte re­
cruitment and activation in response to 
PlGF-1 binding. This correlates with the 
overexpression of Flt-1 on the endothelial 
cells and induction of PlGF-1 in human 
keratinocytes during wound healing 
(Clauss et al. 1996, Failla et al. 2000). Al- I 
though it is known that Flt-1 stimulation 
leads to Ca2+ signaling (De Vries et al. j 
1992), it is unclear as to which cellular re- | 
sponses follow the binding of PlGF to Flt-1. I
Cross-linking experiments show that I 
another class of receptors called the G 
semaphorin receptors act as binding 
partners to the heparin-binding form of 
PlGF (Figure 2). Semaphorin receptors, 
the neuropilins (np-1 and np-2), are in­
volved in axonal guidance. Sequences 
corresponding to exons 6 and 7 of the 
PlGF gene contribute to the functional 
np-1 binding domain on PlGF-2 (Midgal 
et al. 1998). Binding of PlGF-2 to np-1 is 
heparin dependent. It has been shown 
that sulfation of glucosamine-O-6 and/ 
or iduronic acid-O-2 groups of heparin 
is required to augment the binding of 
PlGF-2 to np-1. However, this does not 
modulate the migratory responses in­
duced by binding of PlGF-2 to Flt-1 as 
seen for VEGF-AI65-KDR mediated re­
sponse. Experimental evidence indicates 
that np-1 gene disruption leads to ab­
normalities in the peripheral nervous
130 TCM Vol. 12, No. 3, 2002
system as well as anomalies in the devel­
opment of the cardiovascular system 
(Midgal et al. 1998).
• P lG F: P ro te in  S tru c tu r e
The three-dimensional crystal structure 
of recombinant human PlGF-1 was re­
cently elucidated at 2.0 A resolution (Iyer 
et al. 2001; Figure 3). More recently, the 
resolution was extended to 1.55 A  (Iyer 
et al., unpublished results). Here we 
shall review the functional implications 
of PlGF-1 corresponding to the struc­
tural details at this higher resolution.
PlGF-1 structure is remarkably simi­
lar to VEGF-A,2 i (Figure 3). It occurs as 
a biological homodimer in which the 
monomers initially associate via hydro- 
phobic interactions with the dimer axis 
perpendicular to the plane of the (3-sheet. 
Each monomer consists of two a-helices 
and seven (3-strands. There are very few 
contacts between the two monomers at 
the central, highly irregular and solvent 
accessible (3-sheet region. The dimeric 
structure is stabilized by the cysteine- 
knot motif and a hydrophobic core re­
gion (one each per monomer). The mo­
tif consists of one inter-chain disulfide 
bond that holds the two monomers to­
gether. Conservation of a glycine residue 
at the position that precedes the cys­
teine residue involved in the formation 
of an inter-chain disulfide bond empha­
sizes the importance of the motif in main­
taining structural integrity of the proteins 
belonging to this superfamilv (Figure 4). 
Also, since the glycine residue is devoid of 
a side chain, the structural conformation 
of this motif is optimal. The side-by-side, 
head-to-tail orientation of the monomers 
places the receptor-binding interface at 
each pole of the PlGF-1 dimer. This fa­
cilitates receptor dimerization, which is 
essential for initiating the signal trans­
duction cascade. Residues from both 
the monomers contribute to the recep­
tor-binding interface (Figure 3).
• P lG F: S tru c tu r e  a n d  D ru g  D esig n
Structure-based drug design of small 
molecule antagonists or agonists requires 
a detailed three-dimensional structural 
and functional characterization of the 
target molecule. The structure of PlGF-1 
shows that although it has a structural 
fold very similar to that of VEGF, it dis­
plays important conformational differ­
ences, especially in the flexible loops 
that form part of the receptor-binding 
region of PlGF-1. It has been known that 
the solvent-exposed loops undergo con­
certed movements, which decide the 
receptor-specificity for VEGF. In PlGF-1, 
the flexibility of the loop connecting 
strands (35 and (36 is somewhat restricted 
compared to the corresponding loops in 
VEGF. This is because of amino acid 
changes that involve two prolines that 
affect the movement of the loop vis-a-vis 
their physical properties. There are some 
other changes in the sequence of PlGF-1 
at the receptor-binding interface that 
probably correspond to the inability of 
PlGF-1 to induce proliferation of endo­
thelial cells despite its ability to bind 
Flt-1 like VEGF. These changes include 
Arg93—»Lvs, Gly93—»His and Tyr100—rile 
and might also explain why PlGF-1 has a 
lower affinity for Flt-1 than VEGF and is 
unable to displace VEGF from Flt-1. A 
single change from He46 in VEGF to Met33 
in PlGF-1 significantly affects its binding 
affinity for KDR. Structurally, it was seen 
that unlike lie46 in VEGF, the side chain 
of Met53 is facing awav from the region 
where Flt-1/KDR is proposed to bind the 
ligand (Keyt et al. 1996, Muller et al. 1997).
The structure of the Fit-1 - PlGF-1 
complex is yet to be elucidated. However, 
based on the structure of the VEGF Flt-1 
complex (Wiesmann et al. 1997), it can 
be postulated that Flt-1 binds at the 
monomer-monomer interface of PlGF-1 
and not exclusively to each of the sub­
units in the dimer (Figure 5). Domain 
deletion experiments had revealed that 
domain 2 and 3 of Flt-1 contain the 
key determinants required for signaling. 
These experiments have mapped the 
ligand-binding residues to the second 
domain and those important for receptor 
dimerization have been characterized as 
domain 3 residues (Davis-Smyth et al.
1996). Mutagenesis studies and the crystal 
structure of the complex reveal the bind­
ing determinants on Flt-1 for VEGF. Davis- 
Smyth et al. (1996) have identified Glu137, 
Arg159, Lys171, Glu208, His223, and Arg224 as 
critical residues that contribute towards 
PlGF-1 binding. Modeling studies (Iyer et 
al. 2001) showed that Gin27, Tyr34, Asp72, 
Tyr100, and Glu112 could make both hydro­
gen bonding and van der Waals contacts 
with the residues implicated in PlGF-1 
binding. However, these modeling data 
need to be substantiated with the complex 
structure of PlGF-1 with Flt-1 that will un-
fit-i Acceptor dim erization
SIGNAL
TRANSDUCTIONfit-1
Figure 5. A cartoon  rep resen ta tion  o f  the  
p o ss ib le  even ts lead in g  to receptor d im eriza ­
tion  and form ation  o f  the PlGF-1 Flt-1 c o m ­
plex v ia in ter-subunit b in d in g  o f  Flt-1 to the  
PlGF-1 dim er.
ravel the exact orientation of PlGF-1 when 
it binds Flt-1. This would be very useful, 
as the modeling study is based on the 
assumption that both PlGF-1 and VEGF 
bind to Flt-1 in an analogous fashion.
The unliganded structure of PlGF-1 is 
a starting point for designing drug mole­
cules that can either activate Flt-1 and 
therefore potentiate VEGF stimulation or 
inhibit Flt-1 stimulation by binding either 
to Flt-1 or PlGF-1 itself. The drugs can 
either be small molecule activators/inhib­
itors or peptides that target the protein- 
protein interaction sites. Such peptides 
have a great pharmacological value and 
are possible candidates that can be devel­
oped further as potential therapeutics.
• R o le  o f  PlG F-1 a n d  I ts  R e c e p to rs  
in  A n g io g en e sis
Initial experiments on PlGF-1 were rife 
with contradictions. There were two 
main schools of thought: one considered 
PlGF-1 to be angiogenic and the other 
opposed this view. Although in vitro and 
in vivo experiments by Ziche et al. (1997) 
showed that PIGF-1 induces formation 
of blood vessels and is chemotactic as 
well as mitogenic on certain types of 
endothelial cells (postcapillary venule 
ECs), these results were questioned for a 
long time. It is now generally believed 
that PlGF does play an important role in 
angiogenesis and placental development. 
Its expression during the development
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of the placenta suggests a role for the 
protein during the invasiveness of the 
placental trophoblasts into the maternal 
decidua (Vuorela et al. 1997). Expression 
of the PlGF mRNA and the protein in­
creases during the third trimester of hu­
man pregnancy. This period is charac­
terized by non-branching type villous 
angiogenesis and formation of the ter­
minal villi. This is brought about by the 
binding of PlGF to Flt-1 (Kingdom et al. 
2000). It has been shown that PlGF-1- 
stimulated Flt-1 signaling induces the 
production of tissue factor in monocytes. 
This leads to activation and chemotactic 
recruitment of monocytes and macro­
phages, which are critical players in the 
process of blood vessel formation and tu­
mor progression (Clauss et al. 1996). It 
was also shown that there is a constitu­
tive expression of PlGF mRNA and the 
protein in human keratinocytes during 
wound healing (Failla et al. 2000). The 
microenvironment within the tissue is 
responsible for the effect of PlGF on 
blood vessels, indicating that it has a 
tissue-specific role.
PlGF is produced only by certain types 
of tumors, namely thyroid tumors and 
germ cell tumors, in contrast to VEGF, 
which is produced by all tumor types. PlGF 
is expressed in these tumors and in in­
flamed tissues (Kodama et al. 1997, Taka- 
hashi et al. 1994), and this expression is 
probably a consequence of angiogenic fac­
tors being released from the extracellular 
matrix. The mast cells that are subse­
quently activated during tumor angiogene­
sis provide an exogenous source of heparin 
that potentiates the binding of PlGF-2 to 
neuropilin-1. This increased binding, how­
ever, does not lead to tumor progression or 
neovascularization of the tumors (Midgal 
et al. 1998, Viglietto et al. 1995 and 1996).
Most of the earlier experiments were 
done with recombinant human PlGF-1, 
which was angiogenic only under cer­
tain conditions. These raised several 
doubts and questions regarding the role 
of endogenous PlGF-1 in angiogenesis. 
The recent results reported by Carmeliet 
et al. (2001), based on gene inactivation 
experiments in mice, answer some of 
these queries. Their experiments showed 
that loss of PlGF correlated with im­
paired angiogenesis. Although PlGF de­
ficiency hardly affects vascular develop­
ment, the absence of the protein affected 
VEGF-dependent endothelial cell sur­
vival, migration and proliferation. Their 
results indicate that even though PlGF
on its own is not an effective inducer of 
angiogenesis, it does potentiate the ac­
tivity of VEGF in physiological condi­
tions. Also, the expression of PlGF in 
pathological conditions indicates that it 
might induce the angiogenic switch by 
increasing the bioavailability of VEGF.
Another important aspect that links 
PlGF and VEGF is the ability of the two 
cytokines to form heterodimers. It is hy­
pothesized that PlGF binds to VEGF 
and either reduces the bioavailability of 
VEGF (Cao et al. 1996) or, at the other 
extreme, augments the activity of low 
concentrations of VEGF (Park et al.
1994). P1GF/VEGF heterodimers are 
somewhere between PlGF and VEGF 
homodimers vis-a-vis their mitogenic 
ability. Chick chorio-allantoic membrane 
assays show that the heterodimers, un­
like the PlGF homodimers, can bind to 
KDR, through which they exert their 
stimulatory effects on endothelial cell 
proliferation (Kurz et al. 1998).
• P lG F  a n d  C a rd io v a sc u la r  D ise ase s
The frontiers of cardiovascular health 
have expanded ever since scientists, 
worldwide, have taken an interest in the 
therapeutic use of VEGF in cardiovascu­
lar diseases (Zachary et al. 2000). VEGF 
is the angiogenic cytokine that has been 
shown experimentally to be responsible 
for initiation of angiogenesis. It is be­
lieved that VEGF is a promising candi­
date in therapeutic angiogenesis because 
of its ability to induce vasodilation and 
enhance vascular permeability. Thera­
peutic angiogenesis, as opposed to anti- 
angiogenesis therapy, involves stimula­
tion of blood vessel formation in diseases 
like ischemia, atherosclerosis, throm­
bosis, restenosis, etc. Studies based on 
VEGF-mediated angiogenesis therapy 
show mixed results (Isner 1999), and as 
a consequence it is not possible to draw 
any substantial conclusion from them. 
Also, such a therapy is shrouded by risks 
of unwanted neovascularization (Magli­
one et al. 2000, Zachary et al. 2000).
Recently, however, PlGF seems to be 
making waves not only because of its 
similarity to VEGF but also because 
of its ability to augment the activity of 
VEGF. A fundamental reason that 
makes PlGF such a promising factor is 
that on its own, PlGF cannot initiate 
endothelial cell stimulation. Relatively 
speaking, PlGF-1 has no permeability 
activity compared to VEGF (Maglione
et al. 2000). So, in effect, this growth 
factor should not have any adverse ef­
fects on the blood vessels, both near and 
far from the site of administration. PlGF 
would only enhance the effects of the 
available low concentrations of endoge­
nous VEGF (Park et al. 1994). Another 
important factor that goes in favor of 
PlGF is that it can stimulate the recruit­
ment and activation of monocytes via the 
Flt-1 receptor (Clauss et al. 1996). Mono­
cyte recruitment is yet another essential 
step in the process of formation of ma­
ture vascular networks, especially collat­
eral growth of blood vessels. It is not 
known as yet whether VEGF alone is suf­
ficient for collateral vascular growth.
It was shown in animal models that 
recombinant PlGF-1 explicates protection 
from isoprenaline-induced ischemic le­
sions in the heart without influencing the 
heart beat rate (Maglione et al. 2000). Al­
though these findings need to be con­
firmed with human-based experiments, it 
is safe to suggest that PlGF-1 could be 
considered as a potential therapeutic , 
agent for ischemic myocardial infarction. 
Also, evidence and reasoning seem to sug- | 
gest that since PlGF acts synergistically 
with VEGF (Carmeliet et al. 2001), a com­
bination therapy of VEGF and PlGF 
would probably be more effective in the 
treatment of cardiovascular diseases.
• F u tu re  P ro s p e c ts
Conformational differences at the receptor- 
binding interface between the structures 
of PlGF-1 and VEGF-A12i, despite a high 
degree of sequence homology, have un­
covered crucial structural insights that 
are valuable in the rational design of 
novel angiogenesis inhibitors. Further 
structural studies on PlGF-1 are re­
quired, studies that are largely based on 
receptor-ligand complexes. The struc­
tural basis behind Flt-1 receptor speci­
ficity of PlGF-1 and the other isoforms 
may lead to the development of receptor/ 
ligand specific therapeutics. This needs 
to be complemented with the charac­
terization of the entire sequence of I 
events that occur during PlGF-1-induced 
signal transduction. The next step then 
would be to correlate the signaling 
events with the topological details of 
the ligand and the receptor at the bind­
ing interface. Also, the elucidation of the 
three-dimensional structure of PlGF-2, I 
the heparin binding isoform, will take 
our understanding of these proteins
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a step further. Although PlGF-2 has a 
lighly basic insert of 21 amino acids at 
he C-terminal end of the molecule, the 
:ysteines involved in the formation of 
he ring structure are all conserved and 
lence the structural core of PlGF-2 
should be very similar to PlGF-1. These 
.wo isoforms do not have any other dif­
ferences in their sequence apart from 
he insert. It would be interesting to see 
low different PlGF-2 is from its isoform, 
and mapping of the binding determi­
nants for heparin as well as np-1 should 
enhance our understanding of molecular 
details involved in PlGF recognition.
» C o n c lu s io n
Researchers have spent the last three 
decades trying to bring the totality of 
he complex phenomenon of blood ves­
sel formation into perspective. Three- 
dimensional structures of the various 
proteins involved in angiogenesis have 
pven the researchers great headway 
into realizing this goal and simulta­
neously in the design of small molecule 
nhibitors to fight diseases related to an- 
giogenesis. The recent work bv Carme- 
iet et al. (2001) has introduced a new 
hought process. The structure of PlGF-1, 
along with insights into the mechanism 
af action of PlGF in angiogenesis as 
in important VEGF consort, have made 
PlGF isoforms very promising targets for 
aoth anti- and pro-angiogenesis therapy.
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Angiogenesis is the process of formation of blood vessels from pre-existing blood vessels. It differs from vasculogenesis, 
which means differentiation of angioblasts into blood islands. It occurs in a series of orchestrated network of cooperative 
interactions. This process plays a vital role in reproduction, growth and healing. It was in 1971 that the hypothesis made 
by Judah Folkman first implicated vascular growth in tumour progression. Since then, the need to address questions that 
pertain to the control of blood vessel growth has helped this concept evolve each year with increasing new discoveries. 
The local equilibrium between positive and negative regulators of angiogenesis is the key determinant to the state ofthe 
capillary networks. Integration of growth factors, cytokines, proteases, adhesion molecules and endogenous 
modulators is central to the correct outcome of the process. Switch to malignancy, which is characterised by onset of 
angiogenesis, occurs when this balance tips in favour of the inducers of the process. During the last decade numerous 
angiogenic genes and gene products have been isolated and purified from both normal and neoplastic tissues. These 
regulatory molecules induce or inhibit blood vessel formation by both paracrine and autocrine mechanisms. 
Comprehensive pre-clinical research activities have translated the various advances in basic angiogenesis research into 
possible clinical therapies by using a number of in vitro, in vfvoand transgenic animal models. Although lead compounds 
that proved to be successful in animal models are less promising in treating human cancers, there are about 30 
compounds now in clinical trials that target angiogenesis. This review discusses the different effectors and inhibitors of 
angiogenesis, especially in context with tumour angiogenesis. The review also addresses the therapeutic approaches to 
control blood vessel formation and the compounds in clinical trials.
Key Wards: Angiogenesis, Tumors, Growth factors, Hypoxia, Proteases, Angiotensins, Angioproteins, 
Angloprotelns, Endogenous inhibitors
Introduction
Angiogenesis is the process of formation of vascular 
sprouts from pre-existing microvasculature. 
Physiological angiogenesis occurs only during 
foetal development, a wom an’s endometrial 
cycle, wound healing and muscular growth. The 
process of vascularisation is also essential for the 
progression of several diseases. Pathological 
conditions pertaining to this process can be a 
function of either uncontrolled angiogenesis as 
seen in psoriasis, rheumatoid arthritis, athero­
sclerosis and many cancers (Folkman 1971, 
Folkman 1995, Norrby, 1997) or dysfunctional 
angiogenesis that can be associated with ischemia 
of the heart, poorly healing wounds and 
fractures, ulcers and infertility (Folkman 1998, 
Arnold etal. 1987).
The local release of an angiogenic stimulus from, 
for example, a tumour, tissue injury or 
inflammatory cells, triggers off a highly regulated 
sequence of events leading to the formation of 
blood vessels. A vessel wall is composed of an 
endothelial cell lining, a basement membrane, and 
a layer of cells called pericytes that partially 
surrounds the endothelium. The construction of a 
vascular network requires different sequential 
steps including:
• the disappearance of the pericytes
• the release of proteases from the endothelial cell 
lining of the vessel wall
• the breakdown of the basement membrane 
surrounding the existing vessel
• binding of the angiogenic factors to their 
receptors on the endothelial cells
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Embryogenesis M enstrual cycle
W ound healing
proliferation of the endothelial cells 
m igration of the endothelial cells into the 
interstitial space
the reorganisation of the endothelial cells 
lumen formation
generation of a new basement membrane 
fusion of the newly formed vessels 
initiation of blood flow
Overall, angiogenesis can be viewed as the result of 
an extensive interplay between oncogenes and 
suppressor genes, stim ulatory and inhibitory 
molecules, proteases and endogenous inhibitors 
and environmental factors such as the oxygen level 
or copper ion (Suri et al. 1996). Angiogenesis is such 
a complex phenomenon that a clear-cut distinction 
between angiogenic factors (table 1) as being either 
inducers or inhibitors w ould be an 
oversimplification. Some angiogenic factors act as 
both direct and indirect inducers of the process 
while some function contextually; sometimes as 
inducers and sometimes as inhibitors. In other 
words, angiogenesis is a process tightly regulated 
by the spatially and tem porally coordinated 
activities of a number of key angiogenic regulators, 
both environmental and genetic.
During physiological angiogenesis, there exists 
a dynamic balance between the positive and the 
negative regulators of the process while on the 
other hand the net balance is usually tipped in 
favour of angiogenesis during pathological 
circumstances (figure 1). It has been experimentally 
established that the loss of control of termination 
and stabilisation of the blood vessels is due to the 
up-regulation of the positive regulators as well as 
due to the exhaustion of the endogenous inhibitors 
of the process of blood vessel formation.
Abbreviations: ACE, Angiotensin Converting Enzyme; Ang-1, Angiopoietin-1; Ang-2, Angiopoietin-2; Ang II, Angiotensin- 
II ; ARNT. Arylhydrocarbon Receptor Nuclear Translocator; CAM, Chick Chorioallantoic Membrane ; COX, Cyclooxygenase 
; ECs, Endothelial Cells ; ECM, Extra-cellular Matrix ; EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor 
Receptor ; FGF, Fibroblast Growth Factor; FGFR, Fibroblast Growth Factor Receptor ; FGF-BP, Fibroblast Growth Factor- 
Binding Protein ; FPP, Famesyl Pyrophosphate ; GGPP, Geranylgeranyl Pyrophosphate ; HGF/SF, Hepatocyte Growth 
Factor/Scatter Factor; HIF-la, Hypoxia Inducible Factor-1; HSPGs, Heparan Sulphate Proteoglycans; HUVECs, Human 
Umbilical Vein Endothelial Cells; IL, Interleukin; MAPK, Mitogen-Activated Protein Kinase; MCP-1, Macrophage 
Chemoattractant Protein-1; MMP, Matrix Metallo-Proteinases; L-NAME, N-Nitro-L-Arginine Methyl Ester; NF-kB, 
Nuclear Factor-kappaB; NO,Nitric Oxide; NOS, Nitric Oxide Synthase; PD-£CGF,Platelet-Derived Endothelial Cell 
Growth Factor; PFT, Protein Famesyl Transferase ; PDGF, Platelet-Derived Growth Factor; PDGFR, Platelet-Derived 
Growth Factor Receptor; PGGT-1, Protein Geranylgeranyl Transferase-1; PlGF, Placenta Growth Factor; RAS, Renin- 
Angiotensin System; SMCs, Smooth Muscle Cells; TAMs, Tumour-associated Macrophages; TGF-a , Transforming 
Growth Factor-alpha; TGF-fi. Transforming Growth Factor-beta; TNF-a, Tumour Necrosis Factor-alpha; TSP, 
Thrombospondin; VEGF, Vascular Endothelial Growth Factor; VEGFRiVascular Endothelial Growth Factor Receptor.
F igure 1 A schem atic sh ow in g  the consequences o f  both  
physiological and pathological angiogenesis
1.1. Tumour A ngiogenesis
More often than not, tum our growth starts with 
uncontrolled cell proliferation. The rapidly 
dividing tumour mass soon reaches a steady state 
due to lack of nutrients and oxygen. The tum our 
may remain dormant for several months or years 
yet when the circumstances are beneficial it can 
switch to an angiogenic phenotype. This event can 
be triggered off by environmental stress factors 
such as hypoxia, low pH and pressure generated by 
proliferating endothelial cells (ECs), im mune 
responses, and genetic factors such as activation of 
oncogenes or deletion of tumour-suppressor genes 
that control the production of factors regulating the 
process of angiogenesis (figure 2).
Some tumours and metastases in particular do 
not initiate in an avascular manner (Holash et al. 1999, 
Pezzella 1997). They rather grow by homing in on a 
host vessel and start off as a vascular tum our 
(figure 3). Soon after tum our co-option the host
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Table 1 Different classes of angiogenic regulators
Growth factors
1. Vascular Endothelial Growth Factor (VEGF)
2. Placenta Growth Factor (PlGF)
3. Platelet Derived Growth Factor (PDGF)
4. Transforming Growth Factors CTGFs)
5. Fibroblast Growth Factors (FGFs)
6. Epidermal Growth Factor (EGF)
7. Angiotropin
8. Hepatocyte Growth Factor/Scatter Factor (HGF/SF)
9. Platelet Derived-Endothelial Cell Growth Factor/ 
Thymidine Phoshphorylase (PD-ECGF/TP)
10. Angiogenin
Proteases and protease inhibitors
1. Cathepsins
2. Gelatinase A, B
3. Stromelysins
4. Urokinase-type Plasminogen Activator (uPA)
5. Plasminogen Activator Inhibitor-1 (PAI-1)
Signal transduction enzymes
1. Famesyl transferase (FT)
2. Geranylgeranyl transferase (GGT)
Cytokines
1. Interleukins (IL)



















4. Angiopoietins (Ang 1 and Ang 2)
5. Angiotensins (Ang I and Ang II)
6. Endothelin (ET)
7. Nitric Oxide Synthase (NOS)
8. Thrombospondin (TSP)
9. Prolactin (PRL)_______________________________
vessels begin to die as a result of apoptosis and the 
tumours become secondarily avascular and hypoxic. 
This leads to a definitive increase of tumour derived 
VEGF. The induced VEGF leads to a new burst of 
angiogenic sprouting from the regressing blood 
vessels. Thus the onset of a robust new angiogenesis 
allows the tumour to survive and grow further.
1.2. Models to Study the Process of Angiogenesis
Considerable insight in the molecular and cellular 
biology of angiogenesis has been obtained by in 
vitro  and in vivo  studies. However, comparison 
between different studies is rather difficult because 
of the great diversity in the models being used. 
Also, any given compound that is angiogenic in 
vitro may not show any response in vivo, where it 
might be activated or inactivated by other molecules 
and thereby show results opposite to that of the in 
vitro model. Likewise, substances with no obvious 
effects, chemotactic and/or mitogenic, in vitro may 
play a crucial role in vivo  in angiogenesis. Hence, 
both in vitro and in vivo  models must be employed 
in order to evaluate the efficacy and potency of 
various angiogenic and/or anti-angiogenic 
compounds. Here we have made an attempt to give 
a brief overview of the various models that are 
available to us to study the process of angiogenesis.
1.2.1. In vitro Models
Most steps in the angiogenic cascade can be 
understood by using endothelial cells to analyse 
processes such as proliferation, migration and 
differentiation. The advantages of using in vitro  
models are that the spatial and temporal 
concentrations of the various angiogenic 
mediators involved in the angiogenic cascade can 
be controlled and each step of the cascade can be 
studied individually.
Chemotaxis can be examined in a Boyden 
Chamber. The chamber consists of two wells, an 
upper well and a lower well, separated by a 
membrane filter (figure 4). The chemotactic 
solution is placed in the lower well and the cells in 
the upper well and after a period of incubation, the 
cells on the lower surface of the membrane are 
counted which gives an indication of the number 
of cells that have migrated towards the 
chemotactic stimulus (Fan et al. 1993).




Degradation of the 
basement membrane
\Migration o f  endothelial cells
Angiogenic
s t i m u l u s
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h x t r a - C  e l l u l a r  M a t r i x
Proteases
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F igure 2 A  schem atic o f even ts that can trigger o ff the angiogenic sw itch  in dorm ant tum ours
tum our regression
vessel regression
hypoxia increase in angiogenic 
factors
tum our co-option 
with the host vessel
angiogenic
sprouting
F igure 3 A  schem atic sh ow in g  tum our angiogenesis initiated by tom our co-option  w ith  host vessels
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membrane filterc x w e ll
in c u b a tio n
lower well
chemotactic solution
F igu re 4 C hem otaxis in a B oyden Cham ber
Proliferation studies are based on cell counting, 
thymidine incorporation, or immuno-histochemicai 
staining. The increase in the num ber of cells is 
calculated by measuring Proliferating Cell Nuclear 
Antigen (PCNA; Hall et al. 1990) or by measuring 
apoptosis (by the Tunel Assay, Mori et al. 1994).
Differentiation can be studied by culturing the 
ECs in different extra-cellular matrix (ECM) 
components, including two- and three-dimensional 
fibrin clots, collagen gels and matrigel (Benelli & 
Albini 1999).
1.2.2. In vivo Models
Classical in vivo angiogenic assays include the Chick 
Chorioallantoic Assay (CAM), the rabbit cornea 
assay, sponge implant models, matrigel plugs and 
conventional tumour models. The first evidence of 
tum our induced angiogenesis used a syngeneic 
combination of tumour and mouse cornea, without 
involvement of inflammation (Muthukkaruppan 
etal. 1982, Muthukkaruppan & Auerbach 1979).
CAM assay: The CAM assay is a relatively 
simple, inexpensive and most widely used assay for 
large-scale screening as the early chick embryo lacks 
a mature immune system (Auerbach et al. 1974). 
The major disadvantage of the model is the 
presence of a developed network of blood vessels 
that makes it difficult to differentiate between the 
newly developed capillaries and the already 
existing ones.
Rabbit cornea assay: This assay is more reliable 
than the CAM assay as it represents an in vivo  
avascular site and thus makes it easier to differ­
entiate between newly developed blood vessels 
and already existing ones. Computer image analysis 
after perfusion of the cornea with India ink helps to 
measure the vascular response. It is not a practical 
model for large-scale screening as it is technically 
very demanding and very expensive as well.
Implantation models: Subcutaneous implantation 
of various artificial sponges like gelatin and 
polyvinyl alcohol (incorporated/injected with the 
com pounds to be evaluated) provides another 
means to study the process of angiogenesis. 
However, the implantation of these sponges results 
in some non-specific immune responses which in 
turn may result in a vascular response even in the 
absence of exogenous growth factors in the sponge 
(Andrade et al. 1987).
Matrigel: Matrigel generated from Engelbreth- 
Holm-Swarm (EHS) murine sarcoma contains 
basement membrane components (collagens, 
laminin, and proteoglycans) as well as matrix 
degrading enzymes, their inhibitors and growth 
factors. Role of the ECM receptors and enzymes in 
tum our progression has been well characterised 
using a matrigel incorporated with tum our cells 
(Passaniti et al. 1992).
Transgenic models: Transgenic models are fast 
becoming the gold standard for manipulating the 
angiogenic candidate molecules in a controllable 
m anner (table 2). In the transgenic approach, a 
particular candidate disease gene is chosen and re­
engineered using molecular tools, confirmed as the 
desired gene, and is then introduced into the model 
so it becomes a part of that model’s genome. The 
model then possesses the new trait. Both homolog­
ous and site-specific recombination, in embryonic 
stem (ES) cells, have allowed us to study the 
consequences of deficiencies, m utations and 
conditional expression of the different gene 
products in the transgenic models. The break­
through in the novel gene technologies has enabled 
researchers to study and analyse the patho­
physiological function of disease genes in a 
conclusive manner. Apart from this, gene transfer 
technologies provide us with the potential 
possibility of utilising the gene products in 
therapeutic approaches.
These various models for studying the process 
of angiogenesis along with the pivotal role played 
by the three-dim ensional structures of these 
angiogenic regulatory molecules have broadened 
our understanding of this complex process. What 
follows now is a brief overview of the role played 
by each of these different regulatory molecules 
(table 1) in the process of blood vessel formation.
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Table 2 Some major breakthroughs in angiogenesis research using the transgenic approach
References Findings
(Carmeliet et al. 2001) Specific synergism between VEGF and PlGF potentiates the angiogenic 
response to VEGF and not FGF-2; PlGF has a role to play in pathological and 
not physiological angiogenesis
(Sacco et al. 2000) Liposome-delivered angiostatin strongly inhibits tumor growth in a 
transgenic model of spontaneous breast cancer
(Yokoyama et al. 2000) Endostatin is effective in delaying spontaneous tumour development and 
growth
(Gao et al. 2000) Inhibition of 1k-B alpha degradation abolishes the induction of NF-kB- 
dependent gene expression and up-regulation of VC AM-1 and ICAM-1
(Yamamoto et al. 2000) Advanced glycation endproducts participate in the development of diabetic 
microangiopathy
(Lira 1999) Understanding the biological role of the chemokines and their receptors in 
leukocyte trafficking, angiogenesis, immunoregulation and development
(Karasek 1999) Biology of psoriasis
(Bourdeau et al. 1999) Endoglin, an accessory protein of the TGF-p receptor superfamily, is critical 
for both angiogenesis and heart valve formation
(Wang et al. 1999c) TGF-pi has been implicated in wound healing and skin carcinogenesis
(Asahara et al. 1999) VEGF plays a complementary role to angiogenesis in postnatal 
neovascularisation
(Sariola & Sainio 1998) Identification of the first signalling genes acting in the inductive interactions in 
the kidney for differentiation of the metanephros
(Wong et al. 1999) VEGF is up-regulated in the early pre-malignant stages of colorectal tumour 
progression
(Kowal et al. 1999) EVEC, a new EGF-like repeat containing protein is up-regulated in embryonic 
and adult vasculature
(Tyner et al. 1999) Role of p53 loss independent of other exogenous oncogenic influences
(Achen & Stacker 1998) VEGF family of proteins and their receptors are critical for angiogenesis, EC 
differentiation and vasculogenesis
(Bergers et al. 1998) Interplay between apoptosis and proliferation in pancreatic carcinomas and 
squamous cell carcinomas of the skin
(Edelberg et al. 1998) Environmental induction of PDGF-AB a  receptor interaction is central to the 
regulation of cardiac microvascular EC hemostatic and angiogenic activity
(Thurston et al. 1998) Angiogenic ECs bind and internalise cationic liposomes and liposome-DNA 
complexes but no other types of liposomes in tumours and chronic 
inflammation
(Calmels et al. 1997) Ets-1 transcription factor gene is expressed in ECs during blood vessel 
formation under normal or pathological conditions
(Visvader et al. 1998) SCL/tal-1 (transcription factor) is essential for the angiogenic remodeling of 
the yolk sac capillary network into complex vitelline vessels
(Hicks et al. 1996) Trafficking and compartmentalisation of FGF-1 during cellular transformation
(Dubois-Stringfellow et al. 1994) Pathobiology of hemangiomas as well as investigation of angiogenesis 
inhibitors
(Christofori & Hanahan 1994) Multiple genetic events are responsible for the genesis of malignant tumours 
(molecular characterisation of tumour cell proliferation and tumour 
angiogenesis)
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both in physiological and pathological settings. 
Although the therapeutic approaches for controlling 
angiogenesis have been discussed towards the end 
of this review, we have highlighted some of the 
strategies undertaken, for treatm ent of various 
diseases, while dealing with each individual class of 
regulators.
2. Oncogenes and Angiogenesis
Cellular oncogenes have been shown to induce 
developmental and tumour angiogenesis, leading to 
the enhanced activity of molecules that stimulate 
angiogenesis. However, activated oncogenes have 
also been known to facilitate angiogenesis by 
down-regulating the inhibitors of angiogenesis. 
Several oncogenes have been implicated in the 
process of angiogenesis and tumour progression. 
Most common of them are the c-myc, ras, jun, raf, 
src and p53. Oncogenes and various oncoproteins 
especially associated or related with cell cycle 
regulation have provided important prognostic 
information. Oncogenes are a means for molecular 
substaging of different types of cancer according to 
age, histology, gender etc. For instance, p53 and Rb 
are available as markers for decreased cancer- 
specific survival in women whereas among men 
erb-2 is the only available marker for lung cancer 
(D’Amico et al. 2000).
Experiments by Li et al. (1999) show that de- 
novo methylation of Thrombospondin-1 (TSP-1) 
potentially serves to inactivate its expression in 
human cancers and tumours. Wild type p53 down- 
regulates the endogenous VEGF mRNA level as well 
as the VEGF promoter activity in a dose-dependent 
m anner (M ukhopadhyay et al. 1995a). VEGF 
expression in colon tumours is also regulated by the 
Src family members, c-src, Lyn and Rac. Signalling 
pathways dependent on the src members are major 
mediators of factor VIIa/TF effects in pathophysiol­
ogy (Versteeg et al. 2000). It is believed that the 
hypoxic induction of VEGF occurs on account of c- 
Src activation (M ukhopadhyay et al. 1995b). 
Indirectly this induction of VEGF brings about the 
activation of phospholipase Cxi (PLPC-xl) and the 
formation of Inositol 1, 4, 5-triphosphate (IP3; 
Figure 5).
Disturbances of the cellular signalling cascades 
such as the ras-raf Mitogen Activated Protein
(MAP) kinase cascade, due to oncogenic gene 
m utations, leads to an abnormally high level 
expression of eicosanoid-forming enzymes, eg. 
cyclooxygenases and lipoxygenases during cancer/ 
tumour development (Marks et al. 2000). Mutation 
of the c-k-ras gene is a prerequisite of colon cancer 
progression, apoptosis, growth suppression and 
alteration of angiogenic factor expression 
(Tokunaga et al. 2000). Significantly elevated levels 
of microvessel density in both chronic pancreatitis 
and pancreatic adenocarcinoma further indicate that 
ras mutations potentiate activities that promote 
angiogenesis and thereby tum our progression 
(Banerjee et al. 2000). Ras oncogenes in their active 
state affect gene expression globally by coupling 
extracellular signals with transcription factors and 
transducing signals necessary for angiogenesis, 
invasion and metastasis via pathways involving 
cytoplasmic kinases, small GTP-binding proteins 
such as rho and rac (Zuber et al. 2000) This leads to 
the paracrine and cell-dependent stimulation of the 
potent VEGF indicating a link between the 
oncogenes and tumour angiogenesis.
Another family of oncogenes that are 




PGb pathway follows NO pathway 
through the release of Ca22 but 
diverges prior to NO synthase 
activation
NO synthase Ca'~ t
Figure 5 Indirect activation of PLPC-X1 by hypoxia
KDR/Fllc-l
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indicative of signal transduction. Induction of c-fos, 
c-jun is followed by the VEGF/VPF interaction with 
the cultured endothelium (Mukhopadhyay et al.
1998). Oxidative stimuli and the degradation 
products of hyaluronan induce a rapid transient up- 
regulation of c-jun and thus promote pathological 
angiogenesis in diseases like rheumatoid arthritis, 
endometrial cancers and stimulate overexpression of 
inter-cell adhesion molecule-1 (ICAM-1) and 
monocyte chemoattractant protein-1 (MCP-1) in 
human endothelial cells (Wang et al. 1999b, Fujimoto 
et al. 1998, Deed et al. 1997, Shono et al. 1996). The 
protooncogene, c-myc regulates cell growth, 
differentiation, and apoptosis, and its aberrant 
expression is frequently observed in several human 
cancers. Sustained activation of c-Myc is sufficient to 
induce angiogenesis and pre-malignant changes.
2.1. Role of p53 in Tumour Suppression
p53, the tumour suppressor gene, plays a central 
role in protecting cells against DNA damage and 
numerous other types of physiological stress. This 
protection is mediated by inducing apoptosis and 
by arresting cell cycle. It has been experimentally 
shown that the loss of p53 function leads to 
genomic instability, inactivation of growth regulat­
ory functions and tumorigenesis (Finlay et al. 
1989). Human p53 is a five domain, nuclear 
phosphoprotein with 393 amino acids. Each of the 
five evolutionarily conserved domain has a 
specific function, which are as follows:
(a) Transactivation domain (N-terminus): This 
domain interacts with (Seto et al. 1992; Chao et 
al. 2000) the transcriptional machinery
(b) Proline rich region: This region is important for 
(Venot et al. 1998, Prives & Hall 1999) apoptosis 
It also negatively regulates p53
(c) Central core domain: Involved in sequence 
specific (Levine 1997, el-Deiry et al. 1992) DNA 
binding
(d) Oligomerisation domain: Important for the 
formation (Friedman et al. 1993) of p53 
tetramers
(e) Nuclear Localisation Sequence: Important for 
RNA binding (Wu et al.1995, Cadwell & 
Zambetti 2001)
Normal cells have low levels of p53 protein in a 
latent state. However, a variety of stress factors like
UV rays, DNA damaging drugs, hypoxic conditions 
etc induce an increase in the levels of p53 protein. 
The biological activities of p53 are regulated by a 
variety of different mechanisms (Cadwell & 
Zambetti 2001):
(a) Autoregulatory, negative feedback loop created 
by binding of Mdm2 protooncogene to the N- 
terminus of p53 (Wu et al. 1993, Honda et al. 1997).
(b) Phosphorylation of p53 at N-terminus by DNA 
damage activates p53 (Giaccia & Kastan 1998).
(c) Acetylation of p53 at C-terminus also by DNA 
damage activates p53 (Sakaguchi et al. 1998, Gu 
& Roeder 1997).
3. Signal Transduction Enzym es and the 
Importance of Prenylation for Angiogenesis
Small G-proteins are anchored to cellular 
membranes by means of a post-translationally 
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Figure 6 A flow diagram indicative of prenylation-mediated 
down-regulation of angiogenesis
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Prenylation is important for the G-proteins to 
mediate their signal transduction function (Maltese 
& Sheridan 1987). The prenyl groups, for instance 
the farnesyl group in Ras and the geranylgeranyl 
group in Rac and Rho, are derived from the farnesyl 
pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP) respectively (Casey 1992). 
Protein farnesyl transferase (PFT) and Protein 
geranylgeranyl transferase-1 (PGGT-1) mediate the 
covalent interaction of the G-proteins to the 
cholesterol biosynthesis pathway intermediates 
(FPP & GGPP). Prevention of prenylation of the G- 
proteins renders them inactive and hence there 
occurs inhibition of growth, proliferation, 
differentiation and migration of cells.
Famesylated Ras activates growth factor signal 
transduction. Ras mutations are known to correlate 
with the carcinoma of the colon and the pancreas. 
This provided the incentive to target the 
prenylation enzymes (PFT, PGGT-1) for the search 
of new drugs (Gibbs et al. 1994, Leonard 1997, 
Sebti & Hamilton 1997, Cox & Der 1997). Since 
protein prenylation is associated with cell growth, 
prenylation inhibitors (figure 7) provide a novel 
approach to therapeutics in the treatment of various 
diseases.
These peptidomimetics are highly vulnerable to 
protease degradation. Also the presence of many 
negatively charged phosphate groups impairs their 
cellular uptake. So, their charge is masked by a 
covalently bound Pivaloyl-Oxo-Methyl (POM) 
group (Freeman & Ross 1997). Endogenous
Inhibitors o f  Prenylation
Screening o f  the existing Drugs based on





Figure 7 A flow diagram to show how the various inhibitors 
of prenylation evolved
hydrolases remove the POM group after entering 
the cell where the prodrug gets converted to active 
form (Dickson et al. 1996). These peptidomimetics 
are the mimics of the carboxy-terminal tetrapeptide 
of the unprocessed G-protein, designated as CAAX 
(for FPT) or as CAAL (for PGGT-1). The prenyl 
group is bound to the cysteine residue of CAAX /  
CAAL. In the consensus sequence A stands for any 
aliphatic residue, L for leucine and X for methionine 
or serine.
Many investigations support that for non­
transformed cells geranylgeranylation is more 
important than farnesylation. For instance, co­
addition of GGPP completely suppresses statin- 
induced inhibition of the growth of smooth muscle 
cells (SMCs). The FPP have only a partial effect 
(Terano et al. 1998, Laufs et al. 1999). The normally 
geranylgeranylated Rho has to be inactivated to 
arrest the transition of G1 to S phase during cell 
cycle (Guijarro et al. 1998, Olson et al. 1995). Since, 
Rho and Rac are integral to cell cycle, it becomes 
obvious that both these kinds of prenylation must 
be suppressed. This led to the development of 
inhibitor compounds that are effective against both 
PFT and PGGT-1.
The intracellular mechanism of action of 
prenylation inhibitors is still not exacdy predictable. 
Their efficacy depends upon the type of G-protein 
mutations that occur in different tumours. For 
example, the Ki-ras mutation tumours are blocked 
by a combination of PFT and PGGT-1 inhibitors 
since Ki-ras can also be geranylgeranylated apart 
from being farnesylated (Mazet et al. 1999). 
Specificity of the signalling pathways involved in 
different cells and the sensitivity of the G-proteins 
to the various prenylation inhibitors compound the 
uncertainly associated with their efficacy and 
potency. However, despite all this some of the 
inhibitors designed to inhibit farnesylation have 
reached clinical trials for cancer treatment.
4. Growth Factors in Angiogenesis
The most important and perhaps the most 
extensively studied class of angiogenic regulators 
are the Growth Factors. These growth factors and 
the cytokines present in the tumour’s 
microenvironment regulate a variety of genes 
associated with malignant properties of tumour
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cells such as growth, migration, invasion, and 
metastatic capacities.
4.1. Cysteine-knot Superfamily of Polypeptide 
Growth Factors
Several of the angiogenic polypeptide growth 
factors belong to the cysteine-knot superfamily of 
growth factors. These bioactive proteins exemplify 
the development of distinct biological functionalities 
during the process of blood vessel formation. These 
polypeptides display a common structural 
architecture despite little sequence homology. The 
crystal structures of these growth factors 
demonstrate that all have a similar topology based 
on a cyclic-knot of cysteines involved in both intra- 
chain and inter-chain disulphide bonds. This 
cysteine connectivity stabilises the Ca framework of 
these growth factors for elaboration of the solvent 
exposed loop regions that form the receptor- 
binding surface on these polypeptides. The 
members of this family occur as either homo- or 
hetero-dimers. These molecules differ on the basis 
of the number of disulphide bonds, the orientation 
of the monomers relative to the dimer axis and the 
extent of buried surface, thus varying the residues 
that are involved in the dimer formation. The 
disulphide bonds spatially bring the key residues 
involved in receptor recognition into close 
proximity of each other. The cysteine-knot 
members, although topologically similar, act via 
distinct cell-surface receptors with which they form 
complex signalling systems. The following section 
will review the role of the different members of this 
superfamily in the process of angiogenesis.
4.1.1. Vascular Endothelial Growth Factor 
VEGF-A
Vascular endothelial growth factor (VEGF) is the 
most potent and pivotal regulator of angiogenesis 
and vasculogenesis. A highly specific mitogen for 
vascular endothelial cells, VEGF promotes 
extravasation of proteins from tumour-associated 
blood vessels. Disruption of genes encoding VEGF 
results in severe defects and abnormalities in the 
development of the cardiovascular system (Ferrara 
et al. 1996). VEGF induces cell signalling in different 
ECsdifferent ECs as for example in HUVECs and 
thus initiates a variety of biological effects (figure 8).
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Figure 8 VEGF-A induced biological effects in different 
ECs as a result of various signalling responses
Hypoxia is one of the major up-regulators of VEGF 
expression and is thought to drive angiogenesis 
during organogenesis. In developing organs, 
increasing distance between the migrating cells and 
the existing blood vessels creates hypoxic 
conditions. This stimulates the formation of new 
vasculature towards the VEGF producing cells 
(Stone et al. 1995, Pierce et al. 1995).When cells are 
no longer able to synthesize VEGF, angiogenic 
diseases ensue. Besides hyper-proliferation, blood 
vessels undergo unregulated and excessive fusion 
leading to formation of vessels with exceptionally 
large lumens. On the other hand, limited/reduced 
VEGF supply to the tissues leads to inhibition of 
organ development (Drake & Little 1995, Ferrara 
etal. 1998, Folkman & Hanahan 1991).
Crystal structure of VEGF-A at 1.93 A resolu­
tion (Muller et al. 1997b) showed that each protomer 
consists of three intra-chain disulphide bonds and 
one inter-chain disulphide bond (figure 9). The 
monomers are perpendicular to the dimer axis such 
that there are two disulphide bonds related to each 
other by the dimer axis. Receptor dimerisation via a 
VEGF bridge activates signal transduction events 
that lead to a variety of mitogenic and chemotactic 
responses that are specific to VEGF-A depending 
upon where it is expressed.
VEGF is expressed in spatial and temporal 
association with physiological as well as tumour 
angiogenesis in vivo (Shweiki et al. 1993, Jakeman 
et al. 1993, Kim et al. 1993, Millauer et al. 1994). 
Expression of VEGF induces the formation of 
vesiculo-vacuolar organelles that channelise the 
blood borne proteins into the tumours. This forms 
an extravascular fibrin gel that stimulates ECs and
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Figure 9 The angiogenic m em bers o f  the cysteine-knot 
superfam ily o f grow th factors
tum our cells to proliferate and migrate and also 
supports the invasion of stromal cells into the 
growing tum ours (Dvorak et al. 1995). The 
similarity of mechanism of VEGF induction during 
physiological as well as tum our angiogenesis 
explains why VEGF plays a central role in so many 
types of diverse tumours. A plethora of cytokines, 
growth factors and other external factors regulate 
VEGF production and thus indirectly stim ulate/ 
inhibit angiogenesis. These include FGF, PDGF, 
KGF, TGF-p, TNF-a, IL-6, IL-10 and IL-13.
Like hypoxia, hypoglycaemia is also a major 
VEGF stimulant (Shweiki 1992, Dantz et al. 2002). 
VEGF expression can be stimulated by several other 
factors even in the presence of oxygen. Activated 
oncogenes that are part of the ras/M A P kinase 
signal transduction pathway, potentiate VEGF 
mRNA expression (Grugel et al. 1995, Rak et al.
1995). Hypoxia independent production of VEGF 
(Richard et al. 2000) can also be brought about by 
inactivation of tumour suppressor genes like von 
Hippel Landau (vHL) and p53 genes at both
transcriptional and post-transcriptional level 
(Mukhopadhyay et al. 1997, Iliopoulos et al. 1996, 
Pal et al. 1997). The loss of p53 gene has been 
associated with increased angiogenesis in tumours 
although some reports contradict these findings.
Alternative splicing of VEGF mRNA produces 5 
isoforms: VEGFm, VEGFuy VEGF|65, VEGF]89 and 
VEGF206. These isoforms differ in their heparin and 
heparan sulphate binding ability. Binding of VEGF 
to ECM-associated heparan sulphate proteoglycans 
(HSPGs) releases angiogenic growth factors such as 
the basic-FGF (Jonca et al. 1997). Heparin and not 
heparin like molecules enhance the binding of 
VEGFJ6b to vascular endothelial grow th factor 
receptor-2 (VEGFR-2). HSPGs, like the Glypican, act 
as a chaperone and restore the binding of VEGF165 
to VEGFR-2 after oxidative damage. The same 
however is not true for VEGF12| (Gitay-Goren et al. 
1992, Weksbergetal. 1996).
Apart from binding to cell surface HSPGs/ 
heparin, VEGF binds two receptors belonging to the 
tyrosine kinase receptor family: VEGFR-1 and 
VEGFR-2 (figure 10). These two receptors are, 
predominantly, expressed by the ECs, monocytes, 
trophoblasts and tum ourigenic cell types like 
melanomas. The binding dom ains of the two 
receptors are located at the opposite ends of the 
VEGF monomer such that in the active VEGF 
dimer, the main VEGFR-l/VEGFR-2 binding 
domains are at the opposite ends of the molecule 
(Keyt et al. 1996, Muller et al. 1997a). There is some 
evidence that the two receptors can heterodimerise
NcuropUin VEGFR1 VEGFR2 VEGFR3
(NP-1; NP-2) (Flt-1) (KDR) (Flt-4)
F igure 10 The tyrosine kinase receptors and their ligands. 
The y e llo w  region in VEGFR3/FU-4 depicts the hinge  
region o f  the receptor
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via a VEGF bridge (Wiesmann et al. 1997). 
Activation of VEGFR-2 by VEGF results in a 
mitogenic response while that of VEGFR-1 does not 
induce cell proliferation. Some isoforms of VEGF 
namely the VEGF145 and VEGF]65 bind another class 
of receptors called the neuropilins-1 and 2 (Soker et 
al. 1998). The binding of the VEGF isoforms to these 
receptors is mediated by the exon 7 of the VEGF 
gene (Soker et al. 1997) that is absent in VEGF121 
Gene disruption studies indicate that neuropilins 
may act as co-receptors of VEGF)65 because a 
dysfunctional/ absent neuropilin leads to an 
impaired development of cardiovascular system 
leading to the death of mouse embryos.
Inhibition of VEGF signalling inhibits the 
development of many tumours. Impaired VEGF 
function abrogates tumour metastasis (Millauer et al.
1996, Skobe et al. 1997). Production of antagonistic 
VEGF mutants (Siemeister et al. 1998), VEGF 
receptor inhibitors (Strawn et al. 1996), antisense 
mRNA expressing constructs (Cheng et al. 1996), 
inhibitory soluble receptors (Kendall & Thomas 
1993, Lin et al. 1998), humanised monoclonal 
antibodies against human VEGF (Presta et al. 1997) 
are some of the strategies that are being undertaken 
to treat VEGF induced tumour angiogenesis. VEGF 
is also being used to develop therapeutics for the 
treatment of diseases related with dysfunctional 
angiogenesis (Walder et al. 1996, Magovern et al.
1997, Baumgartner & Isner 1998).
VEGF-B
One amongst the recently discovered novel VEGF 
family members, VEGF-B also like its counterpart 
occurs in alternately spliced forms: VEGF-B167 and 
VEGF-B186 (Olofssonetal.1996, Paavonenetal.1996). 
VEGF-B is both structurally and functionally related 
to VEGF-A and Placenta Growth Factor (P1GF). The 
smaller isoform is highly basic and is associated to 
the cell surface via HSPGs. The receptor through 
which VEGF-B stimulates endothelial cell prolife­
ration is VEGFR1. VEGF-B controls the bio­
availability of VEGF-A by forming heterodimers 
with it. Both the isoforms of VEGF-B are devoid of 
N-glycosylation sites whereas VEGF-B186 has an 
O-glycosylation site instead (Olofsson et al. 1996). 
VEGF-B is known to stimulate DNA synthesis and 
has been characterised as an angiogenic protein like 
VEGF-A (Olofsson et al. 1996).
*P1GF belongs to the PDGF family o f growth factors.
VEGF-C
The pro-peptide VEGF-C undergoes proteolytic 
cleavage to form a 21 kDa protein (Kukk et al. 1996, 
Paavonen et al. 1996, Joukov et al. 1996). VEGF-C 
autophosphorylates a tyrosine kinase receptor Flt-4/ 
VEGFR3 and VEGFR2 (Paavonen et al. 1996). It has a 
higher binding affinity for VEGFR3 than VEGFR2 
(Joukov et al. 1996).In adults, VEGF-C is mainly 
restricted to the lymphatic endothelium and has been 
implicated in the development of lymphatic vessels 
(Kaipainen et al. 1995, Oh et al. 1997). It was recently 
shown that soluble VEGFR3 potently inhibits the 
foetal lymphangiogenesis in transgenic mice by 
suppressing VEGF-C &VEGF-D induced signalling 
(Maikinen et al. 2001).
VEGF-D
VEGF is yet another member of the VEGF family of 
proteins. It shares around 48% amino acid sequence 
identity with VEGF-C (Yamada et al. 1997). Like 
VEGF-C, VEGF-D also binds VEGFR2 and VEGFR3 
(Achen & Stacker 1998). VEGF-D is a tumour 
angiogenesis factor and promotes EC proliferation. 
Experiments with a mouse tumour model reveal that 
VEGF-D stimulates lymphangio-genesis within 
tumours. It promotes tumour metastasis via 
development of the lymphs by activating VEGFR3 and 
not VEGFR2 (Stacker et al. 2001).
4.1.2. Placenta Growth Factor 
The human term placenta seems to be a source of 
several angiogenic factors. A human cDNA coding for 
one such angiogenic protein was isolated from a 
placental cDNA library and named as the Placenta 
Growth Factor (P1GP). The gene encoding this protein 
is located on chromosome 14 of the human genome 
(Maglione et al.1993). DNA sequence analysis of the 
P1GF gene showed that an alternative splicing 
mechanism is responsible for the production of the 
different forms of P1GF. PIGF-mRNA is abundantly 
expressed in the placental tissue and is also present in 
very small amounts in heart, lung, thyroid, goitre and 
skeletal muscle. No expression of P1GF has been detect­
ed in kidney and pancreas (Ziche et aL 1997). The P1GF 
coding sequence is encoded by seven exons spanning 
approximately an 8000-kb long DNA interval. The 
PDGF-like domain exhibited by the P1GF protein is 
encoded by exons 3 and 4. There are three isoforms 
of P1GF, namely P1GF-1, P1GF-2 and P1GF-3, which 
arise from alternative splicing of the PIGF-mRNA 
(Maglione et al. 1993).
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Until recently the biological significance or the 
relevance of the different forms of P1GF with 
different composition was not known, but hybridi­
sation studies reveal that P1GF is well conserved in 
the mammalian, bovine, chicken, amphibian and 
insect genomes (Maglione et al. 1992, Maglione et 
al. 1991). This suggests that the P1GF gene has 
specific and indispensable functions. The 
importance of this protein is emphasised by the fact 
that a dysfunc-tional/absent gene in a mouse 
embryo leads to impaired blood vessel network 
and subsequently the death of the embryo. P1GF 
occurs in the placenta, thyroid and lungs. It is 
important for maintaining the network of blood 
vessels between the mother and the growing baby. 
The development and cell-specific regulation of the 
process of alternative mRNA splicing may have 
important consequences for physiological and 
pathological processes. Studies reveal a preferential 
expression of P1GF-2 in the placental tissue and cell 
lines, suggesting that this long form of P1GF may 
be involved in the growth and maintenance of 
pregnancy (Maglione et al. 1993).
Recently the crystal structure of P1GF-1 was 
elucidated at 2.0 A resolution (Iyer et al. 2001, Iyer & 
Acharya 2002). The structure showed that P1GF-1 
bears a remarkable topological identity to VEGF-A 
with which it shares around 42% sequence identity 
(figure 9). Interestingly it was observed that there 
are conformational differences in the receptor 
binding loop regions of the two molecules as well 
as the side chain orientations of the key residues 
involved in receptor recognitioa Based on model­
ling studies with Flt-1/VEGFR1, the receptor for 
P1GF-1, (figure 10) and the ligand it was hypothes­
ised that these structural differences perhaps render 
P1GF-1 unable to recognise VEGFR2/KDR despite 
high degree of conservation of amino acids at the 
receptor binding regions of P1GF-1 and VEGF-A.
Purification of P1GF-1 from overexpressing 
eukaryotic cells and measurement of angiogenic 
activity of the purified P1GF-1 in vivo in the rabbit 
cornea and CAM assays showed induction of a 
strong neovascularisation process that was blocked 
by affinity-purified anti-PlGF-1 antibody. In the 
avascular cornea, P1GF-1 induced angio-genesis in 
a dose-dependent manner. P1GF-1 has been shown 
to induce comparable cell growth and migration 
of endothelial cells from bovine coronary post­
capillary venules and from human umbilical veins 
(HUVECs) in vitro (Ziche et al. 1997).
Experiments reveal that P1GF is induced in 
human keratinocytes during wound healing 
(Failla et al. 2000). P1GF expression is regulated 
by key cytokines released during an injury or a 
wound. It has also been shown that melanoma 
progression in humans is accompanied by 
deregulated, constitutive P1GF expression 
(Graeven et al. 2000). P1GF, however, serves no 
apparent autocrine role in melanoma prolifera­
tion. In case of P1GF-2 it has been established 
that the recombinant, purified protein is able to 
stimulate bovine aortic endothelial cells (BAECs) 
(Hauser & Weich, 1993) and HUVECs (Hauser 
et al. 1993),but not the ECs from hepatic sinusoids 
(Sawano et a l l 996). P1GF isoforms have very 
little mitogenic or permeability-enhancing 
activity. However, they significantly potentiate 
the action of low concentrations of VEGF in vitro 
and more strikingly in vivo (Park et al. 1994). 
The credibility of these findings were further 
cemented by recent experiments with knock out 
mice (Carmeliet et al. 2001). Synergistic coopera­
tion between P1GF and VEGF in pathological 
conditions is specific. Upregulation of P1GF by 
ECs leads to displacement of VEGF from 
VEGFR1. As a result, increased amounts of VEGF 
are available to bind to the mitogenic response 
inducing receptor, VEGFR2. These experiments 
have implicated P1GF in pathological angiogenesis 
unlike VEGF that is essential for both 
physiological as well as pathological angiogenesis 
(figure 11). This makes P1GF a novel target for 
therapeutic treatment.
4.1.3. Platelet-Derived Growth Factor 
Platelet-Derived Growth Factor (PDGF) is a potent 
inducer of growth and motility in several cell types, 
especially the mesenchymal cells. PDGF occurs in 
three different forms: PDGF A-chain homodimer 
(PDGF-AA), PDGF B-chain homodimer (PDGF-BB) 
and PDGF-AB (the heterodimer). PDGF elicits its 
biological responses via a tyrosine kinase receptor, 
Platelet-Derived Growth Factor Receptor (PDGFR). 
The receptor also occurs in different isoforms: a- 
PDGFR and P-PDGFR. PDGF-AA activates a- 
PDGFR only whereas PDGF-BB activates both the 
receptor forms. a-PDGFR is mainly involved in cell-
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Figure 11 M odification o f the EC response to VEGF by 
PIGF during pathological conditions (A) low  concentration 
of PIGF, (B) increasing concentration o f  PIGF
t y p e  s p e c i f i c  s i g n a l l i n g  t h a t  i s  c r i t i c a l  f o r  t h e  
r e g u l a t i o n  o f  c e l l  m i g r a t i o n .  O n  t h e  o t h e r  h a n d ,  
p - P D G F R  is  i n v o l v e d  in  p r o m o t i n g  c e l l  m i g r a t i o n  
(Y u  e t  a l .  2 0 0 1 ) .  L ik e  m a n y  o t h e r  g r o w t h  f a c t o r s ,  
P D G F  c a n  f u n c t i o n  b o t h  a s  a  p a r a c r i n e  a n d  a n  
a u t o c r i n e  f a c t o r .  T h e  c r y s t a l  s t r u c t u r e  o f  t h e  
h o m o d i m e r i c  B B  i s o f o r m  o f  h u m a n  r e c o m b i n a n t  
p l a t e l e t - d e r i v e d  g r o w t h  f a c t o r  ( P D G F - B B )  w a s  
d e t e r m i n e d  b y  X - r a y  c r y s t a l l o g r a p h y  a t  3 . 0 A  
r e s o lu t io n .  T h e  p o l y p e p t i d e  c h a in  i s  f o l d e d  in t o  t w o  
h i g h l y  t w i s t e d  a n t i p a r a l l e l  p a ir s  o f  P - s t r a n d s  a n d  
c o n t a i n s  a n  u n u s u a l  k n o t t e d  a r r a n g e m e n t  o f  t h r e e  
i n t r a m o l e c u l a r  d i s u l f i d e  b o n d s  ( f i g u r e  9 ) .  
D im e r i s a t io n  le a d s  to  th e  c lu s t e r i n g  o f  th r e e  s u r f a c e  
l o o p s  a t  e a c h  e n d  o f  t h e  e l o n g a t e d  d i m e r ,  w h i c h  
m o s t  p r o b a b l y  f o r m  t h e  r e c e p t o r  r e c o g n i t i o n  s i t e s  
( O e f n e r  e t  a l .  1 9 9 2 ) .  T h e  i m p o r t a n t  f i n d i n g s  in  t h e  
f i e ld  o f  P D G F  r e s e a r c h  h a v e  b e e n  l i s t e d  in  t a b le  3 .
4.1.4. Transforming Growth Factors 
T r a n s f o r m i n g  G r o w t h  F a c t o r s  ( T G F s )  a r e  
p o l y p e p t i d e s  th a t  a r e  p r o d u c e d  b y  th e  t r a n s f o r m e d  
a n d  t u m o u r  c e l l s ,  a n d  t h a t  c a n  c o n f e r  p h e n o t y p i c  
p r o p e r t i e s  a s s o c i a t e d  w i t h  t h e  t r a n s f o r m a t i o n  o f  
n o r m a l  c e l l s  in  c u l tu r e .  T h e s e  a n g i o g e n i c  fa c to r s  a r e  
o f  t w o  t y p e s ,  T G F - a  a n d  T G F - p .  T G F - a  i s  a
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m e m b e r  o f  t h e  e p i d e r m a l  g r o w t h  f a c t o r  (E G F )  
f a m i l y  w i t h  w h i c h  i t  s h a r e s  t h e  s a m e  r e c e p t o r ,  t h e  
E G F R  o r  e r b B l .  T G F - a  is  w i d e l y  d i s t r i b u t e d  in  t h e  
c e n t r a l  n e r v o u s  s y s t e m .  E x p e r i m e n t s  h a v e  p o i n t e d  
o u t  th a t  T G F - a  is  a  m u lt i f u n c t io n a l  fa c to r  in  t h e  C N S .  
I t i s  a  p r i n c i p a l  m o l e c u l e  in  t h e  n o r m a l  a n d  
n e o p l a s t i c  d e v e l o p m e n t  o f  t h e  m a m m a r y  g l a n d .  
T G F - a  o v e r e x p r e s s i o n  c a n  i n d u c e  h y p e r p l a s i a ,  
h y p e r p r o l i f e r a t io n  a n d  o c c a s io n a l  c a r c in o m a .
T r a n s f o r m in g  G r o w t h  F a c to r -p (T G F - p )  b e l o n g s  
to  a  f a m i ly  o f  m u l t i f u n c t io n a l  p r o t e in s  th a t  in h ib it  th e  
g r o w t h  o f  m o s t  c e l l  t y p e s ,  a n d  t h e s e  p r o t e in s  i n d u c e  
t h e  d e p o s i t i o n  o f  e x t r a c e l l u a l r  m a t r i x .  T G F - p  
i n h i b i t s  t h e  g r o w t h  a n d  m i g r a t i o n  o f  e n d o t h e l i a l  
c e l l s  in vitro b u t  i n d u c e s  a n g i o g e n e s i s  in vivo. T h e  
o t h e r  m e m b e r s  o f  t h i s  f a m i l y  i n c l u d e  t h e  a c t i v i n s  
a n d  b o n e  m o r p h o g e n e t i c  p r o t e i n s .  T G F - p  i s  
p r o d u c e d  a s  la te n t  h ig h  m o le c u la r  w e i g h t  c o m p le x e s  
f r o m  t h e  p r o d u c e r  c e l l s  a n d  i s  t h e n  a c t i v a t e d  b y  
p l a s m i n  o r  t h r o m b o s p o n d i n .  L a t e n t  T G F - P  b i n d s  
c o v a l e n t l y  t o  l a t e n t  T G F  b i n d i n g  p r o t e i n  (L T B P )  
t h a t  t a r g e t s  it t o  t h e  E C M . T G F -p  b i n d s  s e v e r a l  c e l l -  
s u r f a c e  r e c e p t o r s ,  i n c l u d i n g  t y p e  III  r e c e p t o r  
( b e t a g ly c a n ) ,  e n d o g l i n ,  t y p e  II a n d  t y p e  I r e c e p t o r  
( A L K - 1 ) .  T y p e  III  r e c e p t o r  a n d  e n d o g l i n  a r e  
in d ir e c t ly  i n v o l v e d  in  s ig n a l  t r a n s d u c t i o n .  T h e  t y p e  
II a n d  t y p e  I r e c e p t o r s  h a v e  i n t r a c e l l u l a r  s e r i n e /  
t h r e o n i n e  k i n a s e  d o m a i n s .  T h e y  f o r m  a  h e t e r o -  
d im e r ic  c o m p l e x  a f t e r  l i g a n d  b i n d i n g  a n d  a r e  m o s t  
i m p o r t a n t  f o r  s i g n a l  t r a n s d u c t i o n .  T h e  t y p e  II  
r e c e p t o r  t r a n s a c t iv a t e s  t h e  t y p e  I r e c e p t o r  w h i c h  in  
t u r n  t r a n s d u c e s  v a r i o u s  s i g n a l s  ( M i y a z o n o  1 9 9 6 ) .  
T h e  t h r e e  - d i m e n s i o n a l  s t r u c t u r e s  o f  t h e  d i f f e r e n t  
i s o f o r m s  h a v e  b e e n  e lu c id a t e d  u s i n g  N M R  a n d  X -r a y  
c r y s t a l l o g r a p h y  ( H in c k  e t  a l. 1 9 9 6 ). T h e s e  s t r u c t u r e s  
s h o w e d  s e v e r a l  n o t a b l e  d i f f e r e n c e s  in  s t r u c t u r e  
a n d  f l e x i b i l i t y  o f  t h e  p - s h e e t  l o o p s  t h a t  r u n  p a r a l le l  
t o  t h e  d i m e r  a x i s  ( f ig u r e  9 ) .  It i s  b e l i e v e d  t h a t  t h e s e  
d i f f e r e n c e s  a r e  r e c o g n i s e d  b y  t h e  T G F - p  r e c e p t o r s  
w h i c h  t h u s  a c c o u n t s  f o r  t h e  d i f f e r e n t  c e l l u l a r  
r e s p o n s e s  ( f ig u r e  12 ).
4.2. Other Im portant Angiogenic Growth  
Factors
4.2.1. Fibroblast Growth Factors 
O n e  o f  t h e  b r o a d e s t  s p e c t r u m s  o f  g r o w t h  f a c t o r s  
c h a r a c t e r is e d  s o  fa r  a r e  th e  f ib r o b la s t  g r o w t h  fa c to r s  
( F G F s ) .  S i n c e  t h e  d i s c o v e r y  o f  t h e  F G F  i n  1 9 7 5  
( G o s p o d a r o w i c z  1 9 7 6 ) ,  a b o u t  2 0  m e m b e r s ,  t h a t
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(Edelberg et al. 1998) PDGF mediates cardiac microvascular communication
(Anand-Apte et al. 1997) Rac and extracellular signal-regulated pathways differentially regulate PDGF and 
fibronectin-stimulated migration
(Schneller et al. 1997) avP3 integrin associates with activated insulin and P-PDGFR to potentiate the 
biological activity of PDGF
(Finkenzeller et al. 1997) PDGF-induced gene expression requires the Spl recognition sites in the proximal 
promoter of the human VEGF gene
(Thommen et al. 1997) PDGF-BB increases EC migration on cord movements during angiogenesis in vitro
(Krupinski et al. 1997) PDGF might have a functional role in angiogenesis and neuroprotection after 
ischemic stroke in humans
(Tolonen et al. 1997) Both VEGF and PDGF are expressed in disc herniation tissue
(Barnhill et al. 1996) PDGF-A, PDGF-B and a-PDGFR are expressed in human malignant melanoma
(Kobayashi et al. 1996) PDGF-BB released by diabetic-state modified macrophages in GK rat are involved 
in tube formation of the aortic ECs
(Homer et al. 1996) A rapidly forming human bone expresses PDGF-A chain mRNA, the protein and 
a-PDGFR
(Landgren et al. 1996) PDGF-BB induces the expression of both FGFR-land the protein
(Zhang & Lo 1995) Fibronectin expression in cultured rat thoracic aortic adventitial fibroblasts is 
regulated by PDGF-BB
(Kuwabara et al. 1995) aFGF, FGF-2 and PDGF induced by hypoxia in mononuclear phagocytes stimulate 
the growth of hypoxic ECs
(Phillips & Stone 1994) PDGF-BB induced chemotaxis is impaired in aged capillary ECs
(Liu et al. 1994) Human brain abscess expresses FGF-2, nerve growth factor (NGF), PDGF and 
transforming growth factor-p (TGF-p)
(Holmgren et al. 1991) Angiogenesis during human extra-embryonic development involves spatio-temporal 
control of PDGF and PDGFR gene expression
s h a r e  a b o u t  5 5 %  i d e n t i t y  a t  t h e  a m i n o  a c i d  l e v e l ,  
h a v e  b e e n  a d d e d  t o  t h i s  f a m i l y  o f  p r o t e i n s .  A c i d i c  
f ib r o b la s t  g r o w t h  f a c t o r  ( a - F G F /F G F - 1 )  a n d  b a s ic -  
f ib r o b la s t  g r o w t h  f a c t o r  ( b - F G F /F G F - 2 )  h a v e  b e e n  
w e l l  c h a r a c t e r i s e d  ( M a c ia g  e t  a l. 1 9 8 4 );  ( S h in g  e t  a l.  
1 9 8 4 ) .  T h e  b - F G F  e x i s t s  in  f o u r  d i f f e r e n t  i s o f o r m s  
r e s u l t i n g  f r o m  a l t e r n a t i v e  i n i t i a t i o n s  o f  t r a n s la t io n  
(P r a ts  e t  a l. 1 9 8 9 ). A l l  th e  fo u r  i s o f o r m s  d i f f e r  in  th e ir  
b i o l o g i c a l  f u n c t i o n s  a n d  o c c u r  in  d i f f e r e n t  
i n t r a c e l lu la r  c o m p a r t m e n t s .
F G F s  a r e  i n v o l v e d  i n  a  n u m b e r  o f  p a t h o ­
p h y s i o l o g i c a l  p r o c e s s e s  t h a t  r a n g e  f r o m  m o r p h o ­
g e n e s i s  t o  t u m o u r  a n g i o g e n e s i s  ( f i g u r e  1 3 ) .  T h e  
F G F  s i g n a l l i n g  i s  m e d i a t e d  v i a  c e l l  m e m b r a n e  
s p a n n i n g  t y r o s i n e  k i n a s e  r e c e p t o r s  F G F  r e c e p t o r s  
( F G F R s )  a n d  t h e i r  v a r i a n t s  ( J a y e  e t  a l .  1 9 9 2 ,  
W i l k i e  e t  a l .  1 9 9 5 ) .  a - F G F  i s  t h e  o n l y  F G F  k n o w n  
t o  b i n d  a l l  t h e  F G F R s  w i t h  h i g h  a f f i n i t y  
( C h e l l a i a h  e t  a l .  1 9 9 4 ) .  B o t h  a - F G F  a n d  b - F G F  a r e  
p o t e n t  m i t o g e n s  f o r  m a n y  c e l l  t y p e s  l i k e  t h e  
f i b r o b l a s t s ,  E C s ,  s m o o t h  m u s c l e  c e l l s  a n d  g l i a l  
c e l l s  ( G o s p o d a r o w i c z  e t  a l .  1 9 8 7 ) .  S i g n a l  t r a n s ­
d u c t i o n  r e q u i r e s  a s s o c i a t i o n  o f  F G F  w i t h  i t s
*-FGF b-FGF
Figure 14 The crystal structures o f  acidic FGF and basic 
FGF (Blaber et al. 1996, Eriksson et al. 1991)
r e c e p t o r  (F G F R )  a n d  h e p a r a n  s u l p h a t e  p r o t e o ­
g l y c a n  ( H S P G )  i n  a  s p e c i f i c  c o m p l e x  o n  t h e  c e l l  
s u r f a c e  ( P e l l e g r i n i  e t  a l .  2 0 0 0 ) .  H S P G s  m o d u l a t e  
t h e  p r e s e n t a t i o n  o f  F G F -2  t o  t h e  F G F R  o n  t h e  c e l l  
s u r f a c e  v i a  l o w - a f f i n i t y  i n t e r a c t i o n s  a n d  r e g u l a t e  
t h e  d i f f u s i o n  r a t e  o f  F G F - 2  ( F a h a m  e t  a l .  1 9 9 6 ,  
O r n i t z  e t  a l .  1 9 9 5 ,  K a n  e t  a l .  1 9 9 3 ,  D o w d  e t  a l .  
1 9 9 9 ) .  T h e r e  i s  c o n f l i c t i n g  b i o c h e m i c a l  a n d  
b i o p h y s i c a l  e v i d e n c e  m a k i n g  i t  u n c l e a r  w h e t h e r  
o r  n o t  F G F  o l i g o m e r i s a t i o n  f a c i l i t a t e d  b y  t h e  
H S P G s  a r e  im p o r t a n t  fo r  s i g i a l l i n g  t h r o u g h  th e  h ig h  
a f f i n i t y  i n t e r a c t i o n s  w i t h  t h e  F G F R . T h e  t h r e e -  
d i m e n s i o n a l  c r y s t a l  s t r u c t u r e s  o f  b o t h  a -F G F  a n d  b -  
F G F  s h o w  t h a t  t h e  r e g i o n  w h e r e  t h e  h i g h  a f f i n i t y  
r e c e p t o r s ,  F G F R s ,  b i n d  t o  t h e  t w o  l i g a n d s  a r e  
s t r u c t u r a l l y  v e r y  s i m i l a r  t o  e a c h  o t h e r  ( f i g u r e  1 4 ) .  
O n  t h e  o t h e r  h a n d ,  t h e  s i t e  w h e r e  t h e  H S P G s  b i n d  
o n  t h e  F G F s  i s  s t r u c t u r a l l y  v e r y  d i f f e r e n t .  X - r a y  
c r y s t a l l o g r a p h y  h a s  t h u s  p r o v i d e d  a  s t r u c t u r a l  
e x p l a n a t i o n  f o r  t h e  r o l e  o f  t h e s e  l o w  a f f i n i t y  
r e c e p t o r s ,  H S P G s ,  in  d i s c r i m i n a t i n g  b e t w e e n  t h e  
F G F R s  (B la b e r  e t a l .  1 9 9 6 ) .
Figure 12 The various pathophysio logical processes in 










Figure 13 The various pathophysiological processes in 
w h ich  the FGFs are involved
4.2.2. Epidermal Growth Factor 
T h e  m a i n t e n a n c e  o f  t h e  i n t e g r i t y  o f  t h e  
g a s t r o i n t e s t i n a l  m u c o s a  a n d  t h e  h e a l i n g  o f  t h e  
g a s t r i c  m u c o s a l  l e s i o n s  a r e  c o n t r o l l e d  b y  g r o w t h  
f a c t o r s ,  e s p e c i a l l y  t h e  e p i d e r m a l  g r o w t h  f a c t o r  
(E G F ) w h i c h  o r i g i n a t e s  f r o m  t h e  s a l i v a r y  g l a n d s  
a n d  t h e  t r a n s f o r m i n g  g r o w t h  f a c t o r - a  ( T G F - a ) .  
T G F - a  i s  r e l e a s e d  in  t h e  g a s t r i c  m u c o s a  i t s e l f ,  
p a r t ic u l a r ly  w h e n  t h e  m u c o s a  i s  e x p o s e d  t o  t o p ic a l  
ir r i ta n t s  a n d  n o x i o u s  s u b s t a n c e s .
E G F  i n h i b i t s  g a s t r i c  a c i d  s e c r e t i o n  a n d  
s t im u la t e s  d u o d e n a l  b ic a r b o n a t e  s e c r e t io n  ( S z a b o  &  
V in c z e  2 0 0 0 ) .  A p a r t  f r o m  b e in g  a n  im p o r t a n t  g r o w t h  
fa c to r  in  th e  p r o c e s s  o f  u lc e r  h e a l in g ,  E G F  a n d  E G F R
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a r e  b e l i e v e d  t o  b e  i m p o r t a n t  f o r  r e g u l a t i n g  
a n g i o g e n e s i s  a n d  v a s c u l a r  f u n c t i o n  in  t h e  h u m a n  
e n d o m e t r i u m  ( M o l l e r  e t  a l .  2 0 0 1 ) .  T h e r e  e x i s t s  a  
c o n s i s t e n t  r e l a t i o n  b e t w e e n  E G F  a c t i v a t i o n  a n d  
V E G F  p r o d u c t io n .  S e v e r a l  h u m a n  g l i o m a  c e l l  l i n e s  
d e m o n s t r a t e  t h i s  r e l a t i o n .  T h i s  s e c r e t i o n  o f  
b i o a c t i v e  V E G F  b y  t h e  g l i o m a  c e l l s  a c c o u n t s  f o r  th e  
k e y  h i s t o p a t h o i o g i c a l  f e a t u r e s  o f  g l i o b l a s t o m a  
m u l t i f o r m e ,  n a m e l y  h y p e r v a s c u la r i t y ,  f o c a l  n e c r o ­
s i s ,  p e r s i s t e n t  c e r e b r a l  o e d e m a  a n d  r a p i d  c e l l u l a r  
p r o l i f e r a t i o n ( G o l d m a n e t a l . l 9 9 3 ) .  P h o s p h o r y la t io n  
o f  E G F R  l e a d s  t o  b i p h a s i c  i n d u c t i o n  o f  V E G F  
f o l l o w i n g  u l t r a v i o l e t  B i r r a d i a t i o n .  U V B  a l s o  
i n i t i a t e s  s y n t h e s i s  o f  T G F - a .  B o t h  t h e s e  g r o w t h  
f a c t o r s  ( V E G F  a n d  T G F - a )  e n h a n c e  c u t a n e o u s  
a n g i o g e n e s i s  in  t h e  c h r o n i c a l l y  s u n - e x p o s e d  s k i n  
( B la u d s c h u n  e t  a l. 2 0 0 0 ) .  E G F R  p r o v i d e s  p r o g n o s t i c  
i n f o r m a t i o n  t o  d e t e r m i n a t i o n  o f  t u m o u r  
a n g i o g e n e s i s  a n d  m i c r o v e s s e l  d e n s i t y  in  w o m e n  
w i t h  i n v a s i v e  b r e a s t  c a r c i n o m a  ( W e i d n e r  &
G a s p a r i n i  1 9 9 4 ) .  I t i s  t h o u g h t  t h a t  t h e  o n c o g e n i c  
p r o p e r t i e s  o f  E G F R  a r e  m e d i a t e d  b y  u p - r e g u l a t i n g  
t h e  p o t e n t  a n g i o g e n i c  m o l e c u l e s  s u c h  a s  t h e  V E G F . 
T h e s e  a r e  p r o b a b l y  e n h a n c e d  b y  e n v i r o n m e n t a l  
f a c t o r s  t h a t  m a x i m a l l y  s t i m u l a t e  t u m o u r  
a n g i o g e n e s i s  ( f ig u r e  1 5 ; P e t i t  e t  a l .  1 9 9 7 ).
4.2.3. Angiotropin
A n g io t r o p in  is  a  p o t e n t  a n g i o g e n e s i s  fa c to r  s e c r e t e d  
f r o m  t h e  a c t i v a t e d  p e r i p h e r a l  m a c r o p h a g e s .  I t  i s  
d i r e c t l y  i n v o l v e d  in  m o n o c y t e - i n d u c e d  
a n g i o g e n e s i s .  It a c t i v a t e s  m i c r o v a s c u l a r  E C s  a n d  
t h u s  t r i g g e r s  o f f  i n f l a m m a t o r y  a n d  p r o l i f e r a t i v e  
r e a c t i o n s  d u r i n g  w o u n d  h e a l i n g  ( H o c k e l  e t  a l .  
1 9 8 8 ) .  In vitro i t  s t i m u l a t e s  m i g r a t i o n ,  p h e n o t y p i c  
d i f f e r e n t i a t i o n ,  a n d  t u b e  f o r m a t i o n  ( f i g u r e  1 6 ) . It 
d o e s  n o t  i n d u c e  p r o l i f e r a t i o n  o f  c a p i l l a r y  E C s .  
I n t r a d e r m a l  a d m in i s t r a t io n  o f  a n g i o t r o p i n  i n d u c e s  
a n g i o g e n e s i s  a s s o c i a t e d  h y p e r p l a s i a  o f  t h e  s k i n  
( H o c k e l  &  B u r k e  1 9 8 9 ) .  A n g i o t r o p i n - i n d u c e d
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Figure 15 An overv iew  o f the various in v iv o  effects o f  Epidermal Growth Factor
432 Shalini Iyer and K Ravi Acharya
Angiotropin
M igration of ECs
M orp h o g en esis
/ X






angiogenesis and tissue 
proliferation
Prevents flap necrosis M igration o f ECs
No scar form ation
Figure 16 A brief overv iew  o f  the in vitro and in v ivo  
properties o f  A ngiotropin
a n g i o g e n e s i s  i s  n o t  i n h i b i t e d  b y  l o c a l  
d e x a m e t h a s o n e .  T r a n s i e n t  p r o l i f e r a t i o n  o c c u r s  in  
t h e  a b s e n c e  o f  t i s s u e  n e c r o s i s  a n d  d o e s  n o t  l e a d  to  
s c a r  f o r m a t i o n  ( H o c k e l  e t  a l .  1 9 8 8 ) .  E x p e r - i m e n t s  
h a v e  r e v e a l e d  t h a t  l o c a l  p r e - t r e a t m e n t  o f  
a n g i o t r o p i n  p r e v e n t s  f l a p  n e c r o s i s  a n d  a u g m e n t s  
d e r m a l  r e g e n e r a t i o n  a f t e r  w o u n d i n g  in  r a b b it  s k in  
( f i g u r e  1 6 ) .  T h e s e  r e s u l t s  i m p l y  t h a t  a n g i o t r o p i n  
m ig h t  b e  u s e f u l  a s  a n  a d j u v a n t  t o  h e a l in g  in  s u r g e r y .  
H o c k e l  e t  a l(1 9 8 7 )  h a v e  a l s o  s h o w n  th a t  a n g io t r o p in  
d o e s  n o t  s t i m u l a t e  p r o l i f e r a t i o n  o f  c a p i l l a r y  
e n d o t h e l ia l  c e l l s  a n d  3 T 3  c e l l s .  H o w e v e r ,  it w a s  s e e n  
th a t  in  c o n c e n t r a t io n s  l e s s  t h a n  l n g / m l ,  it e n h a n c e s  
r a n d o m  m ig r a t i o n  o f  c a p i l l a r y  e n d o t h e l i a l  c e l l s  b u t  
n o t  o f  3 T 3  c e l l s .  A n g i o t r o p i n  l e a d s  t o  d e f i n e d  d o s e -  
d e p e n d e n t  a n d  r e v e r s i b l e  c h a n g e s  o f  c e l l u l a r  
m o r p h o l o g y  o n  c o n f l u e n t  m o n o l a y e r s  o f  c a p i l l a r y  
E C s .  I n  t h e  p r e s e n c e  o f  a n g i o t r o p i n .  c a p i l l a r y  
e n d o t h e l i a l  c e l l s  r a p i d l y  f o r m  t u b e - l i k e  s t r u c t u r e s  
o n  g e l a t i n i s e d  p la t e s .  T h e s e  r e s u l t s  in d ic a t e  t h a t  th e  
b i o l o g i c a l  a c t i o n  o f  a n g i o t r o p i n  i s  d i f f e r e n t  f r o m  
t h a t  o f  o t h e r  g r o w t h  f a c t o r s .
4.2.4. Hepatocyte Growth Factor/Scatter Factor 
H e p a t o c y t e  G r o w t h  F a c t o r  ( H G F )  i s  a n  8 5 k D a  
h e p a r i n  b i n d i n g  p r o t e i n  t h a t  i s  s e c r e t e d  b y  t h e  
m e s e n c h y m a l  c e l l s  a n d  a f f e c t s  e p i t h e l i a l  c e l l  
p r o lif e r a t io n ,  m o t i l i t y  a n d  m o r p h o l o g y  ( M a t s u m o t o  
& N a k a m u r a  1 9 9 2 ,  V i g n a  e t  a l .  1 9 9 4 ,  G h e r a r d i  &  
S t o k e r  1 9 9 1 ,  M o n t e s a n o  e t  a l .  1 9 9 1 ) .  H G F  i s  a n  
i m p o r t a n t  p a r a c r i n e  m e d i a t o r  o f  e p i t h e l i a l -  
m e s e n c h y m a l  c e l l  i n t e r a c t i o n s  ( S o n n e n b e r g  e t  a l .  
1 9 9 3 , R o s e n  e t  a l. 1 9 9 4 ) .  H G F  b i n d s  a n d  a c t i v a t e s  a  
h i g h  a f f i n i t y  t y r o s i n e  k i n a s e  r e c e p t o r  c a l l e d  t h e  c -  
M e t  t h r o u g h  w h i c h  it m e d i a t e s  i t s  d i v e r s e  b io l o g ic a l  
a c t i v i t i e s  ( B o t t a r o  e t  a l .  1 9 9 1 ,  V i g n a  e t  a l .  1 9 9 4 ) .  
H G F  a l s o  h a s  a  l o w - a f f i n i t y  b i n d i n g  s i t e  fo r  h e p a r in  
a n d  H S P G s .  B o t h  t h e  s i z e  a n d  t h e  c h a r g e  o f  t h e  
H S P G s  d e t e r m i n e  t h e  b i n d i n g  a f f i n i t y .  H S P G s  
r e g u la t e  c e l lu la r  s ig n a l l in g  ( f ig u r e  17) b y  m o d u la t in g  
t h e  s ta b ili ty , d i f f u s a b i l i t y  a n d  th e  b io lo g ic a l  a c t iv i t y  o f  
H G F . Z io n c h e c k  e t  a l. (1 9 9 5 ) s h o w e d  t h a t  h e p a r in  o r  
H S P G s  c a n  p o t e n t ia t e  H G F  m i t o g e n e s i s  b u t  t h e y  a r e  
n o t  r e q u ir e d  f o r  t h e  g r o w t h  f a c t o r  t o  b in d  t o  c -M e t .
D e p e n d i n g  u p o n  c e l l  t y p e  a n d  c u l t u r e  
c o n d i t i o n s  H G F  c a n  a c t  a s  a  m i t o g e n  ( i n c r e a s i n g  
D N A  s y n t h e s i s  a n d  c e l l  n u m b e r ) ,  a  m o t o g e n  
( c a u s i n g  c o l o n i e s  o f  c e l l s  t o  s c a t t e r  in t o  i n d i v i d u a l  
c e l l s )  o r  a  m o r p h o g e n  ( c a u s i n g  f o r m a t i o n  o f  
c a p i l l a r y  l i k e  t u b u l e s  in vitro). T h e  H G F  a c t s  
t h r o u g h  t h e  t y r o s i n e  k i n a s e  r e c e p t o r  e n c o d e d  b y
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Figure 17 A schematic sh ow in g  regulation o f HGF induced  
cellular signaling by heparin /H SP G s
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t h e  c - M e t  p r o t o - o n c o g e n e  a n d  i n d u c e s  a  v a r i e t y  o f  
c e l l u l a r  r e s p o n s e s  i n  v a r i o u s  p a t h o l o g i c a l  c o n d i t i o n s  
( f i g u r e  1 8 ) .  T h e  i n a c t i v e  H G F / S F  p r e c u r s o r  
c o m p r i s e s  a n  N - t e r m i n a l  d o m a i n ,  f o u r  k r i n g l e  ( K l ,  
K 2 , K 3  a n d  K 4 )  d o m a i n s  a n d  a  C - t e r m i n a l  d o m a i n .  
T h e  C - t e r m i n a l  d o m a i n  i s  c l e a v e d  o f f  t o  g i v e  t h e  
a c t i v e  m o l e c u l e .  T h e  N - t e r m i n a l  d o m a i n ,  o n  t h e  
o t h e r  h a n d ,  p l a y s  a  c r i t i c a l  r o l e  i n  r e c e p t o r  b i n d i n g .  
A l t e r n a t e  s p l i c i n g  o f  t h e  p r i m a r y  t r a n s c r ip t  p r o d u c e s  
t w o  t r u n c a t e d  f o r m s  o f  H G F / S F ,  n a m e l y ,  N K 1  a n d  
N K 2 .  B o t h  f r a g m e n t s  r e t a i n  t h e  a b i l i t y  t o  b i n d  a n d  
a c t i v a t e  t h e  c - M e t  r e c e p t o r  in vivo . T h e  t h r e e  
d i m e n s i o n a l  s t r u c t u r e  o f  t h e  e n t i r e  H G F / S F  i s  n o t  
k n o w n  a l t h o u g h  t h e  c r y s t a l  s t r u c t u r e  o f  t h e  N K 1  
f r a g m e n t  w a s  e l u c i d a t e d  s o m e t i m e  a g o  ( C h i r g a d z e  
e t  a l .  1 9 9 9 ) .  T h e  s t r u c t u r e  p r o v i d e s  a  b a s i s  f o r  
r a t i o n a l i s a t i o n  o f  i t s  a g o n i s t i c  a c t i v i t y  a n d  s h o w s  
t h a t  t h e  r e c e p t o r  b i n d i n g  s i t e s  c o m p r i s e  o f  r e s i d u e s  
f r o m  b o t h  t h e  N - t e r m i n a l  d o m a i n  a n d  t h e  k r i n g l e  
d o m a i n ,  K l ,  t h u s  h a v e  i m p l i c a t i o n s  f o r  t h e  


















F ig u r e  18 T h e  d i f fe r e n t  p a t h o lo g ic a l  p r o c e s s e s  in  w h ic h  
H G F /S F  is  in v o lv e d
4.2.5. Platelet-Derived Endothelial Cell Growth 
Factor /  Thymidine Phosphorylase 
P l a t e l e t  D e r i v e d  E n d o t h e l i a l  G r o w t h  F a c t o r  ( P D -  
E C G F )  o r  T h y m i d i n e  P h o s p h o r y l a s e  (T P )  i s  a  4 5 k D a  
s i n g l e  c h a i n  p o l y p e p t i d e  t h a t  s t i m u l a t e s  D N A  
s y n t h e s i s  a n d  c h e m o t a x i s  o f  e n d o t h e l i a l  c e l l s  in vitro 
a n d  a n g i o g e n e s i s  in vivo. T P / P D - E C G F  i s  f o u n d  in  
t h e  h u m a n  p l a t e l e t  c e l l s  a n d  t h e  p l a c e n t a .  I t  l a c k s  a  
h y d r o p h o b i c  l e a d e r  s e q u e n c e  a n d  m o s t  o f  t h e  p r o t e i n  
r e m a i n s  i n s i d e  t h e  p r o d u c e r  c e l l s .  T P  c o n t a i n s  
n u c l e o t i d e  c o v a l e n t l y  b o u n d  t o  t h e  s e r i n e  r e s i d u e s  
( M i y a z o n o  e t  a l .  1 9 9 1 ) .  T h e  g e n e  e n c o d i n g  h u m a n  
P D - E C G F  i s  c o m p o s e d  o f  1 0  e x o n s  d i s p e r s e d  o v e r  a  
4 . 3 k b  r e g i o n  o n  c h r o m o s o m e  2 2 .  T h i s  g e n e  i s  
c o n s e r v e d  p h y l o g e n e t i c a l l y  a m o n g  v e r t e b r a t e s  a n d  
c o n t a i n s  s i x  c o p i e s  o f  p o t e n t i a l  S p - 1  b i n d i n g  s i t e s  j u s t  
u p s t r e a m  o f  t r a n s c r i p t i o n  s t a r t  s i t e s  ( H a g i w a r a  e t  a l .
1 9 9 1 ) .  A m i n o  a c i d  s e q u e n c i n g  o f  P D - E C G F  s h o w e d  
t h a t  t h e  p la c e n t a l  f o r m  o f  t h e  p r o t e i n  h a s  a d d i t i o n a l  5  
a m i n o  a c i d s  a t  t h e  N - t e r m i n u s  a s  c o m p a r e d  t o  t h e  
p l a t e l e t  f o r m  ( M i y a z o n o  &  T a k a k u  1 9 9 1 ) .  P D - E C G F  
h a s  t h y m i d i n e  p h o s p h o r y l a s e  a c t i v i t y  a n d  s h a r e s  
a r o u n d  4 0 %  a m i n o  a c i d  s e q u e n c e  s i m i l a r i t y  o v e r  4 3 9  
r e s i d u e s  w i t h  t h e  T P  o f  E.coli, h e n c e  P D - E C G F  is  a l s o  
k n o w n  a s  T h y m i d i n e  P h o s p h o r y l a s e .  H u m a n  T P  
o c c u r s  a s  a  9 0  k D a  b i o l o g i c a l  h o m o d i m e r .  T h e  in vitro 
a n d  t h e  in vivo  e f f e c t s  o f  T P  m a y  o c c u r  b y  a n  i n d i r e c t  
m e c h a n i s m  t h r o u g h  i t s  e n z y m a t i c  a c t i v i t y  ( U s u k i  e t  
a l .  1 9 9 2 ) .  I m m u n o h i s t o c h e m i c a l  s t a i n i n g  o n  s e c t i o n s  
o f  h u m a n  p l a c e n t a  f r o m  e a c h  t r i m e s t e r  o f  p r e g n a n c y  
r e v e a l s  t h a t  T P  i s  e x p r e s s e d  in  t h e  t r o p h o b l a s t  a n d  in  
t h e  c e n t r e  o f  t h e  v i l l o u s  c o r e  d u r i n g  e a r l y  p r e g n a n c y .  
T h i s  i n d i c a t e s  a n  a c t i v e  r o l e  f o r  t h e  p r o t e i n  i n  
i n f l u e n c i n g  t h e  d e v e l o p m e n t  o f  t h e  v i l l o u s  v a s c u l a r  
n e t w o r k  ( J a c k s o n  e t  a l .  1 9 9 4 ) .  T P  c a t a l y s e s  t h e  
r e v e r s i b l e  p h o s p h o r y l a t i o n  o f  t h y m i d i n e  t o  
d e o x y r i b o s e - 1 - p h o s p h a t e  a n d  t h y m i n e .  T P  h a s  a n  
i m p o r t a n t  r o l e  t o  p l a y  i n  c e l l u l a r  m e t a b o l i s m  a n d  in  
a n g i o g e n e s i s ( t a b l e  4 ) .  W e s t e r n  B l o t t i n g  a n d  i m m u n o ­
h i s t o c h e m i c a l  s t u d i e s  u s i n g  a  m o n o c l o n a l  a n t i b o d y  
a g a i n s t  T P  h a v e  r e v e a l e d  t h a t  t h e  e x p r e s s i o n  o f  t h i s  
p r o t e i n  i n  n o r m a l  t i s s u e s  i s  t i g h t l y  r e g u l a t e d  a n d  t h a t  
t h e  c e l l u l a r  t h y m i d i n e  p o o l s  m a y  s e r v e  d i f f e r e n t  
f u n c t i o n s .  F o r  i n s t a n c e ,  i n  t h e  n u c l e u s  i t  m i g h t  
m o d u l a t e  t h e  p o o l  f o r  D N A  s y n t h e s i s .  T h e  h i g h  l e v e l  
e x p r e s s i o n  o f  T P  i n  m a c r o p h a g e s  a n d  s k i n  m a y  b e  
i m p o r t a n t  f o r  t o t a l  b o d y  t h y m i d i n e  h o m e o s t a s i s  ( F o x  
e t  a l .  1 9 9 5 ) .  I t  h a s  b e e n  o b s e r v e d  t h a t  T P  a c t i v i t y  a n d  
e x p r e s s i o n  l e v e l s  in  m a n y  t u m o u r s  a r e  h i g h e r  f r o m
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Table 4 Some important insights into the role of TP/PD-ECGF in angiogenesis
References Experiments Biological significance
(Giatromanolaki 
et al. 1998)
(Relf et al. 1997) Correlation of the expression of TP with
that of Estrogen receptor and vascular 
density in primary breast cancers in 
humans.
(Imazano et al. 1997) Spectrophotometry and immunoblotting
revealed that the enzymatic activity of TP in 
renal carcinoma cells was 9 times higher 
than that in the non-neoplastic kidney 
tissues
(Creamer et al. 1997) Ribonuclease Protection Assay and 
Immunohistochemical studies reveal 
overexpression of TP/PD-ECGF in psoriatic 
epidermis.
Focal expression of TP in non-small-cell 
lung cancer is associated with marked 
stromal lymphocytic infiltration in the area 
of focal TP overexpression.
(Stevenson et al.1998) Effects on the rate of microvessel growth by 
TP and the degradation products, substrate 
and the various metabolites of the enzyme 
reaction.
(Leek et al. 1998) Immunohistochemical studies show that 
TNF-a upregulates TP expression in 
tumour cells in vitro. There is also a 
positive correlation between TNF-a bound 
to its receptor on tumour cells and 
metastasis.
(Balzarini et al. 1998) 7-deazaxanthine inhibits the enzymatic 
reaction catalysed by PD-ECGF in a 
concentration dependent manner. It 
prevents neovascularisation in CAM.
TP activity in gastric cancer cells was found 
to correlate with venous invasion.
(Nakata et al. 1998) 
(Kitazono et al. 1998) Increased expression of TP prevents 
apoptosis induced by hypoxia. Among the 
degradation products of thymidine, 
2-deoxy-D-ribose and thymine partially 
prevent hypoxia induce-apoptosis.
(Gasparini et al. 1999) High levels of TP and low levels of VEGF 
characterise patients with Node Positive 
Breast Cancer (NPBC). When treated with 
adjuvant cyclophosphamide methotrexate 
5-fluorouracil (CMF) the NPBC patients 
have the highest likelihood of favourable 
outcome.
(Sivridis et al. 1999) 
(Tang et al. 2000)
(Hata et al. 2000)
Immunohistochemical studies reveal that 
TP is not a major angiogenic factor in 
endometrial carcinomas. 
Immunohistochemical staining of uterine 
neoplasm suggest that TP expression in 
stromal cells rather than in tumour cells 
plays an important role in promoting 
microvessel growth
Transvaginal colour, pulsed Doppler ultra­
sonography analysis of blood flow velocity 
have shown that intra-tumoral PSV is a 
good indicator of ovarian malignancy.
Angiogenesis may involve a coordinated regulation of 
some vascular growth factors. Implications for a 
broad spectrum therapy using agents that inhibit EC 
migration or are directly toxic to EC by blocking 
features common to the vascular growth factors.
There is no significant association between TP 
expression and other clinicopathological 
characteristics and thus TP expression is an 
unfavourable prognostic factor in hum an renal cell 
carcinoma.
Potential role for TP in the pathophysiology of 
psoriasis and a probable target for antiangiogenesis 
therapy in the treatment of this disease
Direct association of JP/PD-ECGF and angiogenesis, 
stromal macrophage and fibroblast reactivity. 
Important in understanding the behaviour of non­
small-cell lung cancer
PD-ECGF/TP affects angiogenesis by changing the 
relative concentrations of pyrimidine based 
compounds and their metabolites in the interstitial 
fluid surrounding the ECs.
Explains the relationship between increased 
macrophage infiltration and angiogenesis in breast 
cancer and strengthens the idea that tumour- 
associated macrophages represent an important anti- 
angiogenic target.
It is the first purine derivative shown to be a potent 
inhibitor of purified TP and is shown to have marked 
inhibitory effect on angiogenesis.
TP plays an important role in tum our angiogenesis as 
well
Inhibitors of TP and analogs of the degradation 
products of thymidine suppress growth of tumours 
by promoting apoptosis.
Novel therapeutic strategies of adjuvant therapy 
based on angiogenesis.
TP expression cannot be used as a prognostic factor.
Angiogenesis may have an association w ith tumour 
cell invasion in cervical squamous cell carcinoma of 
the cervix.
Biological difference between physiological 
angiogenesis (TIE-2 expression correlates w ith PSV in 
normal ovary) and pathological angiogenesis (TP 
expression correlates with PSV in ovarian cancer).
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t h o s e  in  t h e  a d j a c e n t  n o n - n e o p l a s t i c  t i s s u e s .  T P  m a y  
p e r h a p s  h a v e  a n  i m p o r t a n t  r o l e  t o  p l a y  i n  t h e  
p r o l i f e r a t i o n  o f  s o l i d  t u m o u r s  l i k e  t h o s e  o f  o e s o ­
p h a g e a l ,  g a s t r i c ,  c o l o r e c t a l  a n d  l u n g  c a r c i n o m a s  
( T a k e b a y a s h i e t a l .  1 9 9 6 ) .
T P  d i r e c t l y  i n f l u e n c e s  t u m o u r  o x y g e n a t i o n  
l e v e l s  v i a  i t s  r o l e  i n  f o r m a t i o n  o f  f u n c t i o n a l  
v a s c u l a t u r e  ( G r i f f i t h s  &  S t r a t f o r d  1 9 9 7 ) .  I n h i b i t o r s  
o f  T P  a r e  e x p e c t e d  t o  s u p p r e s s  t h e  g r o w t h  a n d  
m e t a s t a s i s  o f  t u m o u r  c e l l s  b y  i n h i b i t i o n  o f  
a n g i o g e n e s i s  ( H i r o t a  e t  a l . 1 9 9 7 ) .  T h e  c r y s t a l  s t r u c ­
t u r e  o f  h u m a n  T P  i s  n o t  y e t  k n o w n .  H o w e v e r ,  t h e  
t h r e e  d i m e n s i o n a l  s t r u c t u r e  o f  P y r i m i d i n e  
N u c l e o s i d e  P h o s p h o r y l a s e  ( P Y N P )  i n  c l o s e  c o n ­
f o r m a t i o n  w a s  d e t e r m i n e d  b y  P u g m i r e  a n d  E a l i c k  
( P u g m i r e  &  E a l i c k  1 9 9 8 ) .  S i n c e  P Y N P  (a  b a c t e r i a l  
e n z y m e )  s h a r e s  a r o u n d  4 0 %  s e q u e n c e  s i m i l a r i t y  
w i t h  h u m a n  T P , i t  i s  b e l i e v e d  t h a t  t h e y  m a y  s h a r e  
s i g n i f i c a n t  s t r u c t u r a l  s i m i l a r i t y  a s  w e l l .  T h e  c r y s t a l  
s t r u c t u r e  o f  P Y N P  h a s  h e l p e d  u s  u n d e r s t a n d  t h e  
o v e r a l l  f u n c t i o n  o f  t h e  h u m a n  e n z y m e  m u c h  b e t t e r  
a n d  h a s  g i v e n  u s  v a l u a b l e  i n s i g h t s  i n t o  t h e  r a t i o n a l  
d e s i g n  o f  i n h i b i t o r s  b a s e d  o n  t h e  c r y s t a l  s t r u c t u r e .
T h e  o t h e r  a r e a  b e i n g  e x p l o i t e d  b y  r e s e a r c h e r s  i s  
t h e  e n z y m a t i c  f u n c t i o n  o f  T P / P D - E C G F .  T h e  
e n z y m a t i c  a c t i v i t y  o f  T P  i s  a  m a j o r  d e t e r m i n a n t  o f  
t h e  t o x i c i t y  o f  t h e  d r u g s  u s e d  a s  a n t i - c a n c e r  a g e n t s .  
5 - f l u o r o u r a c i l  a n d  i t s  p r o - d r u g s  a r e  b e i n g  
e x t e n s i v e l y  s t u d i e d  a s  p o t e n t i a l  a n t i - a n g i o g e n i c  
t h e r a p e u t i c s  ( G r i f f i t h s  &  S t r a t f o r d  1 9 9 7 ) .  A  n e w l y  
s y n t h e s i s e d  T P  i n h i b i t o r  ( T P I ) ,  5 - c h l o r o - 6 - [ l - 2 -  
i m i n o p y r r o l i d i n y l ) m e t h y l ] u r a c i l  h y d r o c h l o r i d e ,  
i n c r e a s e s  t h e  p r o p o r t i o n  o f  a p o p t o t i c  c e l l s  a n d  
s u p p r e s s e s  t u m o u r  g r o w t h  a n d  i n h i b i t s  a n g i o ­
g e n e s i s  ( M a t s u s h i t a  e t  a l .  1 9 9 9 ) .  A  n e w  c l a s s  o f  
i n h i b i t o r s  h a s  b e e n  d e v e l o p e d  w h i c h  a r e  b a s e  
a n a l o g s  t h a t  a r e  n o t  c o n v e r t e d  i n t o  n u c l e o s i d e  b y  
T P , a n d  t h e r e b y  r e p r e s e n t  p u r e  n o n - s u b s t r a t e  
i n h i b i t o r s  o f  T P  ( f i g u r e  1 9 ) .  A m o n g  t h e s e  a r e  t h e  6 -  
( p h e n y l a l k y l a m i n o )  u r a c i l  d e r i v a t i v e s ,  w h i c h  a t  f iM  
l e v e l s  i n h i b i t  b o t h  c a t a b o l i c  a n d  a n a b o l i c  r e a c t i o n s  
o f  h u m a n  T P  in vitro  ( F o c h e r  e t  a l .  2 0 0 0 ) .
4.2.6. Angiogenin
A n g i o g e n i n  i s  a  p o t e n t  i n d u c e r  o f  a n g i o g e n e s i s  l i k e  
t h e  V E G F . I t b i n d s  t o  h i g h  a f f i n i t y  e n d o t h e l i a l  c e l l  
s u r f a c e  r e c e p t o r s ,  a n d  w i t h  l o w e r  a f f i n i t y  t o  t h e  
e x t r a c e l l u l a r  m a t r ix .  A m o n g  t h e  v a r i o u s  a n g i o g e n i c  
m o l e c u l e s  k n o w n ,  a n g i o g e n i n  i s  a n  e n z y m e  ( F e t t
e t  a l .  1 9 8 5 ) .  I t  i s  a  m e m b e r  o f  t h e  p a n c r e a t i c  
r i b o n u c l e a s e  ( R N a s e  A )  s u p e r f a m i l y  o f  p r o t e i n s  
( 3 3 %  a m i n o  a c i d  s e q u e n c e  i d e n t i t y )  t h a t  h a s  t h e  
a b i l i t y  t o  s t i m u l a t e  n e w  b l o o d  v e s s e l  f o r m a t i o n  
f r o m  p r e - e x i s t i n g  v a s c u l a t u r e .  T h e  w e a k  c a t a l y t i c  
a c t i v i t y  o f  a n g i o g e n i n  i s  b e l i e v e d  t o  b e  v e r y  
i m p o r t a n t  f o r  i t s  a n g i o g e n i c  p r o p e r t i e s  ( t a b l e  5 ) .  I n  
a d d i t i o n ,  t h e  c e l l - b i n d i n g  r e g i o n  a n d  t h e  n u c l e a r  
l o c a l i s a t i o n  s i g n a l  a r e  b o t h  i m p o r t a n t  f o r  t h e  
m o l e c u l e ’s  a n g i o g e n i c i t y  ( f o r  r e c e n t  r e v i e w s  s e e  
R i o r d a n  1 9 9 7 ,  A d a m s  &  S u b r a m a n i a n  2 0 0 0 ) .
T h e  c r y s t a l  s t r u c t u r e  o f  a n g i o g e n i n  ( A c h a r y a  e t  
a l .  1 9 9 4 )  i s  v e r y  s i m i l a r  t o  t h a t  o f  R N a s e  A  ( f i g u r e  
2 0 ) .  I t  w a s  s h o w n  t h a t  t h e  c a t a l y t i c  r e s i d u e s  i n  t h e  
R N a s e  s u p e r f a m i l y  a r e  w e l l  c o n s e r v e d  s p a t i a l l y .  
A l s o  t h e  s t r u c u t r e  p o i n t e d  o u t  n o t a b l e  s t r u c t u r a l  
d i f f e r e n c e s  b e t w e e n  a n g i o g e n i n  a n d  R N a s e  a n d  
t h u s  p r o v i d i n g  a  s t r u c t u r a l  b a s i s  t o  t h e  d i f f e r e n c e s  
in  t h e  a c t i v i t i e s  o f  t h e  t w o  p r o t e i n s .  T h e  s t r u c t u r e  i s  
n o w  o n e  o f  t h e  f o c a l  p o i n t  i n  t h e  d e v e l o p m e n t  o f
TP/PD -EC G F
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Figure 19 A schematic representation of the reaction 
catalysed by TP/PD-ECGF
A N G IO G E N IN
Figure 20 The Ca traces of RNase-A and Angiogenin 
showing the structural similarities as well as the differences 
between the two (Acharya et al. 1994, Wlodawer et al. 1982)
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Table 5 History of angiogenin
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References Organs / molecules 
/ processes affected
Biological significance
(Koga et al. 2000) Ovaries Angiogenin acts as a local angiogenic factor for the development 
of the ovarian follicle and the ensuing formation of corpus 
luteum. Up-regulation is by hCG, cAMP or hypoxia.
(Etoh et al. 2000) Macrophage
infiltration
Angiogenin, induced by pro-inflammatoiy cytokines derived 
from the infiltrating macrophages, advances tumour 
angiogenesis in colorectal cancer. This results in a very low 
survival time for patients with high angiogenin expression.
(Shimoyama & 
Kaminishi 2000)
Gastric tissues Increased angiogenin expression in the serum of patients with 
gastric cancer correlates with cancer progression.
(Eberle et al. 2000) Brain tissues Angiogenin causes malignant transformation of the glioma cells
(Hatzi et al. 2000) Aortic smooth 
muscles
Activates second messenger pathways and inhibits proliferation 
of the aortic smooth muscle cells.
(H uetal. 2000) HUVECs Nuclear translocation of angiogenin suggests a possible role in 
gene expression by direct binding to DNA.
(Hartmann et al. 1999) Melanocytes Up-regulation of angiogenin expression in malignant melanoma 
by hypoxia. The expression is associated with metastatic 
potential of the melanoma.
(Lee et al. 1999) Ovary Involved in the morphological changes in the ovary during the 
endometrial cycle. There is decreased level of angiogenin 
expression during regression.
(Malamitsi-Puchner Organs affected by Proliferative lesions in various organs. Levels of angiogenin vary
et al. 1998) IDDM with gender and not age. Increased levels are found in women 
than in men.
(Kolben et al. 1997) Pregnancy In normal pregnant women, increased levels of angiogenin 
reflect a persisting placental transformation and remodelling 
processes. In patients with highly pathological Doppler flow 
findings, these processes are disturbed and thus the placental 
function is disrupted.
(Ozaki et al. 1996) Eyes Elevated levels of angiogenin reflect a breakdown of the blood- 
ocular barrier in the eyes and causes proliferative diabetic 
retinopathy.
(Hosaka et al. 1995) Synovial fluid ELISA and Immunohistochemical studies reveal that the 
expression levels of angiogenin are not upregulated. Hence, 
angiogenin possibly has a role to play in the physiology of 
normal synovium.
(H uetal. 1994) Endothelial cells Enhances ECs to digest the ECM components and degrade the 
basement membrane and positively induces the process of neo- 
vascularisation.
(Soncin et al. 1994) Metastasis Angiogenin acts as an effective substrate for tumour cell 
adhesion during metastasis.
(Hu & Riordan 1993) Cell surface actin Angiogenin binds and displaces the cell surface actin during cell 
migration and tumour invasiveness.
(Soncin. 1992) ECs and fibroblasts Angiogenin acts as an effective substratum for cell adhesion and 
is critical in the process of angiogensis.
(Xiao et al. 1989) Aortic smooth 
muscle cells
Depresses aortic smooth muscle cell cAMP by pertussis toxin 
sensitive mechanism and hence provides evidence for interaction 
between cellular signalling pathways.
(Bicknell & Vallee 1989) Phospholipase-A2 Activates phospholipase-A2 and stimulates EC prostacyclin 
secretion. This suggests mechanisms of agonist-induced 
intracellular arachidonate mobilisation and relevance to 
angiogenesis.
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inhibitors, which can be used to modulate the 
activity of angiogenin in vivo (Chen & Shapiro 1997, 
Papageorgiou et al. 1997, Leonidas et al. 1999).
5. Involvement of the heparan sulphate 
proteoglycans in angiogenesis and metastasis
Proteoglycans are negatively charged polysaccha­
ride chains com posed of repeating disaccharide 
units, attached to a core protein (Lindahl et al. 1994). 
Proteoglycans are found in almost all cell types. The 
wide spectrum of their biological functions ranges from 
being a purely mechanical support molecule to the one 
with complex cellular functions such as adhesion, 
proliferation and differentiation. These biological 
effects are due to the ability of these molecules to act as 
receptors for a wide range of molecules. One group of 
proteoglycans known as the Heparan Sulphate 
Proteoglycans or HSPGs is involved in both 
physiological as well as pathological angiogenesis.
The biological functions of HSPGs are due to 
their ability to bind to different kinds of angiogenic 
molecules including growth factors, extracellular 
matrix proteins, and protease inhibitors (Lindahl 
et al. 1994). Some of the angiogenesis related HSPG 
binding molecules are:
• Fibroblast Growth Factors
• Vascular Endothelial Growth Factor
• Placenta Growth Factor
• Heparin-binding Epidermal Growth Factor
• Hepatocyte Growth Factor




• Macrophage Inflammatory Protein
• Interferon-y inducible protein-1
• HIV-Tat transactivating factor
• Platelet-Derived Growth Factor
• Plieotropin
The interaction of HSPGs with the molecules 
depends on distinct structural features. These 
interactions depend mainly on the size of the 
polysaccharide chain and on the degree and 
distribution of the sulphate groups (table 6, 
Maccarana 1993). HSPG binding does not depend 
solely on the sulphate groups. For example Ishihara 
et al. (1994) show ed that the carboxyl group of 
heparin is important for FGF-2 interaction. The 
interaction also depends on the biochemical 
properties of the protein. The HSPG binding 
regions on most proteins have been identified as a 
cluster of basic amino acids (Zhang et al. 1991, Zhu 
et al. 1990, Eriksson et al. 1991).
The binding of these growth factors to the ECM 
associated HSPGs is in the range of 5-50 nM. These 
growth factors usually accumulate in the HSPGs of 
ECM and the endothelial cell surface indicating that 
the HSPGs act as a physiological sink for these 
growth factors. Different mechanisms (both 
enzymatic and non-enzymatic) mobilise the ECM- 
stored growth factors. Some of the enzym es 
involved are plasmin (a serine protease), heparitin- 
ase, heparinase, heparanase, phospholipase C and the 
non-enzymatic free glycosaminoglycans.
HSPGs mediate the binding of these growth  
factors to their respective tyrosine kinase receptors 
(Mustonen & Alitalo 1995). There exists a contro­
versy about the absolute requirement of HSPGs for 
the interaction o f the growth factors w ith  their 
receptors. One group reported that heparin  
deficient CHO cells transfected with the FGFR-1 do 
not bind to FGF in the absence of heparin. On the 
other hand, another group showed that FGFR-1 
expressed in the CHO cell mutants retain their 
ability to bind to FGF even when heparin is not 
present (Yayon et al. 1991, Roghani et al. 1994). 
Recent solution experim ents have show n that
Table 6 The different sulphate groups on HSPGs
Angiogenic molecules The important sulphate groups
FGF-2 2-0- and N-sulphate groups (Macarena, 1993)
FGF-1 and FGF-4 2-0- and 6-O-sulphate groups (Grimond et al. 1993)
HGF 6-O-sulphate groups of GlcNS03 (Lyon & Gallagher, 1994)
HIV-Tat Protein 2-0- and 6-0- and N-sulphate groups (Rusnati et al. 1994)
Interleukin-8 6-O-desulphated heparin, N-desulphated/N-acetylated heparin (Rusnati et al. 1994)
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h e p a r i n  a l t h o u g h  i s  n o t  a b s o l u t e l y  n e c e s s a r y  f o r  t h e  
f o r m a t i o n  o f  t h e  r e c e p t o r - l i g a n d  c o m p l e x ,  i t  d o e s  
e n h a n c e  t h e  b i n d i n g  o f  F G F R  t o  F G F - 2  ( R u s n a t i  
e t  a l .  1 9 9 4 ) .  W h a t  i s  c o m m o n  a b o u t  t h e  t e r n a r y  
i n t e r a c t i o n  a m o n g  t h e  H S P G s ,  g r o w t h  f a c t o r s  a n d  
t h e  r e c e p t o r s  i s  t h e  l i g a n d - i n d u c e d  r e c e p t o r  
d i m e r i s a t i o n  f o r  a c t i v a t i n g  t h e  t y r o s i n e  k i n a s e  
r e c e p t o r s  t h a t  i s  r e q u i r e d  t o  i n d u c e  a  m i t o g e n i c  
r e s p o n s e  ( R u o s l a h t i  &  Y a m a g u c h i  1 9 9 1 ,  V l o d a v s k y  
e t  a l .  1 9 9 1 ) .  T h e  s t o r a g e  o f  t h e  H S P G s  i n  t h e  E C M  
i n c r e a s e s  t h e  l o c a l  c o n c e n t r a t i o n  o f  t h e  g r o w t h  
f a c t o r s  a n d  h e n c e  a  d e c r e a s e  i n  t h e  r a d i i  o f  
d i f f u s i o n .  T h i s  f a v o u r s  l i g a n d  o l i g o m e r i s a t i o n ,  
r e c e p t o r  i n t e r a c t i o n  a n d  t h u s  s i g n a l l i n g  ( f i g u r e  2 1 ) .
M o l e c u l e s  t h a t  b i n d  t o  a n  a n g i o g e n i c  g r o w t h  
f a c t o r  t h a t  w i l l  i n t e r f e r e  w i t h  t h e  l a t t e r  i n t e r a c t i n g  
w i t h  E C M  a s s o c i a t e d  p r o t e o g l y c a n s  a r e  p o t e n t i a l  
c o m p o u n d s  ( t a b l e  7 )  w i t h  a n g i o s t a t i c  a c t i v i t y .  
T h e s e  m o l e c u l e s  f a l l  i n t o  t w o  c a t e g o r i e s :
•  M o l e c u l e s  t h a t  c o m p e t e  w i t h  t h e  h e p a r i n -  
b i n d i n g  g r o w t h  f a c t o r s  f o r  H S P G  i n t e r a c t i o n  
( e g .  p o l y c a t i o n i c  c o m p o u n d s ) .
•  M o l e c u l e s  t h a t  c o m p e t e  w i t h  t h e  H S P G s  f o r  
g r o w t h  f a c t o r  b i n d i n g  i n t e r a c t i o n  ( e g .  
p o l y a n i o n i c  c o m p o u n d s ) .
A ternary  com plex o f  ligand 
recep to r and HSPG Ccll-surface receptor
Ligand
Signal transduction
Figure 21 Role of HSPGs in ligand-induced receptor 
dimerisation and thus cell signalling
6. Role o f Proteases and Protease Inhibitors 
in A ngiogenesis
C o n t r o l l e d  d e g r a d a t i o n  o f  e x t r a c e l l u l a r  m a t r i x  
(E C M )  i s  e s s e n t i a l  i n  m a n y  p h y s i o l o g i c a l  p r o c e s s e s  
i n c l u d i n g  d e v e l o p m e n t a l  t i s s u e  r e m o d e l l i n g ,  
a n g i o g e n e s i s ,  t i s s u e  r e p a ir ,  a n d  n o r m a l  t u r n  o v e r  o f  
t h e  E C M . O n e  o f  t h e  i m p o r t a n t  s t e p s  in  a n g i o g e n e s i s  
i s  t h e  l o c a l  p r o t e o l y s i s  o f  t h e  b a s e m e n t  m e m b r a n e .  
L o c a l  p r o t e o l y s i s  i s  f a c i l i t a t e d  b y  p r o t e a s e s  o u t s i d e  
t h e  e n d o t h e l i a l  c e l l  o r  p e r h a p s  b o u n d  t o  t h e  c e l l  
s u r f a c e  a n d / o r  s e c r e t e d  b y  t h e  c e l l  i t s e l f .  
E x t r a c e l l u l a r  p r o t e a s e s  c o o p e r a t i v e l y  i n f l u e n c e  
m a t r i x  d e g r a d a t i o n  a n d  i n v a s i o n  o f  c e l l s  t h r o u g h  
p r o t e o l y t i c  c a s c a d e s  ( f i g u r e  2 2 ) .  E v e r y  i n d i v i d u a l  
p r o t e a s e  h a s  a  d i s t i n c t  r o l e  t o  p l a y  i n  a n g i o g e n e s i s  
a n d  a l s o  i n  t u m o u r - i n d u c e d  g r o w t h ,  i n v a s i o n  a n d
P r o c a th e p s m  B
C a th e p s in s  D , G
P r o - L i  I A
C a th e p s in  B
H eparan sulphate 
proteoglycans (H SPG s)
P la s m in o g e n
V P la s m in
D e g r a d a t io n  o f  E C M  
c o m p o n e n ts  l ik e  t h e  
f i b r in ,  f i b r o n e c t in ,  
l a m in in  e tc .
A c t i v a t i o n  o f  
M M P - 1 ,  M M P - 3 ,  
M M P - 9 ,  M M P 1 2 ,  
M M P - 1 3
Figure 22 An example of a proteolytic cascade
Table 7 Some o f the known inhibitors o f HSPGs
Inhibitors M echanism  of action
Protamine Compete with the heparin-binding growth factors for HSPG interaction
Chemokines Compete with the heparin-binding growth factors for HSPG interaction
Tecogalan sodium Compete with the heparin-binding growth factors for HSPG interaction
Alpha-2 Macroglobulin Compete with the HSPGs for growth factor binding interaction
Suramin and its derivatives Compete with the HSPGs for growth factor binding interaction
Pentosan polysulphate Compete with the HSPGs for growth factor and receptor binding interaction
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metastasis. Endopeptidases are classified into five 
major categories:
♦ Cysteine proteases: cathepsins B, L, K, Q, S;
caspases; bleomycin 
hydrolases.
♦ Aspartic proteases: cathepsins D and E.
♦ Serine proteases: plasmin, urokinase-
type plasminogen  
activator.
♦ Threonine proteases: proteasome.
♦ Metallo proteases: gelatinases A  and B.
Proteases are norm ally synthesised  as latent 
forms known as zym ogens that must be converted 
to their active, mature forms. This conversion m ay 
occur via other enzym es or autocatalytically. It is 
hypothesised that the proteases interact w ith each 
other resulting in the activation o f other proteases 
that then co llec tiv e ly  degrade all the ECM 
com ponents. For exam ple, the activation  o f  
Procathepsin  B by tPA is th ought to in itia te  a 
proteolytic cascade w hereby the end product of  
each degradation  acts as an en zym e for the  
conversion of another latent form o f a protease into 
its m ature active enzym e. O verexpression  and  
activation  o f  one protease m ay p rovid e a 
proteolytically active environment for the onset of  
local proteolysis o f the basement membrane during 
angiogenesis. Cathepsin B w as the first lysosom al 
protease that was associated with breast carcinoma.
Degradation o f the extracellular matrix is also  
important for tum our cell invasion. Experiments 
have revealed that m ost proteases can degrade the 
ECM components both extracellularly at neutral pH  
under normal physiological conditions and at acidic 
pH  under pathological conditions (Griffiths 1991, 
Montcourrier et al. 1997, Baron 1989). Intracellular
degradation  o f  the ECM is also im portant for 
tum our cell invasion. Coopm an et al. (1996) have  
shown a correlation between the invasive ability of  
different cancer cell lin es and their ab ility  to  
phagocytose the ECM.
P roteases p lay  a role in cancer other than  
degradation o f the extracellular matrix. M asson et 
al. (1998) suggest that MMPs are involved in early 
alterations lead in g  to tum our form ation. M ice 
deficient in strom elysin-3 exhibit low er tum our 
in cid en ce and tum our size  after carcinogen  
treatment. Overexpression o f som e MMPs leads to 
developm ent o f pre-malignant and pre-neoplastic 
lesions (Sympson et al. 1995), suggesting that MMPs 
participate in different stages of tumour progression 
prior to invasion and metastasis (Wilson et al. 1997, 
M oser et al. 1990, Su et al. 1992). P roteases are 
believed to increase cell proliferation by activating 
grow th factors or liberating them  from the ECM 
w here they are sequestered. Growth factors like 
bFGF, EGF, IGF, TGF-|3 and VEGF are bound to  
ECM and can be released upon proteolysis o f the 
ECM com p on en ts (Taipale & K eski-Oja 1997, 
Whitelock et al. 1996). Noel et al. (1993) showed that 
the ability o f fibroblasts to promote tumourigenicity 
o f  MCF7 cells requires m atrigel contain ing low - 
molecular w eight factors. MMP inhibitors abolish  
the tum our prom oting effects o f the fibroblasts, 
suggesting that MMPs from the fibroblasts release 
growth factors from the matrigel. Proteases enhance 
the growth o f the tumours beyond 1-2 mm.
We now  know that proteases are important for 
the process o f  an g iogen esis and their increased  
expression, increased activity and altered localisa­
tion o f several proteases are associated with tumour 
progression. Depending upon the source or the cell 
type o f a cytokine, they can act as both inducers and
Table 8 Matrix Metallo Proteinases and their receptors 
MMPs Substrates
Colagenase -1 (MMP-1), An interstitial collagenase IGFBP-2, IGFBP-3, IL-lb and TNF-a
Gelatinase A (MMP-2), type-IVcollagenase FGFR1, IGFBP-3, IGFBP-5, IL-lb, TNF-a, TGF-bl, and MCP-3
Stromelysin-1 (MMP-3), proteoglycanase HB-EGF, IGFBP-3, IL-lb and TNF-a
Matrilysin (MMP-7) TNF-a
Gelatinase B (MMP-9), type-V collagenase IL-lb, IL-8, PF-4, TGF-bl and TNF-a
Stromelysin -3 (MMP-11) IGFBP-1
Metalloelastase (MMP-12), a macrophage elastase TNF-a
MT1-MMP (MMP-14) TNF-a
MT2-MMP (MMP-15) TNF-a
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as inhibitors o f MMP expression (table 8). Both in 
vitro and in vivo studies have show n that protease 
inh ib itors reduce tum ourigenicity . The w id e  
expanse o f  k n ow led ge gained  so far still leaves  
several key q u estion s unansw ered . A n a lysis  o f  
multiple proteases in a single m odel system  w ould  
further enhance the elucidation o f the function o f 
proteases both in normal physiological conditions 
and in tum our environm ent. This w ill help in the 
d esign  o f  better protease-based  drugs and  
inhibitors to combat malignancy.
7. Involvement of environmental factors in 
the process of angiogenesis
The location and the ability to synthesise various 
vasoactive  m ediators m ake the vascu lar en d o ­
thelium  a key com ponent in the m aintenance o f  
vascular homeostasis. Physiology of angiogenesis is 
constrained by the need for various environ-mental 
factors that affect vascular functions by disturbing 
the vascular endothelium. Some of these factors that 
contribute to the process of angiogenesis have been 
discussed below:
7.1. Hypoxia
E ndothelia l ce lls have to cope w ith  all changes  
occurring w ithin the blood as they are the first cell 
layer in contact w ith  the b lood . One o f  these  
changes is the variation  in the oxygen  tension . 
Hypoxia directly regulates the expression of several 
gen es, activates ECs and in itia tes a series o f  
reactions. One o f the m ost spectacular effects o f  
hypoxia  on en dothelia l cells is to increase their 
a d h esiven ess for neutrophils (Ginis et al. 1993, 
M ilhoan et al. 1992, A rnould et al. 1993). N eutro­
p h ils  not on ly  adhere both in vitro and in vivo 
(Baudry et al. 1998) but are also activated w hen in 
contact w ith  h yp oxic  HUVECs (A rnould et al. 
1994). On the other hand, hypoxia has been shown  
to decrease free radical production and cytokine 
syn th esis by neutrophils in response to various 
stim u li (D erevianko et al. 1996). The contact o f  
neutrophils w ith activated endothelial cells delays 
ap op tosis, thereby p ro lon g in g  their u sefu l life  
(Ginis & Faller 1997). H ypoxia can also initiate all 
stages of recruitment and activation o f neutrophils 
in ischemic organs.
ECs display a marked increase in pro-coagulant 
activity when subjected to hypoxia for more than 24
hours (Gertler et al. 1991). This correlates w ith  a 
marked decrease o f thrombomodulin expression at 
the surface o f endothelial cells (Ogawa et al. 1990). 
The exp ression  o f  tissu e  factor and o f  som e  
cytokines like interleukin-6 (IL-6), interleukin-la  
(IL -la ), in terleukin-8 (IL-8) and MCP-1 is also  
enhanced under hypoxic conditions (Yan et al. 1995, 
Karakurum et al. 1994). The production o f these  
pro-inflammatory cytokines m ay perhaps explain  
the developm ent o f an inflam m atory response in 
ischemic tissues.
Both vasorelaxing and vasoconstricting agents 
release ECs to regulate the vascular tone under  
norm al con d ition s (Chien et al. 1998). H ypoxia  
favours vasocon striction  (K ourem banas & 
B ernfield  1994). In contrast, hyp ox ia  gen era lly  
enhances the release o f  en dothelin -1  (ET-1) by  
en d oth elia l ce lls in vitro but th is d ep en d s on  
experim ental con d ition s since, in tw o  cases, a 
decrease has been reported (Gertler & Ocasio 1993, 
Kourembanas et al. 1991, Markewitz et al. 1995). In 
vivo, an increase in ET-1 circulating level is also  
observed and this is correlated with an induction of 
ET-1 gene transcription in lungs (Aversa et al. 1997).
Short-term hypoxic endothelial cell-conditioned 
medium induces the proliferation of smooth muscle 
cells (SMCs). In addition, hypoxia  increases the 
release o f  grow th  factors by stim u la tin g  the  
production o f som e ECM proteins, such as TSP-1 in 
hum an en d oth elia l ce lls  (Phelan et al. 1998). 
K ourem banas’ laboratory su g g est that the  
proliferative response is regulated by a negative  
feed back loop m ediated through sm ooth m uscle 
cell-derived CO. Hypoxic SMCs release CO which  
decreases the transcription o f PDGF-BB and ET-1 
by increasing the c-GMP content o f the ECs. This 
cascade even tu a lly  inh ib its sm ooth  m uscle  cell 
proliferation  in itia ted  by h yp ox ia  (M orita & 
Kourembanas 1995).
E ndothelia l cell p roliferation  itse lf  is  also  
affected by hypoxia. The m ost potent and specific 
m itogen  for the en d oth elia l ce lls is VEGF. It is 
know n to initiate angiogenesis in vivo (Ferrara & 
Davis-Smyth 1997). Its expression is upregulated by 
h yp oxia  in num erous cell ty p es in clu d in g  
endothelial cells (Liu et al. 1995, M ukhopadhyay et 
al. 1995b). H ypoxia functionally up-regulates the 
m itogenic response inducing  receptor o f  VEGF,
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n a m e l y  V E G F R - 2  o r  k i n a s e - i n s e r t  d o m a i n  r e c e p t o r  
( K D R )  ( G e r b e r  e t a l .  1 9 9 7 ,  W a l t e n b e r g e r  e t a l .  1 9 9 6 ) .
T h e  r e l e a s e  o f  a l l  t h e s e  c y t o k i n e s  a n d  g r o w t h  
f a c t o r s  b y  c e l l s  l i k e  t h e  e n d o t h e l i a l  c e l l s  i s  g e n e r a l l y  
t h e  r e s u l t  o f  a  c o m p l e x  c a s c a d e  o f  p r o c e s s e s  t h a t  
e n d s  w i t h  t h e  a c t i v a t i o n  o f  t r a n s c r i p t i o n  f a c t o r s .  T h e  
p r o t o t y p e  o f  a l l  t r a n s c r i p t i o n  f a c t o r s  r e g u l a t e d  b y  
h y p o x i a  i s  t h e  h y p o x i a  i n d u c i b l e  f a c t o r - 1 ( H I F - 1 ) .  
H I F - 1  i s  a  h e t e r o d i m e r  c o m p o s e d  o f  t h e  t w o  
s u b u n i t s ,  H I F - l a  a n d  H I F - 1 '  o r  A R N T  ( a r y l /  
h y d r o c a r b o n  r e c e p t o r  n u c l e a r  t r a n s l o c a t o r ) ,  t h e  f i r s t  
b e i n g  u p r e g u l a t e d  b y  h y p o x i a  ( f i g u r e  2 3 ;  W a n g  &  
S e m e n z a  1 9 9 3 a ,  G u i l l e m i n  &  K r a s n o w  1 9 9 7 ,  
O ’R o u r k e  e t  a l .  1 9 9 7 ) .
N O R M O X IA
(n o rm a l o x y g en  level)
A  r e c e n t  o b s e r v a t i o n  s t a t e s  t h e  p r e s e n c e  o f  H I F -1  
b i n d i n g  s i t e s  in  t h e  5' o r  3' f l a n k i n g  r e g i o n s  o f  t h e  g e n e s  
t h a t  e n c o d e  e r y t h r o p o i e t i n ,  V E G F  ( L iu  e t  a l .  1 9 9 5 ) ,  
V E G F  r e c e p t o r ,  F i t - 1 ( G e r b e r  e t  a l .  1 9 9 7 ) ,  g l u c o s e  
t r a n s p o r t e r ,  G lu t - 1  ( B e h r o o z  &  I s m a i l - B e i g i  1 9 9 7 )  a n d  
s e v e r a l  g l y c o l y t i c  e n z y m e s  ( S e m e n z a  e t  a l .  1 9 9 4 ) .  
H o w e v e r ,  t h e  h y p o x i a - d e p e n d e n t  i n c r e a s e  o f  V E G F  
e x p r e s s i o n  s e e m s  t o  b e  c o n t r o l l e d  b o t h  a t  t h e  
t r a n s c r ip t io n a l  l e v e l  a n d  a t  t h e  l e v e l  o f  m R N A  s t a b i l i t y  
( I k e d a  e t  a l .  1 9 9 5 , S h i m a  e t  a l .1 9 9 5 ) .  H y p o x i a  s t r o n g l y  
a f f e c t s  t h e  r e g u l a t o r y  p a t h w a y s  o f  E C s  a s  w e l l  a s  o f  
S M C s ,  r e s u l t i n g  i n  t h e  f o r m a t i o n  o f  c o n d i t i o n s  
f a v o u r a b le  t o  v a s o c o n s t r i c t io n  a n d  p r o l i f e r a t iv e  a c t iv ity ,  
p a r t i c ip a t in g  in  t h e  r e m o d e l l i n g  o f  t h e  v a s c u l a r  w a l l .
H Y P O X IA
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Figure 23 A schematic representation of HIF-a induced signal transduction under normal and low oxygen levels
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When chronic hypoxic conditions persist, the 
expression o f growth factors, cytokines and pro­
coagulation m olecules is increased which gives 
rise to several pathological conditions. Some of 
these conditions are:
♦ Blood stasis, a situation commonly associated with 
chronic venous insufficiency (Michiels et al. 1996).
♦ Second, adaptation to hypoxia represents a 
key step in tumor progression. On the one 
hand, these conditions induce the activation of 
HIF-1 allow ing the cells to survive via an 
adaptive m odification o f their energetic 
metabolism. On the other hand, HIF-1 is 
involved in the establishment of vascular supply. 
Neoangiogenesis is triggered off by growth  
factors released by the tumour which itself is 
becoming hypoxic while enlarging (Semenza 
1998a, Zhong et al. 1999, Dachs et al. 1997).
♦ Pulmonary hypertension is a frequent 
hemodynamic complication associated with  
respiratory system disorders. A short exposure 
of the pulmonary circulation to a reduced level 
of oxygen tension both in vitro  and in v ivo  
elicits an immediate vasoconstrictive response 
probably through potassium channel inhibition 
in smooth muscle cells (Vender 1994, Ward & 
Robertson 1995).
Analysis of erythropoietin gene regulation uncover­
ed a general mechanism of cellular oxygen sensing 
and transcriptional control. Transiently transfected 
reporter genes linked to the erythropoietin  
enhancer showed similar hypoxia-inducible activity 
in both the hepatoma cells and a w ide variety of 
non-erythropoietin-producing cells, suggesting that 
many other HIF-1-responsive genes might exist 
(Wang & Semenza 1993b).
HIF-1"/ARNT-deficient tumour cells show  
reduced vascularity, and provide strong evidence 
linking erythropoietin regulation, through HIF-1, 
to hypoxia and tumour angiogenesis (Ratcliffe et al.
1998). At cellular level, cooperative effects amongst 
factors necessary for transcriptional activation of 
erythropoietin gene by HIF-1 lead to a pattern of 
inducible expression. There is a rapid nuclear 
accumulation of HIF-la during hypoxia (Wang et 
al. 1995, Huang et al. 1996), which upon re- 
oxygenation declines just as quickly (half-life of ~5 
minutes) in normoxic cells.
Hypoxic conditions induce a well-characterised 
battery of genes that help the cells cope with low  
oxygen concentrations (Semenza et al. 1998b,
Tacchini et al. 1999, Guillemin & Krasnow 1997). 
Transcriptional upregulation has been shown to play 
a major role in the hypoxic induction of these genes, 
and action mediated by the specific binding of HIF-1 
to the hypoxic response element (HRE). HIF-la and 
HIF-1 "are both constitutively expressed and do not 
seem to be significantly m odified by hypoxia. 
However, while the HIF-1" protein is found in 
normoxic cells, nearly no H IF-la can be detected 
under these conditions. Knockout studies show that 
tumour cells deficient in HIF-1 a  as well as in HIF-1' 
grow slower than tumours derived from control 
tumour cells and also show  reduced levels of 
vascularisation (Ryan etal. 1998, Adelman etal. 1999).
The molecular mechanism by which cells sense 
low-oxygen concentration and induce HIF-la is still 
largely unknown. The ability of endothelial cells 
(EC) to not only sense, but also to adapt to, acute 
and chronic changes in p02 is critical to maintaining 
endothelial metabolic functions and, in turn, to 
maintaining homeostasis. Although the involve­
ment of hypoxia in several pathological conditions 
becomes clearer, it is still not known what level of 
oxygen tension will render the alterations of the 
tissue irreversible.
7.2. Nitric Oxide
Nitric oxide (NO) is an important m olecule in 
regulating tumour blood flow  and stimulating 
tumour angiogenesis. Inhibition of NO synthase 
induces an anti-tumour effect by limiting nutrients 
and oxygen to reach tumour tissue and thus affecting 
vascular growth (de Wilt et al. 2000). NO is both anti- 
angiogenic as well a pro-angiogenic in different 
models of in vivo  angiogenesis. The role of NO in 
angiogenesis-m ediated processes using the NO 
donor, S-nitroso N-acetyl penicillamine (SNAP) and 
S-nitroso N-acetyl glutathione (SNAG) have been 
studied. The in vitro studies demonstrated the ability 
of SNAP to inhibit cytokine fibroblast growth factor 
(FGF2)-stimulated tube formation and serum- 
induced cell proliferation. The inhibitory effect on 
cell proliferation by SNAP concentrations above the 
mM range was associated with significant shifts in 
the concentration of NO metabolites. Furthermore, 
using the mouse matrigel implant model and the 
CAM models, SNAP induced 85-95% inhibition of 
neovascularisation induced by FGF2 in both
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in vivo  models (Powell et al. 2000). Endothelium- 
derived nitric oxide (EDNO) plays an important 
role in the regulation o f angiogenesis, whereas 
hypercholesterolemia (HC) impairs EDNO release. 
Studies in a rat model of unilateral hindlimb ischemia 
show ed that the collateral vessel formation and 
angiogenesis in response to hindlimb ischemia were 
significantly attenuated in rats with dietary HC, 
possibly through decreased NO bioactivity. 
Augmentation of the tissue NO activity by oral L- 
arginine supplementation restored the impaired 
angiogenesis in HC, accompanied by improved  
NO /cG M P production (Duan et al. 2000). 
Therefore, a possible therapeutic approach to treat 
patients with peripheral arterial occlusive diseases 
would be to augment endogenous NO bioactivity 
(Duan etal. 2000).
Nitric oxide (NO) is a messenger molecule that 
regulates many physiological functions like 
immunity, vascular tone and serves as a 
neurotransmitter. Experiments on rats with trans- 
dermal wounds treated with Sodium Nitroprusside 
(SNP)/L-arginine showed a decrease in the wound 
collagen content. On the other hand, application of 
N-Nitro-L-arginine methyl ester (L-NAME), a 
competitive inhibitor of NO synthase, resulted in 
an increase in the wound collagen content. The 
results indicate that NO plays an important role in 
regulating the collagen biosynthesis in skin model of 
a healing wound (Shukla et al. 1999).
NO has a multi-factorial role to play in tumori- 
genesis. NO mediates DNA damage in early phases 
of tum origenesis and also augm ents tumour 
progression via angiogenesis and suppression of 
the immune response. NO decreases the ability of 
the hypoxic enhancer to bind to HIF-1 and thus 
suppresses VEGF by via a cyclic GMP-mediated 
signal pathway (Liu et al. 1998).
Nitric oxide, unlike most of the other regulators 
of angiogenesis, has been shown to possess both 
anti- and pro-angiogenic properties. Most 
experiments performed so far indicate that the pro- 
angiogenic effects o f NO are due to the NO  
produced through the constitutive NO synthase 
(cNOS) and is cyclic GMP dependent. On the other 
hand the NO produced via the inducible NO synthase 
(iNOS) is mainly involved in the anti-angiogenic 
effects. In the CAM, NO donors have been shown to 
inhibit basal angiogenesis and the NOS inhibitors to
promote the process (Pipili-Synetos et al. 1995). 
Increased iNOS expression, iNOS activity, and NO 
production are a means of providing an endogenous 
brake on the process of blood vessel formation.
7.3. Copper
Preclinical and in vitro studies have determined that 
copper is an important cofactor for angiogenesis. 
Copper stim ulates proliferation o f human  
endothelial cells under culture. Incubation o f  
HUVECs for 48 hours w ith 500 jjiM C u S 04 in a 
serum-free medium, in the absence of exogenous 
growth factors, results in a two fold increase in cell 
number. This is similar to the cell number increase 
induced by 20 n g /m l of basic fibroblast growth  
factor under the same conditions (Hu 1998). Serum 
copper and zinc concentrations and copper/zinc  
ratios have been shown to increase in several types 
o f human m alignancies. Yoshida et al. (1993) 
showed that the tissue copper concentrations are 
significantly higher in metastatic carcinomas and 
malignant gliomas than control tissues.
Metallothionein (MT) is an intracellular storage 
m olecule for metal ions such as zinc (Zn++) and 
copper (Cu++). Cerebral neoplasm s sequester  
copper to modulate angiogenesis. Brem et al. (1990) 
have demonstrated regional differences in the 
responsiveness of the endothelium, the distribution 
of copper, and the activity of cuproenzymes. They 
showed that the metabolic and pharmacological 
withdrawal o f copper suppresses intracerebral 
tumour angiogenesis. This finding suggests that 
pharmacological and metabolic alteration of the 
cellular microenvironment to inhibit invasiveness 
represents a novel therapeutic approach, especially 
for tumours of the brain in which malignancy is a 
function of regional invasiveness.
Raju et al. (1982) tested the ability o f cerulo­
plasmin, the copper carrier of serum, for its ability 
to induce new capillary formation in the cornea. The 
molecules chosen were fragments o f the cerulo­
plasmin molecule with and without copper, heparin 
and glycyl-L-histidyl-L-lysine (bound or not bound 
to copper ions). All the three molecules were able to 
induce angiogenesis provided that they were bound 
to copper. Fragments of the ceruloplasmin molecule 
also induced angiogenesis but only when copper 
was bound to the peptides. It was interpreted that 
m obilisation o f copper ions is involved in the
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sequence of events leading to angiogenesis and that 
the carrier molecules may be o f quite a different 
nature.
7.4. Hypoglycaemia
Hypoglycaemia is yet another factor that modulates 
the process of blood vessel formation. It usually  
com es into play along w ith hypoxia. It reduces 
proliferation and increases apoptosis in wild-type 
(HIF-la+/+) embryonic stem (ES) cells. However, it is 
ineffective in ES cells with the genotype (HIF-lav ). 
Since H IF -la  forms a com plex w ith aryl- 
hydrocarbon-receptor nuclear translocator (ARNT), 
the latter is crucial in the response to hypoglycaemia. 
A decrease in the bio-availability of ARNT reduces 
the intensity of neovascularisation and consequently 
leads to defective angiogenesis in ARNT deficient 
embryos (Maltepe et al. 1997). In embryos with the 
normal genotype (H IF-la+/+), there occurs a 
situation when cells undergo nutrient deprivation 
during increase in tissue mass (organogenesis). This 
leads to an increase in the expression of VEGF that 
prom otes vascularisation o f the developing  
embryo. Favard et al. (1996) demonstrated that 
vascular endothelial growth factor expression is 
enhanced in vitro  by hypoxia and hypoglycemia; 
and its im m unoreactivity is increased in som e 
although some experiments later showed that VEGF 
expression does not increase in all diabetic patients. 
A decrease in its bio-availability reduces the 
intensity of neovascularisation.
7.5. pH
Among the various environmental factors affecting 
angiogenesis, pH is another independent variable 
that regulates the angiogenic process. Immuno­
histochemical studies reveal that in the regions 
surrounding the necrotic tissues, cells are exposed to 
acidic pH. Shi et al. (1999) show ed that acidosis 
along with hypoxia leads to overexpression of the 
cytokine IL-8 that in turn contributes to the 
aggressive biology of the human pancreatic cancer. 
Experimental studies by Hayashi et al. (2000) reveal 
that pH levels regulate the growth and metastasis of 
tumours. Macrophages secrete substances that 
stimulate angiogenesis and mitogenesis at wound 
sites. H igh lactate concentration and low  pH  
regulate the secretion o f angiogenesis factor or 
factors and change the expression of macrophage 
mitogens (Jensen et al. 1986). One of the most potent
stimuli for increased VEGF production is hypoxia. 
This teleologically sound response is conserved  
across a w ide variety o f cell and tumour lines, 
including osteoblasts. The increased VEGF 
production in response to hypoxia arises from a 
combination of pH and lactate expression. Effects of 
elevated hydrogen ion or lactate concentration on 
VEGF protein production are additive.
8. The Physiological Importance of Endogenous 
Modulators in Angiogenesis
Identification o f the molecular pathways of the 
angiogenic response has been a major focus o f  
interest in academia and industry. Although the full 
identification of players and their cross-talk is still at 
its infancy, it appears that partial blockade of one of 
the steps in the angiogenesis cascade, is sufficient to 
affect capillary morphogenesis. In addition to the 
generation of antibodies or chemical mimetics to 
interfere w ith particular steps during vascular 
organisation, several endogenous (or physiological) 
molecules have also been identified. The list of 
endogenous modulators of angiogenesis is growing 
and can offer additional and important tool for the 
generation o f therapies to restrain tumour 
vascularisation. This section of the review will focus 
on the major endogenous molecules that modulate 
the process of blood vessel formation.
8.1. Integrins
Integrins are a family of heterodimeric cell surface 
receptors, which mediate adhesion of cells to the 
ECM proteins and som etim es to other cells. 
Endothelial cells can express at least 5 or 6 different 
types of integrins (Luscinskas & Lawler 1994). Cell 
surface expression of integrins can be controlled by 
various growth factors, including, notably VEGF. 
They are regulated by the growth factors that are 
known to control the process. Integrins, especially 
the av integrins mediate those biological processes 
that are needed to organise a vasculature like 
adhesion, proliferation, migration and are express­
ed by cells that are involved in the process of vessel 
formation (Varner et al. 1995, Stromblad & Cheresh 
1996a, Hynes & Bader 1997)
The av integrins represent a sub-family of 
integrins that share a common av subunit in 
combination with one of the five B subunits (61,63,65, 
66 and 68). Endothelial cells can express at least avB3 
and avB5 and perhaps avBl as well since they do
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e x p r e s s  6 1 .  R e s t i n g  E C s  e x p r e s s  l i t t l e  o r  n o  a v 6 3 .  
H o w e v e r ,  t h i s  g e t s  m a r k e d l y  u p r e g u l a t e d  o n  v e s s e l s  
u n d e r g o i n g  a n g i o g e n e s i s  ( V a r n e r  e t  a l .  1 9 9 5 ,  
S t r o m b l a d  e t  a l .  1 9 9 6 b ,  B r o o k s  e t  a l .  1 9 9 5 ,  F r i e d l a n d e r  
e t  a l .  1 9 9 6 ) .  I n t e g r i n  a v B 3  h a s  b e e n  i m p l i c a t e d  in  t h e  
p a t h o p h y s i o l o g y  o f  m a l i g n a n t  t u m o u r s .  It i s  s u g g e s t e d  
t h a t  t h e  in t e r a c t io n  o f  t h e  c i r c u la t in g  t u m o u r  c e l l s  w i t h  
p l a t e l e t s  r e p r e s e n t  a  p o t e n t i a l  m e c h a n i s m  f o r  t u m o u r  
c e l l  a r r e s t  w i t h i n  t h e  v a s c u l a t u r e  ( f i g u r e  2 4 ) .  D u r i n g  
b l o o d  f l o w ,  d y n a m i c  f o r c e s  p h y s i c a l l y  o p p o s e  c e l l  
a t t a c h m e n t .  T h e r e f o r e ,  i n t e g r i n s  a r e  e s s e n t i a l  t o  
s u p p o r t  c e l l  a r r e s t .  F o r  e x a m p l e ,  i n t r a v a s c u l a r  
a t t a c h m e n t  o f  l e u k o c y t e s  a n d  p l a t e l e t s  d u r i n g  
i n f l a m m a t i o n  a n d  t h r o m b u s  f o r m a t i o n  i s  h i g h l y  
r e g u l a t e d  a n d  d e p e n d e n t  u p o n  i n t e g r i n  a c t i v a t i o n  
( D i a m o n d  & S p r i n g e r  1 9 9 4 , A l t i e r i  1 9 9 9 ) .
C h a r a c t e r i s a t i o n  o f  a n g i o g e n i c  f a c t o r s  h a s  
r e v e a l e d  t h a t  r e m o d e l l i n g  o f  t h e  E C M  o c c u r s  d u r i n g  
a n g i o g e n e s i s ,  m e d i a t e d  b y  in t e g r i n s  t h a t  a r e  f o u n d  o n  
t h e  e n d o t h e l i a l  c e l l  s u r f a c e  m e m b r a n e .  I n t e g r i n s  
f u n c t i o n  i n  c e l l - t o - c e l l  a n d  c e l l - t o - e x t r a c e l l u l a r  m a t r ix  
( E C M )  a d h e s i v e  i n t e r a c t i o n s  a n d  t r a n s d u c e  s i g n a l s  
f r o m  t h e  E C M  t o  t h e  c e l l  in t e r io r  a n d  v i c e  v e r s a .  S in c e  
t h e s e  p r o p e r t i e s  i m p l i c a t e  i n t e g r in  i n v o l v e m e n t  in  c e l l  
m i g r a t i o n ,  i n v a s i o n ,  i n t r a -  a n d  e x t r a v a s a t i o n ,  a n d  
p l a t e l e t  i n t e r a c t i o n .  T u m o u r  p r o g r e s s i o n  l e a d i n g  t o  
m e t a s t a s i s  a p p e a r s  t o  i n v o l v e  e q u i p p i n g  c a n c e r  c e l l s  
w i t h  t h e  a p p r o p r ia t e  a d h e s i v e  ( in te g r in )  p h e n o t y p e  fo r  
in t e r a c t i o n  w i t h  t h e  E C M .
I n t e g r i n  s u b u n i t s  c a n  h e t e r o d i m e r i s e i n  o v e r  2 0  
c o m b i n a t i o n s .  D i f f e r e n t  i n t e g r i n  c o m b i n a t i o n s  m a y  
r e c o g n i s e  a  s i n g l e  E C M  l i g a n d ,  w h i l e  o t h e r s  b i n d  
s e v e r a l  d i f f e r e n t  E C M  p r o t e i n s .  O f  t h e  w i d e  
s p e c t r u m  o f  i n t e g r i n  s u b u n i t  c o m b i n a t i o n s  t h a t  a r e  
e x p r e s s e d  o n  t h e  s u r f a c e  o f  c e l l s ,  a v B 3  h a s  b e e n  
i d e n t i f i e d  a s  h a v i n g  a n  e s p e c i a l l y  i n t e r e s t i n g  
e x p r e s s i o n  p a t t e r n  a m o n g  v a s c u l a r  c e l l s  d u r i n g  
a n g i o g e n e s i s  a n d  v a s c u l a r  r e m o d e l l i n g .  T h e  e x p r e s ­
s i o n  o f  a v B 3  o n  a c t i v a t e d  e n d o t h e l i a l  c e l l s  s u g g e s t s  
t h a t  t h i s  i n t e g r i n  m a y  h a v e  a n  i m p o r t a n t  f u n c t i o n  
d u r i n g  a n g i o g e n e s i s  a n d  p e r h a p s  d e v e l o p m e n t a l  
n e o v a s c u l a r i s a t i o n .  I n  t u m o u r  m o d e l s ,  i n h i b i t i o n  o f  
b l o o d  v e s s e l s  b y  a v  i n t e g r i n  a n t a g o n i s t s ,  n o t  o n l y  
b l o c k e d  t u m o u r - a s s o c i a t e d  a n g i o g e n e s i s  b u t  in  s o m e  
c a s e s  c a u s e d  t u m o u r  r e g r e s s i o n  a s  w e l l  (K e r r  e t  a l .
1 9 9 9 ) .  T h e  a b i l i t y  o f  s o m e  o r g a n s  t o  s u p p o r t  
n e o v a s c u l a r i s a t i o n ,  e v e n  i n  t h e  a b s e n c e  o f  a v  
i n t e g r i n s ,  m a y  p r o v i d e  a  c l u e  t o  s o m e  o f  t h e  a l t e r n a t e  
i n t e g r i n s  t h a t  m a y  m e d i a t e  v e s s e l  f o r m a t i o n .  T w o




Figure 24 Control of metastatic potential in human 
breast cancer via integrin activation
a n g i o g e n i c  p a t h w a y s  a r e  c h a r a c t e r i s e d  b y  d i s t i n c t  a v  
i n t e g r i n s ,  a v B 3  a n d  a v B 5 .  T h e  b i o l o g i c a l  r e l e v a n c e  o f  
t h e s e  d i s t i n c t  a n g i o g e n i c  p a t h w a y s  r e m a i n s  a  
c h a l l e n g e  b e c a u s e  t h e  t e m p o r a l  a n d  s p a t i a l  
c o o r d i n a t i o n  b e t w e e n  t h e  v a r i o u s  m o l e c u l a r  p l a y e r s  
s t i l l  n e e d s  t o  b e  a d d r e s s e d .
8.2. CD44
C D 4 4  i s  a  m u l t i - f u n c t i o n a l  a d h e s i o n  m o l e c u l e  
i n v o l v e d  i n  c e l l - t o - c e l l  a n d  c e l l  t o  e x t r a c e l l u l a r  m a t r ix  
i n t e r a c t i o n s ,  r e g u l a t i o n  o f  c e l l  t r a f f ic  a n d  t r a p p i n g  o f  
g r o w t h  f a c t o r s  a n d  c y t o k i n e s .  C D 4 4  f u n c t i o n s  a s  a  
g r o w t h  f a c t o r  p r e s e n t i n g  m o l e c u l e .  T h e  g r o w t h  
f a c t o r s  a n d  c y t o k i n e s  m o d i f y  t h e  e x p r e s s i o n  o f  
C D 4 4  i n  s u c h  a  w a y  t h a t  i t  r e s u l t s  i n  c h a n g e s  i n  t h e  
b i o l o g i c a l  p r o p e r t i e s  o f  t h e  c e l l s .  T h e s e  s e r v e  a s  b o t h  
s u p p r e s s o r s  a n d  p r o m o t e r s  i n  c a r c i n o g e n e s i s  a n d  
t h e  s u b s e q u e n t  p r o g r e s s i o n  o f  m a l i g n a n c y .  
H y a l u r o n i c  a c i d  i s  t h e  p r i n c i p a l  l i g a n d  o f  C D 4 4  
( U n d e r h i l l  1 9 9 2 ,  I o z z o  &  M u l l e r - G l a u s e r  1 9 8 5 ) .  I t  
h a s  b e e n  r e p o r t e d  t h a t  a  m a t r i x  r i c h  i n  t h i s  
c o m p o u n d  s u p p o r t s  t u m o u r  g r o w t h  a n d  i n v a s i o n .  
T h e  m o d i f i c a t i o n  o f  C D 4 4  in  b o t h  h o s t  a n d  t u m o u r  
c e l l s  i s  b e l i e v e d  t o  p l a y  a n  i m p o r t a n t  r o l e  i n  t u m o u r  
p r o g r e s s i o n .  T h e s e  s e r v e  a s  b o t h  p r o m o t e r s  a n d  
s u p p r e s s o r s  in  c a r c i n o g e n e s i s  a n d  t h e i r  p r o g r e s s i o n  
t o  m a l i g n a n c y .  G r o w t h  f a c t o r s  m o d i f y  C D 4 4  
e x p r e s s i o n  a n d  f u n c t i o n  ( t a b le  9 ) b y  e i t h e r  i n c r e a s i n g  
o r  d e c r e a s i n g  t h e i r  e x p r e s s i o n  o f  t h e  d i f f e r e n t  
i s o f o r m s  o f  C D 4 4  o r  a f f e c t i n g  t h e  g l y c o s y l a t i o n  
p a t h w a y s  o f  C D 4 4  ( K i n c a d e  e t  a l .  1 9 9 7 )  o r  b y
activation
a v 8 3
P la te le ts
M D A -M B  4 3 5  H u m a n  
B re a s t  C a n c e r  C e lls .
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inducing the activation o f the CD44 m olecules 
(Legras et al. 1997). These growth factors are 
produced in the process o f acute or chronic 
inflammation implying that tumour malignancy is 
enhanced to a great extent by inflammation. 
Experiments suggest that overexpression of CD44 
by tumour cells may be conducive to metastasis 
since CD44 is thought to support the formation of 
both hom otypic and heterotypic aggregates of 
tumour cells and blood cells.
8.3. Thrompospondin
Thrombospondin (TSP) occurs in two isoforms:
Thrombospondin-1 and Thrombospondin-2. TSP-1
Table 9 Different growth factors affecting CD44 in different types of target cells.
is a homotrimeric, matricellular, adhesive, 450 kDa 
glycoprotein. Thrombospondins regulate cellular 
phenotype during tissue genesis and repair. It 
facilitates the bringing together o f the ECM 
components, cytokines, growth factors, membrane 
receptors and extracellular proteases (Chen et al. 
2000). TSP facilitates smooth muscle cell prolifera­
tion and also suppresses capillary growth in 
angiogenesis assays (figure 25). TSP-1 is known to 
reduce tumour size in transgenic overexpressors 
(Iruela-Arispe et al. 1999). TSP-1 binds to several 
cell-surface receptors. The binding sites for these 
receptors on TSP-1 are dispersed throughout the 
molecule and most domains are known to bind
Growth factors Endothelial
cells
Tumour cells Other cell types Fibroblasts References




(Romaris et al. 1995) 
(Griffioen et al. 1997)
IFN-a (interferon-alpha) Renal cell 
carcinoma
(Hathom et al. 1994)
PDGF Human
neuroblastoma
(Fichter et al. 1997)





(Hamada et al. 1998) 
(Romaris et al. 1995)
IFN-% (interferon-gamma) Myelomonocytic
cell
(Mackay et al. 1994)
TNF-a Myelomonocytic
cell
(Mackay et al. 1994)
IL-2 Human renal 
cell carcinoma
(Hathom et al. 1994)
NGF (nerve growth factor) Human
neuroblastoma
(Fichter et al. 1997)
IGF-1 (insulin growth factor-1) Human
neuroblastoma





(Hiscox & Jiang, 1997)
EGF Mouse
fibroblast
(Zhang et al. 1997)
GM-CSF (Granulocyte, CD34+ human (Legras et al. 1997)
Macrophage-Colony hematopoietic
Stimulating Factor) progenitor cell.
IL-3 CD34+ human 
hematopoietic 
progenitor cell.
(Legras et al. 1997)
SCF (Stem Cell Factor) CD34+ human 
hematopoietic 
progenitor cell.
(Legras et al. 1997)
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more than one receptor. The anti-angiogenic domain 
of TSP-1 has been mapped to the type-I (properdin) 
repeat (Iruela-Arispe et all 999). A naturally occurr­
ing inhibitor of TSP-1 is the Histidine-rich glyco­
protein (HRGP), which co-localises with TSP-1 in 
such a way that the anti-angiogenic epitope of the 
molecule gets masked (Simantov et al. 2001).
Experiments done by Taraboletti et al. (2000) 
demonstrated that TSP-1 specifically promotes angio­
genesis in vivo but neutralises neo-vascularisation 
induced by fibroblast growth factor-2 (FGF-2). The 
molecule has dual behaviour due to the presence of 
domains with opposite functions that also differ in 
the ability to activate the degradative and invasive 
behaviour of the vascular endothelium. The pro- 
angiogenic effect o f TSP-1 is on account o f the 
25kDa heparin-binding fragment that is conversely 
counteracted by a 140kDa fragment. According the 
experiments conducted by this group this dual role 
of TSP-1 in angiogenesis most probably relies on the 
environmental set up whereby one or the other 
proteolytic fragment becom es available or 
functional and thus has different end-results.
Disruption studies with thrombospondin-2 
gene have shown that the TSP-2 null mice have a 
very complex phenotype characterised by a variety 
of connective tissue abnormalities and increased 












































Figure 25 An insight into the role of thrombospondins 
when overexpressed and underexpressed in the cells
tissues (Bornstein et al. 2000). It is believed that 
this phenotype is probably due to the non­
clearance o f MMP-2 in the extracellular matrix 
(ECM). Experiments have shown that the TSP-2/ 
MMP-2 com plexes are endocytosed  by Low- 
density Lipoprotein-receptor Related Protein  
(LRP). This helps in regulating the MMP-2 levels in 
the ECM (Yang et al. 2001).
Neovascularisation is a common feature of 
human cancers and associated with this phenotype is 
the decreased expression of TSP-1. The gene for TSP- 
1 (THBS-1) is regulated by p53, anoxia (Tenan et al. 
2000) and Rb. Methylation of the 5' CpG island of the 
THSB-1 gene leads to down-regulation o f its 
expression (Li et al. 1999). The unique cysteine- 
serine-valine-threonine-cysteine-glycine (CSVTCG) 
binding domain of TSP-1 also has an important role 
to play. Immunohistochemistry and computer image 
analysis have revealed that TSP-1 and its CSVTCG 
receptor have a decreased expression during foetal 
repair as cells migrate to the epithelial surface thereby 
suggesting that the receptor finds a role in 
keratinocytic maturation, differentiation and 
epithelial surface formation (Roth et al. 1999). Primary 
tumour cells sometimes produce high levels of TSP-1 
in order to prevent the progressive growth of smaller 
tumours. Volpert et al. (1998) verified this by showing 
that human fibrosarcoma line HT1080 induce 
concomitant resistance and held the experimental 
B16/F10 melanoma metastases in the lung of nude 
mouse in check by producing high levels of TSP-1.
TSP-1 interacts specifically with several cell- 
surface receptors, growth factors, ECM com po­
nents and heparan sulphate proteoglycans. This 
ability of TSP-1 to bind to several molecules and its 
ability to inhibit proteases suggests that exposure 
to TSP-1 probably initiates many intracellular 
signals and influences specific responses from  
different cell types. Integration of these molecular 
signals and interactions would lead to novel thera­
peutic strategies for controlling cancer progression 
and metastases (Roberts 1996). However, one likely 
drawback is that the therapeutic application of TSPs 
might potentially be associated with impaired wound 
vascularisation and tissue repair (Streit et al. 2000).
8.4. Angiopoietins
Angiopoietins are VEGF’s most important partners 
in vascular formation. The angiopoietins were
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d i s c o v e r e d  a s  l i g a n d s  f o r  t h e  T I E s ,  a  f a m i l y  o f  
t y r o s i n e  k i n a s e  r e c e p t o r s .  T h e s e  r e c e p t o r s ,  T I E -1  a n d  
T I E - 2 ,  a r e  e x p r e s s e d  w i t h i n  t h e  v a s c u l a r  e n d o ­
t h e l i u m  a s  w e l l  a s  s o m e  o t h e r  c e l l s  s u c h  a s  t h o s e  
i n v o l v e d  in  h a e m a t o p o i e s i s .  T h e  a n g i o p o i e t i n  f a m i l y  
c o n s i s t s  o f  f o u r  m e m b e r s  o f  w h i c h  o n l y  t w o  h a v e  
b e e n  w e l l  c h a r a c t e r i s e d ,  n a m e l y  A n g - 1  a n d  A n g - 2  
( f i g u r e  2 6 ) .  A l l  t h e s e  r e p r e s e n t  t h e  s p l i c e d  c o u n t e r ­
p a r t s  o f  t h e  s a m e  g e n e  ( M a i s o n p i e r r e  e t  a l .  1 9 9 7 ,  
V a l e n z u e l a  e t  a l .  1 9 9 9 ) .  T h e  p r i m a r y  r e c e p t o r  f o r  t h e s e  
l i g a n d s  i s  t h e  T I E - 2 .  I t  s t i l l  r e m a i n s  u n c l e a r  i f  T I E - 1 
h a s  i n d e p e n d e n t  l i g a n d s  o r  i f  t h e s e  c u r r e n t  a n g i o ­
p o i e t i n s  b i n d  t o  T I E -1  a s  a  s e c o n d  c o m p o n e n t  o f  a  
h e t e r o d i m e r  c o m p l e x  u n d e r  c e r t a i n  c o n d i t i o n s .  T h e  
a n g i o p o i e t i n s  i n f l u e n c e  a  v a r i e t y  o f  p a t h o p h y s i o l ­
o g i c a l  c o n d i t i o n s  ( f i g u r e  2 7 )
8.4.1. A n g io p o ie tin -1
E x p e r i m e n t s  w i t h  m i c e  e n g i n e e r e d  t o  l a c k  A n g - 1  
h a v e  s h o w n  t h a t  e m b r y o s  l a c k i n g  i n  e i t h e r  o r  
b o t h  o f  A n g - 1  a n d  T I E - 2  d e v e l o p  a  n o r m a l  
v a s c u l a t u r e .  H o w e v e r ,  t h i s  v a s c u l a t u r e  d o e s  n o t  
u n d e r g o  n o r m a l  r e m o d e l l i n g  ( S u r i  e t  a l .  1 9 9 6 ,  
D u m o n t  e t  a l .  1 9 9 4 ) .  T h e  h e a r t  s e e m s  t o  b e  t h e  
m o s t  a f f e c t e d  w i t h  f a i l u r e s  in  a s s o c i a t i o n  b e t w e e n  
t h e  e n d o c a r d i u m  a n d  t h e  m y o c a r d i u m .  T h e  
e n d o t h e l i a l  c e l l s  ( E C s )  i n  m a n y  v a s c u l a r  b e d s  d o  
n o t  i n t e g r a t e  p r o p e r l y  w i t h  t h e  u n d e r l y i n g  
s u p p o r t  c e l l s  t h a t  p r o v i d e  A n g - 1  t o  i t s  r e c e p t o r .  
A s  a  r e s u l t  t h e  v a s c u l a r  b e d s  c a n n o t  r e m o d e l  i n t o  
s m a l l  a n d  l a r g e  v e s s e l s  ( S u r i  e t  a l .  1 9 9 6 ) .  A n g - 1  
o p t i m i s e s  t h e  w a y  i n  w h i c h  t h e  E C s  a s s o c i a t e  w i t h  
t h e  s u p p o r t  c e l l s  s o  t h a t  t h e y  c a n  r e c e i v e  o t h e r  
i m p o r t a n t  s i g n a l s  f r o m  t h e  e n v i r o n m e n t  f o r  
v e s s e l  f o r m a t i o n  ( S u r i  e t  a l .  1 9 9 6 ,  f i g u r e  2 8 ) .
O v e r e x p r e s s i o n  o f  A n g - 1  i n  t r a n s g e n i c  m i c e  
r e s u l t s  i n  m a r k e d  i n c r e a s e  i n  v e s s e l  s i z e  u n l i k e  
V E G F  t h a t  i n c r e a s e s  t h e  v e s s e l  n u m b e r .  A n g - 1  
s t a b i l i s e s  t h e  v e s s e l  w a l l .  T h e y  l e a d  t o  v e s s e l s  
t h a t  a r e  r e s i s t a n t  t o  l e a k .  T h e s e  p r o p e r t i e s  o f  A n g -  
1 s u g g e s t  t h a t  A n g - 1 c o u n t e r s  t h e  e f f e c t  o f  V E G F  
o n  v a s c u l a r  f u n c t i o n  a n d  i n t e g r i t y  ( L a r c h e r  e t  a l .  
1 9 9 8 ,  T h u r s t o n  e t  a l .  1 9 9 9 ) .  D i s e a s e s  c h a r a c t e r i s e d  
b y  d a m a g e d  a n d  l e a k y  b l o o d  v e s s e l s  l i k e  d i a b e t i c  
r e t i n o p a t h y ,  o e d e m a  w o u l d  b e n e f i t  e n o r m o u s l y  
f r o m  t h e  A n g - 1  t h e r a p e u t i c  t r e a t m e n t .  T h i s  b e l i e f  
i s  s u p p o r t e d  b y  e x p e r i m e n t s  i n v o l v i n g  
a d e n o v i r a l  a d m i n i s t r a t i o n  o f  A n g - l t o  a d u l t  
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Figure 26 Schematic representation o f the role of 
Angiopoietin-1 during vessel formation
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Figure 27 Angiopoietin induced biological effects in different 
cells and tissues
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Figure 28 Schematic representation o f the role of 
Angiopoietin-2 during vessel formation
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8.4.2. A ngiopoietin -2
A n g - 2  i s  h o m o l o g o u s  t o  A n g - 1  a n d  c a n  b i n d  t o  T I E -2  
w i t h  s i m i l a r  a f f i n i t y  a s  A n g - 1. H o w e v e r ,  t h i s  A n g - 1 
h o m o l o g  d i f f e r s  f r o m  i t s  i s o f r o m  i n  i t s  a b i l i t y  t o  
e i t h e r  a c t i v a t e  o r  i n h i b i t / a n t a g o n i s e  T I E - 2  
d e p e n d i n g  u p o n  t h e  c e l l  o r  s o u r c e  o f  t h e  r e c e p t o r .  It  
i s  p r o p o s e d  t h a t  A n g - 2  a c t s  a s  a  d e s t a b i l i s i n g  s i g n a l  
t h a t  r e v e r t s  t h e  e n d o t h e l i a l  c e l l s  t o  a  m o r e  p l a s t i c  
a n d  t e n u o u s  s t a t e  ( M a i s o n p i e r r e  e t  a l .  1 9 9 7 ,  f i g u r e  
2 9 ) .  A n g - 2  i s  o n e  o f  t h e  e a r l i e s t  m a r k e r s  o f  t u m o u r s  
t h a t  d e v e l o p  b y  c o - o p t i n g  w i t h  t h e  e x i s t i n g  h o s t  
v e s s e l s .  A n g - 2  i s  a  m a r k e r  f o r  t h e  c o - o p t e d  v e s s e l s  
t h e m s e l v e s  a n d  n o t  t h e  t u m o u r  c e l l s .  H e n c e ,  A n g - 2  
c a n  p e r h a p s  b e  u s e d  t o  d e t e c t  p r e s e n c e  o f  t u m o u r s  
e v e n  w h e n  t h e  t u m o u r  i t s e l f  c a n n o t  b e  d e t e c t e d .  It  
i s  t h o u g h t  t h a t  A n g - 2  b l o c k s  i n t e r a c t i o n  o f  A n g - 1  
w i t h  t h e  T I E -2  a n d  h e n c e  t h e  l e a k y  a n d  h a e m o r r h a g i c  
v e s s e l s  a r e  f o r m e d  b y  t h e  t u m o u r -  d e r i v e d  V E G F  
( H o l a s h e t a l . 1 9 9 9 ,  Z a g z a g e t a l .  1 9 9 9 ) .
8.5. A ngio tensins
T h e  c o m p o n e n t s  o f  t h e  R e n i n - A n g i o t e n s i n  S y s t e m  
( f i g u r e  2 9 )  f u n c t i o n  a s  g r o w t h  f a c t o r s  b e s i d e s  
c o n t r o l l i n g  b l o o d  v o l u m e  a n d  h o m e o s t a s i s .  It i s  a n  
i m p o r t a n t  f a c t o r  in  p a t h o g e n e s i s  o f  c a r d i o v a s c u l a r  
d i s e a s e s  i n c l u d i n g  h y p e r t e n s i o n  a n d  c o n g e s t i v e  
h e a r t  f a i l u r e .
T h e  a n g i o t e n s i n s  a c t  i n  o p p o s i t i o n  ( t a b l e  1 0 )  
b o t h  a s  g r o w t h  r e g u l a t o r s  a n d  i n  t h e  c o n t r o l  o f  
s o m e  c a r d i o v a s c u l a r  f u n c t i o n s .  T h e s e  o p p o s i n g  
a c t i o n  s u g g e s t  t h a t  t h e  c o m p o n e n t s  o f  R A S  ( f ig u r e  3 0 )  
m a y  m o d u l a t e  t h e  e n d o g e n o u s  h e a l i n g  p r o c e s s  
a n d / o r  t h e  p e r s i s t e n c e  o f  c h r o n i c  i n f l a m m a t i o n  
a n d  p r o l i f e r a t i v e  p a t h o l o g y .
RAS
A n g io ten s in  C o n v ertin g  EnzymR enin
A n g io te n s in  I A n g io ten s in A n g io ten s in  (1*7)
A n g io te n s in s







(inactive decapeptide) <c HDD angiotensinogen (54 kDa d; globulin)
ACE
V
p u l m o n a n
v a s c u la r  b ed
angiotensin II 
(active octapeptide)
Figure 30 A schematic overview of the Renin-Angiotensin System
Table 10 The differences between the two receptor types o f the angiotensins
ATI AT2
Responsible for all known physiologic actions of The role of AT2 receptor has not been as well characterised as the
angiotensin II ATI receptor
mediates cell growth or cell proliferation activation of the receptor induces inhibition of cell proliferation
and possibly mediates cell differentiation
facilitates angiogenesis inhibits angiogenesis
involved in vasoconstriction involved in vasodilation
increases accumulation of angiotensin II mRNA inhibits accumulation of angiotensin II mRNA via activation of
via activation of PKC and release of Caz' ions protein tyrosine phosphatases.
Angiotensin II induces the expression of Angiotensin II induces the expression of Angiopoietin-2 via AT2.
Angiopoietin-2 via ATI.
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8.5.1. Angiotensin II
This molecule plays an important role in the 
remodelling of the heart and the vessels after myo­
cardial infarction via cell growth-promoting 
effects(Baker etal.l992).It has been shown to induce 
angiogenesis in the rabbit cornea, embryonic 
chorioallantoic membrane and rat cremaster 
muscle (Fernandez et al. 1985, Le Noble et al. 1993, 
Munzenmaier & Greene 1996). Ang II potentiates 
VEGF-induced angiogenesis in the retinal MECs by 
increasing the expression of VEGFR2 (Otani et al. 
1998). It also transactivates EGFR via heparin-binding 
EGF and thus contributes to modulating angio- 
genesis(Abramovitch et al. 1998).Angiotensin II 
increases the transcriptional rate of Angioppoietin-2 
gene without affecting the stability of its mRNA 
(Fujiyama et al. 2001). It is a potent vasoconstrictor 
and has been shown to stimulate angiogenesis 
induced by sponge in mice (Machado et al. 2000). 
Angiotensin II mediates its actions via two receptors: 
ATI andAT2.
8.5.2. Angiotensin (1-7)
This is another component of the RAS and has only 
seven peptides as compared to the ten of 
angiotensin II. This heptapeptide m ediates its 
biological functions via different ways including the 
release o f vassopressin (Schiavone et al. 1988), 
prostaglandins (Santos et al. 1996; Jaiswal et al.
1992) and nitric oxide (Li et al. 1997). The receptors 
ATI and AT2 do not reverse the anti-angiogenic 
effects of this exogenous angiotensin peptide. This 
indicates that there exists an angiotensin (1-7) 
specific receptor that is different from the ATI and 
AT2 receptors. This receptor is responsible for the 
anti-angiogenic effects of the heptapeptide (Benter 
et al. 1993, Fontes et al. 1994, Jaiswal et al. 1992).
8.5.3. Angiotensin Converting Enzyme
ACE as it is com m only known as, Angiotensin  
Converting Enzyme is a Zn2+ metallopeptidase. It is 
so called because it cleaves the C-terminal dipeptide 
from the oligopeptide, Angiotensin I to produce the 
potent vasopressor, Angiotensin II. ACE is abund­
antly found in the lungs where is gets localised on 
the luminal surface of the plasma membranes of the 
endothelial cells in the pulmonary vascular bed 
(Ryan et al. 1975; Caldwell et al. 1976). The lungs are 
the most important site for the generation of the 
circulating Angll. An insight into the expression and
regulation o f ACE w ould  open up possible  
therapeutic strategies for inhibition of angiotensin- 
mediated angiogenesis.
8.6. Endothelin
Endothelins (ET) are peptides expressed in many 
tumours. These may stimulate angiogenesis and 
desmoplasia (Alanen et al. 2000). Endothelins occur 
as big ET-1 (1-38), a precursor that is cleaved into 
smaller peptides ET-1 (1-32), ET-3 by Endothelin 
Converting Enzyme-1 (ECE-1). ECE-1 occurs in four 
different isoforms: ECE-la, ECE-lb, ECE-lc and 
ECE-ld. Vessel tone is determined by the balance of 
various vasodilatory and vasoconstrictor factors. 
ET-1 is one such vasoconstrictor. It participates in 
angiogenesis and vascular remodelling (Akimoto et 
al. 2000). ET-1 is an important factor in gastric 
healing along with VEGF and NO. The active and 
the healing stage of gastric ulcer is characterised by 
ET-1 and iNOS positive ECs in the vascular wall 
(Akimoto et al. 2000). Endothelins, ET-1 and ET-3, 
mediate angiogenic effects via the ET-A receptor. 
The angiogenic effect on the ECs is not mediated by 
leukocytes and is unaffected by ET-B receptor- 
antagonist (Bek & McMillen 2000). ET-1 induces 
angiogenic phenotype in cultured ECs and 
stimulates neovascularisation in vivo. ET-1 can exert 
its angiogenic effects both as an autocrine and as a 
paracrine factor. For instance ovarian carcinomas 
express ET-1 as an autocrine factor via the ET-A 
receptor (Salani et al. 2000) while angiogenesis and 
stromal growth in lung cancer is induced by a 
paracrine ET-1 (Ahmed et al. 2000). ET-1 negatively 
regulates hCG secretion by the trophoblast of the 
receptive phase endometrium (Sunder & Lenton
2000). ET-1 modulates tumour angiogenesis either 
directly or in part via VEGF.
8.7. Prolactin
Prolactin is a multifunctional protein hormone that 
exists in several molecular forms (figure 31) due to 
post-translational modification of the predominant 
23kDa form (Nicoll 1980, Russell 1989). Spatial 
molecular heterogeneity of prolactin suggests that 
the protein functions as a pro-hormone precursor 
that can be processed to biologically active forms. 
These different molecular forms o f the hormone 
occur in the anterior hypophysis, the immune 
system  and the brain. The 23kDa form is
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p r o t e o l y t i c a l l y  c l e a v e d  i n t o  d i f f e r e n t  N - t e r m i n a l  
f r a g m e n t s  t h a t  h a v e  s o m e  s p e c i f i c  p r o p e r t i e s  t h a t  
a r e  n o t  s h a r e  w i t h  t h e  p a r e n t  f o r m ,  a l t h o u g h  t h e y  
d o  r e t a i n  s o m e  o f  t h e  o r i g i n a l  b i o a c t i v i t i e s .
T h e  1 6 k D a  P R L  h a s  a n t i - a n g io g e n i c  p r o p e r t i e s  th a t  
a r e  m e d i a t e d  b y  a  u n i q u e  r e c e p t o r  ( C la p p  e t  a l .  1 9 9 3 ) .  
[ 3 H ] - T h y m i d i n e  i n c o r p o r a t i o n  e x p e r i m e n t s  w e r e  
c a r r i e d  o u t  b y  C l a p p  e t  a l .  ( 1 9 9 3 ) .  T h e y  s h o w e d  t h a t  
1 6 K  P R L  a n t i s e r u m  b l o c k s  t h e  i n h i b i t o r y  e f f e c t s  o f  
t h e  h o r m o n e  a n d  t h e  r a t  n e u r o h y p o p h y s e a l  
c o n d i t i o n e d  m e d i u m  o n  t h e  b - F G F  s t i m u l a t e d  
b o v i n e  b r a i n  c a p i l l a r y  e n d o t h e l i a l  c e l l s .  T h e  1 6 K  
P R L  a l s o  s t i m u l a t e s  n a t r i u r e s i s  a n d  d i u r e s i s  i n  
a n e s t h e t i s e d  r a t s .  T h i s  f o r m  o f  t h e  h o r m o n e  i s  
l o c a t e d  t h r o u g h o u t  t h e  a n t e r i o r  h y p o p h y s i s .  D ’ 
A n g e l o  e t  a l .  ( 1 9 9 5 )  s h o w e d  t h a t  t h e  h u m a n  1 6 K  
P R L  i s  a l s o  a n t i - a n g i o g e n i c .  T h e  p r o t e i n  i n h i b i t s  t h e  
p h o s p h o r y l a t i o n  a n d  s u b s e q u e n t  a c t i v a t i o n  o f  t h e  
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Figure 31 The different splice-variants o f Prolactin (PRL)
o f  e x p e r i m e n t s  c a r r i e d  o u t  b y  C l a p p  e t  a l .  ( 1 9 9 8 )  
s h o w e d  t h a t  t h e  e n d o t h e l i a l  c e l l s  t h e m s e l v e s  
p r o d u c e d  p r o l a c t i n  a n d  p r o l a c t i n - l i k e  p r o t e i n s .  T h e  
r e s u l t s  o f  t h e  e x p e r i m e n t s  w e r e  c o n s i s t e n t  w i t h  t h e  
h y p o t h e s i s  t h a t  t h e  E C  p r o l i f e r a t i o n  i s  s u p p o r t e d  b y  
a u t o c r i n e  r e g u l a t i o n  w i t h i n  t h e  t i s s u e  m i c r o ­
e n v i r o n m e n t  v i a  t h e s e  P R L - r e l a t e d  p r o t e i n s .  T h e  
a n g i o g e n i c  a c t i v i t y  i s  b e l i e v e d  t o  b e  a  g e n e r a l  
p r o p e r t y  o f  t h e  m e m b e r s  o f  t h e  P R L  f a m i l y .  T h e  
i n t a c t  m o l e c u l e s  a r e  a n g i o g e n i c  w h e r e a s  t h e  
p r o t e o l y t i c  N - t e r m i n a l  f r a g m e n t s  o f  t h e  p r o t e i n  a r e  
a n t i - a n g i o g e n i c  ( t a b l e  1 1 ) .  I t  h a s  b e e n  s u g g e s t e d  
t h a t  t h e  r a t i o  o f  t h e  i n t a c t  p r o t e i n  t o  t h a t  o f  t h e  
c l e a v e d  f r a g m e n t s  i s  p r o b a b l y  t h e  a n g i o g e n i c  
s w i t c h  r e g u l a t e d  b y  t h e  e x p r e s s i o n  l e v e l  o f  t h e  
p r o t e i n  a n d  t h e  p r o t e a s e s  t h a t  d i g e s t  t h e  w h o l e -  
l e n g t h  p r o l a c t i n  ( S t r u m a n  e t  a l .  1 9 9 9 ) .
T h e  o p p o s i t e  a c t i o n s  o f  t h e s e  p r o t e i n s  a r e  
m e d i a t e d  b y  r e c e p t o r s  s p e c i f i c  t o  e a c h  p r o t e i n .  T h e y  
d o  n o t  c o m p e t e  f o r  b i n d i n g  t o  t h e  s a m e  r e c e p t o r .  
T h e y  a c t  b y  i n t e r f e r i n g  w i t h  t h e  M A P - k i n a s e  
s i g n a l l i n g  p a t h w a y .  T h e  p r o t e a s e s  t h a t  d i g e s t  t h e  f u l l -  
l e n g t h  p r o t e i n  r e s i d e  w i t h i n  t h e  s a m e  c o m p a r t m e n t  
a s  t h e  h o r m o n e  i t s e l f .  F o r  i n s t a n c e ,  C a t h e p s i n  D  t h a t  
c l e a v e s  P R L  i s  f o u n d  a t  t h e  d e c i d u o p l a c e n t a l  in t e r f a c e  
a l o n g  w i t h  P R L  a n d  p e r h a p s  r e g u l a t e s  t h e  
v a s c u l a r i s a t i o n  o f  t h e  h u m a n  p l a c e n t a .
8.8. A ngiosta tin  and Endostatin
P e r h a p s  t w o  o f  t h e  m o s t  e x c i t i n g  a n d  p r o m i s i n g  
d i s c o v e r i e s  i n  t h e  f i e l d  o f  a n g i o g e n e s i s  a n d  c a n c e r  
r e s e a r c h  a r e  E n d o s t a t i n  a n d  A n g i o s t a t i n .  T h e i r  
d i s c o v e r i e s  c a m e  i n  t h e  w a k e  o f  t h e  r e a l i s a t i o n  t h a t  
p r i m a r y  t u m o u r s  r e l e a s e  a n g i o g e n i c  i n h i b i t o r s  in  
o r d e r  t o  s u p p r e s s  m e t a s t a t i c  g r o w t h .
A n g i o s t a t i n  i s  a  3 8  k D a  p r o t e o l y t i c  f r a g m e n t  o f  
p l a s m i n o g e n  t h a t  w a s  f i r s t  i s o l a t e d  f r o m  m o u s e  
u r i n e  a n d  s e r u m  b y  O ’R e i l l y  e t  a l . ( 1 9 9 4 ) .  A n g i o s t a t i n
EXON-1 EXON-3EXON-2 EXON-4
Table 11 The in vivo and in vitro properties o f Prolactin (PRL)
in vivo in vitro
1) Growing capillaries 1) Bovine Brain Capillary Endothelial Cells
16kDa Prolactin fragment: anti-angiogenic 16kDa Prolactin fragment: anti-angiogenic
full-length prolactin no effect full-length prolactin no effect
2) Queiscent vasculature 2) Pulmonary fibroblasts
16kDa Prolactin fragment: no effect 16kDa Prolactin fragment: stimulates NO production
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Figure 32 Different interleukins involved in the process of angiogenesis
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can almost com pletely suppress metastatic cell 
growth and is able to specifically inhibit 
proliferation of ECs of different origin. It is believed 
that angiostatin perhaps inhibits angiogenesis by 
inducing apoptosis, which consequently kills the 
endothelial cells (Lucas et al.1998). Systemic 
administration of angiostatin has shown nearly 
complete inhibition of angiogenesis and for the first 
time there wasn’t any trace of detectable toxicity or 
resistance (O’Reilly et al. 1996, Sim et al. 1997). 
Adenovirus mediated gene transfer experiments 
have shown that targeted antiangiogenesis is a 
more promising concept than the delivery of the 
anti-angiogenic factors as their bolus injections 
(Griscelli et al. 1998).
Endostatin is a 20 kDa C-terminal fragment of 
collagen XVIII. Generation o f endostatin from 
collagen XVIII is a two-step process. The first step is 
dependent on a metal and the latter step is elastase 
activity dependent (Wen et al. 1999). It specifically 
inhibits EC proliferation, angiogenesis and tumour 
growth (O’Reilly et al. 1997). Endostatin is also 
derived from collagen XV but this form differs from 
the collagen XVIII-derived endostatin both in 
structural and binding properties. It also differs in 
its tissue distribution and anti-angiogenic activity 
(Sasaki et al. 2000). Like angiostatin, endostatin also 
does not cause the onset o f any resistance to the 
treatment (Taddei et al. 1999). According to Standker 
et al. (1997), human endostatin is in circulation. It has 
been shown to have a high affinity for heparin
(Hohenester et al. 1998) although the binding sites 
for endostatin and that for FGF-2 are discrete 
(Chang etal. 1999).
Endostatin binds zinc ions and it was found that 
metal chelating agents induce N-terminal degrada­
tion of endostatin (Boehm et al. 1998). Thoughts of 
Hohenester et al. (1998) and O’Reilly et al. (1997) 
differ in the functional importance of zinc ions in 
endosatin. The former group believes that zinc 
rather plays a structural role than a critical func­
tional role in angiogenesis when bound to 
endostatin. A variety of proteinases are involved in 
the generation and degradation of human endo­
statin. All of them generate fragments that contain 
the N-terminal within the same 15-residue stretch as 
those which occur in the physiological endostatin, 
indicating that this region is sensitive to many 
proteinases although their efficiencies differ 
markedly.
Both angiostatin and endostatin are specific, 
cleaved fragments o f larger, ubiquitous proteins. 
This may be a general mechanism by which the body 
promotes or inhibits angiogenesis. Use of these 
fragments in therapetics requires the knowledge of 
the extent of these mechanisms in physiological as 
well as pathological settings.
The crystal structure of endostatin revealed that 
this endogenous inhibitor of angiogenesis closely 
resembles the carbohydrate recognition domain of 
the mammalian C-type lectins (Hohenester et al. 
1998). Despite a high degree of structural similarity,
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endostatin does not use calcium to bind to oligo­
saccharides like the other c-type lectins. It is 
hypothesised that endostatin inhibits angiogenesis 
by interfering with the heparin-binding requirement 
o f FGF-2 signalling. The crystal structure of 
endostatin reveals a highly basic region on the surface 
of the molecule that comprises of eleven arginine 
residues of the total fifteen for endostatin. This basic 
patch is hypothesised to be the putative heparin- 
binding site for endostatin. The three dimensional 
structure of endostatin is currently being used as a 
reference to delineate the heparin-binding site using 
site-directed mutagenesis as well as to define the 
mode of inhibition of angiogenesis by endostatin. 
The structural insights are proving helpful in the 
development of new anti-angiogenesis therapeutic 
approaches.
9. Cytokines in Angiogenesis
Cytokines are a class of small peptide messenger 
m olecules. These are secreted by the immune 
system cells and transported in the blood (table 
12). Their main function is to facilitate a number of 
immune system responses. These molecules play an 
important role in both normal and pathologic  
cellular activities. Cytokines act mainly as 
intracellular messengers especially in response to 
infection, wounds etc. They cause the proliferation 
and differentiation of immune cells like the T-cells 
(Tasaki et al. 2000), B-cells, and the macrophages. 
Lymphocytes in culture can be stim ulated to 
produce active cytokines that perform a very  
important function of cellular communication. As 
m entioned before growth factors, interferons, 
interleukins (figure 32) can all be categorised as 
cytokines. This confusion in the naming system  
stems from the fact that many of these were initially 
named as growth or stimulating factors before they 
were all traced to originate from various immune 
system cells.
Cytokines act by binding to their receptors that 
are present on the surfaces o f many cell types 
throughout the body. The binding of the 
biochemical messengers to their receptor results in 
transduction of an intracellular message across the 
cell membrane. This signal activates the genes 
responsible for different cellular activities like 
growth, differentiation and proliferation. This
signal also stimulates the production of other kinds 
of cytokines. The cytokines often complement each 
other. These molecules are extremely potent which 
is evident from their active concentration range 
lying between picomolar and femtomolar values. 
Even at such a small range the effects exerted by the 
cytokines are far-reaching and very rapid. 
Cytokines are known to interact w ith  and 
orchestrate several cellular activities that are central 
to the process of inflammation and healing.
10. The Tumour Necrosis Factor-a and Angiogenesis
Tumour necrosis factor-alpha (TNF-a) is multifunc­
tional and has effects in inflammation, sepsis, lipid 
and protein metabolism, haematopoiesis, angio­
genesis and host resistance to parasites and 
malignancy (Gordon & Galli 1990). TNF-a is a pro- 
inflammatory cytokine that can directly modulate 
the inflammatory response by altering the integrity 
of the endothelial barrier, resulting in an increase in 
endothelial permeability. TNF-a is an important 
mediator during the inflammatory phase of wound 
healing. It stimulates the secretion of active MMP-2, 
a type IV collagenase (figure 33).
The role of TNF-a in angiogenesis has been 
controversial (figure 34). In vitro  TNF inhibits 
proliferation of endothelial cells (EC) whereas in the 
cornea it appears to stimulate vessel growth. The 
disc angiogenesis system developed by Fajardo et al. 
(1992) indicate bimodal, dose-dependent opposing 
effects and explain some of the in vitro versus in vivo 
paradoxical results. TNF (native or exogenous) may 
have opposing effects on microvessels of neoplasms 
and inflammatory reactions, depending on its 
local tissue concentrations (Fajardo et al. 1992). 
TN F-a w as first described in activated  
macrophages. IgE-dependent activation of cultured 
or peritoneal mast cells induces extracellular release 
of TNF-a and augments levels of TNF-a messenger 
RNA and bioactivity (Gordon & Galli 1990). These 
findings suggested that the mouse mast cells are a 
home to both the existing and the immunologically 
inducible TNF-a (Gordon & Galli 1990). TNF-a is 
secreted by activated macrophages that are believed 
to mediate tumour cytotoxicity.
TNF-a can also inhibit the proliferation of ECs 
derived from the brain or the adrenal cortex. This 
suggested that the m olecule can also act as a
454
Table 12 The different cytokines produced by different ceil types.
Shalini Iyer and K Ravi Acharya
Cell Types Cytokines
Platelets A ngiopoietins, EGF, FGFs, IGF-1, IL-lp, PDGF, TGF-a, TGF-Ps. VEGF
Endothelial cells A ngiopoietins, EGF, ET, FGFs. IL-lp, IL-6, IL-8, MCP-1, PDGF, TNF-a, TGF-Ps, VEGF
Mast cells ET, FGFs, IL-lp, IL-4, IL-6, IL-8. IL 10, IL-18, MCP-1, M IP-la, MIP-2, PDGF, TGF-a, TGF-Ps, TNF-a, VEGF
M acrophages A ngiopoietins, EGF, ET, FGFs. IF N -a /p , IGF-1, IL-lp, IL-6, IL-8, IL-10. IL-18, MCP-1, M IP-la, MIP-2, PDGF,
SLPl, TGF-a, TGF-ps, TNF-a, VEGF
Fibroblasts A ngiopoietins, EGF, KGF, FGFs, IF N -a /p , IGF-1, IL-lp, IL-6, IL-8, MCP-1, M IP-la , MIP-2, PDGF, TGF-a,
TGF-ps, TNF-a, VEGF
Keratinocytes A ngiopoietins, EGF, ET, FGFs, KGF, IL-lp, IL-6, IL-8, IL-18, SLPl, TGF-a, TGF-ps, TNF-a, VEGF
n e g a t i v e  r e g u l a t o r  o f  a n g i o g e n e s i s  in vivo  a n d  c a n  
a l s o  i n d u c e  s e l e c t i v e  c y t o t o x i c i t y  o f  c a p i l l a r y  E C s .  
T h i s  e x p l a i n s  p e r h a p s  w h y  T N F - a  i n d u c e s  
h a e m o r r h a g i c  n e c r o s i s  o f  c e r t a i n  s o l i d  t u m o u r s  
( S c h w e i g e r e r  e t  a l .  1 9 8 7 ) .  M a n y  g e n e s  a r e  d o w n -  
r e g u l a t e d  b y  t h e  T N F - a  i n c l u d i n g  t h r o m b o m o d u ­
l i n ,  p r o t e i n  C ,  e N O S ,  t h e  F a s  l i g a n d ,  a n d  t h e  
a d h e s i o n  m o l e c u l e ,  I C A M - 2 .
11. Macrophages in A ngiogenesis
M a c r o p h a g e s  a r e  s p e c i a l i s e d  c e l l s  t h a t  i n d u c e  
i m m u n e  r e s p o n s e  t h r o u g h  r e l e a s e  o f  s p e c i f i c  
c y t o k i n e s ,  p r o s t a n o i d s  a n d  o t h e r  m e d i a t o r s  o f  h o s t
C o lla g e n  + its 
v re c e p to r
T N F - a  +  its 
re c e p to r
I-kB
B re a k d o w n  o f  1-KB 
a n d  n u c le a r  
tra n s lo c a tio n  o f  N-kB
N-kB
m tl- m m p  g e n e □
a c tiv e  M M P -2
m -R N A
p ro -M M P -2
M T 1 -M M P A c c u m u la te s  o n  the 
c e llu la r  m e m b ra n e  an d  
b in d s  p ro -M M P -2
Figure 33 A schematic representation of the various steps 
involved in the active secretion of MMP-2 by TNF-a
d e f e n s e s .  A l t h o u g h  a n t i g e n  p r o c e s s i n g  a n d  
p r e s e n t a t i o n  a r e  i m p o r t a n t  f u n c t i o n s  o f  
m a c r o p h a g e s ,  E v i d e n c e  s t a t e s  t h a t  p r o g r e s s i v e l y  
g r o w i n g  s o l i d  t u m o u r s  r e p r o g r a m m e  t h e  c e l l u l a r  
m a c h i n e r y  o f  t h e  a c t i v a t e d  m a c r o p h a g e s  r e s u l t i n g  in  
i m m u n e  s u p p r e s s i o n  o f  h o s t  d e f e n s e s  a n d  h e n c e  a  
d i s o r d e r e d  r e s p o n s e .  T h e s e  m a c r o  p h a g e s  a r e  
k n o w n  a s  t h e  T u m o u r - a s s o c i a t e d  M a c r o p h a g e s  
( T A M s ) .  T A M s  a r e  a n  i m p o r t a n t  c o m p o n e n t  o f  
m a n y  t u m o u r s ,  c a n c e r s .  B u t  it  h a s  a l s o  b e e n  s e e n  t h a t  
T A M s  c a n  i n f l u e n c e  t u m o u r  r e g r e s s i o n  a s  w e l l  
( f i g u r e  3 5 ) .  T h e  m e c h a n i s m s  b y  w h i c h  T A M s  
e n h a n c e  m e t a s t a t i c  s p r e a d  a r e :
♦  E n h a n c e d  g r o w t h  m e d i a t e d  b y  g r o w t h  f a c t o r s  
l i k e  t h e  E G F , P D G F ,  T G F - p ,  c y t o k i n e s  l i k e  t h e  
I L - 6 ,  I L - 1 a n d  T N F - a .
♦  E n h a n c e d  a n g i o g e n e s i s  t h r o u g h  t h e  p r o d u c t i o n  
o f  v a r i o u s  c y t o k i n e s  l i k e  I L - 1, I L - 6 ,  I L - 8 ,  T G F -  
a ,  T G F - p ,  a n d  p r o s t a n o i d s .
♦  I n v a s i o n  a n d  d i s s e m i n a t i o n  v i a  p r o t e o l y t i c  
e n z y m e s  a n d  p r o s t a n o i d s .
♦  I m m u n o s u p p r e s s i o n  m e d i a t e d  b y  c y t o k i n e s  
( I L - 1 0 )  a n d  T G F - p .
T u m o u r  r e g r e s s i o n  b y  T A M s  i s  b r o u g h t  a b o u t  
b y  d i r e c t  c e l l u l a r  c y t o t o x i c i t y ,  m a c r o p h a g e  i n d u c e d  
a p o p t o s i s ,  a n t i b o d y - d e p e n d e n t  c y t o t o x i c i t y  a n d  b y  
s e c r e t i n g  c y t o t o x i c  a n d  c y t o s t a t i c  p r o d u c t s  l i k e  
e i c o s a n o i d s ,  N O ,  T N F - a .  T h e  o u t c o m e  o f  t h e s e  
c o m p l e x  i n t e r a c t i o n s  b e t w e e n  m a c r o p h a g e s ,  
n e o p l a s t i c  c e l l s  a n d  o t h e r  t y p e s  o f  i m m u n e  c e l l s  i s  
e n h a n c e d  t u m o u r  g r o w t h  b o t h  i n  t e r m s  o f  
p r o g r e s s i o n  a n d  r e g r e s s i o n .
12. Role o f C yclooxygenases in A ngiogenesis
C y c l o o x y g e n a s e s  a r e  t h e  k e y  r a t e - l i m i t i n g  e n z y m e s  
i n v o l v e d  i n  t h e  s y n t h e s i s  o f  p r o s t a g l a n d i n s  a n d
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o t h e r  e i c o s a n o i d s  f r o m  a r a c h i d o n i c  a c i d  ( L y s z  &  
N e e d l e m a n  1 9 8 2 ) .  T h e  m e t a b o l i t e s  o f  t h e  e n z y m e ,  
k n o w n  a s  t h e  e i c o s a n o i d s  o r  t h e  p r o s t a n o i d s  
m e d i a t e  s i g n a l s  t o  t h e  a d j a c e n t  c e l l s  f o r  t h e  d e l i c a t e  
r e g u l a t i o n  o f  c e l l u l a r  f u n c t i o n s  ( K a t o r i  &  M a j i m a  
2 0 0 0 ) .  T h e s e  m e t a b o l i t e s  p l a y  a n  i m p o r t a n t  r o l e  i n  
b o t h  p h y s i o l o g i c a l  a s  w e l l  a s  p a t h o l o g i c a l  p r o c e s s e s ,  
e s p e c i a l l y  i n  t h e  g a s t r o i n t e s t i n a l  t r a c t .  T h e  
e i c o s a n o i d s  a r e  r e s p o n s i b l e  f o r  m a i n t e n a n c e  
m u c o s a l  i n t e g r i t y ,  m u c u s  s t i m u l a t i o n ,  s e c r e t i o n  o f  
e l e c t r o l y t e s  a n d  i n f l a m m a t o r y  p r o c e s s e s  ( A d a i k a n  
&  K a r i m  1 9 7 6 ,  I s s e l b a c h e r  1 9 8 7 ,  W a l l a c e  2 0 0 1 ) .  T h e  
e n z y m e  o c c u r s  i n  t w o  i s o f o r m s ,  t h e  c o n s t i t u t i v e l y  
e x p r e s s e d  c y c l o o x y g e n a s e - 1  o r  C O X - 1  a n d  t h e  
m i t o g e n - i n d u c i b l e  c y c l o o x y g e n a s e - 2  o r  C O X - 2  
( K u j u b u  e t  a l .  1 9 9 3 ,  W e n  e t  a l .  1 9 9 3 ) .  C O X - 1 ,  a l s o
TNF-a
blood vessel " formation o f
formation chemotaxis capillary tube-like
structures 
(Bovine Adrenal Capillary 
Endothelial Cells) 
Figure 34 The in vivo and in vitro effects o f TNF-a on 
different models of angiogenesis
(Rat cornea and chick 
chorioallantoic membrane)
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Figure 35 Positive and negative paracrine interactions of 
macrophages with tumour cells and immune system
k n o w n  a s  t h e  h o u s e k e e p i n g  e n z y m e ,  i s  
c y t o p r o t e c t i v e  a n d  i s  p r o p o s e d  t o  r e g u l a t e  
p h y s i o l o g i c a l  f u n c t i o n s .  T h e  i n d u c i b l e  i s o f o r m  o f  t h e  
e n z y m e  i s  o f  m a x i m u m  i n t e r e s t  i n  t h e  f i e l d  o f  
a n g i o g e n e s i s  b e c a u s e  C O X - 2  o v e r e x p r e s s i o n  i s  
l i n k e d  t o  a  v a r i e t y  o f  t u m o u r s  a n d  c a n c e r s  ( F o s s l i e n  
2 0 0 1 ) .  C O X - 2  o v e r e x p r e s s i o n  c a n  b e  i n d u c e d  b y  a  
v a r i e t y  o f  m i t o g e n s  i n c l u d i n g  c y t o k i n e s ,  g r o w t h  
f a c t o r s ,  t u m o u r  p r o m o t i n g  g e n e s  ( G a t e l y  2 0 0 0 )  
C O X - 2  c a n  c o n t i b u t e  t o  t h e  d e v e l o p m e n t  o f  t u m o u r s  
a n d  c a n c e r s  i n  a  v a r i e t y  o f  d i f f e r e n t  w a y s .  T h e s e  
i n c l u d e  i n d u c i n g  c e l l  s u r v i v a l  ( S e e d  e t  a l .  1 9 9 7 ) ,  
i n c r e a s e  i n  a n g i o g e n e s i s  a n d  i n v a s i v e n e s s  ( R o z i c  e t  
a l .  2 0 0 1 )  a n d  s o m e t i m e s  b y  r e g u l a t i n g  i m m u n o ­
s u p p r e s s i o n .  T h e  i n c r e a s e  i n  a n g i o g e n e s i s  i s  
b r o u g h t  a b o u t  b y  i n c r e a s e  i n  t h e  e x p r e s s i o n  o f  
a n g i o g e n i c  f a c t o r s  l i k e  V E G F ,  E G F ,  F G F - 2  a n d  
M M P s  ( M a j im a  e t  a l .  1 9 9 7 ,  M a j im a  e t  a l .  2 0 0 0 ,  O t t i n o  
&  B a z a n  2 0 0 1 ) .
T h e r e  a r e  t w o  c l a s s e s  o f  c y c l o o x y g e n a s e  
i n h i b i t o r s ,  t h e  N o n - s t e r o i d a l  a n t i - i n f l a m m a t o r y  
d r u g s  ( N S A I D s )  a n d  t h e  s e l e c t i v e  C O X - 2  i n h i b i t o r s .  
A s  t h e  n a m e s  s u g g e s t ,  t h e  N S A I D s  a r e  n o n - s p e c i f i c  
C O X  i n h i b i t o r s  t h a t  a r e  e f f e c t i v e  a g a i n s t  b o t h  C O X - 1  
a n d  C O X - 2  w h e r e a s  t h e  C O X - 2  i n h i b i t o r s  ( m o d i f i e d  
N S A I D s )  a r e  s p e c i f i c  f o r  t h e  C O X - 2  e n z y m e  
( C a p r i o t t i  2 0 0 0 ) .  S e l e c t i v e  i n h i b i t i o n  o f  C O X - 2  i s  
p r e f e r r e d  o v e r  n o n s e l e c t i v e  i n h i b i t i o n  b e c a u s e  i t  
i n h i b i t s  c a n c e r  c e l l  p r o l i f e r a t i o n ,  r e d u c e s  c a n c e r  c e l l  
s u r v i v a l  a n d  r e s t o r e s  a p o p t o s i s .  S e l e c t i v i t y  a g a i n s t  
C O X - 2  p r e v e n t s  i n h i b i t i o n  o f  t h e  c y t o p r o t e c t i v e  
a c t i v i t y  o f  C O X - 1  i n  t h e  g a s t r o i n t e s t i n a l  t r a c t .  
H o w e v e r ,  r e c e n t l y  e x p e r i m e n t s  h a v e  r a i s e d  
c o n c e r n s  t h a t  t h e  C O X - 2  i n h i b i t o r s  m i g h t  c a u s e  
t h r o m b o s i s  i n  t h e  i n f a r c t e d  h e a r t  b y  r e d u c i n g  t h e  
p r o d u c t i o n  o f  v a s c u l a r  p r o s t a c y c l i n  ( P G I 2) .  T h i s  
d i s r u p t s  t h e  b a l a n c e  b e t w e e n  t h r o m b o x a n e  a n d  
P G I r  T h i s  h a s  m a d e  i t  i m p e r a t i v e  t h a t  t h e  e f f i c a c y  
o f  C O X - 2  i n h i b i t o r s  a s  a  p o t e n t i a l  t h e r a p e u t i c  
u t i l i t y  i n  s e v e r a l  t y p e s  o f  c a n c e r s  b e  r e - e v a l u a t e d  
e s p e c i a l l y  i n  v i e w  o f  t h e i r  e f f e c t s  i n  c a r d i o v a s c u l a r  
e v e n t s  ( B i n g  &  L o m n i c k a  2 0 0 2 ,  M u k h e r j e e  2 0 0 2 ,  
G r y g l e w s k i  e t  a l .  2 0 0 1 ) .
13. Transcriptional R egulation o f Vascular 
D evelopm ent
T r a n s c r i p t i o n  f a c t o r s  c a n  r e g u l a t e  t h e  e x p r e s s i o n  o f  
o t h e r  g e n e s  i n  a  t i s s u e - s p e c i f i c  a n d  q u a n t i t a t i v e
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manner and are thus major regulators of embryonic 
developmental processes. Several transcription 
factors that regulate specific genes involved in 
angiogenesis have been described. Some of them 
have been described in table 13.
14. From Basic Research to Clinical Trials
The key to the clinical control of cancer and other 
angiogenesis dependent diseases is to find a 
solution to one of the great scientific query of this 
era: What regulates blood vessel formation? The 
hypothesis introduced by Judah Folkman at 
Harvard (USA) alm ost three decades ago has 
evloved into a paradigm. The rapid pace of 
discoveries coming from laboratories, research 
centers and industries worldwide has brought the 
search for an effective, non-toxic, anti-angiogenesis 
therapy a dream within reach.
There are several mechanisms to attack cancer 
cells by cutting off their blood supply. These are:
Inhibit angiogenesis promoting factors 
Inhibit the activated endothelial cells 
Inhibit the proteolytic enzymes that digest the 
extra cellular components 
Inhibit the EC specific adhesion molecules 
Use of chelators of copper 
Gene Therapy 
Endocrine Therapy 
The basic pathway follow ed to translate a 
potential compound from the laboratory to the clinic 
has five major steps (Brem 1999):
• Identification of a molecular target
• Testing the functional activity of putative inhibitor 
eg. receptor binding, mRNA inactivation etc
• In vitro  experiments to test if the potential 
compound inhibits EC migration and proliferation




Ets factors Transactivation of Tie-1 and Tie-2 genes Iljin et al. 1999; Wakiya et al. 1996; 
Dube et al. 1999; Kappel et al. 2000
AP-2 Iljin et al. 1999
SCL/tal factor Yolk sac erythropoiesis and angiogenesis Kappel et al. 2000; Visvader et al. 1998; 
Shivdasani et al. 1995
GATA factors Kappel et al. 2000
A PI Extra-embryonic vascularisation Schreiber et al. 2000
LKLF Smooth muscle architecture of tunica media, ECM deposition, decrease 
in no of ECs and pericytes
Kuoetal. 1997
Tfeb Placental vascularisation Steingrimsson et al. 1998
Hox D3 avP3 expression, EC response to angiogenic factors, Boudreau et al. 1997
Tel Extra-embryonic angiogenesis Wang etal. 1997
Fral Endothelial differentiation Schreiber et al. 2000
Vezfl Endothelial differentiation Xiong et al. 1999
HESR1 Endothelial tube formation and development of arteries Henderson et al. 2001
Hox B3 Capillary morphogenesis Myers et al. 2000
PPAR-y Endothelial tube formation Xinetal. 1999
SMAD-5 Muscle development Yang etal. 1999
MEF2C Muscle development Lin et al. 1998
dHAND Vascularisation of the yolk sac Yamagishi et al. 2000
ARNT/HIF-a Yolk sac angiogenesis, stimulation of production of angiogenic factors Wang et al. 1995; Maltepe et al. 1997
COUP-TFH Regulates angiopoietin-1 levels Pereira et al. 1999
AML-1 Regulates angiopoietin-1 levels Takakura et al. 2000
Fli-1 Tie-2 gene regulation Hart et al. 2000
Lmo 2 Bridging molecule between the GATA factors and the E-box proteins Wadman et al. 1997
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• Further studies are done w ith the chick 
chorioallantoic membrane and the rabbit cornea
• Finally the ultimate rigorous evaluation of the 
compound as an angiogenesis inhibitor is done 
in a vascularised organ such as the brain. Once 
the com pound being tested has passed the 
different rigorous in vitro and in vivo  tests in 
animals, it is administered to human volunteers 
in different phase trials (table 14).
Apart from inhibition o f angiogenesis, 
stim ulation o f the process is also pursued for 
treating diseases that arise from lack or deficiency of 
blood supply like the ischemic heart disease. 
Therapeutic stimulation of angiogenesis is done by 
one of the following mechanisms (Thompson et al. 
1999Thompson et al., 1999):
•  topical application of angiogenic growth factors
• gene transfer vascularisation
• laser-induced vascularisation (Miller et al. 1990, Yi 
et al. 1997, Kovacs et al. 1974, Edelman et al. 2000)
There are several agents (table 15) that are 
currently being studied for their ability to block 
the blood supply to the tumours. The first stage of 
clinical trials have given several feedbacks and 
ideas pertaining to what needs to be dealt with  
the next line of therapeutic modalities (Thompson 
et al. 1999).
14.1 Structure Based Drug Design
The three-dim ensional structures of target 
macromolecules provide starting point for drug 
design once the lead com pounds have been  
screened and identified. The three-dimensional
structures define the interface of the ligands and 
their receptors or other macromolecular targets. 
Study of the key residues at the active site and/or  
protein-protein interface gives strong insights into 
the function of the target molecule. These help in 
the design of drugs that would enhance the desired 
interactions with the target macromolecule and at 
the same time reduce the unwanted ones. Design is 
the combination of docking and linking of available 
com pounds. Structure dictates what and where 
structural modifications are required to improve the 
pharmacodynamic properties of the lead compound.
The availability of structures has helped in the 
design and identification o f many drugs that 
selectively target the macromolecule. Recently, three- 
dimensional structures have impacted heavily on the 
drug design approaches. One recent example of such 
a designed drug is that of Anginex (Griffioen et al.
2001). Anginex is a Ppep-peptide designed by using 
the three dimensional structures o f several anti- 
angiogenic proteins. These proteins have a structural 
commonality among them comprising of anti-parallel 
p-sheet structure. The structural and compositional 
characteristics of these anti-angiogenic proteins have 
been combined to design Anginex. Anginex is a 
potent inhibitor of EC adhesion and migration and 
functions by inducung inducing apoptosis. 
Successful clinical trials are required before Anginex 
can be used to treat arthritis, tumour growth, 
retinopathy and restenosis.
14.2. Anti-angiogenic Gene Therapy for Cancer
Relative instability, economic constraints posed by 
mass manufacturing and high chronic dosage
Table 14 A brief summary o f the aim o f the different clinical trail phases (Hagedom 2000)
Trial stages D uration/ no o f subjects Definition o f  the  stage o f clinical trial
Pre-clinical at least 2-3 months Evaluation of pharmacological effects of the compound through in vivo 
and in vitro animal (rodent and non-rodent) experiments. The animals 
Eire tested on the basis of the genotoxicity of the drug, the metabolism of 
the drug and the excretion pathways.
Phase I 20-80 subjects The new drug is administered to healthy or diseased volunteers for the 
first time under closely monitored conditions and the subjects are 
observed for drug metabolism, side effects relative to dosage
Phase II several hundred patients The main aim is to obtain preliminaiy data on the effectiveness of the 
new drug. This again is carried out under close monitoring
Phase III several hundred or 
thousand patients
Expanded controlled and uncontrolled trial studies to determine the 
benefit-risk relationship of the drug
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Table 15 The various inhibitors that have reached the clinical trial stage
Drug Inhibitor type Endogenous 
/ synthetic
Trial Status Diseases
Endostatin EC inhibitor Endogenous Phase II Solid tumours
Suramin Growth factor inhibitor Synthetic Phase II Glioblastoma
Vitaxin Adhesion molecule inhibitor Synthetic Phase II Leiomyosarcoma
Thalidomide Growth factor inhibitor Synthetic Phase II
Penicillamine Protease inhibitor, EC inhibitor Synthetic Phase II Glioblastoma
Famesyl Transferase 
Inhibitor
EC inhibitor Endogenous Phase I Soild tumours and glioblastoma
Marimastat Protease inhibitor Synthetic Phase in Breast cancer, malignant glioma, non­
small cell lung carcinoma, pancreatic 
carcinoma
T etrathiomoly bdate Copper chelator Synthetic Phase I/II Advanced metastatic cancer and 
multiple tumour types
EMD121974 Adhesion molecule inhibitor Synthetic PhaseI/H Kaposi's sarcoma, brain tumours
PTK787/ZK22584 Growth factor inhibitor Synthetic Phase I/n Kaposi's sarcoma, glioblastoma, von 
Hippel-Lindau disease
Captopril Copper chelator Synthetic Phase I/II -
Interpheron-alpha Growth factor inhibitor Endogenous Phase II/III -
Interleukin-12 Endogenous Phase I/H Ovarian, renal cell, gastrointestinal 
cancers, soild tumours and Kaposi's 
sarcoma
SU5416 Growth factor inhibitor Synthetic Phase I/n Kaposi's sarcoma, colorectal carcinoma
Bay 12-9566 Protease inhibitor Synthetic Phase HI Lung cancer, pancreatic cancer and 
ovarian cancer
Squalamine EC inhibitor Synthetic Phase in Prostate cancer, non-smaU cell lung 
carcinoma, pancreatic carcinoma
1M862 - Synthetic Phase in AIDS-related Kaposi's sarcoma
AG3340 Protease inhibitor Synthetic Phase HI Prostate cancer, non-small cell lung 
carcinoma, pancreatic carcinoma
R115777 EC inhibitor Synthetic - -
CAI - Endogenous Phase n/m Renal cell, non-small-cell lug and 
ovarian cancers





Synthetic Phase I -
TNP-470 EC inhibitor Synthetic Phase H Lymphomas and acute leukemias
ABT-627 ET-1 receptor agonist Synthetic Phase I/H Prostate cancer, glioblastoma
-L-778,123 EC inhibitor Synthetic - -
-SCH66336 EC inhibitor Synthetic - -
Neovastat Protease inhibitor Endogenous Phase HI Colon cancer, non-small cell lung 
carcinoma, pancreatic carcinoma
PNU-145156E Synthetic Phase I/n Solid tumours
Anti-VEGF Antibody VEGF inhibitor Phase n/m Lung cancer, renal cancer, prostate 
cancer, breast cancer and colorectal 
cancer
SU6668 Receptor inhibitor Synthetic Phase I Advanced cancer
CM101/ZDO101 EC inhibitor Synthetic Phase I -
BMS-275291 Protease inhibitor Synthetic Phase I -
Purlyin (SnET2) ET-1 receptor inhibitor Synthetic- Phases I/H/HI Cutaneous skin carcinoma, breast 
carcinoma
Suradista Blocks binding of growth factors Synthetic Phases I/H/HI Brain cancers, glioblastoma, prostate 
cancer, ovarian cancer
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requirem ents for recombinant endogenous 
inhibitors make the anti-angiogenic gene therapy a 
very attractive treatment. Two gene strategies have 
been proposed for this therapeutic treatment:
(a) Tumour Directed Gene Therapy
• Facilitates paracrine activity
• Avoids systemic toxicity of anti-angiogenic 
gene product
• Requires an established tumour blood  
supply to deliver the vector
• Less efficient against micrometastases
• Difficulty in producing tumour-specific 
gene-delivery systems
(b) Systemic Gene Therapy
• Facilitates the use of normal host tissues for 
the production of elevated levels of the anti- 
angiogenic products.
Gene delivery systems can be classified as:
• Viral vectors: These are more efficient in 
entering eukaryotic cells and at inducing 
gene expression. But they are also toxic 
being natural pathogens and thus are 
susceptible to being eradicated by the 
human immune systems.
• Non-viral vectors: These are less efficient 
in entering host cells and at inducing gene 
expression. But they are not toxic as 
opposed to the viral vectors.
Several in vitro and in vivo anti-angiogenic gene 
therapy approaches have been used to evaluate a 
variety o f endogenous inhibitors. Table 16 lists 
some of gene transfer methods for a few important 
inhibitory molecules.
14.3. The Endostatin Paradox
About 5 years ago, Judah Folkman’s endostatin  
produced dramatic results in laboratory
experiments. This led to clinical trials using several 
gene transfer approaches in order to establish its 
magical properties in shrinking tumour in mice 
virtually to nothing. However, this result was not 
obtained all the research groups that tried their 
hand with this wonder molecule. Several questions 
were raised regarding the properties of endostatin 
as projected by the Harvard group. The reason for 
paradoxical behaviour of this molecule lies in the 
method of delivery to the body. It seems that gene 
transfer approach is not as effective as when the 
protein is injected into the body. But then again 
according to Folkman this behaviour itself is not 
consistent as some gene therapy experiments have 
given promising results and not just his laboratory. 
According to him, the inefficiency o f the gene  
transfer m ethod may be because o f endostatin  
rendered inactive at high concentrations produced 
by the gene therapy. Although the perplexity of 
this paradox is still not resolved, Folkman and his 
group believe that w h ilst one continues to 
investigate into the discrepancies of the varied 
results, one should not stop the clinical trials with 
endostatin. Further research in this field would  
enhance our understanding of the anti-angiogenic 
properties of this molecule.
15. Future prospects
The aim of angiogenesis research is to characterise 
the endothelial cells that originate from tumour 
tissues. Today, one o f the major future directions 
for angiogenesis research is to continue to identify 
the biochemical targets and elucidate the three- 
dimensional structures of all the macromolecules 
involved  in the process o f angiogenesis. It is 
important to model and quantify the structure- 
functional relationship of these macromolecules in
Table 16 Gene transfer methods evaluated for some important inhibitory molecules
Genes References
Angiostatin In vitro transfection (Cao et al. 1998); cationic liposome:DNA complex (Liu et al. 1999); Adenovirus
(Griscelli et al. 1998)
Endostatin In vitro transfection (Yoon et al. 1999); polymerised plasmid DNA (Blezinger et al. 1999); cationic
liposome:DNA complex (Chen et al. 1999)
TIMPs Adenovirus (Fernandez et al. 1999); In vitro transfection (Valente et al. 1998)
ILs In vitro transfection (Steams et al. 1999); sf-virus (Asselin-Paturel et al. 1998)
IFNs Retro-viral transduction (Dong et al. 1999)
TSPs Cationic liposome:DNA complex (Xu et al. 1998)
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parametric terms and correlate the dynamics of the 
process with these parameters. This will help in 
incorporating the molecular properties o f these 
targets in a cellular context, which will unravel the 
com plex pathways that are integrated into the 
process o f blood vessel formation. A lso, it is 
necessary to develop new experimental models 
for angiogenesis so that the authenticity o f the 
molecule being tested can be verified to a larger 
extent than now. For this we also need to evaluate 
angiogenesis in human tumours as opposed to 
animal tumours as a prognostic tool. It is necessary to 
design small molecule antagonists taking into account 
the macromolecular target in terms of its biological 
endpoint. The therapeutic applications that need to be 
developed should promote tumour regression by 
death of tumour cells and not normal, healthy cells. 
Also, the need of the hour is to develop drugs or 
vaccines that are easy to deliver, free of delivery risk
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